DDI-MedLine.d116.s0	Rifampin and warfarin: a drug interaction.
Rifampin	drug	0-7	warfarin	drug	13-20	int

DDI-MedLine.d116.s1	The drug interaction between warfarin and rifampin is not well known.
warfarin	drug	29-36	rifampin	drug	42-49	int

DDI-MedLine.d116.s2	Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
Rifampin	drug	0-7	warfarin	drug	43-50	mechanism

DDI-MedLine.d116.s3	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
rifampin	drug	34-41	warfarin	drug	47-54	mechanism
rifampin	drug	34-41	warfarin	drug	119-126	false
warfarin	drug	47-54	warfarin	drug	119-126	false

DDI-MedLine.d116.s4	Withdrawal of rifampin decreased the warfarin requirement by 50%.
rifampin	drug	14-21	warfarin	drug	37-44	mechanism

DDI-MedLine.d116.s5	This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
rifampin	drug	46-53	warfarin	drug	113-120	mechanism

DDI-MedLine.d116.s6	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
rifampin	drug	14-21	warfarin	drug	30-37	effect
rifampin	drug	14-21	rifampin	drug	125-132	false
rifampin	drug	14-21	rifampin	drug	178-185	false
warfarin	drug	30-37	rifampin	drug	125-132	false
warfarin	drug	30-37	rifampin	drug	178-185	false
rifampin	drug	125-132	rifampin	drug	178-185	false

DDI-MedLine.d74.s2	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM).
arginine	drug	216-223	glucose	drug	233-239	false
arginine	drug	216-223	theophylline	drug	275-286	false
glucose	drug	233-239	theophylline	drug	275-286	false

DDI-MedLine.d74.s4	Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals.
Glucose	drug	0-6	theophylline	drug	38-49	false

DDI-MedLine.d74.s5	Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics.
Arginine	drug	0-7	glucose	drug	29-35	false
Arginine	drug	0-7	theophylline	drug	41-52	false
glucose	drug	29-35	theophylline	drug	41-52	false

DDI-MedLine.d74.s6	Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
Arginine	drug	0-7	glucose	drug	28-34	false
Arginine	drug	0-7	theophylline	drug	39-50	false
glucose	drug	28-34	theophylline	drug	39-50	false

DDI-MedLine.d74.s11	Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.
theophylline	drug	108-119	glucose	drug	156-162	false

DDI-MedLine.d23.s0	The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
ketamine	drug	15-22	Innovar	brand	31-37	false
ketamine	drug	15-22	digitalis	group	53-61	false
Innovar	brand	31-37	digitalis	group	53-61	false

DDI-MedLine.d23.s1	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
digitalis	group	19-27	ketamine	drug	65-72	false
digitalis	group	19-27	Innovar Vet	brand	75-85	false
digitalis	group	19-27	pentobarbital	drug	91-103	false
digitalis	group	19-27	ouabain	drug	120-126	false
digitalis	group	19-27	ouabain	drug	213-219	false
digitalis	group	19-27	ketamine	drug	227-234	false
digitalis	group	19-27	Innovar	brand	239-245	false
digitalis	group	19-27	pentobarbital	drug	257-269	false
ketamine	drug	65-72	Innovar Vet	brand	75-85	false
ketamine	drug	65-72	pentobarbital	drug	91-103	false
ketamine	drug	65-72	ouabain	drug	120-126	effect
ketamine	drug	65-72	ouabain	drug	213-219	false
ketamine	drug	65-72	ketamine	drug	227-234	false
ketamine	drug	65-72	Innovar	brand	239-245	false
ketamine	drug	65-72	pentobarbital	drug	257-269	false
Innovar Vet	brand	75-85	pentobarbital	drug	91-103	false
Innovar Vet	brand	75-85	ouabain	drug	120-126	effect
Innovar Vet	brand	75-85	ouabain	drug	213-219	false
Innovar Vet	brand	75-85	ketamine	drug	227-234	false
Innovar Vet	brand	75-85	Innovar	brand	239-245	false
Innovar Vet	brand	75-85	pentobarbital	drug	257-269	false
pentobarbital	drug	91-103	ouabain	drug	120-126	effect
pentobarbital	drug	91-103	ouabain	drug	213-219	false
pentobarbital	drug	91-103	ketamine	drug	227-234	false
pentobarbital	drug	91-103	Innovar	brand	239-245	false
pentobarbital	drug	91-103	pentobarbital	drug	257-269	false
ouabain	drug	120-126	ouabain	drug	213-219	false
ouabain	drug	120-126	ketamine	drug	227-234	false
ouabain	drug	120-126	Innovar	brand	239-245	false
ouabain	drug	120-126	pentobarbital	drug	257-269	false
ouabain	drug	213-219	ketamine	drug	227-234	false
ouabain	drug	213-219	Innovar	brand	239-245	false
ouabain	drug	213-219	pentobarbital	drug	257-269	false
ketamine	drug	227-234	Innovar	brand	239-245	false
ketamine	drug	227-234	pentobarbital	drug	257-269	false
Innovar	brand	239-245	pentobarbital	drug	257-269	false

DDI-MedLine.d23.s2	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
ouabain	drug	35-41	Innovar	brand	111-117	effect
ouabain	drug	35-41	ketamine	drug	120-127	effect
ouabain	drug	35-41	droperidol	drug	133-142	effect
ouabain	drug	35-41	fentayl	drug	176-182	false
ouabain	drug	35-41	pentobarbital	drug	199-211	false
Innovar	brand	111-117	ketamine	drug	120-127	false
Innovar	brand	111-117	droperidol	drug	133-142	false
Innovar	brand	111-117	fentayl	drug	176-182	false
Innovar	brand	111-117	pentobarbital	drug	199-211	false
ketamine	drug	120-127	droperidol	drug	133-142	false
ketamine	drug	120-127	fentayl	drug	176-182	false
ketamine	drug	120-127	pentobarbital	drug	199-211	false
droperidol	drug	133-142	fentayl	drug	176-182	false
droperidol	drug	133-142	pentobarbital	drug	199-211	false
fentayl	drug	176-182	pentobarbital	drug	199-211	false

DDI-MedLine.d57.s1	The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.
antihistaminics	group	83-97	analgesic agents	group	111-126	false
antihistaminics	group	83-97	analgesic adjuvants	group	141-159	false
analgesic agents	group	111-126	analgesic adjuvants	group	141-159	false

DDI-MedLine.d57.s2	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.
diphenhydramine	drug	51-65	hydroxyzine	drug	68-78	false
diphenhydramine	drug	51-65	orphenadrine	drug	81-92	false
diphenhydramine	drug	51-65	pyrilamine	drug	95-104	false
diphenhydramine	drug	51-65	phenyltoloxamine	drug_n	107-122	false
diphenhydramine	drug	51-65	promethazine	drug	125-136	false
diphenhydramine	drug	51-65	methdilazine	drug	139-150	false
diphenhydramine	drug	51-65	tripelennamine	drug	157-170	false
hydroxyzine	drug	68-78	orphenadrine	drug	81-92	false
hydroxyzine	drug	68-78	pyrilamine	drug	95-104	false
hydroxyzine	drug	68-78	phenyltoloxamine	drug_n	107-122	false
hydroxyzine	drug	68-78	promethazine	drug	125-136	false
hydroxyzine	drug	68-78	methdilazine	drug	139-150	false
hydroxyzine	drug	68-78	tripelennamine	drug	157-170	false
orphenadrine	drug	81-92	pyrilamine	drug	95-104	false
orphenadrine	drug	81-92	phenyltoloxamine	drug_n	107-122	false
orphenadrine	drug	81-92	promethazine	drug	125-136	false
orphenadrine	drug	81-92	methdilazine	drug	139-150	false
orphenadrine	drug	81-92	tripelennamine	drug	157-170	false
pyrilamine	drug	95-104	phenyltoloxamine	drug_n	107-122	false
pyrilamine	drug	95-104	promethazine	drug	125-136	false
pyrilamine	drug	95-104	methdilazine	drug	139-150	false
pyrilamine	drug	95-104	tripelennamine	drug	157-170	false
phenyltoloxamine	drug_n	107-122	promethazine	drug	125-136	false
phenyltoloxamine	drug_n	107-122	methdilazine	drug	139-150	false
phenyltoloxamine	drug_n	107-122	tripelennamine	drug	157-170	false
promethazine	drug	125-136	methdilazine	drug	139-150	false
promethazine	drug	125-136	tripelennamine	drug	157-170	false
methdilazine	drug	139-150	tripelennamine	drug	157-170	false

DDI-MedLine.d27.s0	It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
picrotoxin	drug_n	117-126	diazepam	drug	174-181	effect
picrotoxin	drug_n	117-126	phenazepam	drug_n	184-193	effect
picrotoxin	drug_n	117-126	phenibut	drug_n	196-203	effect
picrotoxin	drug_n	117-126	amizyl	drug_n	209-214	effect
picrotoxin	drug_n	117-126	phentolamine	drug	242-253	effect
diazepam	drug	174-181	phenazepam	drug_n	184-193	false
diazepam	drug	174-181	phenibut	drug_n	196-203	false
diazepam	drug	174-181	amizyl	drug_n	209-214	false
diazepam	drug	174-181	phentolamine	drug	242-253	false
phenazepam	drug_n	184-193	phenibut	drug_n	196-203	false
phenazepam	drug_n	184-193	amizyl	drug_n	209-214	false
phenazepam	drug_n	184-193	phentolamine	drug	242-253	false
phenibut	drug_n	196-203	amizyl	drug_n	209-214	false
phenibut	drug_n	196-203	phentolamine	drug	242-253	false
amizyl	drug_n	209-214	phentolamine	drug	242-253	false

DDI-MedLine.d15.s0	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]

DDI-MedLine.d15.s0	It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	75-89	false
cerulein	drug_n	16-23	neuroleptics	group	137-148	false
cerulein	drug_n	16-23	haloperidol	drug	269-279	false
cerulein	drug_n	16-23	pyreneperone	drug_n	298-309	false
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	368-382	false
cerulein	drug_n	16-23	apomorphine	drug	419-429	false
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	466-480	false
cerulein	drug_n	16-23	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	75-89	neuroleptics	group	137-148	false
3H-spiroperidol	drug_n	75-89	haloperidol	drug	269-279	false
3H-spiroperidol	drug_n	75-89	pyreneperone	drug_n	298-309	false
3H-spiroperidol	drug_n	75-89	3H-spiroperidol	drug_n	368-382	false
3H-spiroperidol	drug_n	75-89	apomorphine	drug	419-429	false
3H-spiroperidol	drug_n	75-89	3H-spiroperidol	drug_n	466-480	false
3H-spiroperidol	drug_n	75-89	apomorphine	drug	527-537	false
neuroleptics	group	137-148	haloperidol	drug	269-279	false
neuroleptics	group	137-148	pyreneperone	drug_n	298-309	false
neuroleptics	group	137-148	3H-spiroperidol	drug_n	368-382	false
neuroleptics	group	137-148	apomorphine	drug	419-429	false
neuroleptics	group	137-148	3H-spiroperidol	drug_n	466-480	false
neuroleptics	group	137-148	apomorphine	drug	527-537	false
haloperidol	drug	269-279	pyreneperone	drug_n	298-309	false
haloperidol	drug	269-279	3H-spiroperidol	drug_n	368-382	false
haloperidol	drug	269-279	apomorphine	drug	419-429	false
haloperidol	drug	269-279	3H-spiroperidol	drug_n	466-480	false
haloperidol	drug	269-279	apomorphine	drug	527-537	false
pyreneperone	drug_n	298-309	3H-spiroperidol	drug_n	368-382	false
pyreneperone	drug_n	298-309	apomorphine	drug	419-429	false
pyreneperone	drug_n	298-309	3H-spiroperidol	drug_n	466-480	false
pyreneperone	drug_n	298-309	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	368-382	apomorphine	drug	419-429	false
3H-spiroperidol	drug_n	368-382	3H-spiroperidol	drug_n	466-480	false
3H-spiroperidol	drug_n	368-382	apomorphine	drug	527-537	false
apomorphine	drug	419-429	3H-spiroperidol	drug_n	466-480	false
apomorphine	drug	419-429	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	466-480	apomorphine	drug	527-537	false

DDI-MedLine.d15.s1	After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.
neuroleptics	group	34-45	cerulein	drug_n	72-79	false
neuroleptics	group	34-45	3H-spiroperidol	drug_n	164-178	false
cerulein	drug_n	72-79	3H-spiroperidol	drug_n	164-178	false

DDI-MedLine.d15.s2	It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
3H-spiroperidol	drug_n	49-63	apomorphine	drug	101-111	false
3H-spiroperidol	drug_n	49-63	neuroleptics	group	190-201	false
apomorphine	drug	101-111	neuroleptics	group	190-201	false

DDI-MedLine.d56.s0	Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.
ouabain	drug	15-21	palytoxin	drug_n	30-38	false

DDI-MedLine.d56.s1	Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.
Palytoxin	drug_n	0-8	PTX	drug_n	11-13	false

DDI-MedLine.d56.s2	In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
ouabain	drug	19-25	PTX	drug_n	39-41	effect

DDI-MedLine.d56.s5	When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
ouabain	drug	5-11	phentolamine	drug	58-69	effect
ouabain	drug	5-11	PTX	drug_n	119-121	false
phentolamine	drug	58-69	PTX	drug_n	119-121	false

DDI-MedLine.d56.s8	Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
ouabain	drug	26-32	PTX	drug_n	68-70	effect

DDI-MedLine.d56.s10	The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain.
ouabain	drug	93-99	ouabain	drug	299-305	false

DDI-MedLine.d139.s0	[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports.
neuroleptics	group	50-61	neuroleptics	group	173-184	false

DDI-MedLine.d82.s1	The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique.
arsenate	drug_n	29-36	As(V)	drug_n	38-42	false

DDI-MedLine.d82.s2	By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM.
arsenate	drug_n	40-47	As(V)	drug_n	123-127	false

DDI-MedLine.d82.s4	At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines.
As(V)	drug_n	10-14	As(V)	drug_n	90-94	false

DDI-MedLine.d82.s5	However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V).
As(V)	drug_n	39-43	As(V)	drug_n	137-141	false

DDI-MedLine.d82.s7	Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level.
arsenate	drug_n	13-20	phosphate	drug	26-34	false

DDI-MedLine.d82.s8	Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
Vitamin D3	drug	0-9	arsenate	drug_n	95-102	mechanism

DDI-MedLine.d22.s2	By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone.
spermidine	drug_n	13-22	putrescine	drug_n	35-44	false

DDI-MedLine.d22.s3	Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.
Spermine	drug	0-7	spermidine	drug_n	34-43	false

DDI-MedLine.d100.s5	Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	group	0-28	verapamil	drug	39-47	false
Slow-channel calcium blockers	group	0-28	diltiazem	drug	50-58	false
Slow-channel calcium blockers	group	0-28	nifedipine	drug	64-73	false
verapamil	drug	39-47	diltiazem	drug	50-58	false
verapamil	drug	39-47	nifedipine	drug	64-73	false
diltiazem	drug	50-58	nifedipine	drug	64-73	false

DDI-MedLine.d63.s0	Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
naloxone	drug	36-43	beta-endorphin	drug_n	111-124	false
naloxone	drug	36-43	morphine	drug	130-137	false
beta-endorphin	drug_n	111-124	morphine	drug	130-137	false

DDI-MedLine.d63.s2	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
naloxone	drug	64-71	beta-endorphin	drug_n	144-157	false
naloxone	drug	64-71	morphine	drug	163-170	false
beta-endorphin	drug_n	144-157	morphine	drug	163-170	false

DDI-MedLine.d63.s3	Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats.
beta-endorphin	drug_n	30-43	morphine	drug	49-56	false

DDI-MedLine.d63.s4	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
naloxone	drug	25-32	beta-endorphin	drug_n	184-197	effect
naloxone	drug	25-32	naloxone	drug	219-226	false
naloxone	drug	25-32	beta-endorphin	drug_n	317-330	false
beta-endorphin	drug_n	184-197	naloxone	drug	219-226	false
beta-endorphin	drug_n	184-197	beta-endorphin	drug_n	317-330	false
naloxone	drug	219-226	beta-endorphin	drug_n	317-330	effect

DDI-MedLine.d63.s5	On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
naloxone	drug	31-38	morphine	drug	145-152	effect

DDI-MedLine.d63.s6	Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
naloxone	drug	30-37	beta-endorphin	drug_n	173-186	effect
naloxone	drug	30-37	morphine	drug	192-199	effect
beta-endorphin	drug_n	173-186	morphine	drug	192-199	false

DDI-MedLine.d63.s7	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	35-42	beta-endorphin	drug_n	109-122	false
naloxone	drug	35-42	morphine	drug	132-139	false
naloxone	drug	35-42	beta-endorphin	drug_n	206-219	false
naloxone	drug	35-42	morphine	drug	225-232	false
beta-endorphin	drug_n	109-122	morphine	drug	132-139	false
beta-endorphin	drug_n	109-122	beta-endorphin	drug_n	206-219	false
beta-endorphin	drug_n	109-122	morphine	drug	225-232	false
morphine	drug	132-139	beta-endorphin	drug_n	206-219	false
morphine	drug	132-139	morphine	drug	225-232	false
beta-endorphin	drug_n	206-219	morphine	drug	225-232	false

DDI-MedLine.d63.s8	descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
beta-endorphin	drug_n	38-51	morphine	drug	57-64	false

DDI-MedLine.d73.s0	Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	52-95	MPTP	drug_n	98-101	false
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	52-95	methamphetamine	drug	108-122	false
MPTP	drug_n	98-101	methamphetamine	drug	108-122	false

DDI-MedLine.d73.s1	The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration.
MPTP	drug_n	56-59	methamphetamine	drug	144-158	false

DDI-MedLine.d73.s2	It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
MPTP	drug_n	21-24	pargyline	drug	143-151	effect

DDI-MedLine.d73.s3	The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
MPTP	drug	4-7	amphetamine	drug	83-93	effect
MPTP	drug	4-7	apomorphine	drug	147-157	effect
amphetamine	drug	83-93	apomorphine	drug	147-157	false

DDI-MedLine.d73.s4	Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
Methamphetamine	drug	0-14	MPTP	drug_n	22-25	false
Methamphetamine	drug	0-14	pargyline	drug	107-115	effect
MPTP	drug_n	22-25	pargyline	drug	107-115	false

DDI-MedLine.d12.s0	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
Dexamethasone	drug	0-12	retinyl acetate	drug	18-32	false
Dexamethasone	drug	0-12	EGF	drug_n	66-68	effect
Dexamethasone	drug	0-12	insulin	drug	74-80	effect
retinyl acetate	drug	18-32	EGF	drug_n	66-68	effect
retinyl acetate	drug	18-32	insulin	drug	74-80	effect
EGF	drug_n	66-68	insulin	drug	74-80	false

DDI-MedLine.d12.s1	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).
transferrin	drug_n	101-111	EGF	drug_n	131-133	false
transferrin	drug_n	101-111	insulin	drug	151-157	false
EGF	drug_n	131-133	insulin	drug	151-157	false

DDI-MedLine.d12.s2	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
dexamethasone	drug	17-29	retinyl acetate	drug	35-49	false
dexamethasone	drug	17-29	transferrin	drug_n	125-135	false
dexamethasone	drug	17-29	EGF	drug_n	180-182	effect
dexamethasone	drug	17-29	insulin	drug	188-194	effect
retinyl acetate	drug	35-49	transferrin	drug_n	125-135	false
retinyl acetate	drug	35-49	EGF	drug_n	180-182	effect
retinyl acetate	drug	35-49	insulin	drug	188-194	effect
transferrin	drug_n	125-135	EGF	drug_n	180-182	false
transferrin	drug_n	125-135	insulin	drug	188-194	false
EGF	drug_n	180-182	insulin	drug	188-194	false

DDI-MedLine.d12.s3	Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
Dexamethasone	drug	0-12	retinyl acetate	drug	30-44	false
Dexamethasone	drug	0-12	EGF	drug_n	105-107	effect
retinyl acetate	drug	30-44	EGF	drug_n	105-107	effect

DDI-MedLine.d12.s4	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
dexamethasone	drug	25-37	retinyl acetate	drug	62-76	false
dexamethasone	drug	25-37	EGF	drug_n	136-138	effect
retinyl acetate	drug	62-76	EGF	drug_n	136-138	effect

DDI-MedLine.d12.s5	Dexamethasone had a similar effect in the presence of insulin.
Dexamethasone	drug	0-12	insulin	drug	54-60	false

DDI-MedLine.d12.s6	However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
retinyl acetate	drug	9-23	insulin	drug	105-111	effect

DDI-MedLine.d12.s7	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
dexamethasone	drug	32-44	retinyl acetate	drug	50-64	false
dexamethasone	drug	32-44	glucocorticoids	group	86-100	false
dexamethasone	drug	32-44	retinoids	group	106-114	false
dexamethasone	drug	32-44	insulin	drug	223-229	effect
dexamethasone	drug	32-44	EGF	drug_n	235-237	effect
retinyl acetate	drug	50-64	glucocorticoids	group	86-100	false
retinyl acetate	drug	50-64	retinoids	group	106-114	false
retinyl acetate	drug	50-64	insulin	drug	223-229	effect
retinyl acetate	drug	50-64	EGF	drug_n	235-237	effect
glucocorticoids	group	86-100	retinoids	group	106-114	false
glucocorticoids	group	86-100	insulin	drug	223-229	effect
glucocorticoids	group	86-100	EGF	drug_n	235-237	effect
retinoids	group	106-114	insulin	drug	223-229	effect
retinoids	group	106-114	EGF	drug_n	235-237	effect
insulin	drug	223-229	EGF	drug_n	235-237	false

DDI-MedLine.d9.s3	For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	group	8-36	verapamil	drug	74-82	false
calcium-entry blocking agents	group	8-36	nifedipine	drug	85-94	false
calcium-entry blocking agents	group	8-36	diltiazem	drug	100-108	false
verapamil	drug	74-82	nifedipine	drug	85-94	false
verapamil	drug	74-82	diltiazem	drug	100-108	false
nifedipine	drug	85-94	diltiazem	drug	100-108	false

DDI-MedLine.d9.s5	by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements;
verapamil	drug	45-53	diltiazem	drug	59-67	false
verapamil	drug	45-53	nifedipine	drug	87-96	false
diltiazem	drug	59-67	nifedipine	drug	87-96	false

DDI-MedLine.d45.s0	Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
pentazocine	drug	22-32	tripelennamine	drug	38-51	false

DDI-MedLine.d45.s1	The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine
pentazocine	drug	68-78	tripelennamine	drug	84-97	false

DDI-MedLine.d45.s5	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
heroin	drug_n	74-79	pentazocine	drug	93-103	false
heroin	drug_n	74-79	tripelennamine	drug	109-122	false
pentazocine	drug	93-103	tripelennamine	drug	109-122	effect

DDI-MedLine.d45.s6	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
tripelennamine	drug	105-118	pentazocine	drug	200-210	effect

DDI-MedLine.d45.s9	aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S.
pentazocine	drug	22-32	tripelennamine	drug	38-51	false

DDI-MedLine.d61.s0	Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
digoxin	drug	34-40	amiodarone	drug	42-51	false

DDI-MedLine.d61.s1	Amiodarone is known to raise serum digoxin levels.
Amiodarone	drug	0-9	digoxin	drug	35-41	mechanism

DDI-MedLine.d61.s3	The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.
digoxin	drug	34-40	digoxin	drug	93-99	false
digoxin	drug	34-40	amiodarone	drug	140-149	false
digoxin	drug	93-99	amiodarone	drug	140-149	false

DDI-MedLine.d61.s4	During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
amiodarone	drug	7-16	digoxin	drug	56-62	mechanism

DDI-MedLine.d61.s8	Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics.
Amiodarone	drug	0-9	digoxin	drug	172-178	false

DDI-MedLine.d61.s9	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
digoxin	drug	21-27	amiodarone	drug	58-67	mechanism
digoxin	drug	21-27	digoxin	drug	99-105	false
amiodarone	drug	58-67	digoxin	drug	99-105	false

DDI-MedLine.d85.s0	Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
Misonidazole	drug_n	0-11	CCNU	drug	80-83	effect

DDI-MedLine.d85.s1	Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole.
nitrosourea	group	12-22	CCNU	drug	24-27	false
nitrosourea	group	12-22	CCNU	drug	184-187	false
nitrosourea	group	12-22	misonidazole	drug_n	246-257	false
CCNU	drug	24-27	CCNU	drug	184-187	false
CCNU	drug	24-27	misonidazole	drug_n	246-257	false
CCNU	drug	184-187	misonidazole	drug_n	246-257	false

DDI-MedLine.d85.s7	Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
Misonidazole	drug_n	0-11	CCNU	drug	53-56	effect

DDI-MedLine.d85.s9	Misonidazole has a complex effect on oral CCNU pharmacokinetics.
Misonidazole	drug_n	0-11	CCNU	drug	42-45	mechanism

DDI-MedLine.d85.s14	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
CCNU	drug	98-101	misonidazole	drug_n	119-130	mechanism

DDI-MedLine.d7.s0	Enhanced theophylline clearance secondary to phenytoin therapy.
theophylline	drug	9-20	phenytoin	drug	45-53	mechanism

DDI-MedLine.d7.s1	This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
theophylline	drug	41-52	phenytoin	drug	102-110	mechanism

DDI-MedLine.d7.s4	With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
phenytoin	drug	52-60	theophylline	drug	157-168	effect

DDI-MedLine.d30.s1	The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	drug_n	47-66	NANM	drug_n	69-72	false
N-allylnormetazocine	drug_n	47-66	phencyclidine	drug_n	103-115	false
N-allylnormetazocine	drug_n	47-66	PCP	drug_n	118-120	false
NANM	drug_n	69-72	phencyclidine	drug_n	103-115	false
NANM	drug_n	69-72	PCP	drug_n	118-120	false
phencyclidine	drug_n	103-115	PCP	drug_n	118-120	false

DDI-MedLine.d30.s2	Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
(+)-NANM	drug_n	22-29	PCP	drug_n	34-36	false

DDI-MedLine.d30.s6	In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.
(-)-NANM	drug_n	12-19	(+)-NANM	drug_n	57-64	false
(-)-NANM	drug_n	12-19	(-)-NANM	drug_n	111-118	false
(-)-NANM	drug_n	12-19	(+)-NANM	drug_n	146-153	false
(+)-NANM	drug_n	57-64	(-)-NANM	drug_n	111-118	false
(+)-NANM	drug_n	57-64	(+)-NANM	drug_n	146-153	false
(-)-NANM	drug_n	111-118	(+)-NANM	drug_n	146-153	false

DDI-MedLine.d30.s7	In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
(-)-NANM	drug_n	17-24	(+)-NANM	drug_n	35-42	false
(-)-NANM	drug_n	17-24	morphine	drug	88-95	effect
(+)-NANM	drug_n	35-42	morphine	drug	88-95	false

DDI-MedLine.d30.s8	In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
(-)-NANM	drug_n	27-34	(+)-NANM	drug_n	45-52	false
(-)-NANM	drug_n	27-34	PCP	drug_n	57-59	false
(-)-NANM	drug_n	27-34	naloxone	drug	82-89	effect
(+)-NANM	drug_n	45-52	PCP	drug_n	57-59	false
(+)-NANM	drug_n	45-52	naloxone	drug	82-89	false
PCP	drug_n	57-59	naloxone	drug	82-89	false

DDI-MedLine.d30.s9	the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
naloxone	drug	13-20	(-)-NANM	drug_n	60-67	effect
naloxone	drug	13-20	morphine	drug	150-157	effect
(-)-NANM	drug_n	60-67	morphine	drug	150-157	false

DDI-MedLine.d30.s10	In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP.
naloxone	drug	12-19	(-)-NANM	drug_n	65-72	false
naloxone	drug	12-19	(+)-NANM	drug_n	75-82	false
naloxone	drug	12-19	PCP	drug_n	87-89	false
(-)-NANM	drug_n	65-72	(+)-NANM	drug_n	75-82	false
(-)-NANM	drug_n	65-72	PCP	drug_n	87-89	false
(+)-NANM	drug_n	75-82	PCP	drug_n	87-89	false

DDI-MedLine.d30.s11	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
Haloperidol	drug	0-10	(+)-NANM	drug_n	106-113	effect
Haloperidol	drug	0-10	PCP	drug_n	118-120	effect
Haloperidol	drug	0-10	NANM	drug_n	250-253	false
(+)-NANM	drug_n	106-113	PCP	drug_n	118-120	false
(+)-NANM	drug_n	106-113	NANM	drug_n	250-253	false
PCP	drug_n	118-120	NANM	drug_n	250-253	false

DDI-MedLine.d55.s0	Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
acetaminophen	drug	28-40	caffeine	drug	75-82	effect

DDI-MedLine.d55.s1	Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen.
caffeine	drug	6-13	acetaminophen	drug	50-62	false
caffeine	drug	6-13	caffeine	drug	115-122	false
caffeine	drug	6-13	acetaminophen	drug	149-161	false
acetaminophen	drug	50-62	caffeine	drug	115-122	false
acetaminophen	drug	50-62	acetaminophen	drug	149-161	false
caffeine	drug	115-122	acetaminophen	drug	149-161	false

DDI-MedLine.d55.s4	Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
acetaminophen	drug	58-70	caffeine	drug	91-98	effect

DDI-MedLine.d130.s0	High-dose cisplatin with sodium thiosulfate protection.
cisplatin	drug	10-18	sodium thiosulfate	drug	25-42	effect

DDI-MedLine.d130.s2	Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
Sodium thiosulfate	drug	0-17	cisplatin	drug	47-55	effect

DDI-MedLine.d130.s3	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.
thiosulfate	drug	34-44	cisplatin	drug	75-83	false
thiosulfate	drug	34-44	thiosulfate	drug	130-140	false
thiosulfate	drug	34-44	cisplatin	drug	221-229	false
cisplatin	drug	75-83	thiosulfate	drug	130-140	false
cisplatin	drug	75-83	cisplatin	drug	221-229	false
thiosulfate	drug	130-140	cisplatin	drug	221-229	false

DDI-MedLine.d130.s4	Cisplatin was administered over the last two hours of the thiosulfate infusion.
Cisplatin	drug	0-8	thiosulfate	drug	58-68	false

DDI-MedLine.d130.s6	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.
cisplatin	drug	14-22	thiosulfate	drug	83-93	false
cisplatin	drug	14-22	thiosulfate	drug	147-157	false
cisplatin	drug	14-22	cisplatin	drug	281-289	false
thiosulfate	drug	83-93	thiosulfate	drug	147-157	false
thiosulfate	drug	83-93	cisplatin	drug	281-289	false
thiosulfate	drug	147-157	cisplatin	drug	281-289	false

DDI-MedLine.d130.s8	This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
thiosulfate	drug	58-68	cisplatin	drug	136-144	mechanism

DDI-MedLine.d2.s0	Failure of neomycin to modify ACTH induced hypertension in sheep.
neomycin	drug	11-18	ACTH	group	30-33	false

DDI-MedLine.d2.s1	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
neomycin	drug	32-39	adrenocortical steroid	group	84-105	false
neomycin	drug	32-39	ACTH	drug	141-144	effect
adrenocortical steroid	group	84-105	ACTH	drug	141-144	false

DDI-MedLine.d2.s2	The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep.
neomycin	drug	20-27	ACTH	group	32-35	false

DDI-MedLine.d2.s3	Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.
Neomycin	drug	0-7	ACTH	group	71-74	false

DDI-MedLine.d66.s0	Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.
synthetic steroidal estrogen	group	42-69	synthetic steroidal progestogen	group	42-60;75-85	false

DDI-MedLine.d66.s1	The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine.
ethynyl estradiol	drug	53-69	levonorgestrel	drug	75-88	false

DDI-MedLine.d66.s2	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol.
levonorgestrel	drug	149-162	ethynyl estradiol	drug	219-235	false

DDI-MedLine.d93.s4	Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle.
trimethyl lead	drug_n	109-122	TML	drug_n	125-127	false

DDI-MedLine.d93.s6	The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol.
alcohol	drug	24-30	ethanol	drug	83-89	false

DDI-MedLine.d93.s9	These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
lead	drug_n	53-56	alcohol	drug	129-135	effect

DDI-MedLine.d54.s2	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol.
alcohol	drug	151-157	alcohol	drug	228-234	false

DDI-MedLine.d54.s3	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.
ethanol	drug	110-116	physostigmine	drug	130-142	false
ethanol	drug	110-116	atropine	drug	159-166	false
physostigmine	drug	130-142	atropine	drug	159-166	false

DDI-MedLine.d54.s8	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
Physostigmine	drug	0-12	alcohol	drug	62-68	effect
Physostigmine	drug	0-12	alcohol	drug	123-129	effect
alcohol	drug	62-68	alcohol	drug	123-129	false

DDI-MedLine.d54.s10	Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2.
Atropine	drug	0-7	alcohol	drug	46-52	false

DDI-MedLine.d81.s0	Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
disulfiram	drug	31-40	ethanol	drug	42-48	false

DDI-MedLine.d81.s1	Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER).
disulfiram	drug	88-97	ethanol	drug	99-105	false

DDI-MedLine.d81.s2	Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
ethanol	drug	71-77	disulfiram	drug	117-126	effect
ethanol	drug	71-77	ethanol	drug	147-153	false
disulfiram	drug	117-126	ethanol	drug	147-153	false

DDI-MedLine.d81.s3	The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol.
ethanol	drug	58-64	ethanol	drug	142-148	false

DDI-MedLine.d81.s6	Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol.
ethanol	drug	47-53	ethanol	drug	97-103	false

DDI-MedLine.d131.s0	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
neurotensin	drug_n	50-60	enkephalins	drug_n	66-76	effect
neurotensin	drug_n	50-60	tuftsin	drug_n	81-87	effect
enkephalins	drug_n	66-76	tuftsin	drug_n	81-87	false

DDI-MedLine.d131.s1	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	drug_n	59-69	enkephalins	drug_n	80-90	false
neurotensin	drug_n	59-69	D-Ala2-metenkephalinamide	drug_n	118-142	false
neurotensin	drug_n	59-69	tuftsin	drug_n	148-154	false
enkephalins	drug_n	80-90	D-Ala2-metenkephalinamide	drug_n	118-142	false
enkephalins	drug_n	80-90	tuftsin	drug_n	148-154	false
D-Ala2-metenkephalinamide	drug_n	118-142	tuftsin	drug_n	148-154	false

DDI-MedLine.d131.s3	It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
neurotensin	drug_n	18-28	enkephalins	drug_n	82-92	effect

DDI-MedLine.d131.s4	On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
neurotensin	drug_n	17-27	tuftsin	drug_n	33-39	effect

DDI-MedLine.d131.s5	It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
neurotensin	drug_n	21-31	tuftsin	drug_n	132-138	effect

DDI-MedLine.d97.s8	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
thiabendazole	drug	92-104	melarsoprol	drug	143-153	effect

DDI-MedLine.d97.s10	Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.
anti-helminthic	group	59-73	melarsoprol	drug	171-181	false

DDI-MedLine.d34.s0	Interactions of cobalt and iron in absorption and retention.
cobalt	drug	16-21	iron	drug	27-30	mechanism

DDI-MedLine.d34.s1	The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats.
cobalt	drug	34-39	iron	drug	45-48	false
cobalt	drug	34-39	Co	drug	271-272	false
cobalt	drug	34-39	Fe	drug	297-298	false
iron	drug	45-48	Co	drug	271-272	false
iron	drug	45-48	Fe	drug	297-298	false
Co	drug	271-272	Fe	drug	297-298	false

DDI-MedLine.d34.s4	Cobalt excretion was enhanced by supplementary cobalt;
Cobalt	drug	0-5	cobalt	drug	47-52	false

DDI-MedLine.d34.s7	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
iron	drug	11-14	cobalt	drug	58-63	mechanism
iron	drug	11-14	cobalt	drug	81-86	mechanism
cobalt	drug	58-63	cobalt	drug	81-86	false

DDI-MedLine.d34.s8	The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
Fe	drug	60-61	Fe	drug	83-84	false
Fe	drug	60-61	cobalt	drug	141-146	mechanism
Fe	drug	83-84	cobalt	drug	141-146	false

DDI-MedLine.d34.s9	Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
iron	drug	28-31	cobalt	drug	53-58	mechanism

DDI-MedLine.d34.s11	Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred.
cobalt	drug	27-32	iron	drug	67-70	false
cobalt	drug	27-32	cobalt	drug	108-113	false
cobalt	drug	27-32	iron	drug	118-121	false
iron	drug	67-70	cobalt	drug	108-113	false
iron	drug	67-70	iron	drug	118-121	false
cobalt	drug	108-113	iron	drug	118-121	false

DDI-MedLine.d34.s12	Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)
iron	drug	15-18	Fe	drug	189-190	false

DDI-MedLine.d39.s0	Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.
estradiol	drug	10-18	endotoxin	drug_n	23-31	false

DDI-MedLine.d39.s1	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin.
estradiol	drug	36-44	endotoxin	drug_n	141-149	false
estradiol	drug	36-44	endotoxin	drug_n	216-224	false
endotoxin	drug_n	141-149	endotoxin	drug_n	216-224	false

DDI-MedLine.d39.s2	Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
estradiol	drug	13-21	endotoxin	drug_n	56-64	effect
estradiol	drug	13-21	endotoxin	drug_n	129-137	false
endotoxin	drug_n	56-64	endotoxin	drug_n	129-137	false

DDI-MedLine.d39.s3	The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
estradiol	drug	37-45	endotoxin	drug_n	49-57	mechanism
estradiol	drug	37-45	endotoxin	drug_n	109-117	false
endotoxin	drug_n	49-57	endotoxin	drug_n	109-117	false

DDI-MedLine.d39.s4	The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%
estradiol	drug	37-45	endotoxin	drug_n	49-57	false
estradiol	drug	37-45	endotoxin	drug_n	117-125	false
endotoxin	drug_n	49-57	endotoxin	drug_n	117-125	false

DDI-MedLine.d39.s6	Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
estradiol	drug	10-18	endotoxin	drug_n	65-73	effect

DDI-MedLine.d39.s8	These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
estrogen	group	61-68	estrogens	group	108-116	false

DDI-MedLine.d128.s1	The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction.
16,16-dimethylprostaglandin E2	drug_n	4-33	dmPGE2	drug_n	36-41	false

DDI-MedLine.d128.s10	On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.
dmPGE2	drug_n	62-67	dmPGE2	drug_n	179-184	false

DDI-MedLine.d128.s12	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.)
Loperamide	drug	0-9	morphine	drug	15-22	false

DDI-MedLine.d128.s13	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
Loperamide	drug	0-9	morphine	drug	15-22	false
Loperamide	drug	0-9	dmPGE2	drug_n	64-69	effect
morphine	drug	15-22	dmPGE2	drug_n	64-69	effect

DDI-MedLine.d128.s15	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
N-methyllevallorphan	drug_n	0-19	loperamide	drug	85-94	effect
N-methyllevallorphan	drug_n	0-19	morphine	drug	133-140	effect
loperamide	drug	85-94	morphine	drug	133-140	false

DDI-MedLine.d89.s0	Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
99mTc-methylene diphosphonate	drug	71-99	gentamicin	drug	107-116	effect

DDI-MedLine.d89.s1	Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys.
Gentamicin	drug	0-9	aminoglycoside antibiotic	group	17-41	false

DDI-MedLine.d89.s2	Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
gentamicin	drug	27-36	99mTc-MDP	drug	84-92	mechanism

DDI-MedLine.d89.s7	Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients.
gentamicin	drug	37-46	99mTc-MDP	drug	89-97	false
gentamicin	drug	37-46	radiopharmaceutical	group	106-124	false
99mTc-MDP	drug	89-97	radiopharmaceutical	group	106-124	false

DDI-MedLine.d89.s8	The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.
gentamicin	drug	79-88	gentamicin	drug	127-136	false

DDI-MedLine.d11.s4	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	41-63	corticosteroids	group	74-88	false
immunosuppressive drugs	group	41-63	cyclosporin	drug	91-101	false
immunosuppressive drugs	group	41-63	azathioprine	drug	104-115	false
immunosuppressive drugs	group	41-63	methotrexate	drug	118-129	false
immunosuppressive drugs	group	41-63	cyclophosphamide	drug	132-147	false
corticosteroids	group	74-88	cyclosporin	drug	91-101	false
corticosteroids	group	74-88	azathioprine	drug	104-115	false
corticosteroids	group	74-88	methotrexate	drug	118-129	false
corticosteroids	group	74-88	cyclophosphamide	drug	132-147	false
cyclosporin	drug	91-101	azathioprine	drug	104-115	false
cyclosporin	drug	91-101	methotrexate	drug	118-129	false
cyclosporin	drug	91-101	cyclophosphamide	drug	132-147	false
azathioprine	drug	104-115	methotrexate	drug	118-129	false
azathioprine	drug	104-115	cyclophosphamide	drug	132-147	false
methotrexate	drug	118-129	cyclophosphamide	drug	132-147	false

DDI-MedLine.d107.s1	Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.
ethanol	drug	98-104	acetaldehyde	drug_n	129-140	false

DDI-MedLine.d107.s3	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	drug	111-117	methanol	drug_n	120-127	false
ethanol	drug	111-117	alcohols	drug_n	137-144	false
ethanol	drug	111-117	acetaldehyde	drug_n	150-161	false
methanol	drug_n	120-127	alcohols	drug_n	137-144	false
methanol	drug_n	120-127	acetaldehyde	drug_n	150-161	false
alcohols	drug_n	137-144	acetaldehyde	drug_n	150-161	false

DDI-MedLine.d107.s9	These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
ethanol	drug	47-53	acetaldehyde	drug_n	128-139	effect

DDI-MedLine.d53.s0	Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
vitamin D	group	61-69	antiestrogens	group	75-87	false

DDI-MedLine.d53.s1	1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
25-Dihydroxycholecalciferol D3	drug	2-31	1,25(OH)2D3	drug	34-44	false
25-Dihydroxycholecalciferol D3	drug	2-31	vitamin D	group	73-81	false
1,25(OH)2D3	drug	34-44	vitamin D	group	73-81	false

DDI-MedLine.d53.s3	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	drug	71-81	antiestrogen	group	91-102	false
1,25(OH)2D3	drug	71-81	4-hydroxytamoxifen	drug_n	104-121	false
1,25(OH)2D3	drug	71-81	TAM	drug_n	124-126	false
antiestrogen	group	91-102	4-hydroxytamoxifen	drug_n	104-121	false
antiestrogen	group	91-102	TAM	drug_n	124-126	false
4-hydroxytamoxifen	drug_n	104-121	TAM	drug_n	124-126	false

DDI-MedLine.d53.s4	Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
TAM	drug_n	22-24	1,25(OH)2D3	drug	92-102	effect

DDI-MedLine.d53.s5	Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
1,25(OH)2D3	drug	24-34	TAM	drug_n	40-42	effect

DDI-MedLine.d53.s9	These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.
vitamin-D	group	90-98	estrogen	group	137-144	false

DDI-MedLine.d51.s1	We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
caffeine	drug	63-70	theophylline	drug	73-84	false
caffeine	drug	63-70	8-phenyltheophylline	drug_n	87-106	false
caffeine	drug	63-70	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
caffeine	drug	63-70	DPCPX	drug_n	149-153	false
theophylline	drug	73-84	8-phenyltheophylline	drug_n	87-106	false
theophylline	drug	73-84	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
theophylline	drug	73-84	DPCPX	drug_n	149-153	false
8-phenyltheophylline	drug_n	87-106	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
8-phenyltheophylline	drug_n	87-106	DPCPX	drug_n	149-153	false
8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	DPCPX	drug_n	149-153	false

DDI-MedLine.d51.s3	The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
theophylline	drug	26-37	CGS 21680	drug_n	73-81	effect
theophylline	drug	26-37	N6-cyclopentyladenosine	drug_n	120-142	false
theophylline	drug	26-37	CPA	drug_n	145-147	false
CGS 21680	drug_n	73-81	N6-cyclopentyladenosine	drug_n	120-142	false
CGS 21680	drug_n	73-81	CPA	drug_n	145-147	false
N6-cyclopentyladenosine	drug_n	120-142	CPA	drug_n	145-147	false

DDI-MedLine.d51.s4	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
theophylline	drug	31-42	CGS21680	drug_n	74-81	effect
theophylline	drug	31-42	DPCPX	drug_n	142-146	false
theophylline	drug	31-42	CGS 21680	drug	200-208	false
theophylline	drug	31-42	CPA	drug_n	217-219	false
CGS21680	drug_n	74-81	DPCPX	drug_n	142-146	false
CGS21680	drug_n	74-81	CGS 21680	drug	200-208	false
CGS21680	drug_n	74-81	CPA	drug_n	217-219	false
DPCPX	drug_n	142-146	CGS 21680	drug	200-208	false
DPCPX	drug_n	142-146	CPA	drug_n	217-219	false
CGS 21680	drug	200-208	CPA	drug_n	217-219	false

DDI-MedLine.d4.s0	The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied.
sandimmune	brand	15-24	immunodepressant	group	119-134	false
sandimmune	brand	15-24	sandimmune	brand	146-155	false
immunodepressant	group	119-134	sandimmune	brand	146-155	false

DDI-MedLine.d68.s0	The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
cimetidine	drug	15-24	verografin	drug	52-61	false
cimetidine	drug	15-24	iodamide	drug	67-74	false
cimetidine	drug	15-24	cimetidine	drug	115-124	false
cimetidine	drug	15-24	verografine	drug	157-167	false
cimetidine	drug	15-24	iodamide	drug	173-180	false
verografin	drug	52-61	iodamide	drug	67-74	false
verografin	drug	52-61	cimetidine	drug	115-124	false
verografin	drug	52-61	verografine	drug	157-167	false
verografin	drug	52-61	iodamide	drug	173-180	false
iodamide	drug	67-74	cimetidine	drug	115-124	false
iodamide	drug	67-74	verografine	drug	157-167	false
iodamide	drug	67-74	iodamide	drug	173-180	false
cimetidine	drug	115-124	verografine	drug	157-167	mechanism
cimetidine	drug	115-124	iodamide	drug	173-180	mechanism
verografine	drug	157-167	iodamide	drug	173-180	false

DDI-MedLine.d68.s1	The higher verografine and iodamide excretion was due to their increased renal tubular secretion.
verografine	drug	11-21	iodamide	drug	27-34	false

DDI-MedLine.d68.s2	In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport.
cimetidine	drug	9-18	cardiotrast	drug	47-57	false

DDI-MedLine.d68.s3	Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
cimetidine	drug	44-53	verografine	drug	58-68	false
cimetidine	drug	44-53	iodamide	drug	74-81	false
verografine	drug	58-68	iodamide	drug	74-81	false

DDI-MedLine.d103.s1	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
magnesium	drug	36-44	magnesium	drug	75-83	false
magnesium	drug	36-44	magnesium	drug	144-152	false
magnesium	drug	36-44	magnesium	drug	193-201	false
magnesium	drug	36-44	magnesium	drug	230-238	false
magnesium	drug	36-44	magnesium	drug	302-310	false
magnesium	drug	75-83	magnesium	drug	144-152	false
magnesium	drug	75-83	magnesium	drug	193-201	false
magnesium	drug	75-83	magnesium	drug	230-238	false
magnesium	drug	75-83	magnesium	drug	302-310	false
magnesium	drug	144-152	magnesium	drug	193-201	false
magnesium	drug	144-152	magnesium	drug	230-238	false
magnesium	drug	144-152	magnesium	drug	302-310	false
magnesium	drug	193-201	magnesium	drug	230-238	false
magnesium	drug	193-201	magnesium	drug	302-310	false
magnesium	drug	230-238	magnesium	drug	302-310	false

DDI-MedLine.d103.s2	Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy.
magnesium	drug	22-30	magnesium	drug	98-106	false

DDI-MedLine.d103.s3	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.
magnesium	drug	94-102	magnesium	drug	140-148	false
magnesium	drug	94-102	magnesium	drug	184-192	false
magnesium	drug	94-102	magnesium	drug	260-268	false
magnesium	drug	94-102	magnesium	drug	336-344	false
magnesium	drug	140-148	magnesium	drug	184-192	false
magnesium	drug	140-148	magnesium	drug	260-268	false
magnesium	drug	140-148	magnesium	drug	336-344	false
magnesium	drug	184-192	magnesium	drug	260-268	false
magnesium	drug	184-192	magnesium	drug	336-344	false
magnesium	drug	260-268	magnesium	drug	336-344	false

DDI-MedLine.d103.s4	Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment.
magnesium	drug	19-27	magnesium	drug	77-85	false

DDI-MedLine.d103.s5	Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure.
magnesium	drug	19-27	magnesium salt	drug	110-123	false

DDI-MedLine.d103.s6	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.
magnesium	drug	37-45	magnesium sparing diuretics	group	86-112	false
magnesium	drug	37-45	vitamin B6	drug	140-149	false
magnesium	drug	37-45	vitamin D	group	175-183	false
magnesium	drug	37-45	selenium	drug	192-199	false
magnesium sparing diuretics	group	86-112	vitamin B6	drug	140-149	false
magnesium sparing diuretics	group	86-112	vitamin D	group	175-183	false
magnesium sparing diuretics	group	86-112	selenium	drug	192-199	false
vitamin B6	drug	140-149	vitamin D	group	175-183	false
vitamin B6	drug	140-149	selenium	drug	192-199	false
vitamin D	group	175-183	selenium	drug	192-199	false

DDI-MedLine.d103.s8	There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).
magnesium	drug	79-87	magnesium	drug	155-163	false

DDI-MedLine.d103.s15	Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.
magnesium	drug	71-79	cardioplegic solutions	drug	100-121	false

DDI-MedLine.d20.s0	Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
glycine	drug	20-26	glutamate	drug	32-40	effect

DDI-MedLine.d20.s4	The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
glycine	drug	30-36	glutamate	drug	75-83	effect
glycine	drug	30-36	glutamate	drug	246-254	false
glutamate	drug	75-83	glutamate	drug	246-254	false

DDI-MedLine.d94.s11	The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium.
isoproterenol	drug	20-32	norepinephrine	drug	64-77	false

DDI-MedLine.d94.s12	The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
cocaine	drug	22-28	desipramine	drug	34-44	false
cocaine	drug	22-28	norepinephrine	drug	108-121	effect
desipramine	drug	34-44	norepinephrine	drug	108-121	effect

DDI-MedLine.d94.s13	Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
mazindol	drug	70-77	norepinephrine	drug	135-148	false

DDI-MedLine.d94.s16	This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only.
cocaine	drug	99-105	desipramine	drug	111-121	false

DDI-MedLine.d94.s17	Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine.
norepinephrine	drug	12-25	cocaine	drug	90-96	false
norepinephrine	drug	12-25	desipramine	drug	102-112	false
cocaine	drug	90-96	desipramine	drug	102-112	false

DDI-MedLine.d14.s0	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion]

DDI-MedLine.d14.s0	Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion.
angiotensin	drug_n	45-55	angiotensin 1	drug_n	184-196	false
angiotensin	drug_n	45-55	angiotensin 2	drug_n	202-214	false
angiotensin	drug_n	45-55	pentagastrin	drug	219-230	false
angiotensin	drug_n	45-55	histamine	drug	237-245	false
angiotensin 1	drug_n	184-196	angiotensin 2	drug_n	202-214	false
angiotensin 1	drug_n	184-196	pentagastrin	drug	219-230	false
angiotensin 1	drug_n	184-196	histamine	drug	237-245	false
angiotensin 2	drug_n	202-214	pentagastrin	drug	219-230	false
angiotensin 2	drug_n	202-214	histamine	drug	237-245	false
pentagastrin	drug	219-230	histamine	drug	237-245	false

DDI-MedLine.d14.s1	It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine.
pentagastrin	drug	89-100	histamine	drug	113-121	false

DDI-MedLine.d14.s2	Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.
angiotensins	drug_n	127-138	angiotensin	drug_n	167-177	false

DDI-DrugBank.d429.s0	Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
Antacids	group	0-7	kaolin	drug	13-18	false
Antacids	group	0-7	Antacids	group	21-28	false
Antacids	group	0-7	kaolin	drug	34-39	false
Antacids	group	0-7	chloroquine	drug	66-76	false
kaolin	drug	13-18	Antacids	group	21-28	false
kaolin	drug	13-18	kaolin	drug	34-39	false
kaolin	drug	13-18	chloroquine	drug	66-76	false
Antacids	group	21-28	kaolin	drug	34-39	false
Antacids	group	21-28	chloroquine	drug	66-76	mechanism
kaolin	drug	34-39	chloroquine	drug	66-76	mechanism

DDI-DrugBank.d429.s2	Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	chloroquine	drug	53-63	false
Cimetidine	drug	12-21	chloroquine	drug	53-63	mechanism

DDI-DrugBank.d429.s4	Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
Ampicillin	drug	0-9	chloroquine	drug	46-56	false
Ampicillin	drug	0-9	ampicillin	drug	103-112	false
chloroquine	drug	46-56	ampicillin	drug	103-112	mechanism

DDI-DrugBank.d429.s6	Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
Cyclosporin	drug	0-10	chloroquine	drug	35-45	false
Cyclosporin	drug	0-10	cyclosporin	drug	87-97	false
chloroquine	drug	35-45	cyclosporin	drug	87-97	mechanism

DDI-DrugBank.d429.s7	Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.
cyclosporin	drug	37-47	chloroquine	drug	89-99	false

DDI-DrugBank.d46.s1	- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur
Alcohol	drug	2-8	barbiturates	group	11-22	false
Alcohol	drug	2-8	narcotics	group	28-36	false
barbiturates	group	11-22	narcotics	group	28-36	false

DDI-DrugBank.d46.s3	- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required
Antidiabetic drugs	group	2-19	insulin	drug	39-45	false
Antidiabetic drugs	group	2-19	antidiabetic drug	group	73-89	false
insulin	drug	39-45	antidiabetic drug	group	73-89	false

DDI-DrugBank.d46.s7	- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
Cholestyramine	drug	2-15	colestipol	drug	21-30	false
Cholestyramine	drug	2-15	resins	group	32-37	false
Cholestyramine	drug	2-15	Cholestytamine	drug	40-53	false
Cholestyramine	drug	2-15	colestipol	drug	59-68	false
Cholestyramine	drug	2-15	resins	group	70-75	false
Cholestyramine	drug	2-15	thiazide diuretics	group	107-124	false
Cholestyramine	drug	2-15	diuretic	group	139-146	false
colestipol	drug	21-30	resins	group	32-37	false
colestipol	drug	21-30	Cholestytamine	drug	40-53	false
colestipol	drug	21-30	colestipol	drug	59-68	false
colestipol	drug	21-30	resins	group	70-75	false
colestipol	drug	21-30	thiazide diuretics	group	107-124	false
colestipol	drug	21-30	diuretic	group	139-146	false
resins	group	32-37	Cholestytamine	drug	40-53	false
resins	group	32-37	colestipol	drug	59-68	false
resins	group	32-37	resins	group	70-75	false
resins	group	32-37	thiazide diuretics	group	107-124	false
resins	group	32-37	diuretic	group	139-146	false
Cholestytamine	drug	40-53	colestipol	drug	59-68	false
Cholestytamine	drug	40-53	resins	group	70-75	false
Cholestytamine	drug	40-53	thiazide diuretics	group	107-124	mechanism
Cholestytamine	drug	40-53	diuretic	group	139-146	false
colestipol	drug	59-68	resins	group	70-75	false
colestipol	drug	59-68	thiazide diuretics	group	107-124	mechanism
colestipol	drug	59-68	diuretic	group	139-146	false
resins	group	70-75	thiazide diuretics	group	107-124	false
resins	group	70-75	diuretic	group	139-146	false
thiazide diuretics	group	107-124	diuretic	group	139-146	false

DDI-DrugBank.d46.s9	- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia
Corticosteroids	group	2-16	ACTH	drug	19-22	false

DDI-DrugBank.d46.s13	- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant
Skeletal muscle relaxants	group	2-26	tubocurarine	drug	52-63	false
Skeletal muscle relaxants	group	2-26	muscle relaxant	group	108-122	false
tubocurarine	drug	52-63	muscle relaxant	group	108-122	false

DDI-DrugBank.d46.s15	- Lithium: Generally should not be given with diuretics.
Lithium	drug	2-8	diuretics	group	46-54	advise

DDI-DrugBank.d46.s16	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Diuretic agents	group	0-14	lithium	drug	46-52	mechanism
Diuretic agents	group	0-14	lithium	drug	77-83	mechanism
lithium	drug	46-52	lithium	drug	77-83	false

DDI-DrugBank.d46.s17	Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
lithium	drug	32-38	chlorothiazide	drug	90-103	advise

DDI-DrugBank.d46.s19	- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
Non-steroidal Anti-inflammatory Drugs	group	2-38	non-steroidal anti-inflammatory agent	group	83-119	false
Non-steroidal Anti-inflammatory Drugs	group	2-38	loop diuretics	group	191-194;228-236	false
Non-steroidal Anti-inflammatory Drugs	group	2-38	potassium-sparing diuretics	group	197-213;228-236	false
Non-steroidal Anti-inflammatory Drugs	group	2-38	thiazide diuretics	drug	219-236	false
non-steroidal anti-inflammatory agent	group	83-119	loop diuretics	group	191-194;228-236	effect
non-steroidal anti-inflammatory agent	group	83-119	potassium-sparing diuretics	group	197-213;228-236	effect
non-steroidal anti-inflammatory agent	group	83-119	thiazide diuretics	drug	219-236	effect
loop diuretics	group	191-194;228-236	potassium-sparing diuretics	group	197-213;228-236	false
loop diuretics	group	191-194;228-236	thiazide diuretics	drug	219-236	false
potassium-sparing diuretics	group	197-213;228-236	thiazide diuretics	drug	219-236	false

DDI-DrugBank.d46.s20	Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
chlorothiazide	drug	16-29	non-steroidal anti-inflammatory agents	group	35-72	advise
chlorothiazide	drug	16-29	diuretic	group	179-186	false
non-steroidal anti-inflammatory agents	group	35-72	diuretic	group	179-186	false

DDI-DrugBank.d446.s0	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
Chlorotrianisene	drug	0-15	antidepressants	group	35-49	int
Chlorotrianisene	drug	0-15	aspirin	brand	52-58	int
Chlorotrianisene	drug	0-15	barbiturates	group	61-72	int
Chlorotrianisene	drug	0-15	bromocriptine	drug	75-87	int
Chlorotrianisene	drug	0-15	calcium	drug	90-96	int
Chlorotrianisene	drug	0-15	corticosteroids	group	111-125	int
Chlorotrianisene	drug	0-15	corticotropin	drug	128-140	int
Chlorotrianisene	drug	0-15	cyclosporine	drug	143-154	int
Chlorotrianisene	drug	0-15	dantrolene	drug	157-166	int
Chlorotrianisene	drug	0-15	nicotine	drug	169-176	int
Chlorotrianisene	drug	0-15	somatropin	drug	179-188	int
Chlorotrianisene	drug	0-15	tamoxifen	drug	191-199	int
Chlorotrianisene	drug	0-15	warfarin	drug	206-213	int
antidepressants	group	35-49	aspirin	brand	52-58	false
antidepressants	group	35-49	barbiturates	group	61-72	false
antidepressants	group	35-49	bromocriptine	drug	75-87	false
antidepressants	group	35-49	calcium	drug	90-96	false
antidepressants	group	35-49	corticosteroids	group	111-125	false
antidepressants	group	35-49	corticotropin	drug	128-140	false
antidepressants	group	35-49	cyclosporine	drug	143-154	false
antidepressants	group	35-49	dantrolene	drug	157-166	false
antidepressants	group	35-49	nicotine	drug	169-176	false
antidepressants	group	35-49	somatropin	drug	179-188	false
antidepressants	group	35-49	tamoxifen	drug	191-199	false
antidepressants	group	35-49	warfarin	drug	206-213	false
aspirin	brand	52-58	barbiturates	group	61-72	false
aspirin	brand	52-58	bromocriptine	drug	75-87	false
aspirin	brand	52-58	calcium	drug	90-96	false
aspirin	brand	52-58	corticosteroids	group	111-125	false
aspirin	brand	52-58	corticotropin	drug	128-140	false
aspirin	brand	52-58	cyclosporine	drug	143-154	false
aspirin	brand	52-58	dantrolene	drug	157-166	false
aspirin	brand	52-58	nicotine	drug	169-176	false
aspirin	brand	52-58	somatropin	drug	179-188	false
aspirin	brand	52-58	tamoxifen	drug	191-199	false
aspirin	brand	52-58	warfarin	drug	206-213	false
barbiturates	group	61-72	bromocriptine	drug	75-87	false
barbiturates	group	61-72	calcium	drug	90-96	false
barbiturates	group	61-72	corticosteroids	group	111-125	false
barbiturates	group	61-72	corticotropin	drug	128-140	false
barbiturates	group	61-72	cyclosporine	drug	143-154	false
barbiturates	group	61-72	dantrolene	drug	157-166	false
barbiturates	group	61-72	nicotine	drug	169-176	false
barbiturates	group	61-72	somatropin	drug	179-188	false
barbiturates	group	61-72	tamoxifen	drug	191-199	false
barbiturates	group	61-72	warfarin	drug	206-213	false
bromocriptine	drug	75-87	calcium	drug	90-96	false
bromocriptine	drug	75-87	corticosteroids	group	111-125	false
bromocriptine	drug	75-87	corticotropin	drug	128-140	false
bromocriptine	drug	75-87	cyclosporine	drug	143-154	false
bromocriptine	drug	75-87	dantrolene	drug	157-166	false
bromocriptine	drug	75-87	nicotine	drug	169-176	false
bromocriptine	drug	75-87	somatropin	drug	179-188	false
bromocriptine	drug	75-87	tamoxifen	drug	191-199	false
bromocriptine	drug	75-87	warfarin	drug	206-213	false
calcium	drug	90-96	corticosteroids	group	111-125	false
calcium	drug	90-96	corticotropin	drug	128-140	false
calcium	drug	90-96	cyclosporine	drug	143-154	false
calcium	drug	90-96	dantrolene	drug	157-166	false
calcium	drug	90-96	nicotine	drug	169-176	false
calcium	drug	90-96	somatropin	drug	179-188	false
calcium	drug	90-96	tamoxifen	drug	191-199	false
calcium	drug	90-96	warfarin	drug	206-213	false
corticosteroids	group	111-125	corticotropin	drug	128-140	false
corticosteroids	group	111-125	cyclosporine	drug	143-154	false
corticosteroids	group	111-125	dantrolene	drug	157-166	false
corticosteroids	group	111-125	nicotine	drug	169-176	false
corticosteroids	group	111-125	somatropin	drug	179-188	false
corticosteroids	group	111-125	tamoxifen	drug	191-199	false
corticosteroids	group	111-125	warfarin	drug	206-213	false
corticotropin	drug	128-140	cyclosporine	drug	143-154	false
corticotropin	drug	128-140	dantrolene	drug	157-166	false
corticotropin	drug	128-140	nicotine	drug	169-176	false
corticotropin	drug	128-140	somatropin	drug	179-188	false
corticotropin	drug	128-140	tamoxifen	drug	191-199	false
corticotropin	drug	128-140	warfarin	drug	206-213	false
cyclosporine	drug	143-154	dantrolene	drug	157-166	false
cyclosporine	drug	143-154	nicotine	drug	169-176	false
cyclosporine	drug	143-154	somatropin	drug	179-188	false
cyclosporine	drug	143-154	tamoxifen	drug	191-199	false
cyclosporine	drug	143-154	warfarin	drug	206-213	false
dantrolene	drug	157-166	nicotine	drug	169-176	false
dantrolene	drug	157-166	somatropin	drug	179-188	false
dantrolene	drug	157-166	tamoxifen	drug	191-199	false
dantrolene	drug	157-166	warfarin	drug	206-213	false
nicotine	drug	169-176	somatropin	drug	179-188	false
nicotine	drug	169-176	tamoxifen	drug	191-199	false
nicotine	drug	169-176	warfarin	drug	206-213	false
somatropin	drug	179-188	tamoxifen	drug	191-199	false
somatropin	drug	179-188	warfarin	drug	206-213	false
tamoxifen	drug	191-199	warfarin	drug	206-213	false

DDI-DrugBank.d235.s2	Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.
CNS depressants	group	37-51	MAO inhibitors	group	54-67	false
CNS depressants	group	37-51	tricyclic antidepressants	group	70-94	false
CNS depressants	group	37-51	phenothiazines	group	97-110	false
MAO inhibitors	group	54-67	tricyclic antidepressants	group	70-94	false
MAO inhibitors	group	54-67	phenothiazines	group	97-110	false
tricyclic antidepressants	group	70-94	phenothiazines	group	97-110	false

DDI-DrugBank.d235.s4	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
azole antifungals	group	27-43	ciprofloxacin	drug	46-58	false
azole antifungals	group	27-43	clarithromycin	drug	61-74	false
azole antifungals	group	27-43	diclofenac	drug	77-86	false
azole antifungals	group	27-43	doxycycline	drug	89-99	false
azole antifungals	group	27-43	erythromycin	drug	102-113	false
azole antifungals	group	27-43	imatinib	drug	116-123	false
azole antifungals	group	27-43	isoniazid	drug	126-134	false
azole antifungals	group	27-43	nefazodone	drug	137-146	false
azole antifungals	group	27-43	nicardipine	drug	149-159	false
azole antifungals	group	27-43	propofol	drug	162-169	false
azole antifungals	group	27-43	protease inhibitors	group	172-190	false
azole antifungals	group	27-43	quinidine	drug	193-201	false
azole antifungals	group	27-43	verapamil	drug	208-216	false
ciprofloxacin	drug	46-58	clarithromycin	drug	61-74	false
ciprofloxacin	drug	46-58	diclofenac	drug	77-86	false
ciprofloxacin	drug	46-58	doxycycline	drug	89-99	false
ciprofloxacin	drug	46-58	erythromycin	drug	102-113	false
ciprofloxacin	drug	46-58	imatinib	drug	116-123	false
ciprofloxacin	drug	46-58	isoniazid	drug	126-134	false
ciprofloxacin	drug	46-58	nefazodone	drug	137-146	false
ciprofloxacin	drug	46-58	nicardipine	drug	149-159	false
ciprofloxacin	drug	46-58	propofol	drug	162-169	false
ciprofloxacin	drug	46-58	protease inhibitors	group	172-190	false
ciprofloxacin	drug	46-58	quinidine	drug	193-201	false
ciprofloxacin	drug	46-58	verapamil	drug	208-216	false
clarithromycin	drug	61-74	diclofenac	drug	77-86	false
clarithromycin	drug	61-74	doxycycline	drug	89-99	false
clarithromycin	drug	61-74	erythromycin	drug	102-113	false
clarithromycin	drug	61-74	imatinib	drug	116-123	false
clarithromycin	drug	61-74	isoniazid	drug	126-134	false
clarithromycin	drug	61-74	nefazodone	drug	137-146	false
clarithromycin	drug	61-74	nicardipine	drug	149-159	false
clarithromycin	drug	61-74	propofol	drug	162-169	false
clarithromycin	drug	61-74	protease inhibitors	group	172-190	false
clarithromycin	drug	61-74	quinidine	drug	193-201	false
clarithromycin	drug	61-74	verapamil	drug	208-216	false
diclofenac	drug	77-86	doxycycline	drug	89-99	false
diclofenac	drug	77-86	erythromycin	drug	102-113	false
diclofenac	drug	77-86	imatinib	drug	116-123	false
diclofenac	drug	77-86	isoniazid	drug	126-134	false
diclofenac	drug	77-86	nefazodone	drug	137-146	false
diclofenac	drug	77-86	nicardipine	drug	149-159	false
diclofenac	drug	77-86	propofol	drug	162-169	false
diclofenac	drug	77-86	protease inhibitors	group	172-190	false
diclofenac	drug	77-86	quinidine	drug	193-201	false
diclofenac	drug	77-86	verapamil	drug	208-216	false
doxycycline	drug	89-99	erythromycin	drug	102-113	false
doxycycline	drug	89-99	imatinib	drug	116-123	false
doxycycline	drug	89-99	isoniazid	drug	126-134	false
doxycycline	drug	89-99	nefazodone	drug	137-146	false
doxycycline	drug	89-99	nicardipine	drug	149-159	false
doxycycline	drug	89-99	propofol	drug	162-169	false
doxycycline	drug	89-99	protease inhibitors	group	172-190	false
doxycycline	drug	89-99	quinidine	drug	193-201	false
doxycycline	drug	89-99	verapamil	drug	208-216	false
erythromycin	drug	102-113	imatinib	drug	116-123	false
erythromycin	drug	102-113	isoniazid	drug	126-134	false
erythromycin	drug	102-113	nefazodone	drug	137-146	false
erythromycin	drug	102-113	nicardipine	drug	149-159	false
erythromycin	drug	102-113	propofol	drug	162-169	false
erythromycin	drug	102-113	protease inhibitors	group	172-190	false
erythromycin	drug	102-113	quinidine	drug	193-201	false
erythromycin	drug	102-113	verapamil	drug	208-216	false
imatinib	drug	116-123	isoniazid	drug	126-134	false
imatinib	drug	116-123	nefazodone	drug	137-146	false
imatinib	drug	116-123	nicardipine	drug	149-159	false
imatinib	drug	116-123	propofol	drug	162-169	false
imatinib	drug	116-123	protease inhibitors	group	172-190	false
imatinib	drug	116-123	quinidine	drug	193-201	false
imatinib	drug	116-123	verapamil	drug	208-216	false
isoniazid	drug	126-134	nefazodone	drug	137-146	false
isoniazid	drug	126-134	nicardipine	drug	149-159	false
isoniazid	drug	126-134	propofol	drug	162-169	false
isoniazid	drug	126-134	protease inhibitors	group	172-190	false
isoniazid	drug	126-134	quinidine	drug	193-201	false
isoniazid	drug	126-134	verapamil	drug	208-216	false
nefazodone	drug	137-146	nicardipine	drug	149-159	false
nefazodone	drug	137-146	propofol	drug	162-169	false
nefazodone	drug	137-146	protease inhibitors	group	172-190	false
nefazodone	drug	137-146	quinidine	drug	193-201	false
nefazodone	drug	137-146	verapamil	drug	208-216	false
nicardipine	drug	149-159	propofol	drug	162-169	false
nicardipine	drug	149-159	protease inhibitors	group	172-190	false
nicardipine	drug	149-159	quinidine	drug	193-201	false
nicardipine	drug	149-159	verapamil	drug	208-216	false
propofol	drug	162-169	protease inhibitors	group	172-190	false
propofol	drug	162-169	quinidine	drug	193-201	false
propofol	drug	162-169	verapamil	drug	208-216	false
protease inhibitors	group	172-190	quinidine	drug	193-201	false
protease inhibitors	group	172-190	verapamil	drug	208-216	false
quinidine	drug	193-201	verapamil	drug	208-216	false

DDI-DrugBank.d86.s0	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
antipsychotic drug	group	82-99	chlorpromazine	drug	106-119	false
antipsychotic drug	group	82-99	antiparkinsonian drug	group	126-146	effect
antipsychotic drug	group	82-99	trihexyphenidyl	drug	153-167	effect
antipsychotic drug	group	82-99	tricyclic antidepressant	group	180-203	effect
antipsychotic drug	group	82-99	amitriptyline	drug	210-222	effect
chlorpromazine	drug	106-119	antiparkinsonian drug	group	126-146	effect
chlorpromazine	drug	106-119	trihexyphenidyl	drug	153-167	effect
chlorpromazine	drug	106-119	tricyclic antidepressant	group	180-203	effect
chlorpromazine	drug	106-119	amitriptyline	drug	210-222	effect
antiparkinsonian drug	group	126-146	trihexyphenidyl	drug	153-167	false
antiparkinsonian drug	group	126-146	tricyclic antidepressant	group	180-203	effect
antiparkinsonian drug	group	126-146	amitriptyline	drug	210-222	effect
trihexyphenidyl	drug	153-167	tricyclic antidepressant	group	180-203	effect
trihexyphenidyl	drug	153-167	amitriptyline	drug	210-222	effect
tricyclic antidepressant	group	180-203	amitriptyline	drug	210-222	false

DDI-DrugBank.d86.s1	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
anti-depressants	group	48-63	anti-anxiety drugs	group	65-82	false
anti-depressants	group	48-63	beta-blockers	group	128-140	false
anti-depressants	group	48-63	propranolol	drug	149-159	false
anti-depressants	group	48-63	sparfloxacin	drug	163-174	false
anti-depressants	group	48-63	grepafloxacin	drug	177-189	false
anti-depressants	group	48-63	guanethidine	drug	192-203	false
anti-depressants	group	48-63	guanadrel	drug	206-214	false
anti-depressants	group	48-63	metrizamide	drug	217-227	false
anti-depressants	group	48-63	cabergoline	drug	230-240	false
anti-depressants	group	48-63	lithium	drug	243-249	false
anti-depressants	group	48-63	narcotic	group	252-259	false
anti-depressants	group	48-63	codeine	drug	284-290	false
anti-depressants	group	48-63	antihistamines	group	338-351	false
anti-depressants	group	48-63	diphenhydramine	drug	360-374	false
anti-anxiety drugs	group	65-82	beta-blockers	group	128-140	false
anti-anxiety drugs	group	65-82	propranolol	drug	149-159	false
anti-anxiety drugs	group	65-82	sparfloxacin	drug	163-174	false
anti-anxiety drugs	group	65-82	grepafloxacin	drug	177-189	false
anti-anxiety drugs	group	65-82	guanethidine	drug	192-203	false
anti-anxiety drugs	group	65-82	guanadrel	drug	206-214	false
anti-anxiety drugs	group	65-82	metrizamide	drug	217-227	false
anti-anxiety drugs	group	65-82	cabergoline	drug	230-240	false
anti-anxiety drugs	group	65-82	lithium	drug	243-249	false
anti-anxiety drugs	group	65-82	narcotic	group	252-259	false
anti-anxiety drugs	group	65-82	codeine	drug	284-290	false
anti-anxiety drugs	group	65-82	antihistamines	group	338-351	false
anti-anxiety drugs	group	65-82	diphenhydramine	drug	360-374	false
beta-blockers	group	128-140	propranolol	drug	149-159	false
beta-blockers	group	128-140	sparfloxacin	drug	163-174	false
beta-blockers	group	128-140	grepafloxacin	drug	177-189	false
beta-blockers	group	128-140	guanethidine	drug	192-203	false
beta-blockers	group	128-140	guanadrel	drug	206-214	false
beta-blockers	group	128-140	metrizamide	drug	217-227	false
beta-blockers	group	128-140	cabergoline	drug	230-240	false
beta-blockers	group	128-140	lithium	drug	243-249	false
beta-blockers	group	128-140	narcotic	group	252-259	false
beta-blockers	group	128-140	codeine	drug	284-290	false
beta-blockers	group	128-140	antihistamines	group	338-351	false
beta-blockers	group	128-140	diphenhydramine	drug	360-374	false
propranolol	drug	149-159	sparfloxacin	drug	163-174	false
propranolol	drug	149-159	grepafloxacin	drug	177-189	false
propranolol	drug	149-159	guanethidine	drug	192-203	false
propranolol	drug	149-159	guanadrel	drug	206-214	false
propranolol	drug	149-159	metrizamide	drug	217-227	false
propranolol	drug	149-159	cabergoline	drug	230-240	false
propranolol	drug	149-159	lithium	drug	243-249	false
propranolol	drug	149-159	narcotic	group	252-259	false
propranolol	drug	149-159	codeine	drug	284-290	false
propranolol	drug	149-159	antihistamines	group	338-351	false
propranolol	drug	149-159	diphenhydramine	drug	360-374	false
sparfloxacin	drug	163-174	grepafloxacin	drug	177-189	false
sparfloxacin	drug	163-174	guanethidine	drug	192-203	false
sparfloxacin	drug	163-174	guanadrel	drug	206-214	false
sparfloxacin	drug	163-174	metrizamide	drug	217-227	false
sparfloxacin	drug	163-174	cabergoline	drug	230-240	false
sparfloxacin	drug	163-174	lithium	drug	243-249	false
sparfloxacin	drug	163-174	narcotic	group	252-259	false
sparfloxacin	drug	163-174	codeine	drug	284-290	false
sparfloxacin	drug	163-174	antihistamines	group	338-351	false
sparfloxacin	drug	163-174	diphenhydramine	drug	360-374	false
grepafloxacin	drug	177-189	guanethidine	drug	192-203	false
grepafloxacin	drug	177-189	guanadrel	drug	206-214	false
grepafloxacin	drug	177-189	metrizamide	drug	217-227	false
grepafloxacin	drug	177-189	cabergoline	drug	230-240	false
grepafloxacin	drug	177-189	lithium	drug	243-249	false
grepafloxacin	drug	177-189	narcotic	group	252-259	false
grepafloxacin	drug	177-189	codeine	drug	284-290	false
grepafloxacin	drug	177-189	antihistamines	group	338-351	false
grepafloxacin	drug	177-189	diphenhydramine	drug	360-374	false
guanethidine	drug	192-203	guanadrel	drug	206-214	false
guanethidine	drug	192-203	metrizamide	drug	217-227	false
guanethidine	drug	192-203	cabergoline	drug	230-240	false
guanethidine	drug	192-203	lithium	drug	243-249	false
guanethidine	drug	192-203	narcotic	group	252-259	false
guanethidine	drug	192-203	codeine	drug	284-290	false
guanethidine	drug	192-203	antihistamines	group	338-351	false
guanethidine	drug	192-203	diphenhydramine	drug	360-374	false
guanadrel	drug	206-214	metrizamide	drug	217-227	false
guanadrel	drug	206-214	cabergoline	drug	230-240	false
guanadrel	drug	206-214	lithium	drug	243-249	false
guanadrel	drug	206-214	narcotic	group	252-259	false
guanadrel	drug	206-214	codeine	drug	284-290	false
guanadrel	drug	206-214	antihistamines	group	338-351	false
guanadrel	drug	206-214	diphenhydramine	drug	360-374	false
metrizamide	drug	217-227	cabergoline	drug	230-240	false
metrizamide	drug	217-227	lithium	drug	243-249	false
metrizamide	drug	217-227	narcotic	group	252-259	false
metrizamide	drug	217-227	codeine	drug	284-290	false
metrizamide	drug	217-227	antihistamines	group	338-351	false
metrizamide	drug	217-227	diphenhydramine	drug	360-374	false
cabergoline	drug	230-240	lithium	drug	243-249	false
cabergoline	drug	230-240	narcotic	group	252-259	false
cabergoline	drug	230-240	codeine	drug	284-290	false
cabergoline	drug	230-240	antihistamines	group	338-351	false
cabergoline	drug	230-240	diphenhydramine	drug	360-374	false
lithium	drug	243-249	narcotic	group	252-259	false
lithium	drug	243-249	codeine	drug	284-290	false
lithium	drug	243-249	antihistamines	group	338-351	false
lithium	drug	243-249	diphenhydramine	drug	360-374	false
narcotic	group	252-259	codeine	drug	284-290	false
narcotic	group	252-259	antihistamines	group	338-351	false
narcotic	group	252-259	diphenhydramine	drug	360-374	false
codeine	drug	284-290	antihistamines	group	338-351	false
codeine	drug	284-290	diphenhydramine	drug	360-374	false
antihistamines	group	338-351	diphenhydramine	drug	360-374	false

DDI-DrugBank.d245.s0	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylurea	group	27-38	nonsteroidal anti-inflammatory agents	group	86-122	effect
sulfonylurea	group	27-38	salicylates	group	171-181	effect
sulfonylurea	group	27-38	sulfonamides	group	184-195	effect
sulfonylurea	group	27-38	chloramphenicol	drug	198-212	effect
sulfonylurea	group	27-38	probenecid	drug	215-224	effect
sulfonylurea	group	27-38	coumarins	group	227-235	effect
sulfonylurea	group	27-38	monoamine oxidase inhibitors	group	238-265	effect
sulfonylurea	group	27-38	beta adrenergic blocking agents	group	272-302	effect
nonsteroidal anti-inflammatory agents	group	86-122	salicylates	group	171-181	false
nonsteroidal anti-inflammatory agents	group	86-122	sulfonamides	group	184-195	false
nonsteroidal anti-inflammatory agents	group	86-122	chloramphenicol	drug	198-212	false
nonsteroidal anti-inflammatory agents	group	86-122	probenecid	drug	215-224	false
nonsteroidal anti-inflammatory agents	group	86-122	coumarins	group	227-235	false
nonsteroidal anti-inflammatory agents	group	86-122	monoamine oxidase inhibitors	group	238-265	false
nonsteroidal anti-inflammatory agents	group	86-122	beta adrenergic blocking agents	group	272-302	false
salicylates	group	171-181	sulfonamides	group	184-195	false
salicylates	group	171-181	chloramphenicol	drug	198-212	false
salicylates	group	171-181	probenecid	drug	215-224	false
salicylates	group	171-181	coumarins	group	227-235	false
salicylates	group	171-181	monoamine oxidase inhibitors	group	238-265	false
salicylates	group	171-181	beta adrenergic blocking agents	group	272-302	false
sulfonamides	group	184-195	chloramphenicol	drug	198-212	false
sulfonamides	group	184-195	probenecid	drug	215-224	false
sulfonamides	group	184-195	coumarins	group	227-235	false
sulfonamides	group	184-195	monoamine oxidase inhibitors	group	238-265	false
sulfonamides	group	184-195	beta adrenergic blocking agents	group	272-302	false
chloramphenicol	drug	198-212	probenecid	drug	215-224	false
chloramphenicol	drug	198-212	coumarins	group	227-235	false
chloramphenicol	drug	198-212	monoamine oxidase inhibitors	group	238-265	false
chloramphenicol	drug	198-212	beta adrenergic blocking agents	group	272-302	false
probenecid	drug	215-224	coumarins	group	227-235	false
probenecid	drug	215-224	monoamine oxidase inhibitors	group	238-265	false
probenecid	drug	215-224	beta adrenergic blocking agents	group	272-302	false
coumarins	group	227-235	monoamine oxidase inhibitors	group	238-265	false
coumarins	group	227-235	beta adrenergic blocking agents	group	272-302	false
monoamine oxidase inhibitors	group	238-265	beta adrenergic blocking agents	group	272-302	false

DDI-DrugBank.d245.s4	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
thiazides	group	24-32	diuretics	group	44-52	false
thiazides	group	24-32	corticosteroids	group	55-69	false
thiazides	group	24-32	phenothiazines	group	72-85	false
thiazides	group	24-32	estrogens	group	106-114	false
thiazides	group	24-32	contraceptives	group	122-135	false
thiazides	group	24-32	phenytoin	drug	138-146	false
thiazides	group	24-32	nicotinic acid	drug	149-162	false
thiazides	group	24-32	sympathomimetics	group	165-180	false
thiazides	group	24-32	calcium channel blocking drugs	group	183-212	false
thiazides	group	24-32	isoniazid	drug	219-227	false
diuretics	group	44-52	corticosteroids	group	55-69	false
diuretics	group	44-52	phenothiazines	group	72-85	false
diuretics	group	44-52	estrogens	group	106-114	false
diuretics	group	44-52	contraceptives	group	122-135	false
diuretics	group	44-52	phenytoin	drug	138-146	false
diuretics	group	44-52	nicotinic acid	drug	149-162	false
diuretics	group	44-52	sympathomimetics	group	165-180	false
diuretics	group	44-52	calcium channel blocking drugs	group	183-212	false
diuretics	group	44-52	isoniazid	drug	219-227	false
corticosteroids	group	55-69	phenothiazines	group	72-85	false
corticosteroids	group	55-69	estrogens	group	106-114	false
corticosteroids	group	55-69	contraceptives	group	122-135	false
corticosteroids	group	55-69	phenytoin	drug	138-146	false
corticosteroids	group	55-69	nicotinic acid	drug	149-162	false
corticosteroids	group	55-69	sympathomimetics	group	165-180	false
corticosteroids	group	55-69	calcium channel blocking drugs	group	183-212	false
corticosteroids	group	55-69	isoniazid	drug	219-227	false
phenothiazines	group	72-85	estrogens	group	106-114	false
phenothiazines	group	72-85	contraceptives	group	122-135	false
phenothiazines	group	72-85	phenytoin	drug	138-146	false
phenothiazines	group	72-85	nicotinic acid	drug	149-162	false
phenothiazines	group	72-85	sympathomimetics	group	165-180	false
phenothiazines	group	72-85	calcium channel blocking drugs	group	183-212	false
phenothiazines	group	72-85	isoniazid	drug	219-227	false
estrogens	group	106-114	contraceptives	group	122-135	false
estrogens	group	106-114	phenytoin	drug	138-146	false
estrogens	group	106-114	nicotinic acid	drug	149-162	false
estrogens	group	106-114	sympathomimetics	group	165-180	false
estrogens	group	106-114	calcium channel blocking drugs	group	183-212	false
estrogens	group	106-114	isoniazid	drug	219-227	false
contraceptives	group	122-135	phenytoin	drug	138-146	false
contraceptives	group	122-135	nicotinic acid	drug	149-162	false
contraceptives	group	122-135	sympathomimetics	group	165-180	false
contraceptives	group	122-135	calcium channel blocking drugs	group	183-212	false
contraceptives	group	122-135	isoniazid	drug	219-227	false
phenytoin	drug	138-146	nicotinic acid	drug	149-162	false
phenytoin	drug	138-146	sympathomimetics	group	165-180	false
phenytoin	drug	138-146	calcium channel blocking drugs	group	183-212	false
phenytoin	drug	138-146	isoniazid	drug	219-227	false
nicotinic acid	drug	149-162	sympathomimetics	group	165-180	false
nicotinic acid	drug	149-162	calcium channel blocking drugs	group	183-212	false
nicotinic acid	drug	149-162	isoniazid	drug	219-227	false
sympathomimetics	group	165-180	calcium channel blocking drugs	group	183-212	false
sympathomimetics	group	165-180	isoniazid	drug	219-227	false
calcium channel blocking drugs	group	183-212	isoniazid	drug	219-227	false

DDI-DrugBank.d245.s7	Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
barbiturates	group	48-59	chlorpropamide	drug	94-107	effect
barbiturates	group	48-59	barbiturates	group	110-121	false
chlorpropamide	drug	94-107	barbiturates	group	110-121	false

DDI-DrugBank.d245.s8	In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.
disulfiram	drug	20-29	alcohol	drug	81-87	false

DDI-DrugBank.d245.s9	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	drug	37-46	hypoglycemic agents	group	57-75	effect

DDI-DrugBank.d503.s0	Chlorprothixene may increase the plasma-level of concomitantly given lithium.
Chlorprothixene	drug	0-14	lithium	drug	69-75	mechanism

DDI-DrugBank.d503.s1	In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.
lithium	drug	18-24	lithium	drug	40-46	false

DDI-DrugBank.d503.s2	If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
chlorprothixene	drug	3-17	opioids	group	47-53	advise
chlorprothixene	drug	3-17	opioid	group	60-65	false
chlorprothixene	drug	3-17	chlorprothixene	drug	116-130	false
chlorprothixene	drug	3-17	opioids	group	186-192	false
opioids	group	47-53	opioid	group	60-65	false
opioids	group	47-53	chlorprothixene	drug	116-130	false
opioids	group	47-53	opioids	group	186-192	false
opioid	group	60-65	chlorprothixene	drug	116-130	false
opioid	group	60-65	opioids	group	186-192	false
chlorprothixene	drug	116-130	opioids	group	186-192	effect

DDI-DrugBank.d503.s3	Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
chlorprothixene	drug	29-43	tramadol	drug	49-56	advise
chlorprothixene	drug	29-43	Ultram	brand	59-64	advise
tramadol	drug	49-56	Ultram	brand	59-64	false

DDI-DrugBank.d503.s5	Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
chlorprothixene	drug	72-86	benzodiazepines	group	102-116	effect
chlorprothixene	drug	72-86	barbituates	group	121-131	effect
benzodiazepines	group	102-116	barbituates	group	121-131	false

DDI-DrugBank.d503.s7	Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
chlorprothixene	drug	38-52	anticholinergic drugs	group	65-85	advise
chlorprothixene	drug	38-52	tricyclic antidepressants	group	88-112	advise
chlorprothixene	drug	38-52	antiparkinsonian agents	group	118-140	advise
anticholinergic drugs	group	65-85	tricyclic antidepressants	group	88-112	false
anticholinergic drugs	group	65-85	antiparkinsonian agents	group	118-140	false
tricyclic antidepressants	group	88-112	antiparkinsonian agents	group	118-140	false

DDI-DrugBank.d265.s0	Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
Chlorthalidone	drug	0-13	antihypertensive drugs	group	60-81	effect

DDI-DrugBank.d265.s7	Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
Chlorthalidone	drug	0-13	tubocurarine	drug	68-79	effect

DDI-DrugBank.d265.s8	Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
Chlorthalidone	drug	0-13	norepinephrine	drug	73-86	effect

DDI-DrugBank.d262.s0	The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
alcohol	drug	23-29	central nervous system depressants	group	40-73	false

DDI-DrugBank.d404.s0	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D	group	17-25	Vitamin D2	drug	38-47	false
vitamin D	group	17-25	Vitamin D3	drug	50-59	false
vitamin D	group	17-25	Calcitriol	drug	62-71	false
vitamin D	group	17-25	Calcidiol	drug	78-86	false
vitamin D	group	17-25	Cholestyramine	drug	90-103	false
vitamin D	group	17-25	Cholestyramine	drug	106-119	false
vitamin D	group	17-25	fat soluble vitamins	group	174-193	false
Vitamin D2	drug	38-47	Vitamin D3	drug	50-59	false
Vitamin D2	drug	38-47	Calcitriol	drug	62-71	false
Vitamin D2	drug	38-47	Calcidiol	drug	78-86	false
Vitamin D2	drug	38-47	Cholestyramine	drug	90-103	false
Vitamin D2	drug	38-47	Cholestyramine	drug	106-119	false
Vitamin D2	drug	38-47	fat soluble vitamins	group	174-193	false
Vitamin D3	drug	50-59	Calcitriol	drug	62-71	false
Vitamin D3	drug	50-59	Calcidiol	drug	78-86	false
Vitamin D3	drug	50-59	Cholestyramine	drug	90-103	false
Vitamin D3	drug	50-59	Cholestyramine	drug	106-119	false
Vitamin D3	drug	50-59	fat soluble vitamins	group	174-193	false
Calcitriol	drug	62-71	Calcidiol	drug	78-86	false
Calcitriol	drug	62-71	Cholestyramine	drug	90-103	false
Calcitriol	drug	62-71	Cholestyramine	drug	106-119	false
Calcitriol	drug	62-71	fat soluble vitamins	group	174-193	false
Calcidiol	drug	78-86	Cholestyramine	drug	90-103	false
Calcidiol	drug	78-86	Cholestyramine	drug	106-119	false
Calcidiol	drug	78-86	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	90-103	Cholestyramine	drug	106-119	false
Cholestyramine	drug	90-103	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	106-119	fat soluble vitamins	group	174-193	mechanism

DDI-DrugBank.d404.s2	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	drug	0-8	Phenobarbital	drug	10-22	false
Phenytoin	drug	0-8	phenytoin	drug	49-57	false
Phenytoin	drug	0-8	phenobarbital	drug	62-74	false
Phenytoin	drug	0-8	vitamin D	group	117-125	false
Phenytoin	drug	0-8	calcitriol	drug	171-180	false
Phenobarbital	drug	10-22	phenytoin	drug	49-57	false
Phenobarbital	drug	10-22	phenobarbital	drug	62-74	false
Phenobarbital	drug	10-22	vitamin D	group	117-125	false
Phenobarbital	drug	10-22	calcitriol	drug	171-180	false
phenytoin	drug	49-57	phenobarbital	drug	62-74	false
phenytoin	drug	49-57	vitamin D	group	117-125	false
phenytoin	drug	49-57	calcitriol	drug	171-180	false
phenobarbital	drug	62-74	vitamin D	group	117-125	false
phenobarbital	drug	62-74	calcitriol	drug	171-180	false
vitamin D	group	117-125	calcitriol	drug	171-180	false

DDI-DrugBank.d404.s3	Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	drug	21-30	Rocaltrol	brand	80-88	false

DDI-DrugBank.d404.s4	Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	group	0-8	Thiazides	group	11-19	false

DDI-DrugBank.d404.s5	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	group	63-71	vitamin D	group	78-86	effect

DDI-DrugBank.d404.s7	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	group	0-8	Vitamin D	group	11-19	false
Digitalis	group	0-8	digitalis	group	95-103	false
Vitamin D	group	11-19	digitalis	group	95-103	advise

DDI-DrugBank.d404.s8	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	vitamin D	group	79-87	false
Ketoconazole	drug	14-25	vitamin D	group	79-87	mechanism

DDI-DrugBank.d404.s10	However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	drug	45-56	vitamin D	group	63-71	false

DDI-DrugBank.d404.s11	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	group	0-14	vitamin D	group	72-80	false
Corticosteroids	group	0-14	corticosteroids	group	131-145	false
vitamin D	group	72-80	corticosteroids	group	131-145	effect

DDI-DrugBank.d404.s13	Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	group	0-8	vitamin D	group	46-54	false

DDI-DrugBank.d404.s14	Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	drug	0-6	calcium	drug	55-61	false

DDI-DrugBank.d404.s15	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	drug	0-8	Magnesium	drug	11-19	false
Magnesium	drug	0-8	antacids	group	50-57	false
Magnesium	drug	0-8	vitamin D	group	140-148	false
Magnesium	drug	11-19	antacids	group	50-57	false
Magnesium	drug	11-19	vitamin D	group	140-148	effect
antacids	group	50-57	vitamin D	group	140-148	effect

DDI-DrugBank.d566.s0	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
Cholestyramine	drug	0-13	resin	group	15-19	false
Cholestyramine	drug	0-13	phenylbutazone	group	95-108	mechanism
Cholestyramine	drug	0-13	warfarin	drug	111-118	mechanism
Cholestyramine	drug	0-13	thiazide diuretics	group	121-138	mechanism
Cholestyramine	drug	0-13	propranolol	drug	152-162	mechanism
Cholestyramine	drug	0-13	tetracycline	drug	184-195	mechanism
Cholestyramine	drug	0-13	penicillin G	drug	197-208	mechanism
Cholestyramine	drug	0-13	phenobarbital	drug	211-223	mechanism
Cholestyramine	drug	0-13	thyroxine	drug	238-246	mechanism
Cholestyramine	drug	0-13	estrogens	group	262-270	mechanism
Cholestyramine	drug	0-13	progestins	group	276-285	mechanism
Cholestyramine	drug	0-13	digitalis	group	292-300	mechanism
resin	group	15-19	phenylbutazone	group	95-108	false
resin	group	15-19	warfarin	drug	111-118	false
resin	group	15-19	thiazide diuretics	group	121-138	false
resin	group	15-19	propranolol	drug	152-162	false
resin	group	15-19	tetracycline	drug	184-195	false
resin	group	15-19	penicillin G	drug	197-208	false
resin	group	15-19	phenobarbital	drug	211-223	false
resin	group	15-19	thyroxine	drug	238-246	false
resin	group	15-19	estrogens	group	262-270	false
resin	group	15-19	progestins	group	276-285	false
resin	group	15-19	digitalis	group	292-300	false
phenylbutazone	group	95-108	warfarin	drug	111-118	false
phenylbutazone	group	95-108	thiazide diuretics	group	121-138	false
phenylbutazone	group	95-108	propranolol	drug	152-162	false
phenylbutazone	group	95-108	tetracycline	drug	184-195	false
phenylbutazone	group	95-108	penicillin G	drug	197-208	false
phenylbutazone	group	95-108	phenobarbital	drug	211-223	false
phenylbutazone	group	95-108	thyroxine	drug	238-246	false
phenylbutazone	group	95-108	estrogens	group	262-270	false
phenylbutazone	group	95-108	progestins	group	276-285	false
phenylbutazone	group	95-108	digitalis	group	292-300	false
warfarin	drug	111-118	thiazide diuretics	group	121-138	false
warfarin	drug	111-118	propranolol	drug	152-162	false
warfarin	drug	111-118	tetracycline	drug	184-195	false
warfarin	drug	111-118	penicillin G	drug	197-208	false
warfarin	drug	111-118	phenobarbital	drug	211-223	false
warfarin	drug	111-118	thyroxine	drug	238-246	false
warfarin	drug	111-118	estrogens	group	262-270	false
warfarin	drug	111-118	progestins	group	276-285	false
warfarin	drug	111-118	digitalis	group	292-300	false
thiazide diuretics	group	121-138	propranolol	drug	152-162	false
thiazide diuretics	group	121-138	tetracycline	drug	184-195	false
thiazide diuretics	group	121-138	penicillin G	drug	197-208	false
thiazide diuretics	group	121-138	phenobarbital	drug	211-223	false
thiazide diuretics	group	121-138	thyroxine	drug	238-246	false
thiazide diuretics	group	121-138	estrogens	group	262-270	false
thiazide diuretics	group	121-138	progestins	group	276-285	false
thiazide diuretics	group	121-138	digitalis	group	292-300	false
propranolol	drug	152-162	tetracycline	drug	184-195	false
propranolol	drug	152-162	penicillin G	drug	197-208	false
propranolol	drug	152-162	phenobarbital	drug	211-223	false
propranolol	drug	152-162	thyroxine	drug	238-246	false
propranolol	drug	152-162	estrogens	group	262-270	false
propranolol	drug	152-162	progestins	group	276-285	false
propranolol	drug	152-162	digitalis	group	292-300	false
tetracycline	drug	184-195	penicillin G	drug	197-208	false
tetracycline	drug	184-195	phenobarbital	drug	211-223	false
tetracycline	drug	184-195	thyroxine	drug	238-246	false
tetracycline	drug	184-195	estrogens	group	262-270	false
tetracycline	drug	184-195	progestins	group	276-285	false
tetracycline	drug	184-195	digitalis	group	292-300	false
penicillin G	drug	197-208	phenobarbital	drug	211-223	false
penicillin G	drug	197-208	thyroxine	drug	238-246	false
penicillin G	drug	197-208	estrogens	group	262-270	false
penicillin G	drug	197-208	progestins	group	276-285	false
penicillin G	drug	197-208	digitalis	group	292-300	false
phenobarbital	drug	211-223	thyroxine	drug	238-246	false
phenobarbital	drug	211-223	estrogens	group	262-270	false
phenobarbital	drug	211-223	progestins	group	276-285	false
phenobarbital	drug	211-223	digitalis	group	292-300	false
thyroxine	drug	238-246	estrogens	group	262-270	false
thyroxine	drug	238-246	progestins	group	276-285	false
thyroxine	drug	238-246	digitalis	group	292-300	false
estrogens	group	262-270	progestins	group	276-285	false
estrogens	group	262-270	digitalis	group	292-300	false
progestins	group	276-285	digitalis	group	292-300	false

DDI-DrugBank.d566.s2	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
Cholestyramine	drug	0-13	resin	group	15-19	false
Cholestyramine	drug	0-13	cholestyramine	drug	132-145	false
Cholestyramine	drug	0-13	resin	group	147-151	false
Cholestyramine	drug	0-13	digitalis	group	219-227	false
Cholestyramine	drug	0-13	cholestyramine	drug	300-313	false
Cholestyramine	drug	0-13	resin	group	315-319	false
resin	group	15-19	cholestyramine	drug	132-145	false
resin	group	15-19	resin	group	147-151	false
resin	group	15-19	digitalis	group	219-227	false
resin	group	15-19	cholestyramine	drug	300-313	false
resin	group	15-19	resin	group	315-319	false
cholestyramine	drug	132-145	resin	group	147-151	false
cholestyramine	drug	132-145	digitalis	group	219-227	mechanism
cholestyramine	drug	132-145	cholestyramine	drug	300-313	false
cholestyramine	drug	132-145	resin	group	315-319	false
resin	group	147-151	digitalis	group	219-227	false
resin	group	147-151	cholestyramine	drug	300-313	false
resin	group	147-151	resin	group	315-319	false
digitalis	group	219-227	cholestyramine	drug	300-313	false
digitalis	group	219-227	resin	group	315-319	false
cholestyramine	drug	300-313	resin	group	315-319	false

DDI-DrugBank.d566.s3	Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.
cholestyramine	drug	8-21	cholestyramine	drug	41-54	false
cholestyramine	drug	8-21	resin	group	56-60	false
cholestyramine	drug	8-21	fat soluble vitamins	group	152-171	false
cholestyramine	drug	41-54	resin	group	56-60	false
cholestyramine	drug	41-54	fat soluble vitamins	group	152-171	false
resin	group	56-60	fat soluble vitamins	group	152-171	false

DDI-DrugBank.d566.s4	When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.
cholestyramine	drug	5-18	resin	group	20-24	false
cholestyramine	drug	5-18	fat-soluble vitamins	group	134-153	false
resin	group	20-24	fat-soluble vitamins	group	134-153	false

DDI-DrugBank.d566.s5	SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
CHOLESTYRAMINE	drug	6-19	RESIN	group	21-25	false
CHOLESTYRAMINE	drug	6-19	CHOLESTYRAMINE	drug	162-175	false
CHOLESTYRAMINE	drug	6-19	RESIN	group	177-181	false
RESIN	group	21-25	CHOLESTYRAMINE	drug	162-175	false
RESIN	group	21-25	RESIN	group	177-181	false
CHOLESTYRAMINE	drug	162-175	RESIN	group	177-181	false

DDI-DrugBank.d362.s2	In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.
des-ciclesonide	drug	65-79	warfarin	drug	101-108	false
des-ciclesonide	drug	65-79	salicylic acid	drug	113-126	false
warfarin	drug	101-108	salicylic acid	drug	113-126	false

DDI-DrugBank.d362.s3	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.
ciclesonide	drug	65-75	erythromycin	drug	86-97	false
ciclesonide	drug	65-75	des-ciclesonide	drug	185-199	false
ciclesonide	drug	65-75	erythromycin	drug	204-215	false
erythromycin	drug	86-97	des-ciclesonide	drug	185-199	false
erythromycin	drug	86-97	erythromycin	drug	204-215	false
des-ciclesonide	drug	185-199	erythromycin	drug	204-215	false

DDI-DrugBank.d362.s4	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
ciclesonide	drug	71-81	ketoconazole	drug	92-103	mechanism
ciclesonide	drug	71-81	des-ciclesonide	drug	181-195	false
ciclesonide	drug	71-81	ciclesonide	drug	256-266	false
ketoconazole	drug	92-103	des-ciclesonide	drug	181-195	false
ketoconazole	drug	92-103	ciclesonide	drug	256-266	false
des-ciclesonide	drug	181-195	ciclesonide	drug	256-266	false

DDI-DrugBank.d362.s5	Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
ketoconazole	drug	11-22	ciclesonide	drug	76-86	advise

DDI-DrugBank.d260.s0	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
Probenecid	drug	0-9	Probenecid	drug	13-22	false
Probenecid	drug	0-9	acetaminophen	drug	113-125	false
Probenecid	drug	0-9	acyclovir	drug	128-136	false
Probenecid	drug	0-9	angiotensin-converting enzyme inhibitors	group	139-178	false
Probenecid	drug	0-9	aminosalicylic acid	drug	181-199	false
Probenecid	drug	0-9	barbiturates	group	202-213	false
Probenecid	drug	0-9	benzodiazepines	group	216-230	false
Probenecid	drug	0-9	bumetanide	drug	233-242	false
Probenecid	drug	0-9	clofibrate	drug	245-254	false
Probenecid	drug	0-9	methotrexate	drug	257-268	false
Probenecid	drug	0-9	famotidine	drug	271-280	false
Probenecid	drug	0-9	furosemide	drug	283-292	false
Probenecid	drug	0-9	nonsteroidal anti-inflammatory	group	295-324	false
Probenecid	drug	0-9	theophylline	drug	334-345	false
Probenecid	drug	0-9	zidovudine	drug	352-361	false
Probenecid	drug	13-22	acetaminophen	drug	113-125	mechanism
Probenecid	drug	13-22	acyclovir	drug	128-136	mechanism
Probenecid	drug	13-22	angiotensin-converting enzyme inhibitors	group	139-178	mechanism
Probenecid	drug	13-22	aminosalicylic acid	drug	181-199	mechanism
Probenecid	drug	13-22	barbiturates	group	202-213	mechanism
Probenecid	drug	13-22	benzodiazepines	group	216-230	mechanism
Probenecid	drug	13-22	bumetanide	drug	233-242	mechanism
Probenecid	drug	13-22	clofibrate	drug	245-254	mechanism
Probenecid	drug	13-22	methotrexate	drug	257-268	mechanism
Probenecid	drug	13-22	famotidine	drug	271-280	mechanism
Probenecid	drug	13-22	furosemide	drug	283-292	mechanism
Probenecid	drug	13-22	nonsteroidal anti-inflammatory	group	295-324	mechanism
Probenecid	drug	13-22	theophylline	drug	334-345	mechanism
Probenecid	drug	13-22	zidovudine	drug	352-361	mechanism
acetaminophen	drug	113-125	acyclovir	drug	128-136	false
acetaminophen	drug	113-125	angiotensin-converting enzyme inhibitors	group	139-178	false
acetaminophen	drug	113-125	aminosalicylic acid	drug	181-199	false
acetaminophen	drug	113-125	barbiturates	group	202-213	false
acetaminophen	drug	113-125	benzodiazepines	group	216-230	false
acetaminophen	drug	113-125	bumetanide	drug	233-242	false
acetaminophen	drug	113-125	clofibrate	drug	245-254	false
acetaminophen	drug	113-125	methotrexate	drug	257-268	false
acetaminophen	drug	113-125	famotidine	drug	271-280	false
acetaminophen	drug	113-125	furosemide	drug	283-292	false
acetaminophen	drug	113-125	nonsteroidal anti-inflammatory	group	295-324	false
acetaminophen	drug	113-125	theophylline	drug	334-345	false
acetaminophen	drug	113-125	zidovudine	drug	352-361	false
acyclovir	drug	128-136	angiotensin-converting enzyme inhibitors	group	139-178	false
acyclovir	drug	128-136	aminosalicylic acid	drug	181-199	false
acyclovir	drug	128-136	barbiturates	group	202-213	false
acyclovir	drug	128-136	benzodiazepines	group	216-230	false
acyclovir	drug	128-136	bumetanide	drug	233-242	false
acyclovir	drug	128-136	clofibrate	drug	245-254	false
acyclovir	drug	128-136	methotrexate	drug	257-268	false
acyclovir	drug	128-136	famotidine	drug	271-280	false
acyclovir	drug	128-136	furosemide	drug	283-292	false
acyclovir	drug	128-136	nonsteroidal anti-inflammatory	group	295-324	false
acyclovir	drug	128-136	theophylline	drug	334-345	false
acyclovir	drug	128-136	zidovudine	drug	352-361	false
angiotensin-converting enzyme inhibitors	group	139-178	aminosalicylic acid	drug	181-199	false
angiotensin-converting enzyme inhibitors	group	139-178	barbiturates	group	202-213	false
angiotensin-converting enzyme inhibitors	group	139-178	benzodiazepines	group	216-230	false
angiotensin-converting enzyme inhibitors	group	139-178	bumetanide	drug	233-242	false
angiotensin-converting enzyme inhibitors	group	139-178	clofibrate	drug	245-254	false
angiotensin-converting enzyme inhibitors	group	139-178	methotrexate	drug	257-268	false
angiotensin-converting enzyme inhibitors	group	139-178	famotidine	drug	271-280	false
angiotensin-converting enzyme inhibitors	group	139-178	furosemide	drug	283-292	false
angiotensin-converting enzyme inhibitors	group	139-178	nonsteroidal anti-inflammatory	group	295-324	false
angiotensin-converting enzyme inhibitors	group	139-178	theophylline	drug	334-345	false
angiotensin-converting enzyme inhibitors	group	139-178	zidovudine	drug	352-361	false
aminosalicylic acid	drug	181-199	barbiturates	group	202-213	false
aminosalicylic acid	drug	181-199	benzodiazepines	group	216-230	false
aminosalicylic acid	drug	181-199	bumetanide	drug	233-242	false
aminosalicylic acid	drug	181-199	clofibrate	drug	245-254	false
aminosalicylic acid	drug	181-199	methotrexate	drug	257-268	false
aminosalicylic acid	drug	181-199	famotidine	drug	271-280	false
aminosalicylic acid	drug	181-199	furosemide	drug	283-292	false
aminosalicylic acid	drug	181-199	nonsteroidal anti-inflammatory	group	295-324	false
aminosalicylic acid	drug	181-199	theophylline	drug	334-345	false
aminosalicylic acid	drug	181-199	zidovudine	drug	352-361	false
barbiturates	group	202-213	benzodiazepines	group	216-230	false
barbiturates	group	202-213	bumetanide	drug	233-242	false
barbiturates	group	202-213	clofibrate	drug	245-254	false
barbiturates	group	202-213	methotrexate	drug	257-268	false
barbiturates	group	202-213	famotidine	drug	271-280	false
barbiturates	group	202-213	furosemide	drug	283-292	false
barbiturates	group	202-213	nonsteroidal anti-inflammatory	group	295-324	false
barbiturates	group	202-213	theophylline	drug	334-345	false
barbiturates	group	202-213	zidovudine	drug	352-361	false
benzodiazepines	group	216-230	bumetanide	drug	233-242	false
benzodiazepines	group	216-230	clofibrate	drug	245-254	false
benzodiazepines	group	216-230	methotrexate	drug	257-268	false
benzodiazepines	group	216-230	famotidine	drug	271-280	false
benzodiazepines	group	216-230	furosemide	drug	283-292	false
benzodiazepines	group	216-230	nonsteroidal anti-inflammatory	group	295-324	false
benzodiazepines	group	216-230	theophylline	drug	334-345	false
benzodiazepines	group	216-230	zidovudine	drug	352-361	false
bumetanide	drug	233-242	clofibrate	drug	245-254	false
bumetanide	drug	233-242	methotrexate	drug	257-268	false
bumetanide	drug	233-242	famotidine	drug	271-280	false
bumetanide	drug	233-242	furosemide	drug	283-292	false
bumetanide	drug	233-242	nonsteroidal anti-inflammatory	group	295-324	false
bumetanide	drug	233-242	theophylline	drug	334-345	false
bumetanide	drug	233-242	zidovudine	drug	352-361	false
clofibrate	drug	245-254	methotrexate	drug	257-268	false
clofibrate	drug	245-254	famotidine	drug	271-280	false
clofibrate	drug	245-254	furosemide	drug	283-292	false
clofibrate	drug	245-254	nonsteroidal anti-inflammatory	group	295-324	false
clofibrate	drug	245-254	theophylline	drug	334-345	false
clofibrate	drug	245-254	zidovudine	drug	352-361	false
methotrexate	drug	257-268	famotidine	drug	271-280	false
methotrexate	drug	257-268	furosemide	drug	283-292	false
methotrexate	drug	257-268	nonsteroidal anti-inflammatory	group	295-324	false
methotrexate	drug	257-268	theophylline	drug	334-345	false
methotrexate	drug	257-268	zidovudine	drug	352-361	false
famotidine	drug	271-280	furosemide	drug	283-292	false
famotidine	drug	271-280	nonsteroidal anti-inflammatory	group	295-324	false
famotidine	drug	271-280	theophylline	drug	334-345	false
famotidine	drug	271-280	zidovudine	drug	352-361	false
furosemide	drug	283-292	nonsteroidal anti-inflammatory	group	295-324	false
furosemide	drug	283-292	theophylline	drug	334-345	false
furosemide	drug	283-292	zidovudine	drug	352-361	false
nonsteroidal anti-inflammatory	group	295-324	theophylline	drug	334-345	false
nonsteroidal anti-inflammatory	group	295-324	zidovudine	drug	352-361	false
theophylline	drug	334-345	zidovudine	drug	352-361	false

DDI-DrugBank.d260.s2	Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
Zidovudine	drug	0-9	probenecid	drug	98-107	advise
Zidovudine	drug	0-9	VISTIDE	brand	123-129	false
probenecid	drug	98-107	VISTIDE	brand	123-129	false

DDI-DrugBank.d260.s3	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
VISTIDE	brand	51-57	aminoglycosides	group	116-130	advise
VISTIDE	brand	51-57	tobramycin	drug	139-148	advise
VISTIDE	brand	51-57	gentamicin	drug	151-160	advise
VISTIDE	brand	51-57	amikacin	drug	167-174	advise
VISTIDE	brand	51-57	amphotericin B	drug	178-191	advise
VISTIDE	brand	51-57	foscarnet	drug	194-202	advise
VISTIDE	brand	51-57	pentamidine	drug	217-227	advise
VISTIDE	brand	51-57	vancomycin	drug	230-239	advise
VISTIDE	brand	51-57	non-steroidal anti-inflammatory agents	group	246-283	advise
aminoglycosides	group	116-130	tobramycin	drug	139-148	false
aminoglycosides	group	116-130	gentamicin	drug	151-160	false
aminoglycosides	group	116-130	amikacin	drug	167-174	false
aminoglycosides	group	116-130	amphotericin B	drug	178-191	false
aminoglycosides	group	116-130	foscarnet	drug	194-202	false
aminoglycosides	group	116-130	pentamidine	drug	217-227	false
aminoglycosides	group	116-130	vancomycin	drug	230-239	false
aminoglycosides	group	116-130	non-steroidal anti-inflammatory agents	group	246-283	false
tobramycin	drug	139-148	gentamicin	drug	151-160	false
tobramycin	drug	139-148	amikacin	drug	167-174	false
tobramycin	drug	139-148	amphotericin B	drug	178-191	false
tobramycin	drug	139-148	foscarnet	drug	194-202	false
tobramycin	drug	139-148	pentamidine	drug	217-227	false
tobramycin	drug	139-148	vancomycin	drug	230-239	false
tobramycin	drug	139-148	non-steroidal anti-inflammatory agents	group	246-283	false
gentamicin	drug	151-160	amikacin	drug	167-174	false
gentamicin	drug	151-160	amphotericin B	drug	178-191	false
gentamicin	drug	151-160	foscarnet	drug	194-202	false
gentamicin	drug	151-160	pentamidine	drug	217-227	false
gentamicin	drug	151-160	vancomycin	drug	230-239	false
gentamicin	drug	151-160	non-steroidal anti-inflammatory agents	group	246-283	false
amikacin	drug	167-174	amphotericin B	drug	178-191	false
amikacin	drug	167-174	foscarnet	drug	194-202	false
amikacin	drug	167-174	pentamidine	drug	217-227	false
amikacin	drug	167-174	vancomycin	drug	230-239	false
amikacin	drug	167-174	non-steroidal anti-inflammatory agents	group	246-283	false
amphotericin B	drug	178-191	foscarnet	drug	194-202	false
amphotericin B	drug	178-191	pentamidine	drug	217-227	false
amphotericin B	drug	178-191	vancomycin	drug	230-239	false
amphotericin B	drug	178-191	non-steroidal anti-inflammatory agents	group	246-283	false
foscarnet	drug	194-202	pentamidine	drug	217-227	false
foscarnet	drug	194-202	vancomycin	drug	230-239	false
foscarnet	drug	194-202	non-steroidal anti-inflammatory agents	group	246-283	false
pentamidine	drug	217-227	vancomycin	drug	230-239	false
pentamidine	drug	217-227	non-steroidal anti-inflammatory agents	group	246-283	false
vancomycin	drug	230-239	non-steroidal anti-inflammatory agents	group	246-283	false

DDI-DrugBank.d358.s0	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
PLETAL	brand	6-11	PLETAL	brand	105-110	false
PLETAL	brand	6-11	ketoconazole	drug	164-175	false
PLETAL	brand	6-11	erythromycin	drug	181-192	false
PLETAL	brand	6-11	omeprazole	drug	227-236	false
PLETAL	brand	105-110	ketoconazole	drug	164-175	advise
PLETAL	brand	105-110	erythromycin	drug	181-192	advise
PLETAL	brand	105-110	omeprazole	drug	227-236	advise
ketoconazole	drug	164-175	erythromycin	drug	181-192	false
ketoconazole	drug	164-175	omeprazole	drug	227-236	false
erythromycin	drug	181-192	omeprazole	drug	227-236	false

DDI-DrugBank.d358.s1	Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
omeprazole	drug	47-56	erythromycin	drug	62-73	false
omeprazole	drug	47-56	cilostazol	drug	124-133	mechanism
erythromycin	drug	62-73	cilostazol	drug	124-133	mechanism

DDI-DrugBank.d358.s2	Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
cilostazol	drug	67-76	diltiazem	drug	119-127	mechanism

DDI-DrugBank.d358.s3	Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition.
Pletal	brand	0-5	lovastatin	drug	120-129	false

DDI-DrugBank.d171.s0	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
Tagamet	brand	0-6	warfarin-type anticoagulants	group	130-157	mechanism
Tagamet	brand	0-6	phenytoin	drug	160-168	mechanism
Tagamet	brand	0-6	propranolol	drug	171-181	mechanism
Tagamet	brand	0-6	nifedipine	drug	184-193	mechanism
Tagamet	brand	0-6	chlordiazepoxide	drug	196-211	mechanism
Tagamet	brand	0-6	diazepam	drug	214-221	mechanism
Tagamet	brand	0-6	tricyclic antidepressants	group	232-256	mechanism
Tagamet	brand	0-6	lidocaine	drug	259-267	mechanism
Tagamet	brand	0-6	theophylline	drug	270-281	mechanism
Tagamet	brand	0-6	metronidazole	drug	287-299	mechanism
warfarin-type anticoagulants	group	130-157	phenytoin	drug	160-168	false
warfarin-type anticoagulants	group	130-157	propranolol	drug	171-181	false
warfarin-type anticoagulants	group	130-157	nifedipine	drug	184-193	false
warfarin-type anticoagulants	group	130-157	chlordiazepoxide	drug	196-211	false
warfarin-type anticoagulants	group	130-157	diazepam	drug	214-221	false
warfarin-type anticoagulants	group	130-157	tricyclic antidepressants	group	232-256	false
warfarin-type anticoagulants	group	130-157	lidocaine	drug	259-267	false
warfarin-type anticoagulants	group	130-157	theophylline	drug	270-281	false
warfarin-type anticoagulants	group	130-157	metronidazole	drug	287-299	false
phenytoin	drug	160-168	propranolol	drug	171-181	false
phenytoin	drug	160-168	nifedipine	drug	184-193	false
phenytoin	drug	160-168	chlordiazepoxide	drug	196-211	false
phenytoin	drug	160-168	diazepam	drug	214-221	false
phenytoin	drug	160-168	tricyclic antidepressants	group	232-256	false
phenytoin	drug	160-168	lidocaine	drug	259-267	false
phenytoin	drug	160-168	theophylline	drug	270-281	false
phenytoin	drug	160-168	metronidazole	drug	287-299	false
propranolol	drug	171-181	nifedipine	drug	184-193	false
propranolol	drug	171-181	chlordiazepoxide	drug	196-211	false
propranolol	drug	171-181	diazepam	drug	214-221	false
propranolol	drug	171-181	tricyclic antidepressants	group	232-256	false
propranolol	drug	171-181	lidocaine	drug	259-267	false
propranolol	drug	171-181	theophylline	drug	270-281	false
propranolol	drug	171-181	metronidazole	drug	287-299	false
nifedipine	drug	184-193	chlordiazepoxide	drug	196-211	false
nifedipine	drug	184-193	diazepam	drug	214-221	false
nifedipine	drug	184-193	tricyclic antidepressants	group	232-256	false
nifedipine	drug	184-193	lidocaine	drug	259-267	false
nifedipine	drug	184-193	theophylline	drug	270-281	false
nifedipine	drug	184-193	metronidazole	drug	287-299	false
chlordiazepoxide	drug	196-211	diazepam	drug	214-221	false
chlordiazepoxide	drug	196-211	tricyclic antidepressants	group	232-256	false
chlordiazepoxide	drug	196-211	lidocaine	drug	259-267	false
chlordiazepoxide	drug	196-211	theophylline	drug	270-281	false
chlordiazepoxide	drug	196-211	metronidazole	drug	287-299	false
diazepam	drug	214-221	tricyclic antidepressants	group	232-256	false
diazepam	drug	214-221	lidocaine	drug	259-267	false
diazepam	drug	214-221	theophylline	drug	270-281	false
diazepam	drug	214-221	metronidazole	drug	287-299	false
tricyclic antidepressants	group	232-256	lidocaine	drug	259-267	false
tricyclic antidepressants	group	232-256	theophylline	drug	270-281	false
tricyclic antidepressants	group	232-256	metronidazole	drug	287-299	false
lidocaine	drug	259-267	theophylline	drug	270-281	false
lidocaine	drug	259-267	metronidazole	drug	287-299	false
theophylline	drug	270-281	metronidazole	drug	287-299	false

DDI-DrugBank.d171.s2	therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
anticoagulant	group	86-98	Tagamet	brand	127-133	advise

DDI-DrugBank.d171.s3	Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.
phenytoin	drug	17-25	lidocaine	drug	28-36	false
phenytoin	drug	17-25	theophylline	drug	42-53	false
lidocaine	drug	28-36	theophylline	drug	42-53	false

DDI-DrugBank.d171.s4	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
Tagamet	brand	64-70	theophylline	drug	146-157	mechanism
Tagamet	brand	64-70	Theo-Dur	brand	160-167	mechanism
Tagamet	brand	64-70	theophylline	drug	243-254	false
theophylline	drug	146-157	Theo-Dur	brand	160-167	false
theophylline	drug	146-157	theophylline	drug	243-254	false
Theo-Dur	brand	160-167	theophylline	drug	243-254	false

DDI-DrugBank.d512.s1	Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.
Sensipar	brand	10-17	Sensipar	brand	86-93	false

DDI-DrugBank.d512.s2	Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.
flecainide	drug	143-152	vinblastine	drug	155-165	false
flecainide	drug	143-152	thioridazine	drug	168-179	false
flecainide	drug	143-152	tricyclic antidepressants	group	190-214	false
vinblastine	drug	155-165	thioridazine	drug	168-179	false
vinblastine	drug	155-165	tricyclic antidepressants	group	190-214	false
thioridazine	drug	168-179	tricyclic antidepressants	group	190-214	false

DDI-DrugBank.d512.s3	Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
Amitriptyline	drug	0-12	cinacalcet	drug	60-69	false
Amitriptyline	drug	0-12	amitriptyline	drug	82-94	false
Amitriptyline	drug	0-12	amitriptyline	drug	106-118	false
Amitriptyline	drug	0-12	nortriptyline	drug_n	133-145	false
cinacalcet	drug	60-69	amitriptyline	drug	82-94	mechanism
cinacalcet	drug	60-69	amitriptyline	drug	106-118	false
cinacalcet	drug	60-69	nortriptyline	drug_n	133-145	false
amitriptyline	drug	82-94	amitriptyline	drug	106-118	false
amitriptyline	drug	82-94	nortriptyline	drug_n	133-145	false
amitriptyline	drug	106-118	nortriptyline	drug_n	133-145	false

DDI-DrugBank.d512.s4	Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.
Sensipar	brand	25-32	Sensipar	brand	36-43	false

DDI-DrugBank.d512.s5	Ketoconazole: Sensipar is metabolized in part by CYP3A4.
Ketoconazole	drug	0-11	Sensipar	brand	14-21	false

DDI-DrugBank.d512.s6	Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
ketoconazole	drug	21-32	cinacalcet	drug	75-84	mechanism
ketoconazole	drug	21-32	Sensipar	brand	128-135	false
cinacalcet	drug	75-84	Sensipar	brand	128-135	false

DDI-DrugBank.d512.s7	Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
Sensipar	brand	19-26	ketoconazole	drug	198-209	advise
Sensipar	brand	19-26	erythromycin	drug	212-223	advise
Sensipar	brand	19-26	itraconazole	drug	226-237	advise
ketoconazole	drug	198-209	erythromycin	drug	212-223	false
ketoconazole	drug	198-209	itraconazole	drug	226-237	false
erythromycin	drug	212-223	itraconazole	drug	226-237	false

DDI-DrugBank.d562.s0	Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
theophylline	drug	26-37	quinolones	group	87-96	mechanism

DDI-DrugBank.d562.s1	There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
theophylline	drug	27-38	theophylline	drug	88-99	false
theophylline	drug	27-38	quinolone	group	101-109	false
theophylline	drug	88-99	quinolone	group	101-109	effect

DDI-DrugBank.d562.s2	Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
theophylline	drug	25-36	theophylline	drug	87-98	false

DDI-DrugBank.d562.s3	Quinolones have also been shown to interfere with the metabolism of caffeine.
Quinolones	group	0-9	caffeine	drug	68-75	mechanism

DDI-DrugBank.d562.s5	Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
cinoxacin	drug	53-61	cinoxacin	drug	97-105	false
cinoxacin	drug	53-61	caffeine	drug	135-142	false
cinoxacin	drug	97-105	caffeine	drug	135-142	advise

DDI-DrugBank.d562.s6	Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
Antacids	group	0-7	sucralfate	drug	12-21	false
Antacids	group	0-7	quinolones	group	75-84	mechanism
sucralfate	drug	12-21	quinolones	group	75-84	mechanism

DDI-DrugBank.d562.s7	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
quinolones	group	36-45	iron	drug	72-75	mechanism
quinolones	group	36-45	multivitamins	group	78-90	false
quinolones	group	36-45	zinc	drug	103-106	mechanism
quinolones	group	36-45	Videx	brand	112-116	mechanism
quinolones	group	36-45	didanosine	drug	119-128	mechanism
iron	drug	72-75	multivitamins	group	78-90	false
iron	drug	72-75	zinc	drug	103-106	false
iron	drug	72-75	Videx	brand	112-116	false
iron	drug	72-75	didanosine	drug	119-128	false
multivitamins	group	78-90	zinc	drug	103-106	false
multivitamins	group	78-90	Videx	brand	112-116	false
multivitamins	group	78-90	didanosine	drug	119-128	false
zinc	drug	103-106	Videx	brand	112-116	false
zinc	drug	103-106	didanosine	drug	119-128	false
Videx	brand	112-116	didanosine	drug	119-128	false

DDI-DrugBank.d562.s8	Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
Quinolones	group	0-9	cinoxacin	drug	22-30	false
Quinolones	group	0-9	anticoagulants	group	65-78	effect
Quinolones	group	0-9	warfarin	drug	89-96	effect
cinoxacin	drug	22-30	anticoagulants	group	65-78	effect
cinoxacin	drug	22-30	warfarin	drug	89-96	effect
anticoagulants	group	65-78	warfarin	drug	89-96	false

DDI-DrugBank.d562.s10	Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
quinolone class antimicrobial	group	55-83	nonsteroidal anti-inflammatory drug	group	93-127	effect
quinolone class antimicrobial	group	55-83	fenbufen	drug	129-136	effect
nonsteroidal anti-inflammatory drug	group	93-127	fenbufen	drug	129-136	false

DDI-DrugBank.d562.s13	Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
cinoxacin	drug	110-118	nonsteroidal anti-inflammatory agents	group	132-168	advise

DDI-DrugBank.d562.s14	Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
cyclosporine	drug	9-20	quinolones	group	82-91	false
cyclosporine	drug	9-20	cyclosporine	drug	97-108	false
quinolones	group	82-91	cyclosporine	drug	97-108	mechanism

DDI-DrugBank.d123.s0	Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
quinolones	group	5-14	ciprofloxacin	drug	27-39	false
quinolones	group	5-14	caffeine	drug	99-106	mechanism
ciprofloxacin	drug	27-39	caffeine	drug	99-106	mechanism

DDI-DrugBank.d123.s2	Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
quinolones	group	5-14	ciprofloxacin	drug	27-39	false
quinolones	group	5-14	cyclosporine	drug	131-142	effect
ciprofloxacin	drug	27-39	cyclosporine	drug	131-142	effect

DDI-DrugBank.d123.s3	Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
Glyburide	drug	0-8	ciprofloxacin	drug	45-57	false
Glyburide	drug	0-8	sulfonylurea	group	68-79	false
Glyburide	drug	0-8	glyburide	drug	81-89	false
ciprofloxacin	drug	45-57	sulfonylurea	group	68-79	effect
ciprofloxacin	drug	45-57	glyburide	drug	81-89	effect
sulfonylurea	group	68-79	glyburide	drug	81-89	false

DDI-DrugBank.d123.s4	Histamine H2-receptor antagonists: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.
Histamine H2-receptor antagonists	group	0-32	Histamine H2-receptor antagonists	group	35-67	false
Histamine H2-receptor antagonists	group	0-32	ciprofloxacin	drug	132-144	false
Histamine H2-receptor antagonists	group	35-67	ciprofloxacin	drug	132-144	false

DDI-DrugBank.d123.s5	Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
Methotrexate	drug	0-11	methotrexate	drug	40-51	false
Methotrexate	drug	0-11	ciprofloxacin	drug	103-115	false
Methotrexate	drug	0-11	methotrexate	drug	168-179	false
methotrexate	drug	40-51	ciprofloxacin	drug	103-115	mechanism
methotrexate	drug	40-51	methotrexate	drug	168-179	false
ciprofloxacin	drug	103-115	methotrexate	drug	168-179	false

DDI-DrugBank.d123.s7	Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
methotrexate	drug	26-37	ciprofloxacin	drug	94-106	advise

DDI-DrugBank.d123.s8	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
quinolone	group	71-79	ciprofloxacin	drug	92-104	false
quinolone	group	71-79	magnesium	drug	159-167	mechanism
quinolone	group	71-79	aluminum	drug	172-179	mechanism
quinolone	group	71-79	antacids	group	181-188	mechanism
quinolone	group	71-79	sucralfate	drug	191-200	mechanism
quinolone	group	71-79	VIDEX	brand	203-207	mechanism
quinolone	group	71-79	calcium	drug	279-285	mechanism
quinolone	group	71-79	iron	drug	288-291	mechanism
quinolone	group	71-79	zinc	drug	297-300	mechanism
quinolone	group	71-79	ciprofloxacin	drug	347-359	false
ciprofloxacin	drug	92-104	magnesium	drug	159-167	mechanism
ciprofloxacin	drug	92-104	aluminum	drug	172-179	mechanism
ciprofloxacin	drug	92-104	antacids	group	181-188	mechanism
ciprofloxacin	drug	92-104	sucralfate	drug	191-200	mechanism
ciprofloxacin	drug	92-104	VIDEX	brand	203-207	mechanism
ciprofloxacin	drug	92-104	calcium	drug	279-285	mechanism
ciprofloxacin	drug	92-104	iron	drug	288-291	mechanism
ciprofloxacin	drug	92-104	zinc	drug	297-300	mechanism
ciprofloxacin	drug	92-104	ciprofloxacin	drug	347-359	mechanism
magnesium	drug	159-167	aluminum	drug	172-179	false
magnesium	drug	159-167	antacids	group	181-188	false
magnesium	drug	159-167	sucralfate	drug	191-200	false
magnesium	drug	159-167	VIDEX	brand	203-207	false
magnesium	drug	159-167	calcium	drug	279-285	false
magnesium	drug	159-167	iron	drug	288-291	false
magnesium	drug	159-167	zinc	drug	297-300	false
magnesium	drug	159-167	ciprofloxacin	drug	347-359	false
aluminum	drug	172-179	antacids	group	181-188	false
aluminum	drug	172-179	sucralfate	drug	191-200	false
aluminum	drug	172-179	VIDEX	brand	203-207	false
aluminum	drug	172-179	calcium	drug	279-285	false
aluminum	drug	172-179	iron	drug	288-291	false
aluminum	drug	172-179	zinc	drug	297-300	false
aluminum	drug	172-179	ciprofloxacin	drug	347-359	false
antacids	group	181-188	sucralfate	drug	191-200	false
antacids	group	181-188	VIDEX	brand	203-207	false
antacids	group	181-188	calcium	drug	279-285	false
antacids	group	181-188	iron	drug	288-291	false
antacids	group	181-188	zinc	drug	297-300	false
antacids	group	181-188	ciprofloxacin	drug	347-359	false
sucralfate	drug	191-200	VIDEX	brand	203-207	false
sucralfate	drug	191-200	calcium	drug	279-285	false
sucralfate	drug	191-200	iron	drug	288-291	false
sucralfate	drug	191-200	zinc	drug	297-300	false
sucralfate	drug	191-200	ciprofloxacin	drug	347-359	false
VIDEX	brand	203-207	calcium	drug	279-285	false
VIDEX	brand	203-207	iron	drug	288-291	false
VIDEX	brand	203-207	zinc	drug	297-300	false
VIDEX	brand	203-207	ciprofloxacin	drug	347-359	false
calcium	drug	279-285	iron	drug	288-291	false
calcium	drug	279-285	zinc	drug	297-300	false
calcium	drug	279-285	ciprofloxacin	drug	347-359	false
iron	drug	288-291	zinc	drug	297-300	false
iron	drug	288-291	ciprofloxacin	drug	347-359	false
zinc	drug	297-300	ciprofloxacin	drug	347-359	false

DDI-DrugBank.d123.s10	This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
ciprofloxacin	drug	66-78	antacids	group	144-151	advise

DDI-DrugBank.d123.s11	Non-steroidal anti-inflammatory drugs (but not aspirin): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
Non-steroidal anti-inflammatory drugs	group	0-36	aspirin	brand	47-53	false
Non-steroidal anti-inflammatory drugs	group	0-36	quinolones	group	108-117	false
aspirin	brand	47-53	quinolones	group	108-117	false

DDI-DrugBank.d123.s12	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
Omeprazole	drug	0-9	ciprofloxacin	drug	49-61	false
Omeprazole	drug	0-9	Proquin XR	brand	86-95	false
Omeprazole	drug	0-9	Proquin XR	brand	121-130	false
Omeprazole	drug	0-9	omeprazole	drug	156-165	false
ciprofloxacin	drug	49-61	Proquin XR	brand	86-95	false
ciprofloxacin	drug	49-61	Proquin XR	brand	121-130	false
ciprofloxacin	drug	49-61	omeprazole	drug	156-165	false
Proquin XR	brand	86-95	Proquin XR	brand	121-130	false
Proquin XR	brand	86-95	omeprazole	drug	156-165	false
Proquin XR	brand	121-130	omeprazole	drug	156-165	false

DDI-DrugBank.d123.s13	Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..
Omeprazole	drug	0-9	Proquin XR	brand	43-52	false

DDI-DrugBank.d123.s14	Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
Phenytoin	drug	0-8	phenytoin	drug	35-43	false
Phenytoin	drug	0-8	ciprofloxacin	drug	124-136	false
phenytoin	drug	35-43	ciprofloxacin	drug	124-136	mechanism

DDI-DrugBank.d123.s15	Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
Probenecid	drug	0-9	Probenecid	drug	12-21	false
Probenecid	drug	0-9	ciprofloxacin	drug	66-78	false
Probenecid	drug	0-9	ciprofloxacin	drug	121-133	false
Probenecid	drug	12-21	ciprofloxacin	drug	66-78	mechanism
Probenecid	drug	12-21	ciprofloxacin	drug	121-133	mechanism
ciprofloxacin	drug	66-78	ciprofloxacin	drug	121-133	false

DDI-DrugBank.d123.s16	Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
Theophylline	drug	0-11	quinolones	group	33-42	false
Theophylline	drug	0-11	ciprofloxacin	drug	74-86	false
Theophylline	drug	0-11	theophylline	drug	93-104	false
Theophylline	drug	0-11	theophylline	drug	151-162	false
quinolones	group	33-42	ciprofloxacin	drug	74-86	false
quinolones	group	33-42	theophylline	drug	93-104	mechanism
quinolones	group	33-42	theophylline	drug	151-162	false
ciprofloxacin	drug	74-86	theophylline	drug	93-104	mechanism
ciprofloxacin	drug	74-86	theophylline	drug	151-162	false
theophylline	drug	93-104	theophylline	drug	151-162	false

DDI-DrugBank.d123.s19	Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
Warfarin	drug	0-7	Quinolones	group	10-19	false
Warfarin	drug	0-7	anticoagulant	group	75-87	false
Warfarin	drug	0-7	warfarin	drug	89-96	false
Quinolones	group	10-19	anticoagulant	group	75-87	false
Quinolones	group	10-19	warfarin	drug	89-96	effect
anticoagulant	group	75-87	warfarin	drug	89-96	false

DDI-DrugBank.d237.s1	In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.
cisapride	drug	113-121	cisapride	drug	211-219	false

DDI-DrugBank.d237.s2	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antibiotics	group	0-10	clarithromycin	drug	52-65	false
Antibiotics	group	0-10	erythromycin	drug	68-79	false
Antibiotics	group	0-10	troleandomycin	drug	86-99	false
Antibiotics	group	0-10	cisapride	drug	136-144	false
Antibiotics	group	0-10	cisapride	drug	189-197	false
clarithromycin	drug	52-65	erythromycin	drug	68-79	false
clarithromycin	drug	52-65	troleandomycin	drug	86-99	false
clarithromycin	drug	52-65	cisapride	drug	136-144	mechanism
clarithromycin	drug	52-65	cisapride	drug	189-197	false
erythromycin	drug	68-79	troleandomycin	drug	86-99	false
erythromycin	drug	68-79	cisapride	drug	136-144	mechanism
erythromycin	drug	68-79	cisapride	drug	189-197	false
troleandomycin	drug	86-99	cisapride	drug	136-144	mechanism
troleandomycin	drug	86-99	cisapride	drug	189-197	false
cisapride	drug	136-144	cisapride	drug	189-197	false

DDI-DrugBank.d237.s3	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
Anticholinergics	group	0-15	anticholinergic compounds	group	55-79	false
Anticholinergics	group	0-15	belladonna alkaloids	group	90-109	false
Anticholinergics	group	0-15	dicyclomine	drug	115-125	false
Anticholinergics	group	0-15	cisapride	drug	186-194	false
anticholinergic compounds	group	55-79	belladonna alkaloids	group	90-109	false
anticholinergic compounds	group	55-79	dicyclomine	drug	115-125	false
anticholinergic compounds	group	55-79	cisapride	drug	186-194	effect
belladonna alkaloids	group	90-109	dicyclomine	drug	115-125	false
belladonna alkaloids	group	90-109	cisapride	drug	186-194	effect
dicyclomine	drug	115-125	cisapride	drug	186-194	effect

DDI-DrugBank.d237.s4	Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.
Anticoagulants	group	0-13	anticoagulants	group	50-63	false

DDI-DrugBank.d237.s5	It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
cisapride	drug	107-115	anticoagulant	group	164-176	advise

DDI-DrugBank.d237.s6	Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antidepressants	group	0-14	nefazodone	drug	45-54	false
Antidepressants	group	0-14	cisapride	drug	83-91	false
Antidepressants	group	0-14	cisapride	drug	136-144	false
nefazodone	drug	45-54	cisapride	drug	83-91	mechanism
nefazodone	drug	45-54	cisapride	drug	136-144	false
cisapride	drug	83-91	cisapride	drug	136-144	false

DDI-DrugBank.d237.s7	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antifungals	group	0-10	fluconazole	drug	56-66	false
Antifungals	group	0-10	itraconazole	drug	69-80	false
Antifungals	group	0-10	ketoconazole	drug	92-103	false
Antifungals	group	0-10	cisapride	drug	140-148	false
Antifungals	group	0-10	cisapride	drug	193-201	false
fluconazole	drug	56-66	itraconazole	drug	69-80	false
fluconazole	drug	56-66	ketoconazole	drug	92-103	false
fluconazole	drug	56-66	cisapride	drug	140-148	mechanism
fluconazole	drug	56-66	cisapride	drug	193-201	false
itraconazole	drug	69-80	ketoconazole	drug	92-103	false
itraconazole	drug	69-80	cisapride	drug	140-148	mechanism
itraconazole	drug	69-80	cisapride	drug	193-201	false
ketoconazole	drug	92-103	cisapride	drug	140-148	mechanism
ketoconazole	drug	92-103	cisapride	drug	193-201	false
cisapride	drug	140-148	cisapride	drug	193-201	false

DDI-DrugBank.d237.s8	Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
ketoconazole	drug	46-57	cisapride	drug	95-103	mechanism
ketoconazole	drug	46-57	cisapride	drug	156-164	false
cisapride	drug	95-103	cisapride	drug	156-164	false

DDI-DrugBank.d237.s9	A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
cisapride	drug	82-90	ketoconazole	drug	96-107	effect

DDI-DrugBank.d237.s10	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
H2 Receptor Antagonists	group	0-22	Cimetidine	drug	25-34	false
H2 Receptor Antagonists	group	0-22	cisapride	drug	112-120	false
H2 Receptor Antagonists	group	0-22	cisapride	drug	145-153	false
H2 Receptor Antagonists	group	0-22	ranitidine	drug	197-206	false
Cimetidine	drug	25-34	cisapride	drug	112-120	mechanism
Cimetidine	drug	25-34	cisapride	drug	145-153	false
Cimetidine	drug	25-34	ranitidine	drug	197-206	false
cisapride	drug	112-120	cisapride	drug	145-153	false
cisapride	drug	112-120	ranitidine	drug	197-206	false
cisapride	drug	145-153	ranitidine	drug	197-206	false

DDI-DrugBank.d237.s11	The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
cimetidine	drug	35-44	ranitidine	drug	50-59	false
cimetidine	drug	35-44	cisapride	drug	110-118	mechanism
ranitidine	drug	50-59	cisapride	drug	110-118	mechanism

DDI-DrugBank.d237.s12	Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Protease Inhibitors	group	0-18	indinavir	drug	49-57	false
Protease Inhibitors	group	0-18	ritonavir	drug	63-71	false
Protease Inhibitors	group	0-18	cisapride	drug	108-116	false
Protease Inhibitors	group	0-18	cisapride	drug	160-168	false
indinavir	drug	49-57	ritonavir	drug	63-71	false
indinavir	drug	49-57	cisapride	drug	108-116	mechanism
indinavir	drug	49-57	cisapride	drug	160-168	false
ritonavir	drug	63-71	cisapride	drug	108-116	mechanism
ritonavir	drug	63-71	cisapride	drug	160-168	false
cisapride	drug	108-116	cisapride	drug	160-168	false

DDI-DrugBank.d237.s13	Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.
cisapride	drug	49-57	cisapride	drug	92-100	false

DDI-DrugBank.d237.s14	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
Cisapride	drug	0-8	antiarrhythmics	group	102-116	advise
Cisapride	drug	0-8	quinidine	drug	156-164	advise
Cisapride	drug	0-8	procainamide	drug	170-181	advise
Cisapride	drug	0-8	sotalol	drug	207-213	advise
antiarrhythmics	group	102-116	quinidine	drug	156-164	false
antiarrhythmics	group	102-116	procainamide	drug	170-181	false
antiarrhythmics	group	102-116	sotalol	drug	207-213	false
quinidine	drug	156-164	procainamide	drug	170-181	false
quinidine	drug	156-164	sotalol	drug	207-213	false
procainamide	drug	170-181	sotalol	drug	207-213	false

DDI-DrugBank.d237.s15	tricyclic antidepressants (such as amitriptyline);
tricyclic antidepressants	group	0-24	amitriptyline	drug	35-47	false

DDI-DrugBank.d237.s16	certain tetracyclic antidepressants (such as maprotiline);
tetracyclic antidepressants	group	8-34	maprotiline	drug	45-55	false

DDI-DrugBank.d237.s17	certain antipsychotic medications (such as sertindole);
antipsychotic medications	group	8-32	sertindole	drug	43-52	false

DDI-DrugBank.d237.s18	astemizole, bepridil, sparfloxacin, and terodiline.
astemizole	drug	0-9	bepridil	drug	12-19	false
astemizole	drug	0-9	sparfloxacin	drug	22-33	false
astemizole	drug	0-9	terodiline	drug	40-49	false
bepridil	drug	12-19	sparfloxacin	drug	22-33	false
bepridil	drug	12-19	terodiline	drug	40-49	false
sparfloxacin	drug	22-33	terodiline	drug	40-49	false

DDI-DrugBank.d60.s0	Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
NIMBEX	brand	39-44	succinylcholine	drug	101-115	effect

DDI-DrugBank.d60.s1	The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
NIMBEX	brand	45-50	succinylcholine	drug	115-129	effect

DDI-DrugBank.d60.s2	Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX.
succinylcholine	drug	24-38	NIMBEX	brand	141-146	false

DDI-DrugBank.d60.s3	Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
NIMBEX	brand	25-30	succinylcholine	drug	57-71	false
NIMBEX	brand	25-30	NIMBEX	brand	95-100	false
NIMBEX	brand	25-30	succinylcholine	drug	151-165	false
succinylcholine	drug	57-71	NIMBEX	brand	95-100	effect
succinylcholine	drug	57-71	succinylcholine	drug	151-165	false
NIMBEX	brand	95-100	succinylcholine	drug	151-165	false

DDI-DrugBank.d60.s4	The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
NIMBEX	brand	11-16	succinylcholine	drug	25-39	false
NIMBEX	brand	11-16	succinylcholine	drug	82-96	false
succinylcholine	drug	25-39	succinylcholine	drug	82-96	false

DDI-DrugBank.d60.s5	Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX.
vecuronium	drug	96-105	pancuronium	drug	108-118	false
vecuronium	drug	96-105	atracurium	drug	124-133	false
vecuronium	drug	96-105	NIMBEX	brand	225-230	false
pancuronium	drug	108-118	atracurium	drug	124-133	false
pancuronium	drug	108-118	NIMBEX	brand	225-230	false
atracurium	drug	124-133	NIMBEX	brand	225-230	false

DDI-DrugBank.d60.s6	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
Isoflurane	drug	0-9	enflurane	drug	14-22	false
Isoflurane	drug	0-9	nitrous oxide	drug	42-54	false
Isoflurane	drug	0-9	oxygen	drug	56-61	false
Isoflurane	drug	0-9	NIMBEX	brand	208-213	effect
Isoflurane	drug	0-9	NIMBEX	brand	258-263	effect
enflurane	drug	14-22	nitrous oxide	drug	42-54	false
enflurane	drug	14-22	oxygen	drug	56-61	false
enflurane	drug	14-22	NIMBEX	brand	208-213	effect
enflurane	drug	14-22	NIMBEX	brand	258-263	effect
nitrous oxide	drug	42-54	oxygen	drug	56-61	false
nitrous oxide	drug	42-54	NIMBEX	brand	208-213	effect
nitrous oxide	drug	42-54	NIMBEX	brand	258-263	effect
oxygen	drug	56-61	NIMBEX	brand	208-213	false
oxygen	drug	56-61	NIMBEX	brand	258-263	false
NIMBEX	brand	208-213	NIMBEX	brand	258-263	false

DDI-DrugBank.d60.s8	Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
isoflurane	drug	46-55	enflurane	drug	60-68	false
isoflurane	drug	46-55	NIMBEX	brand	136-141	false
isoflurane	drug	46-55	NIMBEX	brand	217-222	false
enflurane	drug	60-68	NIMBEX	brand	136-141	false
enflurane	drug	60-68	NIMBEX	brand	217-222	false
NIMBEX	brand	136-141	NIMBEX	brand	217-222	false

DDI-DrugBank.d60.s9	In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
enflurane	drug	35-43	isoflurane	drug	48-57	false
enflurane	drug	35-43	NIMBEX	brand	159-164	advise
isoflurane	drug	48-57	NIMBEX	brand	159-164	advise

DDI-DrugBank.d60.s11	In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX.
propofol	drug	20-27	NIMBEX	brand	96-101	false

DDI-DrugBank.d60.s12	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
nondepolarizing agents	group	67-88	NIMBEX	brand	98-103	effect
nondepolarizing agents	group	67-88	antibiotics	group	121-131	effect
nondepolarizing agents	group	67-88	aminoglycosides	group	141-155	effect
nondepolarizing agents	group	67-88	tetracyclines	group	158-170	effect
nondepolarizing agents	group	67-88	bacitracin	drug	173-182	effect
nondepolarizing agents	group	67-88	polymyxins	group	185-194	effect
nondepolarizing agents	group	67-88	lincomycin	drug	197-206	effect
nondepolarizing agents	group	67-88	clindamycin	drug	209-219	effect
nondepolarizing agents	group	67-88	colistin	drug	222-229	effect
nondepolarizing agents	group	67-88	sodium colistemethate	drug	236-256	effect
nondepolarizing agents	group	67-88	magnesium	group	260-268	effect
nondepolarizing agents	group	67-88	lithium	drug	277-283	effect
nondepolarizing agents	group	67-88	anesthetics	group	292-302	effect
nondepolarizing agents	group	67-88	procainamide	drug	305-316	effect
nondepolarizing agents	group	67-88	quinidine	drug	323-331	effect
NIMBEX	brand	98-103	antibiotics	group	121-131	effect
NIMBEX	brand	98-103	aminoglycosides	group	141-155	effect
NIMBEX	brand	98-103	tetracyclines	group	158-170	effect
NIMBEX	brand	98-103	bacitracin	drug	173-182	effect
NIMBEX	brand	98-103	polymyxins	group	185-194	effect
NIMBEX	brand	98-103	lincomycin	drug	197-206	effect
NIMBEX	brand	98-103	clindamycin	drug	209-219	effect
NIMBEX	brand	98-103	colistin	drug	222-229	effect
NIMBEX	brand	98-103	sodium colistemethate	drug	236-256	effect
NIMBEX	brand	98-103	magnesium	group	260-268	effect
NIMBEX	brand	98-103	lithium	drug	277-283	effect
NIMBEX	brand	98-103	anesthetics	group	292-302	effect
NIMBEX	brand	98-103	procainamide	drug	305-316	effect
NIMBEX	brand	98-103	quinidine	drug	323-331	effect
antibiotics	group	121-131	aminoglycosides	group	141-155	false
antibiotics	group	121-131	tetracyclines	group	158-170	false
antibiotics	group	121-131	bacitracin	drug	173-182	false
antibiotics	group	121-131	polymyxins	group	185-194	false
antibiotics	group	121-131	lincomycin	drug	197-206	false
antibiotics	group	121-131	clindamycin	drug	209-219	false
antibiotics	group	121-131	colistin	drug	222-229	false
antibiotics	group	121-131	sodium colistemethate	drug	236-256	false
antibiotics	group	121-131	magnesium	group	260-268	false
antibiotics	group	121-131	lithium	drug	277-283	false
antibiotics	group	121-131	anesthetics	group	292-302	false
antibiotics	group	121-131	procainamide	drug	305-316	false
antibiotics	group	121-131	quinidine	drug	323-331	false
aminoglycosides	group	141-155	tetracyclines	group	158-170	false
aminoglycosides	group	141-155	bacitracin	drug	173-182	false
aminoglycosides	group	141-155	polymyxins	group	185-194	false
aminoglycosides	group	141-155	lincomycin	drug	197-206	false
aminoglycosides	group	141-155	clindamycin	drug	209-219	false
aminoglycosides	group	141-155	colistin	drug	222-229	false
aminoglycosides	group	141-155	sodium colistemethate	drug	236-256	false
aminoglycosides	group	141-155	magnesium	group	260-268	false
aminoglycosides	group	141-155	lithium	drug	277-283	false
aminoglycosides	group	141-155	anesthetics	group	292-302	false
aminoglycosides	group	141-155	procainamide	drug	305-316	false
aminoglycosides	group	141-155	quinidine	drug	323-331	false
tetracyclines	group	158-170	bacitracin	drug	173-182	false
tetracyclines	group	158-170	polymyxins	group	185-194	false
tetracyclines	group	158-170	lincomycin	drug	197-206	false
tetracyclines	group	158-170	clindamycin	drug	209-219	false
tetracyclines	group	158-170	colistin	drug	222-229	false
tetracyclines	group	158-170	sodium colistemethate	drug	236-256	false
tetracyclines	group	158-170	magnesium	group	260-268	false
tetracyclines	group	158-170	lithium	drug	277-283	false
tetracyclines	group	158-170	anesthetics	group	292-302	false
tetracyclines	group	158-170	procainamide	drug	305-316	false
tetracyclines	group	158-170	quinidine	drug	323-331	false
bacitracin	drug	173-182	polymyxins	group	185-194	false
bacitracin	drug	173-182	lincomycin	drug	197-206	false
bacitracin	drug	173-182	clindamycin	drug	209-219	false
bacitracin	drug	173-182	colistin	drug	222-229	false
bacitracin	drug	173-182	sodium colistemethate	drug	236-256	false
bacitracin	drug	173-182	magnesium	group	260-268	false
bacitracin	drug	173-182	lithium	drug	277-283	false
bacitracin	drug	173-182	anesthetics	group	292-302	false
bacitracin	drug	173-182	procainamide	drug	305-316	false
bacitracin	drug	173-182	quinidine	drug	323-331	false
polymyxins	group	185-194	lincomycin	drug	197-206	false
polymyxins	group	185-194	clindamycin	drug	209-219	false
polymyxins	group	185-194	colistin	drug	222-229	false
polymyxins	group	185-194	sodium colistemethate	drug	236-256	false
polymyxins	group	185-194	magnesium	group	260-268	false
polymyxins	group	185-194	lithium	drug	277-283	false
polymyxins	group	185-194	anesthetics	group	292-302	false
polymyxins	group	185-194	procainamide	drug	305-316	false
polymyxins	group	185-194	quinidine	drug	323-331	false
lincomycin	drug	197-206	clindamycin	drug	209-219	false
lincomycin	drug	197-206	colistin	drug	222-229	false
lincomycin	drug	197-206	sodium colistemethate	drug	236-256	false
lincomycin	drug	197-206	magnesium	group	260-268	false
lincomycin	drug	197-206	lithium	drug	277-283	false
lincomycin	drug	197-206	anesthetics	group	292-302	false
lincomycin	drug	197-206	procainamide	drug	305-316	false
lincomycin	drug	197-206	quinidine	drug	323-331	false
clindamycin	drug	209-219	colistin	drug	222-229	false
clindamycin	drug	209-219	sodium colistemethate	drug	236-256	false
clindamycin	drug	209-219	magnesium	group	260-268	false
clindamycin	drug	209-219	lithium	drug	277-283	false
clindamycin	drug	209-219	anesthetics	group	292-302	false
clindamycin	drug	209-219	procainamide	drug	305-316	false
clindamycin	drug	209-219	quinidine	drug	323-331	false
colistin	drug	222-229	sodium colistemethate	drug	236-256	false
colistin	drug	222-229	magnesium	group	260-268	false
colistin	drug	222-229	lithium	drug	277-283	false
colistin	drug	222-229	anesthetics	group	292-302	false
colistin	drug	222-229	procainamide	drug	305-316	false
colistin	drug	222-229	quinidine	drug	323-331	false
sodium colistemethate	drug	236-256	magnesium	group	260-268	false
sodium colistemethate	drug	236-256	lithium	drug	277-283	false
sodium colistemethate	drug	236-256	anesthetics	group	292-302	false
sodium colistemethate	drug	236-256	procainamide	drug	305-316	false
sodium colistemethate	drug	236-256	quinidine	drug	323-331	false
magnesium	group	260-268	lithium	drug	277-283	false
magnesium	group	260-268	anesthetics	group	292-302	false
magnesium	group	260-268	procainamide	drug	305-316	false
magnesium	group	260-268	quinidine	drug	323-331	false
lithium	drug	277-283	anesthetics	group	292-302	false
lithium	drug	277-283	procainamide	drug	305-316	false
lithium	drug	277-283	quinidine	drug	323-331	false
anesthetics	group	292-302	procainamide	drug	305-316	false
anesthetics	group	292-302	quinidine	drug	323-331	false
procainamide	drug	305-316	quinidine	drug	323-331	false

DDI-DrugBank.d60.s13	Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
nondepolarizing neuromuscular blocking agents	group	51-95	phenytoin	drug	156-164	effect
nondepolarizing neuromuscular blocking agents	group	51-95	carbamazepine	drug	169-181	effect
phenytoin	drug	156-164	carbamazepine	drug	169-181	false

DDI-DrugBank.d60.s14	While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
phenytoin	drug	29-37	carbamazepine	drug	42-54	false
phenytoin	drug	29-37	NIMBEX	brand	81-86	effect
carbamazepine	drug	42-54	NIMBEX	brand	81-86	effect

DDI-DrugBank.d145.s0	Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
anticonvulsant agents	group	17-37	cisplatin	drug	72-80	mechanism

DDI-DrugBank.d472.s0	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
Central nervous system depressant	group	0-32	alcohol	drug	56-62	false
Central nervous system depressant	group	0-32	antidepressants	group	65-79	false
Central nervous system depressant	group	0-32	antihistamines	group	82-95	false
Central nervous system depressant	group	0-32	antipsychotics	group	98-111	false
Central nervous system depressant	group	0-32	reserpine	drug	142-150	false
Central nervous system depressant	group	0-32	methyldopa	drug	153-162	false
Central nervous system depressant	group	0-32	beta-blockers	group	165-177	false
Central nervous system depressant	group	0-32	muscle relaxants	group	210-225	false
Central nervous system depressant	group	0-32	narcotics	group	228-236	false
Central nervous system depressant	group	0-32	sedatives	group	239-247	false
Central nervous system depressant	group	0-32	tranquilizers	group	269-281	false
alcohol	drug	56-62	antidepressants	group	65-79	false
alcohol	drug	56-62	antihistamines	group	82-95	false
alcohol	drug	56-62	antipsychotics	group	98-111	false
alcohol	drug	56-62	reserpine	drug	142-150	false
alcohol	drug	56-62	methyldopa	drug	153-162	false
alcohol	drug	56-62	beta-blockers	group	165-177	false
alcohol	drug	56-62	muscle relaxants	group	210-225	false
alcohol	drug	56-62	narcotics	group	228-236	false
alcohol	drug	56-62	sedatives	group	239-247	false
alcohol	drug	56-62	tranquilizers	group	269-281	false
antidepressants	group	65-79	antihistamines	group	82-95	false
antidepressants	group	65-79	antipsychotics	group	98-111	false
antidepressants	group	65-79	reserpine	drug	142-150	false
antidepressants	group	65-79	methyldopa	drug	153-162	false
antidepressants	group	65-79	beta-blockers	group	165-177	false
antidepressants	group	65-79	muscle relaxants	group	210-225	false
antidepressants	group	65-79	narcotics	group	228-236	false
antidepressants	group	65-79	sedatives	group	239-247	false
antidepressants	group	65-79	tranquilizers	group	269-281	false
antihistamines	group	82-95	antipsychotics	group	98-111	false
antihistamines	group	82-95	reserpine	drug	142-150	false
antihistamines	group	82-95	methyldopa	drug	153-162	false
antihistamines	group	82-95	beta-blockers	group	165-177	false
antihistamines	group	82-95	muscle relaxants	group	210-225	false
antihistamines	group	82-95	narcotics	group	228-236	false
antihistamines	group	82-95	sedatives	group	239-247	false
antihistamines	group	82-95	tranquilizers	group	269-281	false
antipsychotics	group	98-111	reserpine	drug	142-150	false
antipsychotics	group	98-111	methyldopa	drug	153-162	false
antipsychotics	group	98-111	beta-blockers	group	165-177	false
antipsychotics	group	98-111	muscle relaxants	group	210-225	false
antipsychotics	group	98-111	narcotics	group	228-236	false
antipsychotics	group	98-111	sedatives	group	239-247	false
antipsychotics	group	98-111	tranquilizers	group	269-281	false
reserpine	drug	142-150	methyldopa	drug	153-162	false
reserpine	drug	142-150	beta-blockers	group	165-177	false
reserpine	drug	142-150	muscle relaxants	group	210-225	false
reserpine	drug	142-150	narcotics	group	228-236	false
reserpine	drug	142-150	sedatives	group	239-247	false
reserpine	drug	142-150	tranquilizers	group	269-281	false
methyldopa	drug	153-162	beta-blockers	group	165-177	false
methyldopa	drug	153-162	muscle relaxants	group	210-225	false
methyldopa	drug	153-162	narcotics	group	228-236	false
methyldopa	drug	153-162	sedatives	group	239-247	false
methyldopa	drug	153-162	tranquilizers	group	269-281	false
beta-blockers	group	165-177	muscle relaxants	group	210-225	false
beta-blockers	group	165-177	narcotics	group	228-236	false
beta-blockers	group	165-177	sedatives	group	239-247	false
beta-blockers	group	165-177	tranquilizers	group	269-281	false
muscle relaxants	group	210-225	narcotics	group	228-236	false
muscle relaxants	group	210-225	sedatives	group	239-247	false
muscle relaxants	group	210-225	tranquilizers	group	269-281	false
narcotics	group	228-236	sedatives	group	239-247	false
narcotics	group	228-236	tranquilizers	group	269-281	false
sedatives	group	239-247	tranquilizers	group	269-281	false

DDI-DrugBank.d419.s0	The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
allopurinol	drug	33-43	ampicillin	drug	49-58	effect
allopurinol	drug	33-43	ampicillin	drug	175-184	false
ampicillin	drug	49-58	ampicillin	drug	175-184	false

DDI-DrugBank.d419.s1	It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
ampicillin	drug	45-54	allopurinol	drug	73-83	effect

DDI-DrugBank.d419.s2	In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.
AUGMENTIN XR	brand	33-44	allopurinol	drug	80-90	false
AUGMENTIN XR	brand	33-44	AUGMENTIN XR	brand	96-107	false
allopurinol	drug	80-90	AUGMENTIN XR	brand	96-107	false

DDI-DrugBank.d419.s4	However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.
AUGMENTIN XR	brand	126-137	allopurinol	drug	143-153	false

DDI-DrugBank.d419.s5	In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
broad-spectrum antibiotics	group	21-46	AUGMENTIN XR	brand	49-60	false
broad-spectrum antibiotics	group	21-46	contraceptives	group	94-107	effect
AUGMENTIN XR	brand	49-60	contraceptives	group	94-107	effect

DDI-DrugBank.d309.s0	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
antihistamines	group	39-52	CNS depressants	group	96-110	effect
antihistamines	group	39-52	barbiturates	group	122-133	effect
antihistamines	group	39-52	tranquilizers	group	136-148	effect
antihistamines	group	39-52	alcohol	drug	155-161	effect
CNS depressants	group	96-110	barbiturates	group	122-133	false
CNS depressants	group	96-110	tranquilizers	group	136-148	false
CNS depressants	group	96-110	alcohol	drug	155-161	false
barbiturates	group	122-133	tranquilizers	group	136-148	false
barbiturates	group	122-133	alcohol	drug	155-161	false
tranquilizers	group	136-148	alcohol	drug	155-161	false

DDI-DrugBank.d309.s1	Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
antihistamines	group	19-32	CNS depressant drugs	group	88-107	advise

DDI-DrugBank.d309.s2	Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
Monoamine oxidase (MAO) inhibitors	group	0-33	antihistamines	group	88-101	effect

DDI-DrugBank.d322.s0	Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
Amantadine	drug	0-9	tricyclic antidepressants	group	12-36	false
Amantadine	drug	0-9	MAOIs	group	43-47	false
Amantadine	drug	0-9	clidinium	drug	88-96	effect
tricyclic antidepressants	group	12-36	MAOIs	group	43-47	false
tricyclic antidepressants	group	12-36	clidinium	drug	88-96	effect
MAOIs	group	43-47	clidinium	drug	88-96	effect

DDI-DrugBank.d322.s1	Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
Clidinium	drug	0-8	phenothiazines	group	37-50	effect
Clidinium	drug	0-8	levodopa	drug	53-60	effect
Clidinium	drug	0-8	ketoconazole	drug	67-78	effect
phenothiazines	group	37-50	levodopa	drug	53-60	false
phenothiazines	group	37-50	ketoconazole	drug	67-78	false
levodopa	drug	53-60	ketoconazole	drug	67-78	false

DDI-DrugBank.d256.s0	Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
Clindamycin	drug	0-10	neuromuscular blocking agents	group	106-134	effect

DDI-DrugBank.d256.s2	Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
clindamycin	drug	41-51	erythromycin	drug	57-68	effect

DDI-DrugBank.d136.s0	Alcohol (increases bioavailability by 50%), cimetidine, and valproates.
Alcohol	drug	0-6	cimetidine	drug	44-53	false

DDI-DrugBank.d399.s0	Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
dapsone	drug	36-42	Lamprene	brand	90-97	effect

DDI-DrugBank.d399.s1	If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
dapsone	drug	84-90	clofazimine	drug	96-106	advise

DDI-DrugBank.d12.s0	Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
anticoagulants	group	33-46	Atromid-S	brand	78-86	advise

DDI-DrugBank.d12.s3	Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
Atromid-S	brand	0-8	phenytoin	drug	44-52	mechanism
Atromid-S	brand	0-8	tolbutamide	drug	57-67	mechanism
phenytoin	drug	44-52	tolbutamide	drug	57-67	false

DDI-DrugBank.d12.s5	The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
tolbutamide	drug	27-37	Atromid-S	brand	74-82	effect

DDI-DrugBank.d12.s6	Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
fibrate	group	113-119	lovastatin	drug	125-134	effect

DDI-DrugBank.d12.s7	For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
lovastatin	drug	168-177	fibrate	group	185-191	effect

DDI-DrugBank.d12.s8	While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
fibrates	group	59-66	gemfibrozil	drug	79-89	false
fibrates	group	59-66	fibrates	group	170-177	false
fibrates	group	59-66	clofibrate	drug	196-205	false
gemfibrozil	drug	79-89	fibrates	group	170-177	false
gemfibrozil	drug	79-89	clofibrate	drug	196-205	false
fibrates	group	170-177	clofibrate	drug	196-205	false

DDI-DrugBank.d12.s9	Therefore, the combined use of lovastatin with fibrates should generally be avoided.
lovastatin	drug	31-40	fibrates	group	47-54	advise

DDI-DrugBank.d238.s2	Anafranil should not be used with MAO inhibitors.
Anafranil	brand	0-8	MAO inhibitors	group	34-47	advise

DDI-DrugBank.d238.s3	Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
Anafranil	brand	69-77	anticholinergic	group	100-114	advise
Anafranil	brand	69-77	sympathomimetic drugs	group	119-139	advise
anticholinergic	group	100-114	sympathomimetic drugs	group	119-139	false

DDI-DrugBank.d238.s4	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
tricyclic antidepressants	group	8-32	guanethidine	drug	91-102	effect
tricyclic antidepressants	group	8-32	clonidine	drug	105-113	effect
tricyclic antidepressants	group	8-32	CMI	drug	178-180	effect
tricyclic antidepressants	group	8-32	tricyclic antidepressants	group	228-252	effect
guanethidine	drug	91-102	clonidine	drug	105-113	false
guanethidine	drug	91-102	CMI	drug	178-180	false
guanethidine	drug	91-102	tricyclic antidepressants	group	228-252	false
clonidine	drug	105-113	CMI	drug	178-180	false
clonidine	drug	105-113	tricyclic antidepressants	group	228-252	false
CMI	drug	178-180	tricyclic antidepressants	group	228-252	false

DDI-DrugBank.d238.s5	The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
CMI	drug	28-30	haloperidol	drug	103-113	mechanism

DDI-DrugBank.d238.s6	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
tricyclic antidepressants	group	41-65	methylphenidate	drug	139-153	mechanism
tricyclic antidepressants	group	41-65	cimetidine	drug	191-200	mechanism
tricyclic antidepressants	group	41-65	fluoxetine	drug	203-212	mechanism
tricyclic antidepressants	group	41-65	barbiturates	group	297-308	mechanism
tricyclic antidepressants	group	41-65	phenytoin	drug	311-319	mechanism
tricyclic antidepressants	group	41-65	CMI	drug	366-368	false
methylphenidate	drug	139-153	cimetidine	drug	191-200	false
methylphenidate	drug	139-153	fluoxetine	drug	203-212	false
methylphenidate	drug	139-153	barbiturates	group	297-308	false
methylphenidate	drug	139-153	phenytoin	drug	311-319	false
methylphenidate	drug	139-153	CMI	drug	366-368	mechanism
cimetidine	drug	191-200	fluoxetine	drug	203-212	false
cimetidine	drug	191-200	barbiturates	group	297-308	false
cimetidine	drug	191-200	phenytoin	drug	311-319	false
cimetidine	drug	191-200	CMI	drug	366-368	mechanism
fluoxetine	drug	203-212	barbiturates	group	297-308	false
fluoxetine	drug	203-212	phenytoin	drug	311-319	false
fluoxetine	drug	203-212	CMI	drug	366-368	mechanism
barbiturates	group	297-308	phenytoin	drug	311-319	false
barbiturates	group	297-308	CMI	drug	366-368	mechanism
phenytoin	drug	311-319	CMI	drug	366-368	mechanism

DDI-DrugBank.d238.s7	Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
CMI	drug	18-20	phenobarbital	drug	73-85	mechanism

DDI-DrugBank.d238.s10	Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	68-92	TCAs	group	95-98	false

DDI-DrugBank.d238.s15	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	Type 1C antiarrhythmics	group	107-129	false
cimetidine	drug	0-9	propafenone	drug	131-141	false
cimetidine	drug	0-9	flecainide	drug	147-156	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	Type 1C antiarrhythmics	group	107-129	false
antidepressants	group	66-80	propafenone	drug	131-141	false
antidepressants	group	66-80	flecainide	drug	147-156	false
phenothiazines	group	83-96	Type 1C antiarrhythmics	group	107-129	false
phenothiazines	group	83-96	propafenone	drug	131-141	false
phenothiazines	group	83-96	flecainide	drug	147-156	false
Type 1C antiarrhythmics	group	107-129	propafenone	drug	131-141	false
Type 1C antiarrhythmics	group	107-129	flecainide	drug	147-156	false
propafenone	drug	131-141	flecainide	drug	147-156	false

DDI-DrugBank.d238.s16	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	69-78	false
selective serotonin reuptake inhibitors	group	14-52	sertraline	drug	81-90	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	93-102	false
selective serotonin reuptake inhibitors	group	14-52	fluvoxamine	drug	109-119	false
SSRIs	group	55-59	fluoxetine	drug	69-78	false
SSRIs	group	55-59	sertraline	drug	81-90	false
SSRIs	group	55-59	paroxetine	drug	93-102	false
SSRIs	group	55-59	fluvoxamine	drug	109-119	false
fluoxetine	drug	69-78	sertraline	drug	81-90	false
fluoxetine	drug	69-78	paroxetine	drug	93-102	false
fluoxetine	drug	69-78	fluvoxamine	drug	109-119	false
sertraline	drug	81-90	paroxetine	drug	93-102	false
sertraline	drug	81-90	fluvoxamine	drug	109-119	false
paroxetine	drug	93-102	fluvoxamine	drug	109-119	false

DDI-DrugBank.d238.s17	Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
Fluvoxamine	drug	0-10	TCA	group	81-83	mechanism

DDI-DrugBank.d238.s18	The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	140-143	false
TCA	group	25-27	SSRI	group	140-143	false

DDI-DrugBank.d238.s19	Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	group	63-66	SSRIs	group	84-88	advise

DDI-DrugBank.d238.s20	Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
TCA	group	72-74	fluoxetine	drug	119-128	advise

DDI-DrugBank.d238.s21	Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.
tricyclic antidepressant class	group	33-62	Anafranil	brand	80-88	false
tricyclic antidepressant class	group	33-62	tricyclic antidepressant agent	group	202-231	false
Anafranil	brand	80-88	tricyclic antidepressant agent	group	202-231	false

DDI-DrugBank.d238.s23	It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
TCA	group	27-29	tricyclic antidepressant class	group	69-98	false
TCA	group	27-29	Anafranil	brand	110-118	false
tricyclic antidepressant class	group	69-98	Anafranil	brand	110-118	false

DDI-DrugBank.d238.s24	Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
Anafranil	brand	8-16	Anafranil	brand	74-82	false
Anafranil	brand	8-16	warfarin	drug	155-162	false
Anafranil	brand	8-16	digoxin	drug	165-171	false
Anafranil	brand	74-82	warfarin	drug	155-162	mechanism
Anafranil	brand	74-82	digoxin	drug	165-171	mechanism
warfarin	drug	155-162	digoxin	drug	165-171	false

DDI-DrugBank.d333.s0	Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
Clonazepam	drug	10-19	Clonazepam	drug	61-70	false
Clonazepam	drug	10-19	phenytoin	drug	121-129	false
Clonazepam	drug	10-19	carbamazepine	drug	132-144	false
Clonazepam	drug	10-19	phenobarbital	drug	150-162	false
Clonazepam	drug	61-70	phenytoin	drug	121-129	false
Clonazepam	drug	61-70	carbamazepine	drug	132-144	false
Clonazepam	drug	61-70	phenobarbital	drug	150-162	false
phenytoin	drug	121-129	carbamazepine	drug	132-144	false
phenytoin	drug	121-129	phenobarbital	drug	150-162	false
carbamazepine	drug	132-144	phenobarbital	drug	150-162	false

DDI-DrugBank.d333.s2	Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.
Clonazepam	drug	49-58	ranitidine	drug	93-102	false
Clonazepam	drug	49-58	clonazepam	drug	169-178	false
ranitidine	drug	93-102	clonazepam	drug	169-178	false

DDI-DrugBank.d333.s3	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
clonazepam	drug	29-38	propantheline	drug	103-115	mechanism
clonazepam	drug	29-38	anticholinergic agent	group	121-141	false
clonazepam	drug	29-38	clonazepam	drug	216-225	false
clonazepam	drug	29-38	clonazepam	drug	257-266	false
clonazepam	drug	29-38	propantheline	drug	335-347	false
propantheline	drug	103-115	anticholinergic agent	group	121-141	false
propantheline	drug	103-115	clonazepam	drug	216-225	false
propantheline	drug	103-115	clonazepam	drug	257-266	false
propantheline	drug	103-115	propantheline	drug	335-347	false
anticholinergic agent	group	121-141	clonazepam	drug	216-225	false
anticholinergic agent	group	121-141	clonazepam	drug	257-266	false
anticholinergic agent	group	121-141	propantheline	drug	335-347	false
clonazepam	drug	216-225	clonazepam	drug	257-266	false
clonazepam	drug	216-225	propantheline	drug	335-347	false
clonazepam	drug	257-266	propantheline	drug	335-347	mechanism

DDI-DrugBank.d333.s4	Fluoxetine does not affect the pharmacokinetics of clonazepam.
Fluoxetine	drug	0-9	clonazepam	drug	51-60	false

DDI-DrugBank.d333.s5	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
phenytoin	drug	35-43	carbamazepine	drug	46-58	false
phenytoin	drug	35-43	phenobarbital	drug	64-76	false
phenytoin	drug	35-43	clonazepam	drug	86-95	mechanism
phenytoin	drug	35-43	clonazepam	drug	157-166	false
carbamazepine	drug	46-58	phenobarbital	drug	64-76	false
carbamazepine	drug	46-58	clonazepam	drug	86-95	mechanism
carbamazepine	drug	46-58	clonazepam	drug	157-166	false
phenobarbital	drug	64-76	clonazepam	drug	86-95	mechanism
phenobarbital	drug	64-76	clonazepam	drug	157-166	false
clonazepam	drug	86-95	clonazepam	drug	157-166	false

DDI-DrugBank.d333.s6	Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
clonazepam	drug	113-122	antifungal agents	group	183-199	false
clonazepam	drug	113-122	clonazepam	drug	250-259	false
antifungal agents	group	183-199	clonazepam	drug	250-259	advise

DDI-DrugBank.d333.s7	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
benzodiazepine class	group	63-82	alcohol	drug	115-121	effect
benzodiazepine class	group	63-82	narcotics	group	124-132	effect
benzodiazepine class	group	63-82	barbiturates	group	135-146	effect
benzodiazepine class	group	63-82	nonbarbiturate hypnotics	group	149-172	effect
benzodiazepine class	group	63-82	antianxiety agents	group	175-192	effect
benzodiazepine class	group	63-82	phenothiazines classes of antipsychotic agents	group	199-212;246-276	effect
benzodiazepine class	group	63-82	thioxanthene classes of antipsychotic agents	group	215-226;246-276	effect
benzodiazepine class	group	63-82	butyrophenone classes of antipsychotic agents	group	232-276	effect
benzodiazepine class	group	63-82	monoamine oxidase inhibitors	group	279-306	effect
benzodiazepine class	group	63-82	tricyclic antidepressants	group	316-340	effect
benzodiazepine class	group	63-82	anticonvulsant drugs	group	356-375	effect
alcohol	drug	115-121	narcotics	group	124-132	false
alcohol	drug	115-121	barbiturates	group	135-146	false
alcohol	drug	115-121	nonbarbiturate hypnotics	group	149-172	false
alcohol	drug	115-121	antianxiety agents	group	175-192	false
alcohol	drug	115-121	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
alcohol	drug	115-121	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
alcohol	drug	115-121	butyrophenone classes of antipsychotic agents	group	232-276	false
alcohol	drug	115-121	monoamine oxidase inhibitors	group	279-306	false
alcohol	drug	115-121	tricyclic antidepressants	group	316-340	false
alcohol	drug	115-121	anticonvulsant drugs	group	356-375	false
narcotics	group	124-132	barbiturates	group	135-146	false
narcotics	group	124-132	nonbarbiturate hypnotics	group	149-172	false
narcotics	group	124-132	antianxiety agents	group	175-192	false
narcotics	group	124-132	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
narcotics	group	124-132	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
narcotics	group	124-132	butyrophenone classes of antipsychotic agents	group	232-276	false
narcotics	group	124-132	monoamine oxidase inhibitors	group	279-306	false
narcotics	group	124-132	tricyclic antidepressants	group	316-340	false
narcotics	group	124-132	anticonvulsant drugs	group	356-375	false
barbiturates	group	135-146	nonbarbiturate hypnotics	group	149-172	false
barbiturates	group	135-146	antianxiety agents	group	175-192	false
barbiturates	group	135-146	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
barbiturates	group	135-146	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
barbiturates	group	135-146	butyrophenone classes of antipsychotic agents	group	232-276	false
barbiturates	group	135-146	monoamine oxidase inhibitors	group	279-306	false
barbiturates	group	135-146	tricyclic antidepressants	group	316-340	false
barbiturates	group	135-146	anticonvulsant drugs	group	356-375	false
nonbarbiturate hypnotics	group	149-172	antianxiety agents	group	175-192	false
nonbarbiturate hypnotics	group	149-172	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
nonbarbiturate hypnotics	group	149-172	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
nonbarbiturate hypnotics	group	149-172	butyrophenone classes of antipsychotic agents	group	232-276	false
nonbarbiturate hypnotics	group	149-172	monoamine oxidase inhibitors	group	279-306	false
nonbarbiturate hypnotics	group	149-172	tricyclic antidepressants	group	316-340	false
nonbarbiturate hypnotics	group	149-172	anticonvulsant drugs	group	356-375	false
antianxiety agents	group	175-192	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
antianxiety agents	group	175-192	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
antianxiety agents	group	175-192	butyrophenone classes of antipsychotic agents	group	232-276	false
antianxiety agents	group	175-192	monoamine oxidase inhibitors	group	279-306	false
antianxiety agents	group	175-192	tricyclic antidepressants	group	316-340	false
antianxiety agents	group	175-192	anticonvulsant drugs	group	356-375	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	butyrophenone classes of antipsychotic agents	group	232-276	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	monoamine oxidase inhibitors	group	279-306	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	tricyclic antidepressants	group	316-340	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	anticonvulsant drugs	group	356-375	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	butyrophenone classes of antipsychotic agents	group	232-276	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	monoamine oxidase inhibitors	group	279-306	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	tricyclic antidepressants	group	316-340	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	anticonvulsant drugs	group	356-375	false
butyrophenone classes of antipsychotic agents	group	232-276	monoamine oxidase inhibitors	group	279-306	false
butyrophenone classes of antipsychotic agents	group	232-276	tricyclic antidepressants	group	316-340	false
butyrophenone classes of antipsychotic agents	group	232-276	anticonvulsant drugs	group	356-375	false
monoamine oxidase inhibitors	group	279-306	tricyclic antidepressants	group	316-340	false
monoamine oxidase inhibitors	group	279-306	anticonvulsant drugs	group	356-375	false
tricyclic antidepressants	group	316-340	anticonvulsant drugs	group	356-375	false

DDI-DrugBank.d495.s0	Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
clonidine hydrochloride	drug	30-52	tricyclic antidepressants	group	69-93	effect
clonidine hydrochloride	drug	30-52	clonidine	drug	110-118	false
tricyclic antidepressants	group	69-93	clonidine	drug	110-118	false

DDI-DrugBank.d495.s1	Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
Clonidine hydrochloride	drug	0-22	alcohol	drug	66-72	effect
Clonidine hydrochloride	drug	0-22	barbiturates	group	75-86	effect
Clonidine hydrochloride	drug	0-22	sedatives	group	97-105	effect
alcohol	drug	66-72	barbiturates	group	75-86	false
alcohol	drug	66-72	sedatives	group	97-105	false
barbiturates	group	75-86	sedatives	group	97-105	false

DDI-DrugBank.d495.s2	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
Amitriptyline	drug	0-12	clonidine	drug	34-42	effect
Amitriptyline	drug	0-12	Clonidine	drug	117-125	false
Amitriptyline	drug	0-12	alcohol	drug	171-177	false
Amitriptyline	drug	0-12	barbiturates	group	180-191	false
Amitriptyline	drug	0-12	sedating drugs	group	202-215	false
clonidine	drug	34-42	Clonidine	drug	117-125	false
clonidine	drug	34-42	alcohol	drug	171-177	false
clonidine	drug	34-42	barbiturates	group	180-191	false
clonidine	drug	34-42	sedating drugs	group	202-215	false
Clonidine	drug	117-125	alcohol	drug	171-177	effect
Clonidine	drug	117-125	barbiturates	group	180-191	effect
Clonidine	drug	117-125	sedating drugs	group	202-215	effect
alcohol	drug	171-177	barbiturates	group	180-191	false
alcohol	drug	171-177	sedating drugs	group	202-215	false
barbiturates	group	180-191	sedating drugs	group	202-215	false

DDI-DrugBank.d495.s3	Narcotic analgesics may potentiate the hypotensive effects of clonidine.
Narcotic analgesics	group	0-18	clonidine	drug	62-70	effect

DDI-DrugBank.d495.s4	Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
Tricyclic antidepressants	group	0-24	clonidine	drug	68-76	effect

DDI-DrugBank.d495.s5	The effects of tricyclic antidepressants on clonidines analgesic actions are not known.
tricyclic antidepressants	group	15-39	clonidine	drug	44-52	false

DDI-DrugBank.d495.s6	Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
Beta blockers	group	0-12	clonidine	drug	65-73	effect

DDI-DrugBank.d495.s7	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
clonidine	drug	125-133	digitalis	group	213-221	advise
clonidine	drug	125-133	calcium channel blockers	group	224-247	advise
clonidine	drug	125-133	beta-blockers	group	254-266	advise
digitalis	group	213-221	calcium channel blockers	group	224-247	false
digitalis	group	213-221	beta-blockers	group	254-266	false
calcium channel blockers	group	224-247	beta-blockers	group	254-266	false

DDI-DrugBank.d495.s8	There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
fluphenazine	drug	100-111	clonidine	drug	122-130	effect

DDI-DrugBank.d495.s9	Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.
clonidine	drug	23-31	clonidine	drug	99-107	false

DDI-DrugBank.d495.s10	Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
clonidine	drug	9-17	anesthetics	group	87-97	effect

DDI-DrugBank.d343.s0	Aspirin, warfarin, heparin, NSAIDs
Aspirin	brand	0-6	warfarin	drug	9-16	false
Aspirin	brand	0-6	heparin	drug	19-25	false
Aspirin	brand	0-6	NSAIDs	group	28-33	false
warfarin	drug	9-16	heparin	drug	19-25	false
warfarin	drug	9-16	NSAIDs	group	28-33	false
heparin	drug	19-25	NSAIDs	group	28-33	false

DDI-DrugBank.d335.s1	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
clorazepate dipotassium	drug	33-55	hexobarbital	drug	90-101	effect
clorazepate dipotassium	drug	33-55	ethyl alcohol	drug	112-124	effect
clorazepate dipotassium	drug	33-55	chlorpromazine	drug	163-176	effect
hexobarbital	drug	90-101	ethyl alcohol	drug	112-124	false
hexobarbital	drug	90-101	chlorpromazine	drug	163-176	false
ethyl alcohol	drug	112-124	chlorpromazine	drug	163-176	false

DDI-DrugBank.d335.s3	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
benzodiazepines	group	19-33	barbiturates	group	57-68	effect
benzodiazepines	group	19-33	narcotics	group	71-79	effect
benzodiazepines	group	19-33	phenothiazines	group	82-95	effect
benzodiazepines	group	19-33	monoamine oxidase inhibitors	group	98-125	effect
benzodiazepines	group	19-33	antidepressants	group	136-150	effect
barbiturates	group	57-68	narcotics	group	71-79	false
barbiturates	group	57-68	phenothiazines	group	82-95	false
barbiturates	group	57-68	monoamine oxidase inhibitors	group	98-125	false
barbiturates	group	57-68	antidepressants	group	136-150	false
narcotics	group	71-79	phenothiazines	group	82-95	false
narcotics	group	71-79	monoamine oxidase inhibitors	group	98-125	false
narcotics	group	71-79	antidepressants	group	136-150	false
phenothiazines	group	82-95	monoamine oxidase inhibitors	group	98-125	false
phenothiazines	group	82-95	antidepressants	group	136-150	false
monoamine oxidase inhibitors	group	98-125	antidepressants	group	136-150	false

DDI-DrugBank.d335.s5	In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.
antacids	group	82-89	TRANXENE	brand	168-175	false

DDI-DrugBank.d480.s4	Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
Clozapine	drug	33-41	alcohol	drug	120-126	effect

DDI-DrugBank.d480.s7	similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.
psychotropic drugs	group	59-76	Clozapine	drug	86-94	false

DDI-DrugBank.d480.s8	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
Clozapine	drug	74-82	benzodiazepines	group	88-102	false
Clozapine	drug	74-82	psychotropics	group	113-125	false
Clozapine	drug	74-82	clozapine	drug	152-160	false
Clozapine	drug	74-82	benzodiazepine	group	196-209	false
Clozapine	drug	74-82	psychotropic drug	group	224-240	false
benzodiazepines	group	88-102	psychotropics	group	113-125	false
benzodiazepines	group	88-102	clozapine	drug	152-160	false
benzodiazepines	group	88-102	benzodiazepine	group	196-209	false
benzodiazepines	group	88-102	psychotropic drug	group	224-240	false
psychotropics	group	113-125	clozapine	drug	152-160	false
psychotropics	group	113-125	benzodiazepine	group	196-209	false
psychotropics	group	113-125	psychotropic drug	group	224-240	false
clozapine	drug	152-160	benzodiazepine	group	196-209	advise
clozapine	drug	152-160	psychotropic drug	group	224-240	advise
benzodiazepine	group	196-209	psychotropic drug	group	224-240	false

DDI-DrugBank.d480.s9	Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
Clozapine	drug	0-8	antihypertensive drugs	group	52-73	effect
Clozapine	drug	0-8	atropine	drug	110-117	effect
antihypertensive drugs	group	52-73	atropine	drug	110-117	false

DDI-DrugBank.d480.s10	The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.
epinephrine	drug	22-32	epinephrine	drug	127-137	false

DDI-DrugBank.d480.s15	Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
Phenytoin	drug	0-8	nicotine	drug	11-18	false
Phenytoin	drug	0-8	rifampin	drug	25-32	false
Phenytoin	drug	0-8	Clozapine	drug	47-55	mechanism
Phenytoin	drug	0-8	Clozapine	drug	139-147	false
nicotine	drug	11-18	rifampin	drug	25-32	false
nicotine	drug	11-18	Clozapine	drug	47-55	mechanism
nicotine	drug	11-18	Clozapine	drug	139-147	false
rifampin	drug	25-32	Clozapine	drug	47-55	mechanism
rifampin	drug	25-32	Clozapine	drug	139-147	false
Clozapine	drug	47-55	Clozapine	drug	139-147	false

DDI-DrugBank.d480.s17	Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
Cimetidine	drug	0-9	caffeine	drug	12-19	false
Cimetidine	drug	0-9	erythromycin	drug	26-37	false
Cimetidine	drug	0-9	Clozapine	drug	69-77	mechanism
caffeine	drug	12-19	erythromycin	drug	26-37	false
caffeine	drug	12-19	Clozapine	drug	69-77	mechanism
erythromycin	drug	26-37	Clozapine	drug	69-77	mechanism

DDI-DrugBank.d480.s18	Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
Clozapine	drug	28-36	carbamazepine	drug	42-54	advise
Clozapine	drug	28-36	carbamazepine	drug	131-143	false
Clozapine	drug	28-36	Clozapine	drug	189-197	false
carbamazepine	drug	42-54	carbamazepine	drug	131-143	false
carbamazepine	drug	42-54	Clozapine	drug	189-197	false
carbamazepine	drug	131-143	Clozapine	drug	189-197	mechanism

DDI-DrugBank.d480.s19	In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.
clozapine	drug	50-58	fluvoxamine	drug	91-101	false
clozapine	drug	50-58	paroxetine	drug	106-115	false
fluvoxamine	drug	91-101	paroxetine	drug	106-115	false

DDI-DrugBank.d480.s20	After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
clozapine	drug	66-74	N-desmethylclozapine	drug_n	97-116	false
clozapine	drug	66-74	clozapine N-oxide	drug_n	122-138	false
clozapine	drug	66-74	fluvoxamine	drug	160-170	false
N-desmethylclozapine	drug_n	97-116	clozapine N-oxide	drug_n	122-138	false
N-desmethylclozapine	drug_n	97-116	fluvoxamine	drug	160-170	false
clozapine N-oxide	drug_n	122-138	fluvoxamine	drug	160-170	false

DDI-DrugBank.d480.s21	Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
Paroxetine	drug	0-9	clozapine	drug	56-64	mechanism

DDI-DrugBank.d480.s22	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
clozapine	drug	84-92	clozapine	drug	129-137	false
clozapine	drug	84-92	paroxetine	drug	154-163	false
clozapine	drug	84-92	fluoxetine	drug	166-175	false
clozapine	drug	84-92	sertraline	drug	182-191	false
clozapine	drug	129-137	paroxetine	drug	154-163	mechanism
clozapine	drug	129-137	fluoxetine	drug	166-175	mechanism
clozapine	drug	129-137	sertraline	drug	182-191	mechanism
paroxetine	drug	154-163	fluoxetine	drug	166-175	false
paroxetine	drug	154-163	sertraline	drug	182-191	false
fluoxetine	drug	166-175	sertraline	drug	182-191	false

DDI-DrugBank.d480.s23	Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
Clozapine	drug	115-123	fluvoxamine	drug	173-183	advise

DDI-DrugBank.d480.s26	Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.
debrisoquin	drug	71-81	dextromethorphan	drug	84-99	false
debrisoquin	drug	71-81	tricyclic antidepressants	group	106-130	false
debrisoquin	drug	71-81	clozapine	drug	137-145	false
dextromethorphan	drug	84-99	tricyclic antidepressants	group	106-130	false
dextromethorphan	drug	84-99	clozapine	drug	137-145	false
tricyclic antidepressants	group	106-130	clozapine	drug	137-145	false

DDI-DrugBank.d480.s28	In addition, certain drugs that are metabolized by this isozyme, including many antidepressants (clozapine, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
antidepressants	group	80-94	clozapine	drug	97-105	false
antidepressants	group	80-94	selective serotonin reuptake inhibitors	group	108-146	false
clozapine	drug	97-105	selective serotonin reuptake inhibitors	group	108-146	false

DDI-DrugBank.d480.s29	Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.
clozapine	drug	19-27	clozapine	drug	140-148	false

DDI-DrugBank.d480.s30	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
clozapine	drug	32-40	antidepressants	group	107-121	advise
clozapine	drug	32-40	phenothiazines	group	124-137	advise
clozapine	drug	32-40	carbamazepine	drug	140-152	advise
clozapine	drug	32-40	Type 1C antiarrhythmics	group	159-181	advise
clozapine	drug	32-40	propafenone	drug	190-200	advise
clozapine	drug	32-40	flecainide	drug	203-212	advise
clozapine	drug	32-40	encainide	drug	218-226	advise
clozapine	drug	32-40	quinidine	drug	265-273	advise
antidepressants	group	107-121	phenothiazines	group	124-137	false
antidepressants	group	107-121	carbamazepine	drug	140-152	false
antidepressants	group	107-121	Type 1C antiarrhythmics	group	159-181	false
antidepressants	group	107-121	propafenone	drug	190-200	false
antidepressants	group	107-121	flecainide	drug	203-212	false
antidepressants	group	107-121	encainide	drug	218-226	false
antidepressants	group	107-121	quinidine	drug	265-273	false
phenothiazines	group	124-137	carbamazepine	drug	140-152	false
phenothiazines	group	124-137	Type 1C antiarrhythmics	group	159-181	false
phenothiazines	group	124-137	propafenone	drug	190-200	false
phenothiazines	group	124-137	flecainide	drug	203-212	false
phenothiazines	group	124-137	encainide	drug	218-226	false
phenothiazines	group	124-137	quinidine	drug	265-273	false
carbamazepine	drug	140-152	Type 1C antiarrhythmics	group	159-181	false
carbamazepine	drug	140-152	propafenone	drug	190-200	false
carbamazepine	drug	140-152	flecainide	drug	203-212	false
carbamazepine	drug	140-152	encainide	drug	218-226	false
carbamazepine	drug	140-152	quinidine	drug	265-273	false
Type 1C antiarrhythmics	group	159-181	propafenone	drug	190-200	false
Type 1C antiarrhythmics	group	159-181	flecainide	drug	203-212	false
Type 1C antiarrhythmics	group	159-181	encainide	drug	218-226	false
Type 1C antiarrhythmics	group	159-181	quinidine	drug	265-273	false
propafenone	drug	190-200	flecainide	drug	203-212	false
propafenone	drug	190-200	encainide	drug	218-226	false
propafenone	drug	190-200	quinidine	drug	265-273	false
flecainide	drug	203-212	encainide	drug	218-226	false
flecainide	drug	203-212	quinidine	drug	265-273	false
encainide	drug	218-226	quinidine	drug	265-273	false

DDI-DrugBank.d221.s0	The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.
NovoSeven	brand	44-52	coagulation factor	group	58-75	false

DDI-DrugBank.d221.s1	Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.
activated prothrombin complex concentrates	group	20-61	prothrombin complex concentrates	group	66-97	false

DDI-DrugBank.d221.s2	Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
tranexamic acid	drug	170-184	aminocaproic acid	drug	187-203	false
tranexamic acid	drug	170-184	NovoSeven	brand	210-218	false
aminocaproic acid	drug	187-203	NovoSeven	brand	210-218	false

DDI-DrugBank.d464.s0	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
Codeine	drug	0-6	narcotic analgesics	group	34-52	effect
Codeine	drug	0-6	anesthetics	group	63-73	effect
Codeine	drug	0-6	phenothiazines	group	76-89	effect
Codeine	drug	0-6	tranquilizers	group	92-104	effect
Codeine	drug	0-6	sedative-hypnotics	group	107-124	effect
Codeine	drug	0-6	CNS depressants	group	136-150	effect
Codeine	drug	0-6	alcohol	drug	163-169	effect
narcotic analgesics	group	34-52	anesthetics	group	63-73	false
narcotic analgesics	group	34-52	phenothiazines	group	76-89	false
narcotic analgesics	group	34-52	tranquilizers	group	92-104	false
narcotic analgesics	group	34-52	sedative-hypnotics	group	107-124	false
narcotic analgesics	group	34-52	CNS depressants	group	136-150	false
narcotic analgesics	group	34-52	alcohol	drug	163-169	false
anesthetics	group	63-73	phenothiazines	group	76-89	false
anesthetics	group	63-73	tranquilizers	group	92-104	false
anesthetics	group	63-73	sedative-hypnotics	group	107-124	false
anesthetics	group	63-73	CNS depressants	group	136-150	false
anesthetics	group	63-73	alcohol	drug	163-169	false
phenothiazines	group	76-89	tranquilizers	group	92-104	false
phenothiazines	group	76-89	sedative-hypnotics	group	107-124	false
phenothiazines	group	76-89	CNS depressants	group	136-150	false
phenothiazines	group	76-89	alcohol	drug	163-169	false
tranquilizers	group	92-104	sedative-hypnotics	group	107-124	false
tranquilizers	group	92-104	CNS depressants	group	136-150	false
tranquilizers	group	92-104	alcohol	drug	163-169	false
sedative-hypnotics	group	107-124	CNS depressants	group	136-150	false
sedative-hypnotics	group	107-124	alcohol	drug	163-169	false
CNS depressants	group	136-150	alcohol	drug	163-169	false

DDI-DrugBank.d146.s0	Colchicine is inhibited by acidifying agents.
Colchicine	drug	0-9	acidifying agents	group	27-43	mechanism

DDI-DrugBank.d146.s1	The action of colchicine is potentiated by alkalinizing agents.
colchicine	drug	14-23	alkalinizing agents	group	43-61	mechanism

DDI-DrugBank.d146.s2	Colchicine may increase sensitivity to the CNS depressants.
Colchicine	drug	0-9	CNS depressants	group	43-57	effect

DDI-DrugBank.d146.s3	Response to sympathomimetic agents may be enhanced by colchicine.
sympathomimetic agents	group	12-33	colchicine	drug	54-63	effect

DDI-DrugBank.d551.s1	WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
WelChol	brand	0-6	digoxin	drug	75-81	false
WelChol	brand	0-6	lovastatin	drug	84-93	false
WelChol	brand	0-6	metoprolol	drug	96-105	false
WelChol	brand	0-6	quinidine	drug	108-116	false
WelChol	brand	0-6	valproic acid	drug	119-131	false
WelChol	brand	0-6	warfarin	drug	138-145	false
digoxin	drug	75-81	lovastatin	drug	84-93	false
digoxin	drug	75-81	metoprolol	drug	96-105	false
digoxin	drug	75-81	quinidine	drug	108-116	false
digoxin	drug	75-81	valproic acid	drug	119-131	false
digoxin	drug	75-81	warfarin	drug	138-145	false
lovastatin	drug	84-93	metoprolol	drug	96-105	false
lovastatin	drug	84-93	quinidine	drug	108-116	false
lovastatin	drug	84-93	valproic acid	drug	119-131	false
lovastatin	drug	84-93	warfarin	drug	138-145	false
metoprolol	drug	96-105	quinidine	drug	108-116	false
metoprolol	drug	96-105	valproic acid	drug	119-131	false
metoprolol	drug	96-105	warfarin	drug	138-145	false
quinidine	drug	108-116	valproic acid	drug	119-131	false
quinidine	drug	108-116	warfarin	drug	138-145	false
valproic acid	drug	119-131	warfarin	drug	138-145	false

DDI-DrugBank.d551.s2	WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
WelChol	brand	0-6	verapamil	drug	57-65	mechanism
WelChol	brand	0-6	Calan SR	brand	68-75	mechanism
verapamil	drug	57-65	Calan SR	brand	68-75	false

DDI-DrugBank.d551.s4	In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
WelChol	brand	41-47	atorvastatin	drug	55-66	false
WelChol	brand	41-47	lovastatin	drug	69-78	false
WelChol	brand	41-47	simvastatin	drug	84-94	false
WelChol	brand	41-47	HMG-CoA reductase inhibitor	group	154-180	false
atorvastatin	drug	55-66	lovastatin	drug	69-78	false
atorvastatin	drug	55-66	simvastatin	drug	84-94	false
atorvastatin	drug	55-66	HMG-CoA reductase inhibitor	group	154-180	false
lovastatin	drug	69-78	simvastatin	drug	84-94	false
lovastatin	drug	69-78	HMG-CoA reductase inhibitor	group	154-180	false
simvastatin	drug	84-94	HMG-CoA reductase inhibitor	group	154-180	false

DDI-DrugBank.d345.s0	Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids.
colestipol hydrochloride	drug	6-29	anion exchange resin	group	37-56	false

DDI-DrugBank.d345.s5	Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
colestipol hydrochloride	drug	18-41	propranolol	drug	75-85	mechanism
colestipol hydrochloride	drug	18-41	propranolol	drug	134-144	false
propranolol	drug	75-85	propranolol	drug	134-144	false

DDI-DrugBank.d345.s6	However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;
colestipol hydrochloride	drug	80-103	propranolol	drug	109-119	false
colestipol hydrochloride	drug	80-103	propranolol	drug	207-217	false
propranolol	drug	109-119	propranolol	drug	207-217	false

DDI-DrugBank.d345.s9	Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
propranolol	drug	23-33	COLESTID	brand	59-66	advise

DDI-DrugBank.d345.s10	Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
chlorothiazide	drug	46-59	colestipol hydrochloride	drug	156-179	mechanism

DDI-DrugBank.d345.s11	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
tetracycline	drug	18-29	furosemide	drug	32-41	false
tetracycline	drug	18-29	penicillin G	drug	44-55	false
tetracycline	drug	18-29	hydrochlorothiazide	drug	58-76	false
tetracycline	drug	18-29	gemfibrozil	drug	83-93	false
tetracycline	drug	18-29	colestipol hydrochloride	drug	154-177	mechanism
furosemide	drug	32-41	penicillin G	drug	44-55	false
furosemide	drug	32-41	hydrochlorothiazide	drug	58-76	false
furosemide	drug	32-41	gemfibrozil	drug	83-93	false
furosemide	drug	32-41	colestipol hydrochloride	drug	154-177	mechanism
penicillin G	drug	44-55	hydrochlorothiazide	drug	58-76	false
penicillin G	drug	44-55	gemfibrozil	drug	83-93	false
penicillin G	drug	44-55	colestipol hydrochloride	drug	154-177	mechanism
hydrochlorothiazide	drug	58-76	gemfibrozil	drug	83-93	false
hydrochlorothiazide	drug	58-76	colestipol hydrochloride	drug	154-177	mechanism
gemfibrozil	drug	83-93	colestipol hydrochloride	drug	154-177	mechanism

DDI-DrugBank.d345.s13	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
colestipol hydrochloride	drug	62-85	aspirin	brand	137-143	false
colestipol hydrochloride	drug	62-85	clindamycin	brand	146-156	false
colestipol hydrochloride	drug	62-85	clofibrate	drug	159-168	false
colestipol hydrochloride	drug	62-85	methyldopa	drug	171-180	false
colestipol hydrochloride	drug	62-85	nicotinic acid	drug	183-196	false
colestipol hydrochloride	drug	62-85	niacin	drug	199-204	false
colestipol hydrochloride	drug	62-85	tolbutamide	drug	208-218	false
colestipol hydrochloride	drug	62-85	phenytoin	drug	221-229	false
colestipol hydrochloride	drug	62-85	warfarin	drug	234-241	false
aspirin	brand	137-143	clindamycin	brand	146-156	false
aspirin	brand	137-143	clofibrate	drug	159-168	false
aspirin	brand	137-143	methyldopa	drug	171-180	false
aspirin	brand	137-143	nicotinic acid	drug	183-196	false
aspirin	brand	137-143	niacin	drug	199-204	false
aspirin	brand	137-143	tolbutamide	drug	208-218	false
aspirin	brand	137-143	phenytoin	drug	221-229	false
aspirin	brand	137-143	warfarin	drug	234-241	false
clindamycin	brand	146-156	clofibrate	drug	159-168	false
clindamycin	brand	146-156	methyldopa	drug	171-180	false
clindamycin	brand	146-156	nicotinic acid	drug	183-196	false
clindamycin	brand	146-156	niacin	drug	199-204	false
clindamycin	brand	146-156	tolbutamide	drug	208-218	false
clindamycin	brand	146-156	phenytoin	drug	221-229	false
clindamycin	brand	146-156	warfarin	drug	234-241	false
clofibrate	drug	159-168	methyldopa	drug	171-180	false
clofibrate	drug	159-168	nicotinic acid	drug	183-196	false
clofibrate	drug	159-168	niacin	drug	199-204	false
clofibrate	drug	159-168	tolbutamide	drug	208-218	false
clofibrate	drug	159-168	phenytoin	drug	221-229	false
clofibrate	drug	159-168	warfarin	drug	234-241	false
methyldopa	drug	171-180	nicotinic acid	drug	183-196	false
methyldopa	drug	171-180	niacin	drug	199-204	false
methyldopa	drug	171-180	tolbutamide	drug	208-218	false
methyldopa	drug	171-180	phenytoin	drug	221-229	false
methyldopa	drug	171-180	warfarin	drug	234-241	false
nicotinic acid	drug	183-196	niacin	drug	199-204	false
nicotinic acid	drug	183-196	tolbutamide	drug	208-218	false
nicotinic acid	drug	183-196	phenytoin	drug	221-229	false
nicotinic acid	drug	183-196	warfarin	drug	234-241	false
niacin	drug	199-204	tolbutamide	drug	208-218	false
niacin	drug	199-204	phenytoin	drug	221-229	false
niacin	drug	199-204	warfarin	drug	234-241	false
tolbutamide	drug	208-218	phenytoin	drug	221-229	false
tolbutamide	drug	208-218	warfarin	drug	234-241	false
phenytoin	drug	221-229	warfarin	drug	234-241	false

DDI-DrugBank.d345.s14	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
digitalis preparations	group	43-64	colestipol hydrochloride	drug	120-143	effect
digitalis preparations	group	43-64	digoxin	drug	168-174	false
digitalis preparations	group	43-64	digitoxin	drug	180-188	false
colestipol hydrochloride	drug	120-143	digoxin	drug	168-174	mechanism
colestipol hydrochloride	drug	120-143	digitoxin	drug	180-188	mechanism
digoxin	drug	168-174	digitoxin	drug	180-188	false

DDI-DrugBank.d345.s16	Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.
colestipol hydrochloride	drug	14-37	resin	group	132-136	false
colestipol hydrochloride	drug	14-37	colestipol hydrochloride	drug	208-231	false
resin	group	132-136	colestipol hydrochloride	drug	208-231	false

DDI-DrugBank.d345.s17	Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
Bile acid binding resins	group	0-23	phosphate	drug	72-80	mechanism
Bile acid binding resins	group	0-23	hydrocortisone	drug	98-111	mechanism
phosphate	drug	72-80	hydrocortisone	drug	98-111	false

DDI-DrugBank.d250.s0	Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
antibiotics	group	14-24	aminoglycosides	group	27-41	false
antibiotics	group	14-24	polymyxin	group	47-55	false
aminoglycosides	group	27-41	polymyxin	group	47-55	false

DDI-DrugBank.d250.s2	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
Curariform muscle relaxants	brand	0-26	tubocurarine	drug	33-44	false
Curariform muscle relaxants	brand	0-26	succinylcholine	drug	81-95	false
Curariform muscle relaxants	brand	0-26	gallamine	drug	98-106	false
Curariform muscle relaxants	brand	0-26	decamethonium	drug	109-121	false
Curariform muscle relaxants	brand	0-26	sodium citrate	drug	127-140	false
Curariform muscle relaxants	brand	0-26	Coly-Mycin M	brand	259-270	effect
tubocurarine	drug	33-44	succinylcholine	drug	81-95	false
tubocurarine	drug	33-44	gallamine	drug	98-106	false
tubocurarine	drug	33-44	decamethonium	drug	109-121	false
tubocurarine	drug	33-44	sodium citrate	drug	127-140	false
tubocurarine	drug	33-44	Coly-Mycin M	brand	259-270	effect
succinylcholine	drug	81-95	gallamine	drug	98-106	false
succinylcholine	drug	81-95	decamethonium	drug	109-121	false
succinylcholine	drug	81-95	sodium citrate	drug	127-140	false
succinylcholine	drug	81-95	Coly-Mycin M	brand	259-270	effect
gallamine	drug	98-106	decamethonium	drug	109-121	false
gallamine	drug	98-106	sodium citrate	drug	127-140	false
gallamine	drug	98-106	Coly-Mycin M	brand	259-270	effect
decamethonium	drug	109-121	sodium citrate	drug	127-140	false
decamethonium	drug	109-121	Coly-Mycin M	brand	259-270	effect
sodium citrate	drug	127-140	Coly-Mycin M	brand	259-270	effect

DDI-DrugBank.d250.s3	Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
Sodium cephalothin	drug	0-17	Coly-Mycin M	brand	53-64	effect

DDI-DrugBank.d250.s4	The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
sodium cephalothin	drug	23-40	Coly-Mycin M	brand	46-57	advise

DDI-DrugBank.d315.s0	Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
Digoxin	drug	0-6	digoxin	drug	29-35	false
Digoxin	drug	0-6	conivaptan	drug	76-85	false
Digoxin	drug	0-6	digoxin	drug	143-149	false
digoxin	drug	29-35	conivaptan	drug	76-85	mechanism
digoxin	drug	29-35	digoxin	drug	143-149	false
conivaptan	drug	76-85	digoxin	drug	143-149	false

DDI-DrugBank.d315.s1	Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
digoxin	drug	14-20	VAPRISOL	brand	43-50	mechanism
digoxin	drug	14-20	digoxin	drug	118-124	false
VAPRISOL	brand	43-50	digoxin	drug	118-124	false

DDI-DrugBank.d317.s4	decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
antithrombin III	drug	39-54	antithrombin III	drug	67-82	false

DDI-DrugBank.d317.s5	increased levels of fibrinogen and fibrinogen activity;
fibrinogen	drug	20-29	fibrinogen	drug	35-44	false

DDI-DrugBank.d317.s13	Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.
corticosteroids	group	171-185	sex steroids	group	191-202	false

DDI-DrugBank.d25.s0	Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
Corticotropin	drug	0-12	diuretic	drug	66-73	effect

DDI-DrugBank.d487.s1	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
phenobarbital	drug	42-54	phenytoin	drug	57-65	false
phenobarbital	drug	42-54	rifampin	drug	71-78	false
phenobarbital	drug	42-54	corticosteroids	group	110-124	mechanism
phenobarbital	drug	42-54	corticosteroid	group	155-168	advise
phenytoin	drug	57-65	rifampin	drug	71-78	false
phenytoin	drug	57-65	corticosteroids	group	110-124	mechanism
phenytoin	drug	57-65	corticosteroid	group	155-168	advise
rifampin	drug	71-78	corticosteroids	group	110-124	mechanism
rifampin	drug	71-78	corticosteroid	group	155-168	advise
corticosteroids	group	110-124	corticosteroid	group	155-168	false

DDI-DrugBank.d487.s2	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
troleandomycin	drug	14-27	ketoconazole	drug	33-44	false
troleandomycin	drug	14-27	corticosteroids	group	76-90	mechanism
ketoconazole	drug	33-44	corticosteroids	group	76-90	mechanism

DDI-DrugBank.d487.s4	Corticosteroids may increase the clearance of chronic high dose aspirin.
Corticosteroids	group	0-14	aspirin	brand	64-70	effect

DDI-DrugBank.d487.s5	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
salicylate	group	29-38	salicylate	group	77-86	false
salicylate	group	29-38	corticosteroid	drug	102-115	false
salicylate	group	77-86	corticosteroid	drug	102-115	effect

DDI-DrugBank.d487.s6	Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
Aspirin	brand	0-6	cortico-steroids	group	54-69	advise

DDI-DrugBank.d487.s7	The effect of corticosteroids on oral anticoagulants is variable.
corticosteroids	group	14-28	anticoagulants	group	38-51	effect

DDI-DrugBank.d487.s8	There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
anticoagulants	group	63-76	corticosteroids	group	107-121	effect

DDI-DrugBank.d439.s0	Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
Corticotropin	drug	0-12	diuretic	group	66-73	effect

DDI-DrugBank.d229.s0	Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.
Cromolyn sodium	drug	35-49	isoproterenol	drug	55-67	false

DDI-DrugBank.d229.s3	The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
cromolyn sodium	drug	33-47	isoproterenol	drug	168-180	effect

DDI-DrugBank.d39.s0	Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.
antibiotics	group	20-30	methotrexate	drug	33-44	false
antibiotics	group	20-30	pyrimethamine	drug	50-62	false
antibiotics	group	20-30	folic acid	drug	75-84	false
antibiotics	group	20-30	vitamin B12	drug	90-100	false
methotrexate	drug	33-44	pyrimethamine	drug	50-62	false
methotrexate	drug	33-44	folic acid	drug	75-84	false
methotrexate	drug	33-44	vitamin B12	drug	90-100	false
pyrimethamine	drug	50-62	folic acid	drug	75-84	false
pyrimethamine	drug	50-62	vitamin B12	drug	90-100	false
folic acid	drug	75-84	vitamin B12	drug	90-100	false

DDI-DrugBank.d39.s1	Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
Colchicine	drug	0-9	para-aminosalicylic acid	drug	11-34	false
Colchicine	drug	0-9	alcohol	drug	46-52	false
Colchicine	drug	0-9	vitamin B12	drug	114-124	mechanism
para-aminosalicylic acid	drug	11-34	alcohol	drug	46-52	false
para-aminosalicylic acid	drug	11-34	vitamin B12	drug	114-124	mechanism
alcohol	drug	46-52	vitamin B12	drug	114-124	mechanism

DDI-DrugBank.d150.s0	FLEXERIL may have life-threatening interactions with MAO inhibitors.
FLEXERIL	brand	0-7	MAO inhibitors	group	53-66	int

DDI-DrugBank.d150.s1	FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
FLEXERIL	brand	0-7	alcohol	drug	36-42	effect
FLEXERIL	brand	0-7	barbiturates	group	45-56	effect
FLEXERIL	brand	0-7	CNS depressants	group	69-83	effect
alcohol	drug	36-42	barbiturates	group	45-56	false
alcohol	drug	36-42	CNS depressants	group	69-83	false
barbiturates	group	45-56	CNS depressants	group	69-83	false

DDI-DrugBank.d150.s2	Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
Tricyclic antidepressants	group	0-24	guanethidine	drug	67-78	effect

DDI-DrugBank.d150.s3	Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
Tricyclic antidepressants	group	0-24	tramadol	drug	74-81	effect

DDI-DrugBank.d298.s0	Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
Cyclopentolate	drug	0-13	carbachol	drug	62-70	effect
Cyclopentolate	drug	0-13	pilocarpine	drug	75-85	effect
carbachol	drug	62-70	pilocarpine	drug	75-85	false

DDI-DrugBank.d7.s0	The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
cyclophosphamide	drug	54-69	phenobarbital	drug	139-151	mechanism

DDI-DrugBank.d7.s1	The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
cyclophosphamide	drug	102-117	cyclophosphamide	drug	131-146	false

DDI-DrugBank.d7.s2	Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
Cyclophosphamide	drug	0-15	succinylcholine chloride	drug	130-153	effect

DDI-DrugBank.d128.s0	May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).
Trecator-SC	brand	31-41	isoniazid	drug	48-56	false
Trecator-SC	brand	31-41	Nydrazid	brand	59-66	false
isoniazid	drug	48-56	Nydrazid	brand	59-66	false

DDI-DrugBank.d492.s0	MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
MAO inhibitors	group	0-13	antihistamines	group	68-81	effect

DDI-DrugBank.d492.s1	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
Antihistamines	group	0-13	alcohol	drug	46-52	effect
Antihistamines	group	0-13	CNS depressants	group	64-78	effect
Antihistamines	group	0-13	hypnotics	group	87-95	effect
Antihistamines	group	0-13	sedatives	group	98-106	effect
Antihistamines	group	0-13	tranquilizers	group	109-121	effect
Antihistamines	group	0-13	antianxiety agents	group	124-141	effect
alcohol	drug	46-52	CNS depressants	group	64-78	false
alcohol	drug	46-52	hypnotics	group	87-95	false
alcohol	drug	46-52	sedatives	group	98-106	false
alcohol	drug	46-52	tranquilizers	group	109-121	false
alcohol	drug	46-52	antianxiety agents	group	124-141	false
CNS depressants	group	64-78	hypnotics	group	87-95	false
CNS depressants	group	64-78	sedatives	group	98-106	false
CNS depressants	group	64-78	tranquilizers	group	109-121	false
CNS depressants	group	64-78	antianxiety agents	group	124-141	false
hypnotics	group	87-95	sedatives	group	98-106	false
hypnotics	group	87-95	tranquilizers	group	109-121	false
hypnotics	group	87-95	antianxiety agents	group	124-141	false
sedatives	group	98-106	tranquilizers	group	109-121	false
sedatives	group	98-106	antianxiety agents	group	124-141	false
tranquilizers	group	109-121	antianxiety agents	group	124-141	false

DDI-DrugBank.d294.s0	Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.
Dactinomycin	drug	33-44	antibacterial drug	group	110-127	false

DDI-DrugBank.d305.s1	However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.
phenobarbital	drug	17-29	diazepam	drug	35-42	false
phenobarbital	drug	17-29	Dantrium	brand	62-69	false
diazepam	drug	35-42	Dantrium	brand	62-69	false

DDI-DrugBank.d305.s2	Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.
diazepam	drug	58-65	diphenylhydantoin	drug	68-84	false
diazepam	drug	58-65	phenylbutazone	drug	90-103	false
diphenylhydantoin	drug	68-84	phenylbutazone	drug	90-103	false

DDI-DrugBank.d305.s3	Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide.
warfarin	drug	41-48	tolbutamide	drug	82-92	false

DDI-DrugBank.d305.s5	The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
dantrolene sodium	drug	52-68	verapamil	drug	74-82	false
dantrolene sodium	drug	52-68	halothane	drug	87-95	false
verapamil	drug	74-82	halothane	drug	87-95	false

DDI-DrugBank.d305.s6	It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
dantrolene sodium	drug	54-70	calcium channel blockers	group	76-99	advise
dantrolene sodium	drug	54-70	verapamil	drug	110-118	advise
calcium channel blockers	group	76-99	verapamil	drug	110-118	false

DDI-DrugBank.d305.s7	Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
dantrolene	drug	18-27	vecuronium	drug	44-53	effect

DDI-DrugBank.d185.s0	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX).
ACZONE	brand	65-70	trimethoprim	drug	133-144	false
ACZONE	brand	65-70	sulfamethoxazole	drug	146-161	false
ACZONE	brand	65-70	TMP	drug	164-166	false
ACZONE	brand	65-70	SMX	drug	168-170	false
trimethoprim	drug	133-144	sulfamethoxazole	drug	146-161	false
trimethoprim	drug	133-144	TMP	drug	164-166	false
trimethoprim	drug	133-144	SMX	drug	168-170	false
sulfamethoxazole	drug	146-161	TMP	drug	164-166	false
sulfamethoxazole	drug	146-161	SMX	drug	168-170	false
TMP	drug	164-166	SMX	drug	168-170	false

DDI-DrugBank.d185.s1	During co-administration, systemic levels of TMP and SMX were essentially unchanged.
TMP	drug	45-47	SMX	drug	53-55	false

DDI-DrugBank.d185.s2	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX.
dapsone hydroxylamine	drug_n	40-60	DHA	drug_n	63-65	false
dapsone hydroxylamine	drug_n	40-60	TMP	drug	109-111	false
dapsone hydroxylamine	drug_n	40-60	SMX	drug	113-115	false
DHA	drug_n	63-65	TMP	drug	109-111	false
DHA	drug_n	63-65	SMX	drug	113-115	false
TMP	drug	109-111	SMX	drug	113-115	false

DDI-DrugBank.d185.s3	Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.
TMP	drug	118-120	SMX	drug	122-124	false

DDI-DrugBank.d185.s4	Certain concomitant medications (such as rifampin, anticonvulsants, St.
rifampin	drug	41-48	anticonvulsants	group	51-65	false

DDI-DrugBank.d185.s5	John s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.
dapsone hydroxylamine	drug_n	43-63	dapsone	drug	82-88	false

DDI-DrugBank.d185.s6	With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
dapsone	drug	10-16	folic acid antagonists	group	29-50	effect
dapsone	drug	10-16	pyrimethamine	drug	60-72	effect
folic acid antagonists	group	29-50	pyrimethamine	drug	60-72	false

DDI-DrugBank.d337.s0	Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
Warfarin	drug	0-7	daptomycin	drug	40-49	false
Warfarin	drug	0-7	warfarin	drug	96-103	false
daptomycin	drug	40-49	warfarin	drug	96-103	false

DDI-DrugBank.d337.s1	HMG-CoA Reductase Inhibitors: Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.
HMG-CoA Reductase Inhibitors	group	0-27	Inhibitors of HMG-CoA reductase	group	30-60	false

DDI-DrugBank.d337.s2	There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.
simvastatin	drug	120-130	daptomycin	drug	171-180	false

DDI-DrugBank.d337.s3	Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
HMG-CoA reductase inhibitors	group	37-64	Fentanyl	drug	70-77	false
HMG-CoA reductase inhibitors	group	37-64	HMG-CoA reductase inhibitors	group	175-202	false
HMG-CoA reductase inhibitors	group	37-64	Fentanyl	drug	226-233	false
Fentanyl	drug	70-77	HMG-CoA reductase inhibitors	group	175-202	false
Fentanyl	drug	70-77	Fentanyl	drug	226-233	false
HMG-CoA reductase inhibitors	group	175-202	Fentanyl	drug	226-233	advise

DDI-DrugBank.d459.s0	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
ENABLEX	brand	18-24	ketoconazole	drug	108-119	advise
ENABLEX	brand	18-24	itraconazole	drug	122-133	advise
ENABLEX	brand	18-24	ritonavir	drug	136-144	advise
ENABLEX	brand	18-24	nelfinavir	drug	147-156	advise
ENABLEX	brand	18-24	clarithromycin	drug	159-172	advise
ketoconazole	drug	108-119	itraconazole	drug	122-133	false
ketoconazole	drug	108-119	ritonavir	drug	136-144	false
ketoconazole	drug	108-119	nelfinavir	drug	147-156	false
ketoconazole	drug	108-119	clarithromycin	drug	159-172	false
itraconazole	drug	122-133	ritonavir	drug	136-144	false
itraconazole	drug	122-133	nelfinavir	drug	147-156	false
itraconazole	drug	122-133	clarithromycin	drug	159-172	false
ritonavir	drug	136-144	nelfinavir	drug	147-156	false
ritonavir	drug	136-144	clarithromycin	drug	159-172	false
nelfinavir	drug	147-156	clarithromycin	drug	159-172	false

DDI-DrugBank.d459.s1	Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
ENABLEX	brand	29-35	flecainide	drug	173-182	advise
ENABLEX	brand	29-35	thioridazine	drug	185-196	advise
ENABLEX	brand	29-35	tricyclic antidepressants	group	202-226	advise
flecainide	drug	173-182	thioridazine	drug	185-196	false
flecainide	drug	173-182	tricyclic antidepressants	group	202-226	false
thioridazine	drug	185-196	tricyclic antidepressants	group	202-226	false

DDI-DrugBank.d459.s2	The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
ENABLEX	brand	23-29	anticholinergic agents	group	42-63	effect

DDI-DrugBank.d48.s0	Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.
dasatinib	drug	24-32	Dasatinib	drug	75-83	false

DDI-DrugBank.d48.s1	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
SPRYCEL	brand	19-25	ketoconazole	drug	62-73	mechanism
SPRYCEL	brand	19-25	itraconazole	drug	76-87	mechanism
SPRYCEL	brand	19-25	erythromycin	drug	90-101	mechanism
SPRYCEL	brand	19-25	clarithromycin	drug	104-117	mechanism
SPRYCEL	brand	19-25	ritonavir	drug	120-128	mechanism
SPRYCEL	brand	19-25	atazanavir	drug	131-140	mechanism
SPRYCEL	brand	19-25	indinavir	drug	143-151	mechanism
SPRYCEL	brand	19-25	nefazodone	drug	154-163	mechanism
SPRYCEL	brand	19-25	nelfinavir	drug	166-175	mechanism
SPRYCEL	brand	19-25	saquinavir	drug	178-187	mechanism
SPRYCEL	brand	19-25	telithromycin	drug	190-202	mechanism
SPRYCEL	brand	19-25	dasatinib	drug	230-238	false
ketoconazole	drug	62-73	itraconazole	drug	76-87	false
ketoconazole	drug	62-73	erythromycin	drug	90-101	false
ketoconazole	drug	62-73	clarithromycin	drug	104-117	false
ketoconazole	drug	62-73	ritonavir	drug	120-128	false
ketoconazole	drug	62-73	atazanavir	drug	131-140	false
ketoconazole	drug	62-73	indinavir	drug	143-151	false
ketoconazole	drug	62-73	nefazodone	drug	154-163	false
ketoconazole	drug	62-73	nelfinavir	drug	166-175	false
ketoconazole	drug	62-73	saquinavir	drug	178-187	false
ketoconazole	drug	62-73	telithromycin	drug	190-202	false
ketoconazole	drug	62-73	dasatinib	drug	230-238	false
itraconazole	drug	76-87	erythromycin	drug	90-101	false
itraconazole	drug	76-87	clarithromycin	drug	104-117	false
itraconazole	drug	76-87	ritonavir	drug	120-128	false
itraconazole	drug	76-87	atazanavir	drug	131-140	false
itraconazole	drug	76-87	indinavir	drug	143-151	false
itraconazole	drug	76-87	nefazodone	drug	154-163	false
itraconazole	drug	76-87	nelfinavir	drug	166-175	false
itraconazole	drug	76-87	saquinavir	drug	178-187	false
itraconazole	drug	76-87	telithromycin	drug	190-202	false
itraconazole	drug	76-87	dasatinib	drug	230-238	false
erythromycin	drug	90-101	clarithromycin	drug	104-117	false
erythromycin	drug	90-101	ritonavir	drug	120-128	false
erythromycin	drug	90-101	atazanavir	drug	131-140	false
erythromycin	drug	90-101	indinavir	drug	143-151	false
erythromycin	drug	90-101	nefazodone	drug	154-163	false
erythromycin	drug	90-101	nelfinavir	drug	166-175	false
erythromycin	drug	90-101	saquinavir	drug	178-187	false
erythromycin	drug	90-101	telithromycin	drug	190-202	false
erythromycin	drug	90-101	dasatinib	drug	230-238	false
clarithromycin	drug	104-117	ritonavir	drug	120-128	false
clarithromycin	drug	104-117	atazanavir	drug	131-140	false
clarithromycin	drug	104-117	indinavir	drug	143-151	false
clarithromycin	drug	104-117	nefazodone	drug	154-163	false
clarithromycin	drug	104-117	nelfinavir	drug	166-175	false
clarithromycin	drug	104-117	saquinavir	drug	178-187	false
clarithromycin	drug	104-117	telithromycin	drug	190-202	false
clarithromycin	drug	104-117	dasatinib	drug	230-238	false
ritonavir	drug	120-128	atazanavir	drug	131-140	false
ritonavir	drug	120-128	indinavir	drug	143-151	false
ritonavir	drug	120-128	nefazodone	drug	154-163	false
ritonavir	drug	120-128	nelfinavir	drug	166-175	false
ritonavir	drug	120-128	saquinavir	drug	178-187	false
ritonavir	drug	120-128	telithromycin	drug	190-202	false
ritonavir	drug	120-128	dasatinib	drug	230-238	false
atazanavir	drug	131-140	indinavir	drug	143-151	false
atazanavir	drug	131-140	nefazodone	drug	154-163	false
atazanavir	drug	131-140	nelfinavir	drug	166-175	false
atazanavir	drug	131-140	saquinavir	drug	178-187	false
atazanavir	drug	131-140	telithromycin	drug	190-202	false
atazanavir	drug	131-140	dasatinib	drug	230-238	false
indinavir	drug	143-151	nefazodone	drug	154-163	false
indinavir	drug	143-151	nelfinavir	drug	166-175	false
indinavir	drug	143-151	saquinavir	drug	178-187	false
indinavir	drug	143-151	telithromycin	drug	190-202	false
indinavir	drug	143-151	dasatinib	drug	230-238	false
nefazodone	drug	154-163	nelfinavir	drug	166-175	false
nefazodone	drug	154-163	saquinavir	drug	178-187	false
nefazodone	drug	154-163	telithromycin	drug	190-202	false
nefazodone	drug	154-163	dasatinib	drug	230-238	false
nelfinavir	drug	166-175	saquinavir	drug	178-187	false
nelfinavir	drug	166-175	telithromycin	drug	190-202	false
nelfinavir	drug	166-175	dasatinib	drug	230-238	false
saquinavir	drug	178-187	telithromycin	drug	190-202	false
saquinavir	drug	178-187	dasatinib	drug	230-238	false
telithromycin	drug	190-202	dasatinib	drug	230-238	false

DDI-DrugBank.d48.s2	In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.
SPRYCEL	brand	37-43	SPRYCEL	brand	82-88	false

DDI-DrugBank.d48.s3	Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.
dasatinib	drug	24-32	dasatinib	drug	120-128	false

DDI-DrugBank.d48.s4	In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
dexamethasone	drug	41-53	phenytoin	drug	56-64	false
dexamethasone	drug	41-53	carbamazepine	drug	67-79	false
dexamethasone	drug	41-53	rifampicin	drug	82-91	false
dexamethasone	drug	41-53	phenobarbital	drug	94-106	false
phenytoin	drug	56-64	carbamazepine	drug	67-79	false
phenytoin	drug	56-64	rifampicin	drug	82-91	false
phenytoin	drug	56-64	phenobarbital	drug	94-106	false
carbamazepine	drug	67-79	rifampicin	drug	82-91	false
carbamazepine	drug	67-79	phenobarbital	drug	94-106	false
rifampicin	drug	82-91	phenobarbital	drug	94-106	false

DDI-DrugBank.d48.s5	If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.
SPRYCEL	brand	3-9	SPRYCEL	brand	74-80	false

DDI-DrugBank.d48.s8	Antacids: Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.
Antacids	group	0-7	dasatinib	drug	62-70	false

DDI-DrugBank.d48.s9	Simultaneous administration of SPRYCEL with antacids should be avoided.
SPRYCEL	brand	31-37	antacids	group	44-51	advise

DDI-DrugBank.d48.s10	If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
antacid	group	3-9	SPRYCEL	brand	125-131	advise

DDI-DrugBank.d48.s11	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
H2 Blockers	group	0-10	Proton Pump Inhibitors	group	12-33	false
H2 Blockers	group	0-10	H2 blockers	group	87-97	false
H2 Blockers	group	0-10	proton pump inhibitors	group	102-123	false
H2 Blockers	group	0-10	famotidine	drug	130-139	false
H2 Blockers	group	0-10	omeprazole	drug	145-154	false
H2 Blockers	group	0-10	dasatinib	drug	177-185	false
Proton Pump Inhibitors	group	12-33	H2 blockers	group	87-97	false
Proton Pump Inhibitors	group	12-33	proton pump inhibitors	group	102-123	false
Proton Pump Inhibitors	group	12-33	famotidine	drug	130-139	false
Proton Pump Inhibitors	group	12-33	omeprazole	drug	145-154	false
Proton Pump Inhibitors	group	12-33	dasatinib	drug	177-185	false
H2 blockers	group	87-97	proton pump inhibitors	group	102-123	false
H2 blockers	group	87-97	famotidine	drug	130-139	false
H2 blockers	group	87-97	omeprazole	drug	145-154	false
H2 blockers	group	87-97	dasatinib	drug	177-185	effect
proton pump inhibitors	group	102-123	famotidine	drug	130-139	false
proton pump inhibitors	group	102-123	omeprazole	drug	145-154	false
proton pump inhibitors	group	102-123	dasatinib	drug	177-185	effect
famotidine	drug	130-139	omeprazole	drug	145-154	false
famotidine	drug	130-139	dasatinib	drug	177-185	effect
omeprazole	drug	145-154	dasatinib	drug	177-185	effect

DDI-DrugBank.d48.s12	The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
H2 blockers	group	23-33	proton pump inhibitors	group	38-59	false
H2 blockers	group	23-33	SPRYCEL	brand	66-72	advise
proton pump inhibitors	group	38-59	SPRYCEL	brand	66-72	advise

DDI-DrugBank.d48.s13	The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
antacids	group	11-18	H2 blockers	group	53-63	false
antacids	group	11-18	proton pump inhibitors	group	68-89	false
antacids	group	11-18	SPRYCEL	brand	113-119	false
H2 blockers	group	53-63	proton pump inhibitors	group	68-89	false
H2 blockers	group	53-63	SPRYCEL	brand	113-119	advise
proton pump inhibitors	group	68-89	SPRYCEL	brand	113-119	advise

DDI-DrugBank.d48.s14	Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.
dasatinib	drug	58-66	Dasatinib	drug	87-95	false

DDI-DrugBank.d48.s15	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
alfentanil	drug	78-87	astemizole	drug	90-99	false
alfentanil	drug	78-87	terfenadine	drug	102-112	false
alfentanil	drug	78-87	cisapride	drug	115-123	false
alfentanil	drug	78-87	cyclosporine	drug	126-137	false
alfentanil	drug	78-87	fentanyl	drug	140-147	false
alfentanil	drug	78-87	pimozide	drug	150-157	false
alfentanil	drug	78-87	quinidine	drug	160-168	false
alfentanil	drug	78-87	sirolimus	drug	171-179	false
alfentanil	drug	78-87	tacrolimus	drug	182-191	false
alfentanil	drug	78-87	ergot alkaloids	group	197-211	false
alfentanil	drug	78-87	ergotamine	drug	214-223	false
alfentanil	drug	78-87	dihydroergotamine	drug	226-242	false
alfentanil	drug	78-87	SPRYCEL	brand	303-309	advise
astemizole	drug	90-99	terfenadine	drug	102-112	false
astemizole	drug	90-99	cisapride	drug	115-123	false
astemizole	drug	90-99	cyclosporine	drug	126-137	false
astemizole	drug	90-99	fentanyl	drug	140-147	false
astemizole	drug	90-99	pimozide	drug	150-157	false
astemizole	drug	90-99	quinidine	drug	160-168	false
astemizole	drug	90-99	sirolimus	drug	171-179	false
astemizole	drug	90-99	tacrolimus	drug	182-191	false
astemizole	drug	90-99	ergot alkaloids	group	197-211	false
astemizole	drug	90-99	ergotamine	drug	214-223	false
astemizole	drug	90-99	dihydroergotamine	drug	226-242	false
astemizole	drug	90-99	SPRYCEL	brand	303-309	advise
terfenadine	drug	102-112	cisapride	drug	115-123	false
terfenadine	drug	102-112	cyclosporine	drug	126-137	false
terfenadine	drug	102-112	fentanyl	drug	140-147	false
terfenadine	drug	102-112	pimozide	drug	150-157	false
terfenadine	drug	102-112	quinidine	drug	160-168	false
terfenadine	drug	102-112	sirolimus	drug	171-179	false
terfenadine	drug	102-112	tacrolimus	drug	182-191	false
terfenadine	drug	102-112	ergot alkaloids	group	197-211	false
terfenadine	drug	102-112	ergotamine	drug	214-223	false
terfenadine	drug	102-112	dihydroergotamine	drug	226-242	false
terfenadine	drug	102-112	SPRYCEL	brand	303-309	advise
cisapride	drug	115-123	cyclosporine	drug	126-137	false
cisapride	drug	115-123	fentanyl	drug	140-147	false
cisapride	drug	115-123	pimozide	drug	150-157	false
cisapride	drug	115-123	quinidine	drug	160-168	false
cisapride	drug	115-123	sirolimus	drug	171-179	false
cisapride	drug	115-123	tacrolimus	drug	182-191	false
cisapride	drug	115-123	ergot alkaloids	group	197-211	false
cisapride	drug	115-123	ergotamine	drug	214-223	false
cisapride	drug	115-123	dihydroergotamine	drug	226-242	false
cisapride	drug	115-123	SPRYCEL	brand	303-309	advise
cyclosporine	drug	126-137	fentanyl	drug	140-147	false
cyclosporine	drug	126-137	pimozide	drug	150-157	false
cyclosporine	drug	126-137	quinidine	drug	160-168	false
cyclosporine	drug	126-137	sirolimus	drug	171-179	false
cyclosporine	drug	126-137	tacrolimus	drug	182-191	false
cyclosporine	drug	126-137	ergot alkaloids	group	197-211	false
cyclosporine	drug	126-137	ergotamine	drug	214-223	false
cyclosporine	drug	126-137	dihydroergotamine	drug	226-242	false
cyclosporine	drug	126-137	SPRYCEL	brand	303-309	advise
fentanyl	drug	140-147	pimozide	drug	150-157	false
fentanyl	drug	140-147	quinidine	drug	160-168	false
fentanyl	drug	140-147	sirolimus	drug	171-179	false
fentanyl	drug	140-147	tacrolimus	drug	182-191	false
fentanyl	drug	140-147	ergot alkaloids	group	197-211	false
fentanyl	drug	140-147	ergotamine	drug	214-223	false
fentanyl	drug	140-147	dihydroergotamine	drug	226-242	false
fentanyl	drug	140-147	SPRYCEL	brand	303-309	advise
pimozide	drug	150-157	quinidine	drug	160-168	false
pimozide	drug	150-157	sirolimus	drug	171-179	false
pimozide	drug	150-157	tacrolimus	drug	182-191	false
pimozide	drug	150-157	ergot alkaloids	group	197-211	false
pimozide	drug	150-157	ergotamine	drug	214-223	false
pimozide	drug	150-157	dihydroergotamine	drug	226-242	false
pimozide	drug	150-157	SPRYCEL	brand	303-309	advise
quinidine	drug	160-168	sirolimus	drug	171-179	false
quinidine	drug	160-168	tacrolimus	drug	182-191	false
quinidine	drug	160-168	ergot alkaloids	group	197-211	false
quinidine	drug	160-168	ergotamine	drug	214-223	false
quinidine	drug	160-168	dihydroergotamine	drug	226-242	false
quinidine	drug	160-168	SPRYCEL	brand	303-309	advise
sirolimus	drug	171-179	tacrolimus	drug	182-191	false
sirolimus	drug	171-179	ergot alkaloids	group	197-211	false
sirolimus	drug	171-179	ergotamine	drug	214-223	false
sirolimus	drug	171-179	dihydroergotamine	drug	226-242	false
sirolimus	drug	171-179	SPRYCEL	brand	303-309	advise
tacrolimus	drug	182-191	ergot alkaloids	group	197-211	false
tacrolimus	drug	182-191	ergotamine	drug	214-223	false
tacrolimus	drug	182-191	dihydroergotamine	drug	226-242	false
tacrolimus	drug	182-191	SPRYCEL	brand	303-309	advise
ergot alkaloids	group	197-211	ergotamine	drug	214-223	false
ergot alkaloids	group	197-211	dihydroergotamine	drug	226-242	false
ergot alkaloids	group	197-211	SPRYCEL	brand	303-309	advise
ergotamine	drug	214-223	dihydroergotamine	drug	226-242	false
ergotamine	drug	214-223	SPRYCEL	brand	303-309	advise
dihydroergotamine	drug	226-242	SPRYCEL	brand	303-309	advise

DDI-DrugBank.d69.s0	Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
Cerubidine	brand	7-16	doxorubicin	drug	59-69	effect

DDI-DrugBank.d69.s1	Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
Cerubidine	brand	0-9	doxorubicin	drug	115-125	advise
Cerubidine	brand	0-9	Cerubidine	brand	130-139	false
doxorubicin	drug	115-125	Cerubidine	brand	130-139	false

DDI-DrugBank.d69.s2	Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
Cyclophosphamide	drug	0-15	Cerubidine	brand	40-49	effect

DDI-DrugBank.d167.s1	Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
Anticholinesterases	group	0-18	physostigmine	drug	33-45	false
Anticholinesterases	group	0-18	lignocaine	drug	49-58	false
Anticholinesterases	group	0-18	quinine	drug	61-67	false
Anticholinesterases	group	0-18	procainamide	drug	70-81	false
physostigmine	drug	33-45	lignocaine	drug	49-58	false
physostigmine	drug	33-45	quinine	drug	61-67	false
physostigmine	drug	33-45	procainamide	drug	70-81	false
lignocaine	drug	49-58	quinine	drug	61-67	false
lignocaine	drug	49-58	procainamide	drug	70-81	false
quinine	drug	61-67	procainamide	drug	70-81	false

DDI-DrugBank.d167.s2	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
anesthetics	group	66-76	anesthetics	group	85-95	false
anesthetics	group	66-76	lidocaine	drug	102-110	false
anesthetics	group	66-76	procaine	drug	113-120	false
anesthetics	group	66-76	beta-blockers	group	123-135	false
anesthetics	group	66-76	metaclopramide	drug	138-151	false
anesthetics	group	66-76	lithium carbonate	drug	154-170	false
anesthetics	group	66-76	terbutaline	drug	177-187	false
anesthetics	group	85-95	lidocaine	drug	102-110	false
anesthetics	group	85-95	procaine	drug	113-120	false
anesthetics	group	85-95	beta-blockers	group	123-135	false
anesthetics	group	85-95	metaclopramide	drug	138-151	false
anesthetics	group	85-95	lithium carbonate	drug	154-170	false
anesthetics	group	85-95	terbutaline	drug	177-187	false
lidocaine	drug	102-110	procaine	drug	113-120	false
lidocaine	drug	102-110	beta-blockers	group	123-135	false
lidocaine	drug	102-110	metaclopramide	drug	138-151	false
lidocaine	drug	102-110	lithium carbonate	drug	154-170	false
lidocaine	drug	102-110	terbutaline	drug	177-187	false
procaine	drug	113-120	beta-blockers	group	123-135	false
procaine	drug	113-120	metaclopramide	drug	138-151	false
procaine	drug	113-120	lithium carbonate	drug	154-170	false
procaine	drug	113-120	terbutaline	drug	177-187	false
beta-blockers	group	123-135	metaclopramide	drug	138-151	false
beta-blockers	group	123-135	lithium carbonate	drug	154-170	false
beta-blockers	group	123-135	terbutaline	drug	177-187	false
metaclopramide	drug	138-151	lithium carbonate	drug	154-170	false
metaclopramide	drug	138-151	terbutaline	drug	177-187	false
lithium carbonate	drug	154-170	terbutaline	drug	177-187	false

DDI-DrugBank.d84.s0	The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.
Exjade	brand	34-39	aluminum	drug	45-52	false
Exjade	brand	34-39	antacid preparations	group	65-84	false
aluminum	drug	45-52	antacid preparations	group	65-84	false

DDI-DrugBank.d84.s1	Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
deferasirox	drug	9-19	aluminum	drug	46-53	false
deferasirox	drug	9-19	iron	drug	64-67	false
deferasirox	drug	9-19	Exjade	brand	70-75	false
deferasirox	drug	9-19	aluminum	drug	102-109	false
deferasirox	drug	9-19	antacid preparations	group	122-141	false
aluminum	drug	46-53	iron	drug	64-67	false
aluminum	drug	46-53	Exjade	brand	70-75	false
aluminum	drug	46-53	aluminum	drug	102-109	false
aluminum	drug	46-53	antacid preparations	group	122-141	false
iron	drug	64-67	Exjade	brand	70-75	false
iron	drug	64-67	aluminum	drug	102-109	false
iron	drug	64-67	antacid preparations	group	122-141	false
Exjade	brand	70-75	aluminum	drug	102-109	advise
Exjade	brand	70-75	antacid preparations	group	122-141	false
aluminum	drug	102-109	antacid preparations	group	122-141	false

DDI-DrugBank.d84.s2	In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin.
Exjade	brand	23-28	digoxin	drug	71-77	false

DDI-DrugBank.d84.s3	The effect of digoxin on Exjade pharmacokinetics has not been studied.
digoxin	drug	14-20	Exjade	brand	25-30	false

DDI-DrugBank.d84.s4	The concomitant administration of Exjade and vitamin C has not been formally studied.
Exjade	brand	34-39	vitamin C	drug	45-53	false

DDI-DrugBank.d84.s6	The interaction of Exjade with hydroxyurea has not been formally studied.
Exjade	brand	19-24	hydroxyurea	drug	31-41	false

DDI-DrugBank.d84.s7	No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
deferasirox	drug	17-27	hydroxyurea	drug	43-53	false

DDI-DrugBank.d251.s0	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
clarithromycin	drug	10-23	Didanosine	drug	26-35	false
clarithromycin	drug	10-23	Fluconazole	drug	38-48	false
clarithromycin	drug	10-23	Fluoxetine	drug	51-60	false
clarithromycin	drug	10-23	Ketoconazole	drug	74-85	false
clarithromycin	drug	10-23	Phenytoin	drug	88-96	false
clarithromycin	drug	10-23	carbamazepine	drug	114-126	false
clarithromycin	drug	10-23	Rifabutin	drug	129-137	false
clarithromycin	drug	10-23	Rifampin	drug	140-147	false
clarithromycin	drug	10-23	Saquinavir	drug	161-170	false
Didanosine	drug	26-35	Fluconazole	drug	38-48	false
Didanosine	drug	26-35	Fluoxetine	drug	51-60	false
Didanosine	drug	26-35	Ketoconazole	drug	74-85	false
Didanosine	drug	26-35	Phenytoin	drug	88-96	false
Didanosine	drug	26-35	carbamazepine	drug	114-126	false
Didanosine	drug	26-35	Rifabutin	drug	129-137	false
Didanosine	drug	26-35	Rifampin	drug	140-147	false
Didanosine	drug	26-35	Saquinavir	drug	161-170	false
Fluconazole	drug	38-48	Fluoxetine	drug	51-60	false
Fluconazole	drug	38-48	Ketoconazole	drug	74-85	false
Fluconazole	drug	38-48	Phenytoin	drug	88-96	false
Fluconazole	drug	38-48	carbamazepine	drug	114-126	false
Fluconazole	drug	38-48	Rifabutin	drug	129-137	false
Fluconazole	drug	38-48	Rifampin	drug	140-147	false
Fluconazole	drug	38-48	Saquinavir	drug	161-170	false
Fluoxetine	drug	51-60	Ketoconazole	drug	74-85	false
Fluoxetine	drug	51-60	Phenytoin	drug	88-96	false
Fluoxetine	drug	51-60	carbamazepine	drug	114-126	false
Fluoxetine	drug	51-60	Rifabutin	drug	129-137	false
Fluoxetine	drug	51-60	Rifampin	drug	140-147	false
Fluoxetine	drug	51-60	Saquinavir	drug	161-170	false
Ketoconazole	drug	74-85	Phenytoin	drug	88-96	false
Ketoconazole	drug	74-85	carbamazepine	drug	114-126	false
Ketoconazole	drug	74-85	Rifabutin	drug	129-137	false
Ketoconazole	drug	74-85	Rifampin	drug	140-147	false
Ketoconazole	drug	74-85	Saquinavir	drug	161-170	false
Phenytoin	drug	88-96	carbamazepine	drug	114-126	false
Phenytoin	drug	88-96	Rifabutin	drug	129-137	false
Phenytoin	drug	88-96	Rifampin	drug	140-147	false
Phenytoin	drug	88-96	Saquinavir	drug	161-170	false
carbamazepine	drug	114-126	Rifabutin	drug	129-137	false
carbamazepine	drug	114-126	Rifampin	drug	140-147	false
carbamazepine	drug	114-126	Saquinavir	drug	161-170	false
Rifabutin	drug	129-137	Rifampin	drug	140-147	false
Rifabutin	drug	129-137	Saquinavir	drug	161-170	false
Rifampin	drug	140-147	Saquinavir	drug	161-170	false

DDI-DrugBank.d149.s0	Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
HUMORSOL	brand	30-37	succinylcholine	drug	44-58	int
HUMORSOL	brand	30-37	anticholinesterase agents	group	74-98	int
succinylcholine	drug	44-58	anticholinesterase agents	group	74-98	false

DDI-DrugBank.d409.s0	Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	group	12-24	anticoagulant	group	102-114	advise
tetracyclines	group	12-24	anticoagulant	group	165-177	false
anticoagulant	group	102-114	anticoagulant	group	165-177	false

DDI-DrugBank.d409.s1	Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
tetracycline class	group	40-57	antibiotics	group	62-72	false
tetracycline class	group	40-57	penicillins	group	121-131	effect
antibiotics	group	62-72	penicillins	group	121-131	false

DDI-DrugBank.d409.s2	Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
tetracyclines	group	18-30	contraceptives	group	42-55	effect
tetracyclines	group	18-30	contraceptives	group	73-86	false
contraceptives	group	42-55	contraceptives	group	73-86	false

DDI-DrugBank.d311.s0	Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
rauwolfia alkaloid	group	9-26	MAO inhibitors	group	77-90	effect

DDI-DrugBank.d363.s0	No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.
muscle relaxants	group	120-135	anesthetic agents	group	168-184	false

DDI-DrugBank.d363.s2	Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.
isoflurane	drug	5-14	desflurane	drug	17-26	false
isoflurane	drug	5-14	epinephrine	drug	124-134	false
desflurane	drug	17-26	epinephrine	drug	124-134	false

DDI-DrugBank.d386.s3	Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	69-93	TCAs	group	96-99	false

DDI-DrugBank.d386.s9	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	flecainide	drug	148-157	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	flecainide	drug	148-157	false
phenothiazines	group	83-96	flecainide	drug	148-157	false

DDI-DrugBank.d386.s10	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	69-78	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	97-106	false
SSRIs	group	55-59	fluoxetine	drug	69-78	false
SSRIs	group	55-59	paroxetine	drug	97-106	false
fluoxetine	drug	69-78	paroxetine	drug	97-106	false

DDI-DrugBank.d386.s11	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	141-144	false
TCA	group	25-27	SSRI	group	141-144	false

DDI-DrugBank.d386.s12	Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
T.A.	group	63-66	SSRIs	group	84-88	advise

DDI-DrugBank.d386.s14	Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	156-179	false

DDI-DrugBank.d386.s16	It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	group	27-29	TCA	group	56-58	false

DDI-DrugBank.d386.s18	Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.
anticholinergic	group	107-121	sympathomimetic drugs	group	126-146	false

DDI-DrugBank.d386.s23	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
desipramine hydrochloride	drug	3-27	psychotropic agents	group	58-76	effect
desipramine hydrochloride	drug	3-27	tranquilizers	group	86-98	effect
desipramine hydrochloride	drug	3-27	sedative	group	103-110	effect
desipramine hydrochloride	drug	3-27	hypnotics	group	112-120	effect
desipramine hydrochloride	drug	3-27	desipramine	drug	234-244	false
desipramine hydrochloride	drug	3-27	benzodiazepines	group	250-264	false
desipramine hydrochloride	drug	3-27	chlordiazepoxide	drug	273-288	false
desipramine hydrochloride	drug	3-27	diazepam	drug	293-300	false
psychotropic agents	group	58-76	tranquilizers	group	86-98	false
psychotropic agents	group	58-76	sedative	group	103-110	false
psychotropic agents	group	58-76	hypnotics	group	112-120	false
psychotropic agents	group	58-76	desipramine	drug	234-244	false
psychotropic agents	group	58-76	benzodiazepines	group	250-264	false
psychotropic agents	group	58-76	chlordiazepoxide	drug	273-288	false
psychotropic agents	group	58-76	diazepam	drug	293-300	false
tranquilizers	group	86-98	sedative	group	103-110	false
tranquilizers	group	86-98	hypnotics	group	112-120	false
tranquilizers	group	86-98	desipramine	drug	234-244	false
tranquilizers	group	86-98	benzodiazepines	group	250-264	false
tranquilizers	group	86-98	chlordiazepoxide	drug	273-288	false
tranquilizers	group	86-98	diazepam	drug	293-300	false
sedative	group	103-110	hypnotics	group	112-120	false
sedative	group	103-110	desipramine	drug	234-244	false
sedative	group	103-110	benzodiazepines	group	250-264	false
sedative	group	103-110	chlordiazepoxide	drug	273-288	false
sedative	group	103-110	diazepam	drug	293-300	false
hypnotics	group	112-120	desipramine	drug	234-244	false
hypnotics	group	112-120	benzodiazepines	group	250-264	false
hypnotics	group	112-120	chlordiazepoxide	drug	273-288	false
hypnotics	group	112-120	diazepam	drug	293-300	false
desipramine	drug	234-244	benzodiazepines	group	250-264	effect
desipramine	drug	234-244	chlordiazepoxide	drug	273-288	effect
desipramine	drug	234-244	diazepam	drug	293-300	effect
benzodiazepines	group	250-264	chlordiazepoxide	drug	273-288	false
benzodiazepines	group	250-264	diazepam	drug	293-300	false
chlordiazepoxide	drug	273-288	diazepam	drug	293-300	false

DDI-DrugBank.d386.s24	Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
major tranquilizers	group	53-71	desipramine	drug	103-113	effect

DDI-DrugBank.d386.s26	Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
cimetidine	drug	29-38	tricyclic antidepressants	group	44-68	mechanism
cimetidine	drug	29-38	tricyclic antidepressants	group	143-167	false
tricyclic antidepressants	group	44-68	tricyclic antidepressants	group	143-167	false

DDI-DrugBank.d386.s27	Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
tricyclic antidepressants	group	46-70	cimetidine	drug	115-124	mechanism
tricyclic antidepressants	group	46-70	tricyclic antidepressant	group	190-213	false
cimetidine	drug	115-124	tricyclic antidepressant	group	190-213	false

DDI-DrugBank.d386.s28	There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
tricyclic antidepressants	group	86-110	fluoxetine	drug	117-126	mechanism

DDI-DrugBank.d67.s0	In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.
desloratadine	drug	140-152	erythromycin	drug	223-234	false
desloratadine	drug	140-152	ketoconazole	drug	260-271	false
erythromycin	drug	223-234	ketoconazole	drug	260-271	false

DDI-DrugBank.d67.s1	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
desloratadine	drug	76-88	azithromycin	drug	148-159	false
desloratadine	drug	76-88	fluoxetine	drug	224-233	false
desloratadine	drug	76-88	fluoxetine	drug	303-312	false
desloratadine	drug	76-88	cimetidine	drug	329-338	false
azithromycin	drug	148-159	fluoxetine	drug	224-233	false
azithromycin	drug	148-159	fluoxetine	drug	303-312	false
azithromycin	drug	148-159	cimetidine	drug	329-338	false
fluoxetine	drug	224-233	fluoxetine	drug	303-312	false
fluoxetine	drug	224-233	cimetidine	drug	329-338	false
fluoxetine	drug	303-312	cimetidine	drug	329-338	false

DDI-DrugBank.d67.s2	Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
desloratadine	drug	69-81	3-hydroxydesloratadine	drug_n	87-108	false
desloratadine	drug	69-81	desloratadine	drug	193-205	false
3-hydroxydesloratadine	drug_n	87-108	desloratadine	drug	193-205	false

DDI-DrugBank.d67.s3	Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
Desloratadine	drug	19-31	3-Hydroxydesloratadine	drug_n	37-58	false

DDI-DrugBank.d67.s5	Desloratadine 3-Hydroxydesloratadine
Desloratadine	drug	0-12	3-Hydroxydesloratadine	drug_n	14-35	false

DDI-DrugBank.d348.s0	Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.
Desmopressin	drug	33-44	Desmopressin	drug	112-123	false

DDI-DrugBank.d285.s1	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)
barbiturates	group	67-78	phenytoin sodium	drug	98-113	false
barbiturates	group	67-78	carbamazepine	drug	116-128	false
barbiturates	group	67-78	griseofulvin	drug	148-159	false
barbiturates	group	67-78	ampicillin	drug	162-171	false
barbiturates	group	67-78	tetracyclines	group	178-190	false
phenytoin sodium	drug	98-113	carbamazepine	drug	116-128	false
phenytoin sodium	drug	98-113	griseofulvin	drug	148-159	false
phenytoin sodium	drug	98-113	ampicillin	drug	162-171	false
phenytoin sodium	drug	98-113	tetracyclines	group	178-190	false
carbamazepine	drug	116-128	griseofulvin	drug	148-159	false
carbamazepine	drug	116-128	ampicillin	drug	162-171	false
carbamazepine	drug	116-128	tetracyclines	group	178-190	false
griseofulvin	drug	148-159	ampicillin	drug	162-171	false
griseofulvin	drug	148-159	tetracyclines	group	178-190	false
ampicillin	drug	162-171	tetracyclines	group	178-190	false

DDI-DrugBank.d314.s0	Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
Aminoglutethimide	drug	0-16	Aminoglutethimide	drug	19-35	false
Aminoglutethimide	drug	0-16	corticosteroids	group	73-87	false
Aminoglutethimide	drug	19-35	corticosteroids	group	73-87	effect

DDI-DrugBank.d314.s1	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
Amphotericin B	drug	0-13	corticosteroids	group	62-76	false
Amphotericin B	drug	0-13	amphotericin B	drug	148-161	false
Amphotericin B	drug	0-13	diuretics	group	164-172	false
corticosteroids	group	62-76	amphotericin B	drug	148-161	advise
corticosteroids	group	62-76	diuretics	group	164-172	advise
amphotericin B	drug	148-161	diuretics	group	164-172	false

DDI-DrugBank.d314.s2	In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
amphotericin B	drug	72-85	hydrocortisone	drug	91-104	effect

DDI-DrugBank.d314.s3	Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
Antibiotics	group	0-10	Macrolide antibiotics	group	13-33	false
Antibiotics	group	0-10	corticosteroid	group	89-102	false
Macrolide antibiotics	group	13-33	corticosteroid	group	89-102	mechanism

DDI-DrugBank.d314.s4	Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
Anticholinesterases	group	0-18	anticholinesterase agents	group	40-64	false
Anticholinesterases	group	0-18	corticosteroids	group	70-84	false
anticholinesterase agents	group	40-64	corticosteroids	group	70-84	effect

DDI-DrugBank.d314.s5	If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
anticholinesterase agents	group	13-37	corticosteroid	group	95-108	advise

DDI-DrugBank.d314.s6	Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
Anticoagulants	group	0-13	corticosteroids	group	43-57	false
Anticoagulants	group	0-13	warfarin	drug	63-70	false
Anticoagulants	group	0-13	warfarin	drug	117-124	false
corticosteroids	group	43-57	warfarin	drug	63-70	effect
corticosteroids	group	43-57	warfarin	drug	117-124	false
warfarin	drug	63-70	warfarin	drug	117-124	false

DDI-DrugBank.d314.s8	Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
Antidiabetics	group	0-12	corticosteroids	group	23-37	false
Antidiabetics	group	0-12	antidiabetic agents	group	104-122	false
corticosteroids	group	23-37	antidiabetic agents	group	104-122	effect

DDI-DrugBank.d314.s10	Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
Cholestyramine	drug	0-13	Cholestyramine	drug	16-29	false
Cholestyramine	drug	0-13	corticosteroids	group	61-75	false
Cholestyramine	drug	16-29	corticosteroids	group	61-75	mechanism

DDI-DrugBank.d314.s11	Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
Cyclosporine	drug	0-11	cyclosporine	drug	41-52	false
Cyclosporine	drug	0-11	corticosteroids	group	58-72	false
cyclosporine	drug	41-52	corticosteroids	group	58-72	effect

DDI-DrugBank.d314.s15	Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
Digitalis glycosides	group	0-19	digitalis glycosides	group	34-53	false

DDI-DrugBank.d314.s16	Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
Ephedrine	drug	0-8	Ephedrine	drug	11-19	false
Ephedrine	drug	0-8	corticosteroids	group	60-74	false
Ephedrine	drug	0-8	corticosteroid	group	178-191	false
Ephedrine	drug	11-19	corticosteroids	group	60-74	mechanism
Ephedrine	drug	11-19	corticosteroid	group	178-191	false
corticosteroids	group	60-74	corticosteroid	group	178-191	false

DDI-DrugBank.d314.s17	Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens	group	0-8	contraceptives	group	26-39	false
Estrogens	group	0-8	Estrogens	group	42-50	false
Estrogens	group	0-8	corticosteroids	group	99-113	false
contraceptives	group	26-39	Estrogens	group	42-50	false
contraceptives	group	26-39	corticosteroids	group	99-113	false
Estrogens	group	42-50	corticosteroids	group	99-113	mechanism

DDI-DrugBank.d314.s18	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
barbiturates	group	124-135	phenytoin	drug	138-146	false
barbiturates	group	124-135	carbamazepine	drug	149-161	false
barbiturates	group	124-135	rifampin	drug	164-171	false
barbiturates	group	124-135	corticosteroids	group	204-218	mechanism
barbiturates	group	124-135	corticosteroid	group	255-268	false
phenytoin	drug	138-146	carbamazepine	drug	149-161	false
phenytoin	drug	138-146	rifampin	drug	164-171	false
phenytoin	drug	138-146	corticosteroids	group	204-218	mechanism
phenytoin	drug	138-146	corticosteroid	group	255-268	false
carbamazepine	drug	149-161	rifampin	drug	164-171	false
carbamazepine	drug	149-161	corticosteroids	group	204-218	mechanism
carbamazepine	drug	149-161	corticosteroid	group	255-268	false
rifampin	drug	164-171	corticosteroids	group	204-218	mechanism
rifampin	drug	164-171	corticosteroid	group	255-268	false
corticosteroids	group	204-218	corticosteroid	group	255-268	false

DDI-DrugBank.d314.s19	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
ketoconazole	drug	35-46	macrolide antibiotics	group	49-69	false
ketoconazole	drug	35-46	erythromycin	drug	79-90	false
ketoconazole	drug	35-46	corticosteroids	group	160-174	mechanism
macrolide antibiotics	group	49-69	erythromycin	drug	79-90	false
macrolide antibiotics	group	49-69	corticosteroids	group	160-174	mechanism
erythromycin	drug	79-90	corticosteroids	group	160-174	mechanism

DDI-DrugBank.d314.s21	Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.
indinavir	drug	74-82	erythromycin	drug	85-96	false

DDI-DrugBank.d314.s22	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	corticosteroids	group	83-97	false
Ketoconazole	drug	0-11	corticosteroid	group	142-155	false
Ketoconazole	drug	14-25	corticosteroids	group	83-97	mechanism
Ketoconazole	drug	14-25	corticosteroid	group	142-155	false
corticosteroids	group	83-97	corticosteroid	group	142-155	false

DDI-DrugBank.d314.s23	In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
ketoconazole	drug	13-24	corticosteroid	drug	52-65	effect

DDI-DrugBank.d314.s24	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
Nonsteroidal anti-inflammatory agents	group	0-36	NSAIDS	group	39-44	false
Nonsteroidal anti-inflammatory agents	group	0-36	aspirin	brand	67-73	false
Nonsteroidal anti-inflammatory agents	group	0-36	nonsteroidal antiinflammatory agents	group	85-120	false
Nonsteroidal anti-inflammatory agents	group	0-36	corticosteroids	group	127-141	false
NSAIDS	group	39-44	aspirin	brand	67-73	false
NSAIDS	group	39-44	nonsteroidal antiinflammatory agents	group	85-120	false
NSAIDS	group	39-44	corticosteroids	group	127-141	false
aspirin	brand	67-73	nonsteroidal antiinflammatory agents	group	85-120	false
aspirin	brand	67-73	corticosteroids	group	127-141	effect
nonsteroidal antiinflammatory agents	group	85-120	corticosteroids	group	127-141	effect

DDI-DrugBank.d314.s25	Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Aspirin	brand	0-6	corticosteroids	group	54-68	advise

DDI-DrugBank.d314.s26	The clearance of salicylates may be increased with concurrent use of corticosteroids.
salicylates	group	17-27	corticosteroids	group	69-83	mechanism

DDI-DrugBank.d314.s27	Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
Phenytoin	drug	0-8	phenytoin	drug	100-108	false
Phenytoin	drug	0-8	dexamethasone	drug	122-134	false
phenytoin	drug	100-108	dexamethasone	drug	122-134	mechanism

DDI-DrugBank.d314.s29	Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.
Thalidomide	drug	0-10	thalidomide	drug	36-46	false

DDI-DrugBank.d314.s30	Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
Vaccines	group	0-7	corticosteroid	group	22-35	false
Vaccines	group	0-7	live vaccines	group	94-97;114-121	false
Vaccines	group	0-7	inactivated vaccines	group	102-121	false
corticosteroid	group	22-35	live vaccines	group	94-97;114-121	effect
corticosteroid	group	22-35	inactivated vaccines	group	102-121	effect
live vaccines	group	94-97;114-121	inactivated vaccines	group	102-121	false

DDI-DrugBank.d314.s31	Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
Corticosteroids	group	0-14	live attenuated vaccines	group	83-106	effect

DDI-DrugBank.d314.s32	Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
vaccines	group	26-33	corticosteroid	group	71-84	advise

DDI-DrugBank.d62.s0	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
Dexbrompheniramine	drug	0-17	alcohol	drug	37-43	int
Dexbrompheniramine	drug	0-17	CNS depressants	group	54-68	int
Dexbrompheniramine	drug	0-17	antihistamines	group	144-157	false
Dexbrompheniramine	drug	0-17	anticholinergics	group	161-176	int
Dexbrompheniramine	drug	0-17	antihistamines	group	323-336	false
Dexbrompheniramine	drug	0-17	monoamine oxidase (MAO) inhibitors	group	344-377	int
Dexbrompheniramine	drug	0-17	antihistamines	group	400-413	false
Dexbrompheniramine	drug	0-17	antihistamines	group	491-504	false
alcohol	drug	37-43	CNS depressants	group	54-68	false
alcohol	drug	37-43	antihistamines	group	144-157	false
alcohol	drug	37-43	anticholinergics	group	161-176	false
alcohol	drug	37-43	antihistamines	group	323-336	false
alcohol	drug	37-43	monoamine oxidase (MAO) inhibitors	group	344-377	false
alcohol	drug	37-43	antihistamines	group	400-413	false
alcohol	drug	37-43	antihistamines	group	491-504	false
CNS depressants	group	54-68	antihistamines	group	144-157	false
CNS depressants	group	54-68	anticholinergics	group	161-176	false
CNS depressants	group	54-68	antihistamines	group	323-336	false
CNS depressants	group	54-68	monoamine oxidase (MAO) inhibitors	group	344-377	false
CNS depressants	group	54-68	antihistamines	group	400-413	false
CNS depressants	group	54-68	antihistamines	group	491-504	false
antihistamines	group	144-157	anticholinergics	group	161-176	false
antihistamines	group	144-157	antihistamines	group	323-336	false
antihistamines	group	144-157	monoamine oxidase (MAO) inhibitors	group	344-377	false
antihistamines	group	144-157	antihistamines	group	400-413	false
antihistamines	group	144-157	antihistamines	group	491-504	false
anticholinergics	group	161-176	antihistamines	group	323-336	false
anticholinergics	group	161-176	monoamine oxidase (MAO) inhibitors	group	344-377	false
anticholinergics	group	161-176	antihistamines	group	400-413	false
anticholinergics	group	161-176	antihistamines	group	491-504	false
antihistamines	group	323-336	monoamine oxidase (MAO) inhibitors	group	344-377	false
antihistamines	group	323-336	antihistamines	group	400-413	false
antihistamines	group	323-336	antihistamines	group	491-504	false
monoamine oxidase (MAO) inhibitors	group	344-377	antihistamines	group	400-413	false
monoamine oxidase (MAO) inhibitors	group	344-377	antihistamines	group	491-504	false
antihistamines	group	400-413	antihistamines	group	491-504	false

DDI-DrugBank.d423.s0	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
monoamine oxidase inhibitors	group	35-62	MAOIs	group	65-69	false
monoamine oxidase inhibitors	group	35-62	selegiline hydrochloride	drug	79-102	false
monoamine oxidase inhibitors	group	35-62	serotoninergic agents	group	125-145	effect
monoamine oxidase inhibitors	group	35-62	fluoxetine	drug	154-163	effect
monoamine oxidase inhibitors	group	35-62	fluvoxamine	drug	166-176	effect
monoamine oxidase inhibitors	group	35-62	paroxetine	drug	179-188	effect
monoamine oxidase inhibitors	group	35-62	sertraline	drug	191-200	effect
monoamine oxidase inhibitors	group	35-62	venlafaxine	drug	203-213	effect
MAOIs	group	65-69	selegiline hydrochloride	drug	79-102	false
MAOIs	group	65-69	serotoninergic agents	group	125-145	effect
MAOIs	group	65-69	fluoxetine	drug	154-163	effect
MAOIs	group	65-69	fluvoxamine	drug	166-176	effect
MAOIs	group	65-69	paroxetine	drug	179-188	effect
MAOIs	group	65-69	sertraline	drug	191-200	effect
MAOIs	group	65-69	venlafaxine	drug	203-213	effect
selegiline hydrochloride	drug	79-102	serotoninergic agents	group	125-145	effect
selegiline hydrochloride	drug	79-102	fluoxetine	drug	154-163	effect
selegiline hydrochloride	drug	79-102	fluvoxamine	drug	166-176	effect
selegiline hydrochloride	drug	79-102	paroxetine	drug	179-188	effect
selegiline hydrochloride	drug	79-102	sertraline	drug	191-200	effect
selegiline hydrochloride	drug	79-102	venlafaxine	drug	203-213	effect
serotoninergic agents	group	125-145	fluoxetine	drug	154-163	false
serotoninergic agents	group	125-145	fluvoxamine	drug	166-176	false
serotoninergic agents	group	125-145	paroxetine	drug	179-188	false
serotoninergic agents	group	125-145	sertraline	drug	191-200	false
serotoninergic agents	group	125-145	venlafaxine	drug	203-213	false
fluoxetine	drug	154-163	fluvoxamine	drug	166-176	false
fluoxetine	drug	154-163	paroxetine	drug	179-188	false
fluoxetine	drug	154-163	sertraline	drug	191-200	false
fluoxetine	drug	154-163	venlafaxine	drug	203-213	false
fluvoxamine	drug	166-176	paroxetine	drug	179-188	false
fluvoxamine	drug	166-176	sertraline	drug	191-200	false
fluvoxamine	drug	166-176	venlafaxine	drug	203-213	false
paroxetine	drug	179-188	sertraline	drug	191-200	false
paroxetine	drug	179-188	venlafaxine	drug	203-213	false
sertraline	drug	191-200	venlafaxine	drug	203-213	false

DDI-DrugBank.d423.s1	Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
dexfenfluramine	drug	8-22	dexfenfluramine	drug	72-86	false
dexfenfluramine	drug	8-22	MAO inhibitor	group	128-140	false
dexfenfluramine	drug	72-86	MAO inhibitor	group	128-140	advise

DDI-DrugBank.d423.s2	At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
MAO inhibitor	group	60-72	dexfenfluramine	drug	107-121	advise

DDI-DrugBank.d423.s3	At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
dexfenfluramine	drug	58-72	MAO inhibitor	group	109-121	advise

DDI-DrugBank.d423.s4	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
selective serotonin reuptake inhibitors	group	121-159	SSRIs	group	162-166	false
selective serotonin reuptake inhibitors	group	121-159	Imitrex	brand	210-216	effect
selective serotonin reuptake inhibitors	group	121-159	sumatriptan succinate	drug	219-239	effect
selective serotonin reuptake inhibitors	group	121-159	dihydroergotamine	drug	246-262	effect
SSRIs	group	162-166	Imitrex	brand	210-216	effect
SSRIs	group	162-166	sumatriptan succinate	drug	219-239	effect
SSRIs	group	162-166	dihydroergotamine	drug	246-262	effect
Imitrex	brand	210-216	sumatriptan succinate	drug	219-239	false
Imitrex	brand	210-216	dihydroergotamine	drug	246-262	false
sumatriptan succinate	drug	219-239	dihydroergotamine	drug	246-262	false

DDI-DrugBank.d423.s6	Dexfenfluramine should not be administered with other serotoninergic agents.
Dexfenfluramine	drug	0-14	serotoninergic agents	group	54-74	advise

DDI-DrugBank.d197.s1	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
Anesthetics	group	0-10	Sedatives	group	12-20	false
Anesthetics	group	0-10	Hypnotics	group	22-30	false
Anesthetics	group	0-10	Opioids	group	32-38	false
Anesthetics	group	0-10	PRECEDEX	brand	62-69	false
Anesthetics	group	0-10	anesthetics	group	76-86	false
Anesthetics	group	0-10	sedatives	group	89-97	false
Anesthetics	group	0-10	hypnotics	group	100-108	false
Anesthetics	group	0-10	opioids	group	115-121	false
Sedatives	group	12-20	Hypnotics	group	22-30	false
Sedatives	group	12-20	Opioids	group	32-38	false
Sedatives	group	12-20	PRECEDEX	brand	62-69	false
Sedatives	group	12-20	anesthetics	group	76-86	false
Sedatives	group	12-20	sedatives	group	89-97	false
Sedatives	group	12-20	hypnotics	group	100-108	false
Sedatives	group	12-20	opioids	group	115-121	false
Hypnotics	group	22-30	Opioids	group	32-38	false
Hypnotics	group	22-30	PRECEDEX	brand	62-69	false
Hypnotics	group	22-30	anesthetics	group	76-86	false
Hypnotics	group	22-30	sedatives	group	89-97	false
Hypnotics	group	22-30	hypnotics	group	100-108	false
Hypnotics	group	22-30	opioids	group	115-121	false
Opioids	group	32-38	PRECEDEX	brand	62-69	false
Opioids	group	32-38	anesthetics	group	76-86	false
Opioids	group	32-38	sedatives	group	89-97	false
Opioids	group	32-38	hypnotics	group	100-108	false
Opioids	group	32-38	opioids	group	115-121	false
PRECEDEX	brand	62-69	anesthetics	group	76-86	effect
PRECEDEX	brand	62-69	sedatives	group	89-97	effect
PRECEDEX	brand	62-69	hypnotics	group	100-108	effect
PRECEDEX	brand	62-69	opioids	group	115-121	effect
anesthetics	group	76-86	sedatives	group	89-97	false
anesthetics	group	76-86	hypnotics	group	100-108	false
anesthetics	group	76-86	opioids	group	115-121	false
sedatives	group	89-97	hypnotics	group	100-108	false
sedatives	group	89-97	opioids	group	115-121	false
hypnotics	group	100-108	opioids	group	115-121	false

DDI-DrugBank.d197.s2	Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.
sevoflurane	drug	51-61	isoflurane	drug	64-73	false
sevoflurane	drug	51-61	propofol	drug	76-83	false
sevoflurane	drug	51-61	alfentanil	drug	86-95	false
sevoflurane	drug	51-61	midazolam	drug	102-110	false
isoflurane	drug	64-73	propofol	drug	76-83	false
isoflurane	drug	64-73	alfentanil	drug	86-95	false
isoflurane	drug	64-73	midazolam	drug	102-110	false
propofol	drug	76-83	alfentanil	drug	86-95	false
propofol	drug	76-83	midazolam	drug	102-110	false
alfentanil	drug	86-95	midazolam	drug	102-110	false

DDI-DrugBank.d197.s3	No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.
dexmedetomidine	drug	40-54	isoflurane	drug	60-69	false
dexmedetomidine	drug	40-54	propofol	drug	72-79	false
dexmedetomidine	drug	40-54	alfentanil	drug	82-91	false
dexmedetomidine	drug	40-54	midazolam	drug	98-106	false
isoflurane	drug	60-69	propofol	drug	72-79	false
isoflurane	drug	60-69	alfentanil	drug	82-91	false
isoflurane	drug	60-69	midazolam	drug	98-106	false
propofol	drug	72-79	alfentanil	drug	82-91	false
propofol	drug	72-79	midazolam	drug	98-106	false
alfentanil	drug	82-91	midazolam	drug	98-106	false

DDI-DrugBank.d197.s4	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
PRECEDEX	brand	81-88	PRECEDEX	brand	116-123	false
PRECEDEX	brand	81-88	anesthetic	group	144-153	false
PRECEDEX	brand	81-88	sedative	group	156-163	false
PRECEDEX	brand	81-88	hypnotic	group	166-173	false
PRECEDEX	brand	81-88	opioid	group	178-183	false
PRECEDEX	brand	116-123	anesthetic	group	144-153	advise
PRECEDEX	brand	116-123	sedative	group	156-163	advise
PRECEDEX	brand	116-123	hypnotic	group	166-173	advise
PRECEDEX	brand	116-123	opioid	group	178-183	advise
anesthetic	group	144-153	sedative	group	156-163	false
anesthetic	group	144-153	hypnotic	group	166-173	false
anesthetic	group	144-153	opioid	group	178-183	false
sedative	group	156-163	hypnotic	group	166-173	false
sedative	group	156-163	opioid	group	178-183	false
hypnotic	group	166-173	opioid	group	178-183	false

DDI-DrugBank.d197.s5	Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.
Neuromuscular Blockers	group	0-21	PRECEDEX	brand	81-88	false
Neuromuscular Blockers	group	0-21	rocuronium	drug	254-263	false
PRECEDEX	brand	81-88	rocuronium	drug	254-263	false

DDI-DrugBank.d38.s0	ZINECARD does not influence the pharmacokinetics of doxorubicin.
ZINECARD	brand	0-7	doxorubicin	drug	52-62	false

DDI-DrugBank.d236.s0	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
Acidifying agents	group	0-16	Gastrointestinal acidifying agents	group	19-52	false
Acidifying agents	group	0-16	guanethidine	drug	55-66	false
Acidifying agents	group	0-16	reserpine	drug	69-77	false
Acidifying agents	group	0-16	glutamic acid HCl	drug	80-96	false
Acidifying agents	group	0-16	ascorbic acid	drug	99-111	false
Acidifying agents	group	0-16	amphetamines	group	154-165	false
Gastrointestinal acidifying agents	group	19-52	guanethidine	drug	55-66	false
Gastrointestinal acidifying agents	group	19-52	reserpine	drug	69-77	false
Gastrointestinal acidifying agents	group	19-52	glutamic acid HCl	drug	80-96	false
Gastrointestinal acidifying agents	group	19-52	ascorbic acid	drug	99-111	false
Gastrointestinal acidifying agents	group	19-52	amphetamines	group	154-165	mechanism
guanethidine	drug	55-66	reserpine	drug	69-77	false
guanethidine	drug	55-66	glutamic acid HCl	drug	80-96	false
guanethidine	drug	55-66	ascorbic acid	drug	99-111	false
guanethidine	drug	55-66	amphetamines	group	154-165	mechanism
reserpine	drug	69-77	glutamic acid HCl	drug	80-96	false
reserpine	drug	69-77	ascorbic acid	drug	99-111	false
reserpine	drug	69-77	amphetamines	group	154-165	mechanism
glutamic acid HCl	drug	80-96	ascorbic acid	drug	99-111	false
glutamic acid HCl	drug	80-96	amphetamines	group	154-165	mechanism
ascorbic acid	drug	99-111	amphetamines	group	154-165	mechanism

DDI-DrugBank.d236.s1	Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
Urinary acidifying agents	group	0-24	ammonium chloride	drug	27-43	false
Urinary acidifying agents	group	0-24	sodium acid phosphate	drug	46-66	false
Urinary acidifying agents	group	0-24	amphetamine	drug	132-142	mechanism
ammonium chloride	drug	27-43	sodium acid phosphate	drug	46-66	false
ammonium chloride	drug	27-43	amphetamine	drug	132-142	mechanism
sodium acid phosphate	drug	46-66	amphetamine	drug	132-142	mechanism

DDI-DrugBank.d236.s3	Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
Adrenergic blockers	group	0-18	Adrenergic blockers	group	21-39	false
Adrenergic blockers	group	0-18	amphetamines	group	58-69	false
Adrenergic blockers	group	21-39	amphetamines	group	58-69	effect

DDI-DrugBank.d236.s4	Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
sodium bicarbonate	drug	59-76	amphetamines	drug	108-119	mechanism

DDI-DrugBank.d236.s5	Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
acetazolamide	drug	29-41	thiazides	group	49-57	false
acetazolamide	drug	29-41	amphetamine	drug	121-131	mechanism
thiazides	group	49-57	amphetamine	drug	121-131	mechanism

DDI-DrugBank.d236.s7	Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
Antidepressants	group	0-14	tricyclic	group	17-25	false
Antidepressants	group	0-14	Amphetamines	group	28-39	false
Antidepressants	group	0-14	tricyclic	group	69-77	false
Antidepressants	group	0-14	sympathomimetic agents	group	82-103	false
tricyclic	group	17-25	Amphetamines	group	28-39	false
tricyclic	group	17-25	tricyclic	group	69-77	false
tricyclic	group	17-25	sympathomimetic agents	group	82-103	false
Amphetamines	group	28-39	tricyclic	group	69-77	effect
Amphetamines	group	28-39	sympathomimetic agents	group	82-103	effect
tricyclic	group	69-77	sympathomimetic agents	group	82-103	false

DDI-DrugBank.d236.s8	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
d-amphetamine	drug	0-12	desipramine	drug	19-29	mechanism
d-amphetamine	drug	0-12	protriptyline	drug	34-46	mechanism
d-amphetamine	drug	0-12	tricyclics	group	67-76	mechanism
d-amphetamine	drug	0-12	d-amphetamine	drug	141-153	false
desipramine	drug	19-29	protriptyline	drug	34-46	false
desipramine	drug	19-29	tricyclics	group	67-76	false
desipramine	drug	19-29	d-amphetamine	drug	141-153	false
protriptyline	drug	34-46	tricyclics	group	67-76	false
protriptyline	drug	34-46	d-amphetamine	drug	141-153	false
tricyclics	group	67-76	d-amphetamine	drug	141-153	false

DDI-DrugBank.d236.s10	MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
MAO inhibitors	group	0-13	MAOI antidepressants	group	16-35	false
MAO inhibitors	group	0-13	furazolidone	drug	65-76	false
MAO inhibitors	group	0-13	amphetamine	group	84-94	false
MAOI antidepressants	group	16-35	furazolidone	drug	65-76	false
MAOI antidepressants	group	16-35	amphetamine	group	84-94	mechanism
furazolidone	drug	65-76	amphetamine	group	84-94	mechanism

DDI-DrugBank.d236.s14	Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
Antihistamines	group	0-13	Amphetamines	group	16-27	false
Antihistamines	group	0-13	antihistamines	group	67-80	false
Amphetamines	group	16-27	antihistamines	group	67-80	effect

DDI-DrugBank.d236.s15	Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
Antihypertensives	group	0-16	Amphetamines	group	19-30	false
Antihypertensives	group	0-16	antihypertensives	group	74-90	false
Amphetamines	group	19-30	antihypertensives	group	74-90	effect

DDI-DrugBank.d236.s16	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
Chlorpromazine	drug	0-13	Chlorpromazine	drug	16-29	false
Chlorpromazine	drug	0-13	amphetamines	group	125-136	false
Chlorpromazine	drug	0-13	amphetamine	group	164-174	false
Chlorpromazine	drug	16-29	amphetamines	group	125-136	effect
Chlorpromazine	drug	16-29	amphetamine	group	164-174	false
amphetamines	group	125-136	amphetamine	group	164-174	false

DDI-DrugBank.d236.s17	Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
Ethosuximide	drug	0-11	Amphetamines	group	14-25	false
Ethosuximide	drug	0-11	ethosuximide	drug	62-73	false
Amphetamines	group	14-25	ethosuximide	drug	62-73	mechanism

DDI-DrugBank.d236.s18	Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
Haloperidol	drug	0-10	Haloperidol	drug	13-23	false
Haloperidol	drug	0-10	amphetamines	group	119-130	false
Haloperidol	drug	13-23	amphetamines	group	119-130	effect

DDI-DrugBank.d236.s19	Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
Lithium carbonate	drug	0-16	amphetamines	group	46-57	false
Lithium carbonate	drug	0-16	lithium carbonate	drug	79-95	false
amphetamines	group	46-57	lithium carbonate	drug	79-95	effect

DDI-DrugBank.d236.s20	Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
Meperidine	drug	0-9	Amphetamines	group	12-23	false
Meperidine	drug	0-9	meperidine	drug	60-69	false
Amphetamines	group	12-23	meperidine	drug	60-69	effect

DDI-DrugBank.d236.s21	Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
Methenamine	drug	0-10	amphetamines	group	42-53	false
Methenamine	drug	0-10	acidifying agents	group	97-113	false
Methenamine	drug	0-10	methenamine	drug	123-133	false
amphetamines	group	42-53	acidifying agents	group	97-113	mechanism
amphetamines	group	42-53	methenamine	drug	123-133	false
acidifying agents	group	97-113	methenamine	drug	123-133	false

DDI-DrugBank.d236.s22	Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
Norepinephrine	drug	0-13	Amphetamines	group	16-27	false
Norepinephrine	drug	0-13	norepinephrine	drug	62-75	false
Amphetamines	group	16-27	norepinephrine	drug	62-75	effect

DDI-DrugBank.d236.s23	Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
Phenobarbital	drug	0-12	Amphetamines	group	15-26	false
Phenobarbital	drug	0-12	phenobarbital	drug	63-75	false
Amphetamines	group	15-26	phenobarbital	drug	63-75	mechanism

DDI-DrugBank.d236.s25	Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
Phenytoin	drug	0-8	Amphetamines	group	11-22	false
Phenytoin	drug	0-8	phenytoin	drug	59-67	false
Amphetamines	group	11-22	phenytoin	drug	59-67	mechanism

DDI-DrugBank.d236.s27	Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Propoxyphene	drug	0-11	propoxyphene	drug	26-37	false
Propoxyphene	drug	0-11	amphetamine	group	51-61	false
propoxyphene	drug	26-37	amphetamine	group	51-61	effect

DDI-DrugBank.d236.s28	Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
Veratrum alkaloids	group	0-17	Amphetamines	group	20-31	false
Veratrum alkaloids	group	0-17	veratrum alkaloids	group	67-84	false
Amphetamines	group	20-31	veratrum alkaloids	group	67-84	effect

DDI-DrugBank.d236.s29	Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
Amphetamines	group	35-46	corticosteroid	group	92-105	int

DDI-DrugBank.d461.s0	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.
anesthetics	group	50-60	sedatives	group	63-71	false
anesthetics	group	50-60	antianxiety drugs	group	74-90	false
anesthetics	group	50-60	hypnotics	group	93-101	false
anesthetics	group	50-60	alcohol	drug	104-110	false
anesthetics	group	50-60	opiate analgesics	group	123-139	false
sedatives	group	63-71	antianxiety drugs	group	74-90	false
sedatives	group	63-71	hypnotics	group	93-101	false
sedatives	group	63-71	alcohol	drug	104-110	false
sedatives	group	63-71	opiate analgesics	group	123-139	false
antianxiety drugs	group	74-90	hypnotics	group	93-101	false
antianxiety drugs	group	74-90	alcohol	drug	104-110	false
antianxiety drugs	group	74-90	opiate analgesics	group	123-139	false
hypnotics	group	93-101	alcohol	drug	104-110	false
hypnotics	group	93-101	opiate analgesics	group	123-139	false
alcohol	drug	104-110	opiate analgesics	group	123-139	false

DDI-DrugBank.d293.s0	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
levothyroxine	drug	44-56	iodine	drug	60-65	false
levothyroxine	drug	44-56	antacids	group	88-95	false
levothyroxine	drug	44-56	H2-antagonists	group	98-111	false
levothyroxine	drug	44-56	famotidine	drug	120-129	false
levothyroxine	drug	44-56	ranitidine	drug	132-141	false
levothyroxine	drug	44-56	proton pump inhibitors	group	149-170	false
levothyroxine	drug	44-56	lansoprazole	drug	179-190	false
levothyroxine	drug	44-56	omeprazole	drug	193-202	false
iodine	drug	60-65	antacids	group	88-95	false
iodine	drug	60-65	H2-antagonists	group	98-111	false
iodine	drug	60-65	famotidine	drug	120-129	false
iodine	drug	60-65	ranitidine	drug	132-141	false
iodine	drug	60-65	proton pump inhibitors	group	149-170	false
iodine	drug	60-65	lansoprazole	drug	179-190	false
iodine	drug	60-65	omeprazole	drug	193-202	false
antacids	group	88-95	H2-antagonists	group	98-111	false
antacids	group	88-95	famotidine	drug	120-129	false
antacids	group	88-95	ranitidine	drug	132-141	false
antacids	group	88-95	proton pump inhibitors	group	149-170	false
antacids	group	88-95	lansoprazole	drug	179-190	false
antacids	group	88-95	omeprazole	drug	193-202	false
H2-antagonists	group	98-111	famotidine	drug	120-129	false
H2-antagonists	group	98-111	ranitidine	drug	132-141	false
H2-antagonists	group	98-111	proton pump inhibitors	group	149-170	false
H2-antagonists	group	98-111	lansoprazole	drug	179-190	false
H2-antagonists	group	98-111	omeprazole	drug	193-202	false
famotidine	drug	120-129	ranitidine	drug	132-141	false
famotidine	drug	120-129	proton pump inhibitors	group	149-170	false
famotidine	drug	120-129	lansoprazole	drug	179-190	false
famotidine	drug	120-129	omeprazole	drug	193-202	false
ranitidine	drug	132-141	proton pump inhibitors	group	149-170	false
ranitidine	drug	132-141	lansoprazole	drug	179-190	false
ranitidine	drug	132-141	omeprazole	drug	193-202	false
proton pump inhibitors	group	149-170	lansoprazole	drug	179-190	false
proton pump inhibitors	group	149-170	omeprazole	drug	193-202	false
lansoprazole	drug	179-190	omeprazole	drug	193-202	false

DDI-DrugBank.d36.s0	Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
aspirin	brand	63-69	carbonic anhydrase inhibitors	group	75-103	advise

DDI-DrugBank.d249.s0	Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
Aspirin	brand	0-6	diclofenac	drug	39-48	false
Aspirin	brand	0-6	aspirin	brand	54-60	false
Aspirin	brand	0-6	diclofenac	drug	89-98	false
Aspirin	brand	0-6	aspirin	brand	177-183	false
diclofenac	drug	39-48	aspirin	brand	54-60	advise
diclofenac	drug	39-48	diclofenac	drug	89-98	false
diclofenac	drug	39-48	aspirin	brand	177-183	false
aspirin	brand	54-60	diclofenac	drug	89-98	false
aspirin	brand	54-60	aspirin	brand	177-183	false
diclofenac	drug	89-98	aspirin	brand	177-183	mechanism

DDI-DrugBank.d249.s1	Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
Anticoagulants	group	0-13	diclofenac	drug	45-54	false
Anticoagulants	group	0-13	anticoagulants of the warfarin type	group	73-107	false
Anticoagulants	group	0-13	NSAIDs	group	197-202	false
diclofenac	drug	45-54	anticoagulants of the warfarin type	group	73-107	false
diclofenac	drug	45-54	NSAIDs	group	197-202	advise
anticoagulants of the warfarin type	group	73-107	NSAIDs	group	197-202	false

DDI-DrugBank.d249.s2	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
NSAIDs	group	65-70	NSAIDs	group	134-139	false
NSAIDs	group	65-70	diclofenac	drug	152-161	false
NSAIDs	group	65-70	warfarin	drug	168-175	false
NSAIDs	group	65-70	anticoagulant	group	253-265	false
NSAIDs	group	134-139	diclofenac	drug	152-161	false
NSAIDs	group	134-139	warfarin	drug	168-175	advise
NSAIDs	group	134-139	anticoagulant	group	253-265	false
diclofenac	drug	152-161	warfarin	drug	168-175	advise
diclofenac	drug	152-161	anticoagulant	group	253-265	false
warfarin	drug	168-175	anticoagulant	group	253-265	false

DDI-DrugBank.d249.s3	Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
Digoxin	drug	0-6	Methotrexate	drug	9-20	false
Digoxin	drug	0-6	Cyclosporine	drug	23-34	false
Digoxin	drug	0-6	Diclofenac	drug	37-46	false
Digoxin	drug	0-6	NSAIDs	group	60-65	false
Methotrexate	drug	9-20	Cyclosporine	drug	23-34	false
Methotrexate	drug	9-20	Diclofenac	drug	37-46	false
Methotrexate	drug	9-20	NSAIDs	group	60-65	false
Cyclosporine	drug	23-34	Diclofenac	drug	37-46	false
Cyclosporine	drug	23-34	NSAIDs	group	60-65	false
Diclofenac	drug	37-46	NSAIDs	group	60-65	false

DDI-DrugBank.d249.s4	Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
diclofenac	drug	13-22	digoxin	drug	61-67	mechanism
diclofenac	drug	13-22	methotrexate	drug	73-84	mechanism
diclofenac	drug	13-22	cyclosporine	drug	99-110	effect
digoxin	drug	61-67	methotrexate	drug	73-84	false
digoxin	drug	61-67	cyclosporine	drug	99-110	false
methotrexate	drug	73-84	cyclosporine	drug	99-110	false

DDI-DrugBank.d249.s5	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
diclofenac	drug	26-35	diclofenac	drug	59-68	false
diclofenac	drug	26-35	NSAID	group	88-92	false
diclofenac	drug	26-35	digoxin	drug	107-113	effect
diclofenac	drug	26-35	methotrexate	drug	116-127	effect
diclofenac	drug	26-35	cyclosporine	drug	133-144	effect
diclofenac	drug	59-68	NSAID	group	88-92	false
diclofenac	drug	59-68	digoxin	drug	107-113	false
diclofenac	drug	59-68	methotrexate	drug	116-127	false
diclofenac	drug	59-68	cyclosporine	drug	133-144	false
NSAID	group	88-92	digoxin	drug	107-113	effect
NSAID	group	88-92	methotrexate	drug	116-127	effect
NSAID	group	88-92	cyclosporine	drug	133-144	effect
digoxin	drug	107-113	methotrexate	drug	116-127	false
digoxin	drug	107-113	cyclosporine	drug	133-144	false
methotrexate	drug	116-127	cyclosporine	drug	133-144	false

DDI-DrugBank.d249.s8	Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
Lithium	drug	0-6	Diclofenac	drug	9-18	false
Lithium	drug	0-6	lithium	drug	30-36	false
Lithium	drug	0-6	lithium	drug	68-74	false
Diclofenac	drug	9-18	lithium	drug	30-36	mechanism
Diclofenac	drug	9-18	lithium	drug	68-74	mechanism
lithium	drug	30-36	lithium	drug	68-74	false

DDI-DrugBank.d249.s9	In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
diclofenac	drug	19-28	lithium	drug	34-40	effect
diclofenac	drug	19-28	lithium	drug	57-63	false
lithium	drug	34-40	lithium	drug	57-63	false

DDI-DrugBank.d249.s10	Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.
Hypoglycemics	group	5-17	Diclofenac	drug	20-29	false
Hypoglycemics	group	5-17	hypoglycemic agents	group	122-140	false
Diclofenac	drug	20-29	hypoglycemic agents	group	122-140	false

DDI-DrugBank.d249.s11	There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
insulin	drug	86-92	hypoglycemic agents	group	102-120	false
insulin	drug	86-92	diclofenac	drug	141-150	effect
hypoglycemic agents	group	102-120	diclofenac	drug	141-150	effect

DDI-DrugBank.d249.s13	A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
diclofenac	drug	107-116	insulin	drug	161-167	effect
diclofenac	drug	107-116	hypoglycemic agents	group	177-195	effect
insulin	drug	161-167	hypoglycemic agents	group	177-195	false

DDI-DrugBank.d249.s14	Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
Diuretics	group	0-8	Diclofenac	drug	11-20	false
Diuretics	group	0-8	NSAIDs	group	32-37	false
Diuretics	group	0-8	diuretics	group	67-75	false
Diclofenac	drug	11-20	NSAIDs	group	32-37	false
Diclofenac	drug	11-20	diuretics	group	67-75	effect
NSAIDs	group	32-37	diuretics	group	67-75	effect

DDI-DrugBank.d249.s16	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
azathioprine	drug	101-112	gold	group	115-118	false
azathioprine	drug	101-112	chloroquine	drug	121-131	false
azathioprine	drug	101-112	D-penicillamine	drug	134-148	false
azathioprine	drug	101-112	prednisolone	drug	151-162	false
azathioprine	drug	101-112	doxycycline	drug	165-175	false
azathioprine	drug	101-112	digitoxin	drug	181-189	false
azathioprine	drug	101-112	diclofenac	drug	254-263	false
gold	group	115-118	chloroquine	drug	121-131	false
gold	group	115-118	D-penicillamine	drug	134-148	false
gold	group	115-118	prednisolone	drug	151-162	false
gold	group	115-118	doxycycline	drug	165-175	false
gold	group	115-118	digitoxin	drug	181-189	false
gold	group	115-118	diclofenac	drug	254-263	false
chloroquine	drug	121-131	D-penicillamine	drug	134-148	false
chloroquine	drug	121-131	prednisolone	drug	151-162	false
chloroquine	drug	121-131	doxycycline	drug	165-175	false
chloroquine	drug	121-131	digitoxin	drug	181-189	false
chloroquine	drug	121-131	diclofenac	drug	254-263	false
D-penicillamine	drug	134-148	prednisolone	drug	151-162	false
D-penicillamine	drug	134-148	doxycycline	drug	165-175	false
D-penicillamine	drug	134-148	digitoxin	drug	181-189	false
D-penicillamine	drug	134-148	diclofenac	drug	254-263	false
prednisolone	drug	151-162	doxycycline	drug	165-175	false
prednisolone	drug	151-162	digitoxin	drug	181-189	false
prednisolone	drug	151-162	diclofenac	drug	254-263	false
doxycycline	drug	165-175	digitoxin	drug	181-189	false
doxycycline	drug	165-175	diclofenac	drug	254-263	false
digitoxin	drug	181-189	diclofenac	drug	254-263	false

DDI-DrugBank.d249.s17	Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
Phenobarbital	drug	0-12	phenobarbital	drug	82-94	false
Phenobarbital	drug	0-12	diclofenac	drug	134-143	false
phenobarbital	drug	82-94	diclofenac	drug	134-143	effect

DDI-DrugBank.d249.s18	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
diclofenac	drug	26-35	salicylic acid	drug	100-113	mechanism
diclofenac	drug	26-35	tolbutamide	drug	142-152	mechanism
diclofenac	drug	26-35	prednisolone	drug	155-166	mechanism
diclofenac	drug	26-35	warfarin	drug	198-205	mechanism
salicylic acid	drug	100-113	tolbutamide	drug	142-152	false
salicylic acid	drug	100-113	prednisolone	drug	155-166	false
salicylic acid	drug	100-113	warfarin	drug	198-205	false
tolbutamide	drug	142-152	prednisolone	drug	155-166	false
tolbutamide	drug	142-152	warfarin	drug	198-205	false
prednisolone	drug	155-166	warfarin	drug	198-205	false

DDI-DrugBank.d249.s19	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
Benzylpenicillin	drug	0-15	ampicillin	drug	18-27	false
Benzylpenicillin	drug	0-15	oxacillin	drug	30-38	false
Benzylpenicillin	drug	0-15	chlortetracycline	drug	41-57	false
Benzylpenicillin	drug	0-15	doxycycline	drug	60-70	false
Benzylpenicillin	drug	0-15	cephalothin	drug	73-83	false
Benzylpenicillin	drug	0-15	erythromycin	drug	86-97	false
Benzylpenicillin	drug	0-15	sulfamethoxazole	drug	104-119	false
Benzylpenicillin	drug	0-15	diclofenac	drug	174-183	false
ampicillin	drug	18-27	oxacillin	drug	30-38	false
ampicillin	drug	18-27	chlortetracycline	drug	41-57	false
ampicillin	drug	18-27	doxycycline	drug	60-70	false
ampicillin	drug	18-27	cephalothin	drug	73-83	false
ampicillin	drug	18-27	erythromycin	drug	86-97	false
ampicillin	drug	18-27	sulfamethoxazole	drug	104-119	false
ampicillin	drug	18-27	diclofenac	drug	174-183	false
oxacillin	drug	30-38	chlortetracycline	drug	41-57	false
oxacillin	drug	30-38	doxycycline	drug	60-70	false
oxacillin	drug	30-38	cephalothin	drug	73-83	false
oxacillin	drug	30-38	erythromycin	drug	86-97	false
oxacillin	drug	30-38	sulfamethoxazole	drug	104-119	false
oxacillin	drug	30-38	diclofenac	drug	174-183	false
chlortetracycline	drug	41-57	doxycycline	drug	60-70	false
chlortetracycline	drug	41-57	cephalothin	drug	73-83	false
chlortetracycline	drug	41-57	erythromycin	drug	86-97	false
chlortetracycline	drug	41-57	sulfamethoxazole	drug	104-119	false
chlortetracycline	drug	41-57	diclofenac	drug	174-183	false
doxycycline	drug	60-70	cephalothin	drug	73-83	false
doxycycline	drug	60-70	erythromycin	drug	86-97	false
doxycycline	drug	60-70	sulfamethoxazole	drug	104-119	false
doxycycline	drug	60-70	diclofenac	drug	174-183	false
cephalothin	drug	73-83	erythromycin	drug	86-97	false
cephalothin	drug	73-83	sulfamethoxazole	drug	104-119	false
cephalothin	drug	73-83	diclofenac	drug	174-183	false
erythromycin	drug	86-97	sulfamethoxazole	drug	104-119	false
erythromycin	drug	86-97	diclofenac	drug	174-183	false
sulfamethoxazole	drug	104-119	diclofenac	drug	174-183	false

DDI-DrugBank.d517.s0	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	drug	0-11	bacteriostatic antibiotic	group	16-40	false
Tetracycline	drug	0-11	penicillin	drug	84-93	effect
bacteriostatic antibiotic	group	16-40	penicillin	drug	84-93	false

DDI-DrugBank.d543.s0	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
anticholinergic drugs	group	69-89	amantadine	drug	92-101	false
anticholinergic drugs	group	69-89	antiarrhythmic agents	group	103-123	false
anticholinergic drugs	group	69-89	quinidine	drug	140-148	false
anticholinergic drugs	group	69-89	antihistamines	group	152-165	false
anticholinergic drugs	group	69-89	antipsychotic agents	group	167-186	false
anticholinergic drugs	group	69-89	phenothiazines	group	194-207	false
anticholinergic drugs	group	69-89	benzodiazepines	group	211-225	false
amantadine	drug	92-101	antiarrhythmic agents	group	103-123	false
amantadine	drug	92-101	quinidine	drug	140-148	false
amantadine	drug	92-101	antihistamines	group	152-165	false
amantadine	drug	92-101	antipsychotic agents	group	167-186	false
amantadine	drug	92-101	phenothiazines	group	194-207	false
amantadine	drug	92-101	benzodiazepines	group	211-225	false
antiarrhythmic agents	group	103-123	quinidine	drug	140-148	false
antiarrhythmic agents	group	103-123	antihistamines	group	152-165	false
antiarrhythmic agents	group	103-123	antipsychotic agents	group	167-186	false
antiarrhythmic agents	group	103-123	phenothiazines	group	194-207	false
antiarrhythmic agents	group	103-123	benzodiazepines	group	211-225	false
quinidine	drug	140-148	antihistamines	group	152-165	false
quinidine	drug	140-148	antipsychotic agents	group	167-186	false
quinidine	drug	140-148	phenothiazines	group	194-207	false
quinidine	drug	140-148	benzodiazepines	group	211-225	false
antihistamines	group	152-165	antipsychotic agents	group	167-186	false
antihistamines	group	152-165	phenothiazines	group	194-207	false
antihistamines	group	152-165	benzodiazepines	group	211-225	false
antipsychotic agents	group	167-186	phenothiazines	group	194-207	false
antipsychotic agents	group	167-186	benzodiazepines	group	211-225	false
phenothiazines	group	194-207	benzodiazepines	group	211-225	false

DDI-DrugBank.d543.s1	MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
MAO inhibitors	group	0-13	narcotic analgesics	group	16-34	false
MAO inhibitors	group	0-13	meperidine	drug	43-52	false
MAO inhibitors	group	0-13	nitrates	group	56-63	false
MAO inhibitors	group	0-13	nitrites	group	69-76	false
MAO inhibitors	group	0-13	sympathomimetic agents	group	79-100	false
MAO inhibitors	group	0-13	tricyclic antidepressants	group	103-127	false
narcotic analgesics	group	16-34	meperidine	drug	43-52	false
narcotic analgesics	group	16-34	nitrates	group	56-63	false
narcotic analgesics	group	16-34	nitrites	group	69-76	false
narcotic analgesics	group	16-34	sympathomimetic agents	group	79-100	false
narcotic analgesics	group	16-34	tricyclic antidepressants	group	103-127	false
meperidine	drug	43-52	nitrates	group	56-63	false
meperidine	drug	43-52	nitrites	group	69-76	false
meperidine	drug	43-52	sympathomimetic agents	group	79-100	false
meperidine	drug	43-52	tricyclic antidepressants	group	103-127	false
nitrates	group	56-63	nitrites	group	69-76	false
nitrates	group	56-63	sympathomimetic agents	group	79-100	false
nitrates	group	56-63	tricyclic antidepressants	group	103-127	false
nitrites	group	69-76	sympathomimetic agents	group	79-100	false
nitrites	group	69-76	tricyclic antidepressants	group	103-127	false
sympathomimetic agents	group	79-100	tricyclic antidepressants	group	103-127	false

DDI-DrugBank.d543.s2	Anticholinergics antagonize the effects of antiglaucoma agents.
Anticholinergics	group	0-15	antiglaucoma agents	group	43-61	false

DDI-DrugBank.d543.s4	Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
Anticholinergic agents	group	0-21	digoxin	drug	122-128	mechanism

DDI-DrugBank.d543.s6	Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
Anticholinergic drugs	group	0-20	metoclopramide	drug	108-121	mechanism

DDI-DrugBank.d543.s7	Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
antacids	group	8-15	anticholinergic agents	group	54-75	mechanism

DDI-DrugBank.d43.s1	Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).
stavudine	drug	119-127	VIDEX	brand	195-199	false

DDI-DrugBank.d43.s2	Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
Allopurinol	drug	0-10	didanosine	drug	24-33	false
Allopurinol	drug	0-10	allopurinol	drug	67-77	false
Allopurinol	drug	0-10	VIDEX	brand	141-145	false
didanosine	drug	24-33	allopurinol	drug	67-77	false
didanosine	drug	24-33	VIDEX	brand	141-145	false
allopurinol	drug	67-77	VIDEX	brand	141-145	mechanism

DDI-DrugBank.d43.s3	The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.
allopurinol	drug	15-25	didanosine	drug	30-39	false

DDI-DrugBank.d43.s4	Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
Antacids	group	0-7	antacids	group	40-47	false
Antacids	group	0-7	magnesium	drug	60-68	false
Antacids	group	0-7	aluminum	drug	73-80	false
Antacids	group	0-7	VIDEX	brand	87-91	false
Antacids	group	0-7	antacid	group	219-225	false
antacids	group	40-47	magnesium	drug	60-68	false
antacids	group	40-47	aluminum	drug	73-80	false
antacids	group	40-47	VIDEX	brand	87-91	effect
antacids	group	40-47	antacid	group	219-225	false
magnesium	drug	60-68	aluminum	drug	73-80	false
magnesium	drug	60-68	VIDEX	brand	87-91	effect
magnesium	drug	60-68	antacid	group	219-225	false
aluminum	drug	73-80	VIDEX	brand	87-91	effect
aluminum	drug	73-80	antacid	group	219-225	false
VIDEX	brand	87-91	antacid	group	219-225	false

DDI-DrugBank.d43.s5	Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
ketoconazole	drug	93-104	itraconazole	drug	110-121	false
ketoconazole	drug	93-104	VIDEX	brand	184-188	advise
itraconazole	drug	110-121	VIDEX	brand	184-188	advise

DDI-DrugBank.d43.s6	Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
Ganciclovir	drug	0-10	VIDEX	brand	31-35	false
Ganciclovir	drug	0-10	ganciclovir	drug	78-88	false
Ganciclovir	drug	0-10	didanosine	drug	159-168	false
VIDEX	brand	31-35	ganciclovir	drug	78-88	mechanism
VIDEX	brand	31-35	didanosine	drug	159-168	false
ganciclovir	drug	78-88	didanosine	drug	159-168	false

DDI-DrugBank.d43.s7	A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
ganciclovir	drug	47-57	VIDEX	brand	77-81	false
ganciclovir	drug	47-57	ganciclovir	drug	117-127	false
VIDEX	brand	77-81	ganciclovir	drug	117-127	mechanism

DDI-DrugBank.d43.s8	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
Quinolone Antibiotic	group	0-19	VIDEX	brand	23-27	false
Quinolone Antibiotic	group	0-19	ciprofloxacin	drug	105-117	false
Quinolone Antibiotic	group	0-19	ciprofloxacin	drug	152-164	false
Quinolone Antibiotic	group	0-19	antacids	group	203-210	false
Quinolone Antibiotic	group	0-19	magnesium	drug	223-231	false
Quinolone Antibiotic	group	0-19	calcium	drug	234-240	false
Quinolone Antibiotic	group	0-19	aluminum	drug	246-253	false
VIDEX	brand	23-27	ciprofloxacin	drug	105-117	advise
VIDEX	brand	23-27	ciprofloxacin	drug	152-164	false
VIDEX	brand	23-27	antacids	group	203-210	false
VIDEX	brand	23-27	magnesium	drug	223-231	false
VIDEX	brand	23-27	calcium	drug	234-240	false
VIDEX	brand	23-27	aluminum	drug	246-253	false
ciprofloxacin	drug	105-117	ciprofloxacin	drug	152-164	false
ciprofloxacin	drug	105-117	antacids	group	203-210	false
ciprofloxacin	drug	105-117	magnesium	drug	223-231	false
ciprofloxacin	drug	105-117	calcium	drug	234-240	false
ciprofloxacin	drug	105-117	aluminum	drug	246-253	false
ciprofloxacin	drug	152-164	antacids	group	203-210	false
ciprofloxacin	drug	152-164	magnesium	drug	223-231	mechanism
ciprofloxacin	drug	152-164	calcium	drug	234-240	mechanism
ciprofloxacin	drug	152-164	aluminum	drug	246-253	mechanism
antacids	group	203-210	magnesium	drug	223-231	false
antacids	group	203-210	calcium	drug	234-240	false
antacids	group	203-210	aluminum	drug	246-253	false
magnesium	drug	223-231	calcium	drug	234-240	false
magnesium	drug	223-231	aluminum	drug	246-253	false
calcium	drug	234-240	aluminum	drug	246-253	false

DDI-DrugBank.d43.s9	In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
ciprofloxacin	drug	56-68	ciprofloxacin	drug	127-139	false
ciprofloxacin	drug	56-68	VIDEX	brand	229-233	false
ciprofloxacin	drug	127-139	VIDEX	brand	229-233	mechanism

DDI-DrugBank.d43.s10	The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
ciprofloxacin	drug	11-23	ciprofloxacin	drug	90-102	false
ciprofloxacin	drug	11-23	didanosine	drug	108-117	false
ciprofloxacin	drug	90-102	didanosine	drug	108-117	mechanism

DDI-DrugBank.d43.s11	In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
ciprofloxacin	drug	38-50	didanosine	drug	76-85	mechanism
ciprofloxacin	drug	38-50	ciprofloxacin	drug	147-159	false
didanosine	drug	76-85	ciprofloxacin	drug	147-159	false

DDI-DrugBank.d43.s12	Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
quinolone antibiotics	group	25-45	antacids	group	84-91	false
quinolone antibiotics	group	25-45	magnesium	drug	104-112	mechanism
quinolone antibiotics	group	25-45	calcium	drug	115-121	mechanism
quinolone antibiotics	group	25-45	aluminum	drug	127-134	mechanism
antacids	group	84-91	magnesium	drug	104-112	false
antacids	group	84-91	calcium	drug	115-121	false
antacids	group	84-91	aluminum	drug	127-134	false
magnesium	drug	104-112	calcium	drug	115-121	false
magnesium	drug	104-112	aluminum	drug	127-134	false
calcium	drug	115-121	aluminum	drug	127-134	false

DDI-DrugBank.d43.s13	The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.
VIDEX	brand	54-58	quinolone	group	111-119	false

DDI-DrugBank.d43.s14	Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
Antiretroviral Drugs	group	24-43	delavirdine	drug	82-92	false
Antiretroviral Drugs	group	24-43	indinavir	drug	104-112	false
Antiretroviral Drugs	group	24-43	VIDEX	brand	188-192	false
delavirdine	drug	82-92	indinavir	drug	104-112	false
delavirdine	drug	82-92	VIDEX	brand	188-192	mechanism
indinavir	drug	104-112	VIDEX	brand	188-192	mechanism

DDI-DrugBank.d43.s15	To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
delavirdine	drug	27-37	indinavir	drug	42-50	false
delavirdine	drug	27-37	VIDEX	brand	96-100	advise
indinavir	drug	42-50	VIDEX	brand	96-100	advise

DDI-DrugBank.d43.s16	The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.
nelfinavir	drug	24-33	VIDEX	brand	141-145	false

DDI-DrugBank.d570.s0	Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
estrogen	group	97-104	contraceptives	group	122-135	false

DDI-DrugBank.d352.s0	Antidiabetic drug requirements (i.e., insulin) may be altered.
Antidiabetic drug	group	0-16	insulin	drug	38-44	false

DDI-DrugBank.d352.s3	conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
diethylpropion	drug	12-25	antihypertensive drugs	group	46-67	int
diethylpropion	drug	12-25	guanethidine	drug	76-87	int
diethylpropion	drug	12-25	a-methyldopa	drug	90-101	int
antihypertensive drugs	group	46-67	guanethidine	drug	76-87	false
antihypertensive drugs	group	46-67	a-methyldopa	drug	90-101	false
guanethidine	drug	76-87	a-methyldopa	drug	90-101	false

DDI-DrugBank.d352.s4	Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
phenothiazines	group	18-31	diethylpropion	drug	72-85	effect

DDI-DrugBank.d248.s0	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
anticoagulants	group	13-26	barbiturates	group	67-78	false
anticoagulants	group	13-26	rifampin	drug	81-88	false
anticoagulants	group	13-26	diethylstilbestrol	drug	176-193	false
anticoagulants	group	13-26	corticosteroids	group	197-211	false
anticoagulants	group	13-26	corticosteroids	group	234-248	false
barbiturates	group	67-78	rifampin	drug	81-88	false
barbiturates	group	67-78	diethylstilbestrol	drug	176-193	false
barbiturates	group	67-78	corticosteroids	group	197-211	false
barbiturates	group	67-78	corticosteroids	group	234-248	false
rifampin	drug	81-88	diethylstilbestrol	drug	176-193	false
rifampin	drug	81-88	corticosteroids	group	197-211	false
rifampin	drug	81-88	corticosteroids	group	234-248	false
diethylstilbestrol	drug	176-193	corticosteroids	group	197-211	false
diethylstilbestrol	drug	176-193	corticosteroids	group	234-248	false
corticosteroids	group	197-211	corticosteroids	group	234-248	false

DDI-DrugBank.d132.s0	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
Anticoagulants	group	5-18	diflunisal	drug	82-91	false
Anticoagulants	group	5-18	warfarin	drug	97-104	false
Anticoagulants	group	5-18	acenocoumarol	drug	107-119	false
Anticoagulants	group	5-18	phenprocoumon	drug	125-137	false
diflunisal	drug	82-91	warfarin	drug	97-104	effect
diflunisal	drug	82-91	acenocoumarol	drug	107-119	effect
diflunisal	drug	82-91	phenprocoumon	drug	125-137	effect
warfarin	drug	97-104	acenocoumarol	drug	107-119	false
warfarin	drug	97-104	phenprocoumon	drug	125-137	false
acenocoumarol	drug	107-119	phenprocoumon	drug	125-137	false

DDI-DrugBank.d132.s1	This may occur because diflunisal competitively displaces coumarins from protein binding sites.
diflunisal	drug	23-32	coumarins	group	58-66	mechanism

DDI-DrugBank.d132.s2	Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
diflunisal	drug	18-27	anticoagulants	group	55-68	advise

DDI-DrugBank.d132.s4	Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.
Tolbutamide	drug	0-10	diflunisal	drug	44-53	false
Tolbutamide	drug	0-10	tolbutamide	drug	59-69	false
Tolbutamide	drug	0-10	tolbutamide	drug	108-118	false
diflunisal	drug	44-53	tolbutamide	drug	59-69	false
diflunisal	drug	44-53	tolbutamide	drug	108-118	false
tolbutamide	drug	59-69	tolbutamide	drug	108-118	false

DDI-DrugBank.d132.s5	Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
Hydrochlorothiazide	drug	0-18	diflunisal	drug	73-82	false
Hydrochlorothiazide	drug	0-18	hydrochlorothiazide	drug	88-106	false
Hydrochlorothiazide	drug	0-18	hydrochlorothiazide	drug	161-179	false
diflunisal	drug	73-82	hydrochlorothiazide	drug	88-106	mechanism
diflunisal	drug	73-82	hydrochlorothiazide	drug	161-179	false
hydrochlorothiazide	drug	88-106	hydrochlorothiazide	drug	161-179	false

DDI-DrugBank.d132.s6	Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
Diflunisal	drug	0-9	hydrochlorothiazide	drug	49-67	effect

DDI-DrugBank.d132.s7	Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.
Furosemide	drug	0-9	diflunisal	drug	68-77	false
Furosemide	drug	0-9	furosemide	drug	83-92	false
Furosemide	drug	0-9	furosemide	drug	136-145	false
diflunisal	drug	68-77	furosemide	drug	83-92	false
diflunisal	drug	68-77	furosemide	drug	136-145	false
furosemide	drug	83-92	furosemide	drug	136-145	false

DDI-DrugBank.d132.s8	Diflunisal decreased the hyperuricemic effect of furosemide.
Diflunisal	drug	0-9	furosemide	drug	49-58	effect

DDI-DrugBank.d132.s9	Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
Antacids	group	0-7	antacids	group	40-47	false
Antacids	group	0-7	diflunisal	drug	77-86	false
antacids	group	40-47	diflunisal	drug	77-86	mechanism

DDI-DrugBank.d132.s10	This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.
antacids	group	46-53	antacids	group	95-102	false

DDI-DrugBank.d132.s11	Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
Acetaminophen	drug	0-12	diflunisal	drug	67-76	false
Acetaminophen	drug	0-12	acetaminophen	drug	82-94	false
Acetaminophen	drug	0-12	acetaminophen	drug	156-168	false
diflunisal	drug	67-76	acetaminophen	drug	82-94	mechanism
diflunisal	drug	67-76	acetaminophen	drug	156-168	false
acetaminophen	drug	82-94	acetaminophen	drug	156-168	false

DDI-DrugBank.d132.s12	Acetaminophen had no effect on plasma levels of diflunisal.
Acetaminophen	drug	0-12	diflunisal	drug	48-57	false

DDI-DrugBank.d132.s13	Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
acetaminophen	drug	6-18	diflunisal	drug	105-114	false
acetaminophen	drug	6-18	acetaminophen	drug	120-132	false
diflunisal	drug	105-114	acetaminophen	drug	120-132	advise

DDI-DrugBank.d132.s14	Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
diflunisal	drug	30-39	acetaminophen	drug	45-57	effect
diflunisal	drug	30-39	diflunisal	drug	188-197	false
diflunisal	drug	30-39	acetaminophen	drug	199-211	false
acetaminophen	drug	45-57	diflunisal	drug	188-197	false
acetaminophen	drug	45-57	acetaminophen	drug	199-211	false
diflunisal	drug	188-197	acetaminophen	drug	199-211	false

DDI-DrugBank.d132.s16	Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
Methotrexate	drug	0-11	diflunisal	drug	40-49	false
Methotrexate	drug	0-11	methotrexate	drug	86-97	false
diflunisal	drug	40-49	methotrexate	drug	86-97	advise

DDI-DrugBank.d132.s17	Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
Nonsteroidal anti-inflammatory drugs	group	0-35	methotrexate	drug	93-104	mechanism

DDI-DrugBank.d132.s18	Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
Cyclosporine	drug	0-11	nonsteroial anti-inflammatory drugs	group	32-66	false
Cyclosporine	drug	0-11	cyclosporine	drug	87-98	false
Cyclosporine	drug	0-11	cyclosporine	drug	140-151	false
nonsteroial anti-inflammatory drugs	group	32-66	cyclosporine	drug	87-98	mechanism
nonsteroial anti-inflammatory drugs	group	32-66	cyclosporine	drug	140-151	false
cyclosporine	drug	87-98	cyclosporine	drug	140-151	false

DDI-DrugBank.d132.s19	NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
NSAIDs	group	0-5	cyclosporine	drug	54-65	advise

DDI-DrugBank.d132.s20	Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	diflunisal	drug	60-69	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	indomethacin	drug	102-113	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	indomethacin	drug	194-205	false
diflunisal	drug	60-69	indomethacin	drug	102-113	mechanism
diflunisal	drug	60-69	indomethacin	drug	194-205	false
indomethacin	drug	102-113	indomethacin	drug	194-205	false

DDI-DrugBank.d132.s21	In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
indomethacin	drug	37-48	diflunisal	drug	54-63	effect

DDI-DrugBank.d132.s22	Therefore, indomethacin and diflunisal should not be used concomitantly.
indomethacin	drug	11-22	diflunisal	drug	28-37	advise

DDI-DrugBank.d132.s23	The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
diflunisal	drug	23-32	NSAIDs	group	52-57	effect

DDI-DrugBank.d132.s25	Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
Aspirin	brand	0-6	diflunisal	drug	51-60	false
Aspirin	brand	0-6	diflunisal	drug	105-114	false
Aspirin	brand	0-6	aspirin	brand	120-126	false
diflunisal	drug	51-60	diflunisal	drug	105-114	false
diflunisal	drug	51-60	aspirin	brand	120-126	false
diflunisal	drug	105-114	aspirin	brand	120-126	mechanism

DDI-DrugBank.d132.s26	Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
Sulindac	drug	0-7	diflunisal	drug	44-53	false
Sulindac	drug	0-7	sulindac	drug	59-66	false
diflunisal	drug	44-53	sulindac	drug	59-66	mechanism

DDI-DrugBank.d132.s27	Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
Naproxen	drug	0-7	diflunisal	drug	44-53	false
Naproxen	drug	0-7	naproxen	drug	59-66	false
Naproxen	drug	0-7	naproxen	drug	127-134	false
Naproxen	drug	0-7	naproxen	drug	190-197	false
diflunisal	drug	44-53	naproxen	drug	59-66	mechanism
diflunisal	drug	44-53	naproxen	drug	127-134	false
diflunisal	drug	44-53	naproxen	drug	190-197	false
naproxen	drug	59-66	naproxen	drug	127-134	false
naproxen	drug	59-66	naproxen	drug	190-197	false
naproxen	drug	127-134	naproxen	drug	190-197	false

DDI-DrugBank.d132.s28	Naproxen had no effect on plasma levels of diflunisal.
Naproxen	drug	0-7	diflunisal	drug	43-52	false

DDI-DrugBank.d450.s0	Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
Potassium-depleting diuretics	group	0-28	digitalis	group	65-73	effect

DDI-DrugBank.d450.s2	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
Quinidine	drug	0-8	verapamil	drug	11-19	false
Quinidine	drug	0-8	amiodarone	drug	22-31	false
Quinidine	drug	0-8	propafenone	drug	34-44	false
Quinidine	drug	0-8	indomethacin	drug	47-58	false
Quinidine	drug	0-8	itraconazole	drug	61-72	false
Quinidine	drug	0-8	alprazolam	drug	75-84	false
Quinidine	drug	0-8	spironolactone	drug	91-104	false
Quinidine	drug	0-8	digoxin	drug	122-128	mechanism
Quinidine	drug	0-8	digitalis	group	248-256	false
verapamil	drug	11-19	amiodarone	drug	22-31	false
verapamil	drug	11-19	propafenone	drug	34-44	false
verapamil	drug	11-19	indomethacin	drug	47-58	false
verapamil	drug	11-19	itraconazole	drug	61-72	false
verapamil	drug	11-19	alprazolam	drug	75-84	false
verapamil	drug	11-19	spironolactone	drug	91-104	false
verapamil	drug	11-19	digoxin	drug	122-128	mechanism
verapamil	drug	11-19	digitalis	group	248-256	false
amiodarone	drug	22-31	propafenone	drug	34-44	false
amiodarone	drug	22-31	indomethacin	drug	47-58	false
amiodarone	drug	22-31	itraconazole	drug	61-72	false
amiodarone	drug	22-31	alprazolam	drug	75-84	false
amiodarone	drug	22-31	spironolactone	drug	91-104	false
amiodarone	drug	22-31	digoxin	drug	122-128	mechanism
amiodarone	drug	22-31	digitalis	group	248-256	false
propafenone	drug	34-44	indomethacin	drug	47-58	false
propafenone	drug	34-44	itraconazole	drug	61-72	false
propafenone	drug	34-44	alprazolam	drug	75-84	false
propafenone	drug	34-44	spironolactone	drug	91-104	false
propafenone	drug	34-44	digoxin	drug	122-128	mechanism
propafenone	drug	34-44	digitalis	group	248-256	false
indomethacin	drug	47-58	itraconazole	drug	61-72	false
indomethacin	drug	47-58	alprazolam	drug	75-84	false
indomethacin	drug	47-58	spironolactone	drug	91-104	false
indomethacin	drug	47-58	digoxin	drug	122-128	mechanism
indomethacin	drug	47-58	digitalis	group	248-256	false
itraconazole	drug	61-72	alprazolam	drug	75-84	false
itraconazole	drug	61-72	spironolactone	drug	91-104	false
itraconazole	drug	61-72	digoxin	drug	122-128	mechanism
itraconazole	drug	61-72	digitalis	group	248-256	false
alprazolam	drug	75-84	spironolactone	drug	91-104	false
alprazolam	drug	75-84	digoxin	drug	122-128	mechanism
alprazolam	drug	75-84	digitalis	group	248-256	false
spironolactone	drug	91-104	digoxin	drug	122-128	mechanism
spironolactone	drug	91-104	digitalis	group	248-256	false
digoxin	drug	122-128	digitalis	group	248-256	false

DDI-DrugBank.d450.s3	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
Erythromycin	drug	0-11	clarithromycin	drug	17-30	false
Erythromycin	drug	0-11	macrolide antibiotics	group	52-72	false
Erythromycin	drug	0-11	tetracycline	drug	79-90	false
Erythromycin	drug	0-11	digoxin	drug	105-111	mechanism
Erythromycin	drug	0-11	digoxin	drug	151-157	false
Erythromycin	drug	0-11	digitalis	group	215-223	false
clarithromycin	drug	17-30	macrolide antibiotics	group	52-72	false
clarithromycin	drug	17-30	tetracycline	drug	79-90	false
clarithromycin	drug	17-30	digoxin	drug	105-111	mechanism
clarithromycin	drug	17-30	digoxin	drug	151-157	false
clarithromycin	drug	17-30	digitalis	group	215-223	false
macrolide antibiotics	group	52-72	tetracycline	drug	79-90	false
macrolide antibiotics	group	52-72	digoxin	drug	105-111	mechanism
macrolide antibiotics	group	52-72	digoxin	drug	151-157	false
macrolide antibiotics	group	52-72	digitalis	group	215-223	false
tetracycline	drug	79-90	digoxin	drug	105-111	mechanism
tetracycline	drug	79-90	digoxin	drug	151-157	false
tetracycline	drug	79-90	digitalis	group	215-223	false
digoxin	drug	105-111	digoxin	drug	151-157	false
digoxin	drug	105-111	digitalis	group	215-223	false
digoxin	drug	151-157	digitalis	group	215-223	false

DDI-DrugBank.d450.s5	Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
Propantheline	drug	0-12	diphenoxylate	drug	18-30	false
Propantheline	drug	0-12	digoxin	drug	74-80	mechanism
diphenoxylate	drug	18-30	digoxin	drug	74-80	mechanism

DDI-DrugBank.d450.s6	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
Antacids	group	0-7	kaolin	drug	10-15	false
Antacids	group	0-7	sulfasalazine	drug	25-37	false
Antacids	group	0-7	neomycin	drug	40-47	false
Antacids	group	0-7	cholestyramine	drug	50-63	false
Antacids	group	0-7	metoclopramide	drug	96-109	false
Antacids	group	0-7	digoxin	drug	141-147	mechanism
kaolin	drug	10-15	sulfasalazine	drug	25-37	false
kaolin	drug	10-15	neomycin	drug	40-47	false
kaolin	drug	10-15	cholestyramine	drug	50-63	false
kaolin	drug	10-15	metoclopramide	drug	96-109	false
kaolin	drug	10-15	digoxin	drug	141-147	mechanism
sulfasalazine	drug	25-37	neomycin	drug	40-47	false
sulfasalazine	drug	25-37	cholestyramine	drug	50-63	false
sulfasalazine	drug	25-37	metoclopramide	drug	96-109	false
sulfasalazine	drug	25-37	digoxin	drug	141-147	mechanism
neomycin	drug	40-47	cholestyramine	drug	50-63	false
neomycin	drug	40-47	metoclopramide	drug	96-109	false
neomycin	drug	40-47	digoxin	drug	141-147	mechanism
cholestyramine	drug	50-63	metoclopramide	drug	96-109	false
cholestyramine	drug	50-63	digoxin	drug	141-147	mechanism
metoclopramide	drug	96-109	digoxin	drug	141-147	mechanism

DDI-DrugBank.d450.s7	Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
Rifampin	drug	0-7	digoxin	drug	28-34	mechanism
Rifampin	drug	0-7	digoxin	drug	139-145	false
digoxin	drug	28-34	digoxin	drug	139-145	false

DDI-DrugBank.d450.s8	There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.
quinine	drug	81-87	penicillamine	drug	90-102	false
quinine	drug	81-87	digoxin	drug	114-120	false
penicillamine	drug	90-102	digoxin	drug	114-120	false

DDI-DrugBank.d450.s9	Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
Thyroid	group	0-6	digoxin	drug	98-104	advise

DDI-DrugBank.d450.s10	Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
digoxin	drug	19-25	sympathomimetics	group	31-46	effect

DDI-DrugBank.d450.s12	Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
beta-adrenergic blockers	group	9-32	calcium channel blockers	group	37-60	false
beta-adrenergic blockers	group	9-32	digoxin	drug	66-72	effect
calcium channel blockers	group	37-60	digoxin	drug	66-72	effect

DDI-DrugBank.d450.s14	Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
digoxin	drug	56-62	digoxin	drug	230-236	false

DDI-DrugBank.d410.s0	Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
Vasoconstrictors	group	0-15	D.H.E. 45	brand	18-26	false
Vasoconstrictors	group	0-15	dihydroergotamine mesylate	drug	30-55	false
Vasoconstrictors	group	0-15	peripheral vasoconstrictors	group	97-123	false
D.H.E. 45	brand	18-26	dihydroergotamine mesylate	drug	30-55	false
D.H.E. 45	brand	18-26	peripheral vasoconstrictors	group	97-123	effect
dihydroergotamine mesylate	drug	30-55	peripheral vasoconstrictors	group	97-123	effect

DDI-DrugBank.d410.s1	Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
Sumatriptan	drug	0-10	Sumatriptan	drug	13-23	false
Sumatriptan	drug	0-10	D.H.E. 45	brand	117-125	false
Sumatriptan	drug	0-10	dihydroergotamine mesylate	drug	129-154	false
Sumatriptan	drug	13-23	D.H.E. 45	brand	117-125	effect
Sumatriptan	drug	13-23	dihydroergotamine mesylate	drug	129-154	effect
D.H.E. 45	brand	117-125	dihydroergotamine mesylate	drug	129-154	false

DDI-DrugBank.d410.s2	Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
Sumatriptan	drug	0-10	D.H.E. 45	brand	16-24	advise
Sumatriptan	drug	0-10	dihydroergotamine mesylate	drug	28-53	advise
D.H.E. 45	brand	16-24	dihydroergotamine mesylate	drug	28-53	false

DDI-DrugBank.d410.s3	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
Beta Blockers	group	0-12	D.H.E. 45	brand	126-134	false
Beta Blockers	group	0-12	dihydroergotamine mesylate	drug	138-163	false
Beta Blockers	group	0-12	propranolol	drug	211-221	false
Beta Blockers	group	0-12	propranolol	drug	253-263	false
Beta Blockers	group	0-12	ergotamine	drug	311-320	false
D.H.E. 45	brand	126-134	dihydroergotamine mesylate	drug	138-163	false
D.H.E. 45	brand	126-134	propranolol	drug	211-221	false
D.H.E. 45	brand	126-134	propranolol	drug	253-263	false
D.H.E. 45	brand	126-134	ergotamine	drug	311-320	false
dihydroergotamine mesylate	drug	138-163	propranolol	drug	211-221	false
dihydroergotamine mesylate	drug	138-163	propranolol	drug	253-263	false
dihydroergotamine mesylate	drug	138-163	ergotamine	drug	311-320	false
propranolol	drug	211-221	propranolol	drug	253-263	false
propranolol	drug	211-221	ergotamine	drug	311-320	false
propranolol	drug	253-263	ergotamine	drug	311-320	effect

DDI-DrugBank.d410.s4	Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
Nicotine	drug	0-7	Nicotine	drug	10-17	false
Nicotine	drug	0-7	ergot	drug	113-117	false
Nicotine	drug	10-17	ergot	drug	113-117	effect

DDI-DrugBank.d410.s5	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
Macrolide Antibiotics	group	0-20	erythromycin	drug	29-40	false
Macrolide Antibiotics	group	0-20	troleandomycin	drug	46-59	false
Macrolide Antibiotics	group	0-20	ergot alkaloid class	group	77-96	false
Macrolide Antibiotics	group	0-20	D.H.E. 45	brand	108-116	false
Macrolide Antibiotics	group	0-20	dihydroergotamine mesylate	drug	120-145	false
Macrolide Antibiotics	group	0-20	antibiotics	group	209-219	false
Macrolide Antibiotics	group	0-20	macrolide class	group	228-242	false
erythromycin	drug	29-40	troleandomycin	drug	46-59	false
erythromycin	drug	29-40	ergot alkaloid class	group	77-96	false
erythromycin	drug	29-40	D.H.E. 45	brand	108-116	false
erythromycin	drug	29-40	dihydroergotamine mesylate	drug	120-145	false
erythromycin	drug	29-40	antibiotics	group	209-219	false
erythromycin	drug	29-40	macrolide class	group	228-242	false
troleandomycin	drug	46-59	ergot alkaloid class	group	77-96	false
troleandomycin	drug	46-59	D.H.E. 45	brand	108-116	false
troleandomycin	drug	46-59	dihydroergotamine mesylate	drug	120-145	false
troleandomycin	drug	46-59	antibiotics	group	209-219	false
troleandomycin	drug	46-59	macrolide class	group	228-242	false
ergot alkaloid class	group	77-96	D.H.E. 45	brand	108-116	false
ergot alkaloid class	group	77-96	dihydroergotamine mesylate	drug	120-145	false
ergot alkaloid class	group	77-96	antibiotics	group	209-219	false
ergot alkaloid class	group	77-96	macrolide class	group	228-242	mechanism
D.H.E. 45	brand	108-116	dihydroergotamine mesylate	drug	120-145	false
D.H.E. 45	brand	108-116	antibiotics	group	209-219	false
D.H.E. 45	brand	108-116	macrolide class	group	228-242	mechanism
dihydroergotamine mesylate	drug	120-145	antibiotics	group	209-219	false
dihydroergotamine mesylate	drug	120-145	macrolide class	group	228-242	mechanism
antibiotics	group	209-219	macrolide class	group	228-242	false

DDI-DrugBank.d410.s6	Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
ergotamine	drug	67-76	antibiotics	group	127-137	effect

DDI-DrugBank.d410.s7	SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
SSRIs	group	0-4	5-HT1 agonists	group	81-94	false
SSRIs	group	0-4	SSRIs	group	127-131	false
5-HT1 agonists	group	81-94	SSRIs	group	127-131	effect

DDI-DrugBank.d410.s8	fluoxetine, fluvoxamine, paroxetine, sertraline).
fluoxetine	drug	0-9	fluvoxamine	drug	12-22	false
fluoxetine	drug	0-9	paroxetine	drug	25-34	false
fluoxetine	drug	0-9	sertraline	drug	37-46	false
fluvoxamine	drug	12-22	paroxetine	drug	25-34	false
fluvoxamine	drug	12-22	sertraline	drug	37-46	false
paroxetine	drug	25-34	sertraline	drug	37-46	false

DDI-DrugBank.d410.s9	There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
SSRIs	group	87-91	D.H.E. 45	brand	97-105	false
SSRIs	group	87-91	dihydroergotamine mesylate	drug	109-134	false
D.H.E. 45	brand	97-105	dihydroergotamine mesylate	drug	109-134	false

DDI-DrugBank.d410.s10	Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.
Contraceptives	group	5-18	contraceptives	group	40-53	false
Contraceptives	group	5-18	D.H.E. 45	brand	82-90	false
Contraceptives	group	5-18	dihydroergotamine mesylate	drug	94-119	false
contraceptives	group	40-53	D.H.E. 45	brand	82-90	false
contraceptives	group	40-53	dihydroergotamine mesylate	drug	94-119	false
D.H.E. 45	brand	82-90	dihydroergotamine mesylate	drug	94-119	false

DDI-DrugBank.d452.s0	Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
thiazide diuretics	group	18-35	dihydrotachysterol	drug	105-122	effect

DDI-DrugBank.d565.s1	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
beta-blockers	group	105-117	digitalis	group	122-130	false
beta-blockers	group	105-117	Tiazac	brand	151-156	effect
digitalis	group	122-130	Tiazac	brand	151-156	effect

DDI-DrugBank.d565.s7	Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.
diltiazem hydrochloride	drug	77-99	beta-blockers	group	105-117	false

DDI-DrugBank.d565.s8	Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
diltiazem hydrochloride	drug	18-40	propranolol	drug	61-71	mechanism
diltiazem hydrochloride	drug	18-40	propranolol	drug	121-131	false
diltiazem hydrochloride	drug	18-40	propranolol	drug	179-189	false
propranolol	drug	61-71	propranolol	drug	121-131	false
propranolol	drug	61-71	propranolol	drug	179-189	false
propranolol	drug	121-131	propranolol	drug	179-189	false

DDI-DrugBank.d565.s9	In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
propranolol	drug	10-20	diltiazem	drug	72-80	mechanism

DDI-DrugBank.d565.s10	If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.
propranolol	drug	69-79	propranolol	drug	103-113	false

DDI-DrugBank.d565.s12	A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
diltiazem	drug	75-83	cimetidine	drug	144-153	false
diltiazem	drug	75-83	diltiazem	drug	188-196	false
cimetidine	drug	144-153	diltiazem	drug	188-196	mechanism

DDI-DrugBank.d565.s14	The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
cimetidine	drug	30-39	diltiazem	drug	151-159	mechanism

DDI-DrugBank.d565.s15	Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
diltiazem	drug	29-37	cimetidine	drug	163-172	advise

DDI-DrugBank.d565.s18	Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
diltiazem hydrochloride	drug	18-40	digoxin	drug	47-53	mechanism
diltiazem hydrochloride	drug	18-40	digoxin	drug	100-106	false
digoxin	drug	47-53	digoxin	drug	100-106	false

DDI-DrugBank.d565.s20	Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
digoxin	drug	66-72	digoxin	drug	105-111	false
digoxin	drug	66-72	diltiazem hydrochloride	drug	179-201	false
digoxin	drug	105-111	diltiazem hydrochloride	drug	179-201	advise

DDI-DrugBank.d565.s22	The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
anesthetics	group	121-131	calcium channel blockers	group	155-178	effect

DDI-DrugBank.d565.s23	When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
anesthetics	group	25-35	calcium channel blockers	group	41-64	advise

DDI-DrugBank.d565.s25	A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
diltiazem	drug	38-46	cyclosporine	drug	52-63	int

DDI-DrugBank.d565.s26	In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
cyclosporine	drug	59-70	cyclosporine	drug	127-138	false
cyclosporine	drug	59-70	diltiazem	drug	209-217	mechanism
cyclosporine	drug	127-138	diltiazem	drug	209-217	false

DDI-DrugBank.d565.s27	If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
cyclosporine	drug	53-64	diltiazem	drug	118-126	advise

DDI-DrugBank.d565.s28	The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.
cyclosporine	drug	14-25	diltiazem	drug	30-38	false

DDI-DrugBank.d565.s30	Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
diltiazem	drug	30-38	carbamazepine	drug	45-57	mechanism
diltiazem	drug	30-38	carbamazepine	drug	115-127	false
carbamazepine	drug	45-57	carbamazepine	drug	115-127	false

DDI-DrugBank.d565.s33	Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
diltiazem	drug	20-28	midazolam	drug	51-59	mechanism
diltiazem	drug	20-28	triazolam	drug	65-73	mechanism
midazolam	drug	51-59	triazolam	drug	65-73	false

DDI-DrugBank.d565.s34	The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
midazolam	drug	29-37	triazolam	drug	43-51	false
midazolam	drug	29-37	diltiazem	drug	112-120	mechanism
triazolam	drug	43-51	diltiazem	drug	112-120	mechanism

DDI-DrugBank.d565.s35	These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
diltiazem	drug	42-50	midazolam	drug	144-152	effect
diltiazem	drug	42-50	triazolam	drug	158-166	effect
midazolam	drug	144-152	triazolam	drug	158-166	false

DDI-DrugBank.d565.s37	In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
diltiazem	drug	44-52	lovastatin	drug	72-81	mechanism
diltiazem	drug	44-52	lovastatin	drug	124-133	false
diltiazem	drug	44-52	lovastatin	drug	152-161	false
lovastatin	drug	72-81	lovastatin	drug	124-133	false
lovastatin	drug	72-81	lovastatin	drug	152-161	false
lovastatin	drug	124-133	lovastatin	drug	152-161	false

DDI-DrugBank.d565.s38	no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.
pravastatin	drug	13-23	diltiazem	drug	58-66	false

DDI-DrugBank.d565.s39	Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.
Diltiazem	drug	0-8	lovastatin	drug	59-68	false
Diltiazem	drug	0-8	pravastatin	drug	73-83	false
lovastatin	drug	59-68	pravastatin	drug	73-83	false

DDI-DrugBank.d565.s41	Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
rifampin	drug	20-27	diltiazem	drug	34-42	mechanism
rifampin	drug	20-27	diltiazem	drug	56-64	false
diltiazem	drug	34-42	diltiazem	drug	56-64	false

DDI-DrugBank.d565.s42	Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
diltiazem	drug	20-28	rifampin	drug	35-42	advise

DDI-DrugBank.d96.s0	Dimenhydrinate may decrease emetic response to apomorphine.
Dimenhydrinate	drug	0-13	emetic	group	28-33	false
Dimenhydrinate	drug	0-13	apomorphine	drug	47-57	effect
emetic	group	28-33	apomorphine	drug	47-57	false

DDI-DrugBank.d181.s0	Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
Oxytocin	drug	0-7	oxytocics	group	18-26	false
Oxytocin	drug	0-7	dinoprost	drug	49-57	effect
oxytocics	group	18-26	dinoprost	drug	49-57	effect

DDI-DrugBank.d2.s0	PROSTIN E2 may augment the activity of other oxytocic drugs.
PROSTIN E2	brand	0-9	oxytocic drugs	group	45-58	effect

DDI-DrugBank.d296.s0	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
Diphenhydramine hydrochloride	drug	0-28	alcohol	drug	56-62	effect
Diphenhydramine hydrochloride	drug	0-28	CNS depressants	group	74-88	effect
Diphenhydramine hydrochloride	drug	0-28	hypnotics	group	91-99	effect
Diphenhydramine hydrochloride	drug	0-28	sedatives	group	102-110	effect
Diphenhydramine hydrochloride	drug	0-28	tranquilizers	group	113-125	effect
alcohol	drug	56-62	CNS depressants	group	74-88	false
alcohol	drug	56-62	hypnotics	group	91-99	false
alcohol	drug	56-62	sedatives	group	102-110	false
alcohol	drug	56-62	tranquilizers	group	113-125	false
CNS depressants	group	74-88	hypnotics	group	91-99	false
CNS depressants	group	74-88	sedatives	group	102-110	false
CNS depressants	group	74-88	tranquilizers	group	113-125	false
hypnotics	group	91-99	sedatives	group	102-110	false
hypnotics	group	91-99	tranquilizers	group	113-125	false
sedatives	group	102-110	tranquilizers	group	113-125	false

DDI-DrugBank.d296.s1	MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
MAO inhibitors	group	0-13	antihistamines	group	77-90	effect

DDI-DrugBank.d120.s1	anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;
anticholinergics	group	0-15	diphenidol	drug	163-172	false

DDI-DrugBank.d120.s2	apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
apomorphine	drug	0-10	diphenidol	drug	33-42	false
apomorphine	drug	0-10	emetic	group	61-66	false
apomorphine	drug	0-10	apomorphine	drug	80-90	false
diphenidol	drug	33-42	emetic	group	61-66	false
diphenidol	drug	33-42	apomorphine	drug	80-90	effect
emetic	group	61-66	apomorphine	drug	80-90	false

DDI-DrugBank.d538.s0	Known drug interactions include barbiturates, tranquilizers, and alcohol.
barbiturates	group	32-43	tranquilizers	group	46-58	false
barbiturates	group	32-43	alcohol	drug	65-71	false
tranquilizers	group	46-58	alcohol	drug	65-71	false

DDI-DrugBank.d538.s1	Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
Diphenoxylate HCl	drug	0-16	atropine sulfate	drug	22-37	false
Diphenoxylate HCl	drug	0-16	MAO inhibitors	group	57-70	int
Diphenoxylate HCl	drug	0-16	diphenoxylate hydrochloride	drug	99-125	false
atropine sulfate	drug	22-37	MAO inhibitors	group	57-70	int
atropine sulfate	drug	22-37	diphenoxylate hydrochloride	drug	99-125	false
MAO inhibitors	group	57-70	diphenoxylate hydrochloride	drug	99-125	false

DDI-DrugBank.d168.s0	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
alcohol	drug	28-34	CNS depressants	group	45-59	false
alcohol	drug	28-34	antihistamines	group	135-148	false
alcohol	drug	28-34	anticholinergics	group	152-167	false
alcohol	drug	28-34	antihistamines	group	314-327	false
alcohol	drug	28-34	monoamine oxidase (MAO) inhibitors	group	335-368	false
alcohol	drug	28-34	antihistamines	drug	391-404	false
alcohol	drug	28-34	antihistamines	drug	482-495	false
CNS depressants	group	45-59	antihistamines	group	135-148	false
CNS depressants	group	45-59	anticholinergics	group	152-167	false
CNS depressants	group	45-59	antihistamines	group	314-327	false
CNS depressants	group	45-59	monoamine oxidase (MAO) inhibitors	group	335-368	false
CNS depressants	group	45-59	antihistamines	drug	391-404	false
CNS depressants	group	45-59	antihistamines	drug	482-495	false
antihistamines	group	135-148	anticholinergics	group	152-167	false
antihistamines	group	135-148	antihistamines	group	314-327	false
antihistamines	group	135-148	monoamine oxidase (MAO) inhibitors	group	335-368	false
antihistamines	group	135-148	antihistamines	drug	391-404	false
antihistamines	group	135-148	antihistamines	drug	482-495	false
anticholinergics	group	152-167	antihistamines	group	314-327	false
anticholinergics	group	152-167	monoamine oxidase (MAO) inhibitors	group	335-368	false
anticholinergics	group	152-167	antihistamines	drug	391-404	false
anticholinergics	group	152-167	antihistamines	drug	482-495	false
antihistamines	group	314-327	monoamine oxidase (MAO) inhibitors	group	335-368	false
antihistamines	group	314-327	antihistamines	drug	391-404	false
antihistamines	group	314-327	antihistamines	drug	482-495	false
monoamine oxidase (MAO) inhibitors	group	335-368	antihistamines	drug	391-404	false
monoamine oxidase (MAO) inhibitors	group	335-368	antihistamines	drug	482-495	false
antihistamines	drug	391-404	antihistamines	drug	482-495	false

DDI-DrugBank.d505.s0	No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE  (dipyridamole USP) Tablets.
PERSANTINE	brand	69-78	dipyridamole	drug	82-93	false

DDI-DrugBank.d505.s2	Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
Adenosine	drug	0-8	Dipyridamole	drug	11-22	false
Adenosine	drug	0-8	adenosine	drug	102-110	false
Dipyridamole	drug	11-22	adenosine	drug	102-110	mechanism

DDI-DrugBank.d505.s4	Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
Cholinesterase Inhibitors	group	0-24	Dipyridamole	drug	27-38	false
Cholinesterase Inhibitors	group	0-24	cholinesterase inhibitors	group	88-112	false
Dipyridamole	drug	27-38	cholinesterase inhibitors	group	88-112	effect

DDI-DrugBank.d522.s0	Terfenadine: In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine.
Terfenadine	drug	0-10	dirithromycin	drug	75-87	false
Terfenadine	drug	0-10	terfenadine	drug	122-132	false
dirithromycin	drug	75-87	terfenadine	drug	122-132	false

DDI-DrugBank.d522.s1	These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.
terfenadine	drug	30-40	terfenadine	drug	92-102	false
terfenadine	drug	30-40	dirithromycin	drug	124-136	false
terfenadine	drug	92-102	dirithromycin	drug	124-136	false

DDI-DrugBank.d522.s3	The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.
terfenadine	drug	24-34	terfenadine	drug	143-153	false
terfenadine	drug	24-34	terfenadine	drug	171-181	false
terfenadine	drug	24-34	dirithromycin	drug	188-200	false
terfenadine	drug	143-153	terfenadine	drug	171-181	false
terfenadine	drug	143-153	dirithromycin	drug	188-200	false
terfenadine	drug	171-181	dirithromycin	drug	188-200	false

DDI-DrugBank.d522.s5	in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
terfenadine	drug	25-35	terfenadine	drug	56-66	false
terfenadine	drug	25-35	terfenadine	drug	93-103	false
terfenadine	drug	25-35	dirithromycin	drug	110-122	false
terfenadine	drug	56-66	terfenadine	drug	93-103	false
terfenadine	drug	56-66	dirithromycin	drug	110-122	false
terfenadine	drug	93-103	dirithromycin	drug	110-122	mechanism

DDI-DrugBank.d522.s7	The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
terfenadine	drug	43-53	terfenadine	drug	74-84	false
terfenadine	drug	43-53	dirithromycin	drug	91-103	false
terfenadine	drug	74-84	dirithromycin	drug	91-103	effect

DDI-DrugBank.d522.s8	Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine.
dirithromycin	drug	70-82	terfenadine	drug	88-98	false

DDI-DrugBank.d522.s9	Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
erythromycin	drug	39-50	terfenadine	drug	56-66	int
erythromycin	drug	39-50	dirithromycin	drug	88-100	false
terfenadine	drug	56-66	dirithromycin	drug	88-100	false

DDI-DrugBank.d522.s10	Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
terfenadine	drug	91-101	macrolide antibiotics	group	128-148	effect

DDI-DrugBank.d522.s11	In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
macrolides	group	18-27	terfenadine	drug	71-81	advise

DDI-DrugBank.d522.s12	Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
Theophylline	drug	0-11	dirithromycin	drug	56-68	false
Theophylline	drug	0-11	theophylline	drug	114-125	false
Theophylline	drug	0-11	theophylline	drug	237-248	false
dirithromycin	drug	56-68	theophylline	drug	114-125	false
dirithromycin	drug	56-68	theophylline	drug	237-248	false
theophylline	drug	114-125	theophylline	drug	237-248	false

DDI-DrugBank.d522.s13	In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
dirithromycin	drug	39-51	theophylline	drug	83-94	false
dirithromycin	drug	39-51	theophylline	drug	142-153	false
dirithromycin	drug	39-51	theophylline	drug	179-190	false
theophylline	drug	83-94	theophylline	drug	142-153	false
theophylline	drug	83-94	theophylline	drug	179-190	false
theophylline	drug	142-153	theophylline	drug	179-190	false

DDI-DrugBank.d522.s14	However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.
theophylline	drug	9-20	theophylline	drug	169-180	false
theophylline	drug	9-20	theophylline	drug	254-265	false
theophylline	drug	169-180	theophylline	drug	254-265	false

DDI-DrugBank.d522.s15	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
Antacids	group	0-7	H 2 receptor antagonists	group	12-35	false
Antacids	group	0-7	dirithromycin	drug	43-55	false
Antacids	group	0-7	antacids	group	95-102	false
Antacids	group	0-7	H 2 -receptor antagonists	group	107-131	false
Antacids	group	0-7	dirithromycin	drug	152-164	false
H 2 receptor antagonists	group	12-35	dirithromycin	drug	43-55	false
H 2 receptor antagonists	group	12-35	antacids	group	95-102	false
H 2 receptor antagonists	group	12-35	H 2 -receptor antagonists	group	107-131	false
H 2 receptor antagonists	group	12-35	dirithromycin	drug	152-164	false
dirithromycin	drug	43-55	antacids	group	95-102	mechanism
dirithromycin	drug	43-55	H 2 -receptor antagonists	group	107-131	mechanism
dirithromycin	drug	43-55	dirithromycin	drug	152-164	false
antacids	group	95-102	H 2 -receptor antagonists	group	107-131	false
antacids	group	95-102	dirithromycin	drug	152-164	false
H 2 -receptor antagonists	group	107-131	dirithromycin	drug	152-164	false

DDI-DrugBank.d522.s19	Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
Triazolam	drug	0-8	Erythromycin	drug	11-22	false
Triazolam	drug	0-8	triazolam	drug	71-79	false
Triazolam	drug	0-8	triazolam	drug	133-141	false
Erythromycin	drug	11-22	triazolam	drug	71-79	mechanism
Erythromycin	drug	11-22	triazolam	drug	133-141	effect
triazolam	drug	71-79	triazolam	drug	133-141	false

DDI-DrugBank.d522.s20	Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
Digoxin	drug	0-6	erythromycin	drug	39-50	false
Digoxin	drug	0-6	digoxin	drug	56-62	false
Digoxin	drug	0-6	digoxin	drug	104-110	false
erythromycin	drug	39-50	digoxin	drug	56-62	mechanism
erythromycin	drug	39-50	digoxin	drug	104-110	false
digoxin	drug	56-62	digoxin	drug	104-110	false

DDI-DrugBank.d522.s21	Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
Anticoagulants	group	0-13	erythromycin	drug	80-91	false
Anticoagulants	group	0-13	anticoagulants	group	102-115	false
erythromycin	drug	80-91	anticoagulants	group	102-115	effect

DDI-DrugBank.d522.s23	Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Ergotamine	drug	0-9	erythromycin	drug	30-41	false
Ergotamine	drug	0-9	ergotamine	drug	47-56	false
Ergotamine	drug	0-9	dihydroergotamine	drug	61-77	false
erythromycin	drug	30-41	ergotamine	drug	47-56	effect
erythromycin	drug	30-41	dihydroergotamine	drug	61-77	effect
ergotamine	drug	47-56	dihydroergotamine	drug	61-77	false

DDI-DrugBank.d522.s24	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
erythromycin	drug	84-95	cyclosporine	drug	130-141	int
erythromycin	drug	84-95	hexobarbital	drug	144-155	int
erythromycin	drug	84-95	carbamazepine	drug	158-170	int
erythromycin	drug	84-95	alfentanil	drug	173-182	int
erythromycin	drug	84-95	disopyramide	drug	185-196	int
erythromycin	drug	84-95	phenytoin	drug	199-207	int
erythromycin	drug	84-95	bromocriptine	drug	210-222	int
erythromycin	drug	84-95	valproate	drug	225-233	int
erythromycin	drug	84-95	astemizole	drug	236-245	int
erythromycin	drug	84-95	lovastatin	drug	252-261	int
cyclosporine	drug	130-141	hexobarbital	drug	144-155	false
cyclosporine	drug	130-141	carbamazepine	drug	158-170	false
cyclosporine	drug	130-141	alfentanil	drug	173-182	false
cyclosporine	drug	130-141	disopyramide	drug	185-196	false
cyclosporine	drug	130-141	phenytoin	drug	199-207	false
cyclosporine	drug	130-141	bromocriptine	drug	210-222	false
cyclosporine	drug	130-141	valproate	drug	225-233	false
cyclosporine	drug	130-141	astemizole	drug	236-245	false
cyclosporine	drug	130-141	lovastatin	drug	252-261	false
hexobarbital	drug	144-155	carbamazepine	drug	158-170	false
hexobarbital	drug	144-155	alfentanil	drug	173-182	false
hexobarbital	drug	144-155	disopyramide	drug	185-196	false
hexobarbital	drug	144-155	phenytoin	drug	199-207	false
hexobarbital	drug	144-155	bromocriptine	drug	210-222	false
hexobarbital	drug	144-155	valproate	drug	225-233	false
hexobarbital	drug	144-155	astemizole	drug	236-245	false
hexobarbital	drug	144-155	lovastatin	drug	252-261	false
carbamazepine	drug	158-170	alfentanil	drug	173-182	false
carbamazepine	drug	158-170	disopyramide	drug	185-196	false
carbamazepine	drug	158-170	phenytoin	drug	199-207	false
carbamazepine	drug	158-170	bromocriptine	drug	210-222	false
carbamazepine	drug	158-170	valproate	drug	225-233	false
carbamazepine	drug	158-170	astemizole	drug	236-245	false
carbamazepine	drug	158-170	lovastatin	drug	252-261	false
alfentanil	drug	173-182	disopyramide	drug	185-196	false
alfentanil	drug	173-182	phenytoin	drug	199-207	false
alfentanil	drug	173-182	bromocriptine	drug	210-222	false
alfentanil	drug	173-182	valproate	drug	225-233	false
alfentanil	drug	173-182	astemizole	drug	236-245	false
alfentanil	drug	173-182	lovastatin	drug	252-261	false
disopyramide	drug	185-196	phenytoin	drug	199-207	false
disopyramide	drug	185-196	bromocriptine	drug	210-222	false
disopyramide	drug	185-196	valproate	drug	225-233	false
disopyramide	drug	185-196	astemizole	drug	236-245	false
disopyramide	drug	185-196	lovastatin	drug	252-261	false
phenytoin	drug	199-207	bromocriptine	drug	210-222	false
phenytoin	drug	199-207	valproate	drug	225-233	false
phenytoin	drug	199-207	astemizole	drug	236-245	false
phenytoin	drug	199-207	lovastatin	drug	252-261	false
bromocriptine	drug	210-222	valproate	drug	225-233	false
bromocriptine	drug	210-222	astemizole	drug	236-245	false
bromocriptine	drug	210-222	lovastatin	drug	252-261	false
valproate	drug	225-233	astemizole	drug	236-245	false
valproate	drug	225-233	lovastatin	drug	252-261	false
astemizole	drug	236-245	lovastatin	drug	252-261	false

DDI-DrugBank.d506.s0	If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
phenytoin	drug	3-11	Norpace	brand	74-80	mechanism
phenytoin	drug	3-11	Norpace CR	brand	85-94	mechanism
phenytoin	drug	3-11	disopyramide	drug	120-131	false
Norpace	brand	74-80	Norpace CR	brand	85-94	false
Norpace	brand	74-80	disopyramide	drug	120-131	false
Norpace CR	brand	85-94	disopyramide	drug	120-131	false

DDI-DrugBank.d506.s2	Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
antiarrhythmic drugs	group	6-25	quinidine	drug	32-40	false
antiarrhythmic drugs	group	6-25	procainamide	drug	43-54	false
antiarrhythmic drugs	group	6-25	lidocaine	drug	57-65	false
antiarrhythmic drugs	group	6-25	propranolol	drug	68-78	false
antiarrhythmic drugs	group	6-25	Norpace	brand	127-133	false
quinidine	drug	32-40	procainamide	drug	43-54	false
quinidine	drug	32-40	lidocaine	drug	57-65	false
quinidine	drug	32-40	propranolol	drug	68-78	false
quinidine	drug	32-40	Norpace	brand	127-133	false
procainamide	drug	43-54	lidocaine	drug	57-65	false
procainamide	drug	43-54	propranolol	drug	68-78	false
procainamide	drug	43-54	Norpace	brand	127-133	false
lidocaine	drug	57-65	propranolol	drug	68-78	false
lidocaine	drug	57-65	Norpace	brand	127-133	false
propranolol	drug	68-78	Norpace	brand	127-133	false

DDI-DrugBank.d506.s4	In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.
Norpace	brand	76-82	propranolol	drug	115-125	false
Norpace	brand	76-82	diazepam	drug	130-137	false
propranolol	drug	115-125	diazepam	drug	130-137	false

DDI-DrugBank.d506.s5	Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
Norpace	brand	30-36	quinidine	drug	42-50	mechanism
Norpace	brand	30-36	disopyramide	drug	91-102	false
Norpace	brand	30-36	quinidine	drug	142-150	false
quinidine	drug	42-50	disopyramide	drug	91-102	false
quinidine	drug	42-50	quinidine	drug	142-150	false
disopyramide	drug	91-102	quinidine	drug	142-150	false

DDI-DrugBank.d506.s6	Norpace does not increase serum digoxin levels.
Norpace	brand	0-6	digoxin	drug	32-38	false

DDI-DrugBank.d506.s7	Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
disopyramide phosphate	drug	16-37	erythromycin	drug	43-54	mechanism
disopyramide phosphate	drug	16-37	disopyramide	drug	116-127	false
erythromycin	drug	43-54	disopyramide	drug	116-127	false

DDI-DrugBank.d506.s9	Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
verapamil	drug	44-52	disopyramide phosphate	drug	58-79	false
verapamil	drug	44-52	disopyramide	drug	95-106	false
verapamil	drug	44-52	verapamil	drug	176-184	false
disopyramide phosphate	drug	58-79	disopyramide	drug	95-106	false
disopyramide phosphate	drug	58-79	verapamil	drug	176-184	false
disopyramide	drug	95-106	verapamil	drug	176-184	advise

DDI-DrugBank.d19.s1	DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
DISULFIRAM	drug	0-9	PHENYTOIN	drug	67-75	advise

DDI-DrugBank.d19.s2	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
PHENYTOIN	drug	68-76	DISULFIRAM	drug	115-124	false
PHENYTOIN	drug	68-76	PHENYTOIN	drug	142-150	false
PHENYTOIN	drug	68-76	PHENYTOIN	drug	172-180	false
DISULFIRAM	drug	115-124	PHENYTOIN	drug	142-150	effect
DISULFIRAM	drug	115-124	PHENYTOIN	drug	172-180	false
PHENYTOIN	drug	142-150	PHENYTOIN	drug	172-180	false

DDI-DrugBank.d19.s6	It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
anticoagulants	group	49-62	disulfiram	drug	91-100	advise
anticoagulants	group	49-62	disulfiram	drug	109-118	false
disulfiram	drug	91-100	disulfiram	drug	109-118	false

DDI-DrugBank.d19.s7	Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
isoniazid	drug	16-24	disulfiram	drug	31-40	advise

DDI-DrugBank.d19.s9	In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
disulfiram	drug	35-44	nitrite	drug	50-56	effect
disulfiram	drug	35-44	disulfiram	drug	149-158	false
disulfiram	drug	35-44	nitrites	group	175-182	false
nitrite	drug	50-56	disulfiram	drug	149-158	false
nitrite	drug	50-56	nitrites	group	175-182	false
disulfiram	drug	149-158	nitrites	group	175-182	effect

DDI-DrugBank.d274.s0	Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
dobutamine	drug	29-38	b-blocking drug	group	98-112	effect

DDI-DrugBank.d274.s2	Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
dobutamine	drug	57-66	nitroprusside	drug	72-84	effect

DDI-DrugBank.d274.s3	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
dobutamine	drug	72-81	digitalis preparations	group	141-162	false
dobutamine	drug	72-81	furosemide	drug	165-174	false
dobutamine	drug	72-81	spironolactone	drug	177-190	false
dobutamine	drug	72-81	lidocaine	drug	193-201	false
dobutamine	drug	72-81	glyceryl trinitrate	drug	204-222	false
dobutamine	drug	72-81	isosorbide dinitrate	drug	225-244	false
dobutamine	drug	72-81	morphine	drug	247-254	false
dobutamine	drug	72-81	atropine	drug	257-264	false
dobutamine	drug	72-81	heparin	drug	267-273	false
dobutamine	drug	72-81	protamine	drug	276-284	false
dobutamine	drug	72-81	potassium chloride	drug	287-304	false
dobutamine	drug	72-81	folic acid	drug	307-316	false
dobutamine	drug	72-81	acetaminophen	drug	323-335	false
digitalis preparations	group	141-162	furosemide	drug	165-174	false
digitalis preparations	group	141-162	spironolactone	drug	177-190	false
digitalis preparations	group	141-162	lidocaine	drug	193-201	false
digitalis preparations	group	141-162	glyceryl trinitrate	drug	204-222	false
digitalis preparations	group	141-162	isosorbide dinitrate	drug	225-244	false
digitalis preparations	group	141-162	morphine	drug	247-254	false
digitalis preparations	group	141-162	atropine	drug	257-264	false
digitalis preparations	group	141-162	heparin	drug	267-273	false
digitalis preparations	group	141-162	protamine	drug	276-284	false
digitalis preparations	group	141-162	potassium chloride	drug	287-304	false
digitalis preparations	group	141-162	folic acid	drug	307-316	false
digitalis preparations	group	141-162	acetaminophen	drug	323-335	false
furosemide	drug	165-174	spironolactone	drug	177-190	false
furosemide	drug	165-174	lidocaine	drug	193-201	false
furosemide	drug	165-174	glyceryl trinitrate	drug	204-222	false
furosemide	drug	165-174	isosorbide dinitrate	drug	225-244	false
furosemide	drug	165-174	morphine	drug	247-254	false
furosemide	drug	165-174	atropine	drug	257-264	false
furosemide	drug	165-174	heparin	drug	267-273	false
furosemide	drug	165-174	protamine	drug	276-284	false
furosemide	drug	165-174	potassium chloride	drug	287-304	false
furosemide	drug	165-174	folic acid	drug	307-316	false
furosemide	drug	165-174	acetaminophen	drug	323-335	false
spironolactone	drug	177-190	lidocaine	drug	193-201	false
spironolactone	drug	177-190	glyceryl trinitrate	drug	204-222	false
spironolactone	drug	177-190	isosorbide dinitrate	drug	225-244	false
spironolactone	drug	177-190	morphine	drug	247-254	false
spironolactone	drug	177-190	atropine	drug	257-264	false
spironolactone	drug	177-190	heparin	drug	267-273	false
spironolactone	drug	177-190	protamine	drug	276-284	false
spironolactone	drug	177-190	potassium chloride	drug	287-304	false
spironolactone	drug	177-190	folic acid	drug	307-316	false
spironolactone	drug	177-190	acetaminophen	drug	323-335	false
lidocaine	drug	193-201	glyceryl trinitrate	drug	204-222	false
lidocaine	drug	193-201	isosorbide dinitrate	drug	225-244	false
lidocaine	drug	193-201	morphine	drug	247-254	false
lidocaine	drug	193-201	atropine	drug	257-264	false
lidocaine	drug	193-201	heparin	drug	267-273	false
lidocaine	drug	193-201	protamine	drug	276-284	false
lidocaine	drug	193-201	potassium chloride	drug	287-304	false
lidocaine	drug	193-201	folic acid	drug	307-316	false
lidocaine	drug	193-201	acetaminophen	drug	323-335	false
glyceryl trinitrate	drug	204-222	isosorbide dinitrate	drug	225-244	false
glyceryl trinitrate	drug	204-222	morphine	drug	247-254	false
glyceryl trinitrate	drug	204-222	atropine	drug	257-264	false
glyceryl trinitrate	drug	204-222	heparin	drug	267-273	false
glyceryl trinitrate	drug	204-222	protamine	drug	276-284	false
glyceryl trinitrate	drug	204-222	potassium chloride	drug	287-304	false
glyceryl trinitrate	drug	204-222	folic acid	drug	307-316	false
glyceryl trinitrate	drug	204-222	acetaminophen	drug	323-335	false
isosorbide dinitrate	drug	225-244	morphine	drug	247-254	false
isosorbide dinitrate	drug	225-244	atropine	drug	257-264	false
isosorbide dinitrate	drug	225-244	heparin	drug	267-273	false
isosorbide dinitrate	drug	225-244	protamine	drug	276-284	false
isosorbide dinitrate	drug	225-244	potassium chloride	drug	287-304	false
isosorbide dinitrate	drug	225-244	folic acid	drug	307-316	false
isosorbide dinitrate	drug	225-244	acetaminophen	drug	323-335	false
morphine	drug	247-254	atropine	drug	257-264	false
morphine	drug	247-254	heparin	drug	267-273	false
morphine	drug	247-254	protamine	drug	276-284	false
morphine	drug	247-254	potassium chloride	drug	287-304	false
morphine	drug	247-254	folic acid	drug	307-316	false
morphine	drug	247-254	acetaminophen	drug	323-335	false
atropine	drug	257-264	heparin	drug	267-273	false
atropine	drug	257-264	protamine	drug	276-284	false
atropine	drug	257-264	potassium chloride	drug	287-304	false
atropine	drug	257-264	folic acid	drug	307-316	false
atropine	drug	257-264	acetaminophen	drug	323-335	false
heparin	drug	267-273	protamine	drug	276-284	false
heparin	drug	267-273	potassium chloride	drug	287-304	false
heparin	drug	267-273	folic acid	drug	307-316	false
heparin	drug	267-273	acetaminophen	drug	323-335	false
protamine	drug	276-284	potassium chloride	drug	287-304	false
protamine	drug	276-284	folic acid	drug	307-316	false
protamine	drug	276-284	acetaminophen	drug	323-335	false
potassium chloride	drug	287-304	folic acid	drug	307-316	false
potassium chloride	drug	287-304	acetaminophen	drug	323-335	false
folic acid	drug	307-316	acetaminophen	drug	323-335	false

DDI-DrugBank.d371.s1	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
docetaxel	drug	51-59	cyclosporine	drug	197-208	mechanism
docetaxel	drug	51-59	terfenadine	drug	211-221	mechanism
docetaxel	drug	51-59	ketoconazole	drug	224-235	mechanism
docetaxel	drug	51-59	erythromycin	drug	238-249	mechanism
docetaxel	drug	51-59	troleandomycin	drug	256-269	mechanism
cyclosporine	drug	197-208	terfenadine	drug	211-221	false
cyclosporine	drug	197-208	ketoconazole	drug	224-235	false
cyclosporine	drug	197-208	erythromycin	drug	238-249	false
cyclosporine	drug	197-208	troleandomycin	drug	256-269	false
terfenadine	drug	211-221	ketoconazole	drug	224-235	false
terfenadine	drug	211-221	erythromycin	drug	238-249	false
terfenadine	drug	211-221	troleandomycin	drug	256-269	false
ketoconazole	drug	224-235	erythromycin	drug	238-249	false
ketoconazole	drug	224-235	troleandomycin	drug	256-269	false
erythromycin	drug	238-249	troleandomycin	drug	256-269	false

DDI-DrugBank.d558.s1	Drug-Drug Interactions Cimetidine: Concomitant use of cimetidine is contraindicated.
Cimetidine	drug	23-32	cimetidine	drug	54-63	false

DDI-DrugBank.d558.s2	Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
Cimetidine	drug	0-9	TIKOSYN	brand	76-82	mechanism
Cimetidine	drug	0-9	dofetilide	drug	136-145	false
TIKOSYN	brand	76-82	dofetilide	drug	136-145	false

DDI-DrugBank.d558.s3	Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
Cimetidine	drug	0-9	dofetilide	drug	75-84	mechanism

DDI-DrugBank.d558.s5	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
TIKOSYN	brand	22-28	anti-ulcer	group	34-43	false
TIKOSYN	brand	22-28	omeprazole	drug	75-84	false
TIKOSYN	brand	22-28	ranitidine	drug	87-96	false
TIKOSYN	brand	22-28	antacids	group	102-109	false
TIKOSYN	brand	22-28	aluminum hydroxide	drug	112-119;135-143	false
TIKOSYN	brand	22-28	magnesium hydroxide	drug	125-143	false
TIKOSYN	brand	22-28	cimetidine	drug	174-183	advise
TIKOSYN	brand	22-28	TIKOSYN	brand	251-257	false
anti-ulcer	group	34-43	omeprazole	drug	75-84	false
anti-ulcer	group	34-43	ranitidine	drug	87-96	false
anti-ulcer	group	34-43	antacids	group	102-109	false
anti-ulcer	group	34-43	aluminum hydroxide	drug	112-119;135-143	false
anti-ulcer	group	34-43	magnesium hydroxide	drug	125-143	false
anti-ulcer	group	34-43	cimetidine	drug	174-183	false
anti-ulcer	group	34-43	TIKOSYN	brand	251-257	false
omeprazole	drug	75-84	ranitidine	drug	87-96	false
omeprazole	drug	75-84	antacids	group	102-109	false
omeprazole	drug	75-84	aluminum hydroxide	drug	112-119;135-143	false
omeprazole	drug	75-84	magnesium hydroxide	drug	125-143	false
omeprazole	drug	75-84	cimetidine	drug	174-183	false
omeprazole	drug	75-84	TIKOSYN	brand	251-257	false
ranitidine	drug	87-96	antacids	group	102-109	false
ranitidine	drug	87-96	aluminum hydroxide	drug	112-119;135-143	false
ranitidine	drug	87-96	magnesium hydroxide	drug	125-143	false
ranitidine	drug	87-96	cimetidine	drug	174-183	false
ranitidine	drug	87-96	TIKOSYN	brand	251-257	false
antacids	group	102-109	aluminum hydroxide	drug	112-119;135-143	false
antacids	group	102-109	magnesium hydroxide	drug	125-143	false
antacids	group	102-109	cimetidine	drug	174-183	false
antacids	group	102-109	TIKOSYN	brand	251-257	false
aluminum hydroxide	drug	112-119;135-143	magnesium hydroxide	drug	125-143	false
aluminum hydroxide	drug	112-119;135-143	cimetidine	drug	174-183	false
aluminum hydroxide	drug	112-119;135-143	TIKOSYN	brand	251-257	false
magnesium hydroxide	drug	125-143	cimetidine	drug	174-183	false
magnesium hydroxide	drug	125-143	TIKOSYN	brand	251-257	false
cimetidine	drug	174-183	TIKOSYN	brand	251-257	false

DDI-DrugBank.d558.s6	Verapamil: Concomitant use of verapamil is contraindicated.
Verapamil	drug	0-8	verapamil	drug	30-38	false

DDI-DrugBank.d558.s7	Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
TIKOSYN	brand	21-27	verapamil	drug	34-42	mechanism
TIKOSYN	brand	21-27	dofetilide	drug	69-78	false
TIKOSYN	brand	21-27	dofetilide	drug	136-145	false
verapamil	drug	34-42	dofetilide	drug	69-78	false
verapamil	drug	34-42	dofetilide	drug	136-145	false
dofetilide	drug	69-78	dofetilide	drug	136-145	false

DDI-DrugBank.d558.s8	In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
verapamil	drug	117-125	dofetilide	drug	132-141	effect

DDI-DrugBank.d558.s9	Ketoconazole: Concomitant use of ketoconazole is contraindicated.
Ketoconazole	drug	0-11	ketoconazole	drug	33-44	false

DDI-DrugBank.d558.s10	Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
Ketoconazole	drug	0-11	TIKOSYN	brand	91-97	mechanism
Ketoconazole	drug	0-11	dofetilide	drug	151-160	false
TIKOSYN	brand	91-97	dofetilide	drug	151-160	false

DDI-DrugBank.d558.s11	Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
Trimethoprim	drug	0-11	Sulfamethoxazole	drug	42-57	false
Trimethoprim	drug	0-11	trimethoprim	drug	79-90	false
Trimethoprim	drug	0-11	sulfamethoxazole	drug	121-136	false
Sulfamethoxazole	drug	42-57	trimethoprim	drug	79-90	false
Sulfamethoxazole	drug	42-57	sulfamethoxazole	drug	121-136	false
trimethoprim	drug	79-90	sulfamethoxazole	drug	121-136	false

DDI-DrugBank.d558.s12	Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
Hydrochlorothiazide	drug	0-18	HCTZ	drug	21-24	false
Hydrochlorothiazide	drug	0-18	Triamterene	drug	56-66	false
Hydrochlorothiazide	drug	0-18	HCTZ	drug	88-91	false
Hydrochlorothiazide	drug	0-18	triamterene	drug	122-132	false
HCTZ	drug	21-24	Triamterene	drug	56-66	false
HCTZ	drug	21-24	HCTZ	drug	88-91	false
HCTZ	drug	21-24	triamterene	drug	122-132	false
Triamterene	drug	56-66	HCTZ	drug	88-91	false
Triamterene	drug	56-66	triamterene	drug	122-132	false
HCTZ	drug	88-91	triamterene	drug	122-132	false

DDI-DrugBank.d558.s13	HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
HCTZ	drug	0-3	HCTZ	drug	17-20	false
HCTZ	drug	0-3	triamterene	drug	22-32	false
HCTZ	drug	0-3	TIKOSYN	brand	72-78	false
HCTZ	drug	0-3	diuretic	group	126-133	false
HCTZ	drug	17-20	triamterene	drug	22-32	false
HCTZ	drug	17-20	TIKOSYN	brand	72-78	false
HCTZ	drug	17-20	diuretic	group	126-133	false
triamterene	drug	22-32	TIKOSYN	brand	72-78	false
triamterene	drug	22-32	diuretic	group	126-133	false
TIKOSYN	brand	72-78	diuretic	group	126-133	false

DDI-DrugBank.d558.s14	In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
HCTZ	drug	22-25	dofetilide	drug	34-43	mechanism

DDI-DrugBank.d558.s18	In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.
TIKOSYN	brand	55-61	diuretics	group	67-75	false
TIKOSYN	brand	55-61	diuretics	group	177-185	false
diuretics	group	67-75	diuretics	group	177-185	false

DDI-DrugBank.d558.s19	Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).
potassium depleting diuretics	group	28-56	TIKOSYN	brand	136-142	false

DDI-DrugBank.d558.s22	In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
triamterene	drug	68-78	metformin	drug	81-89	false
triamterene	drug	68-78	amiloride	drug	95-103	false
triamterene	drug	68-78	dofetilide	drug	165-174	advise
metformin	drug	81-89	amiloride	drug	95-103	false
metformin	drug	81-89	dofetilide	drug	165-174	advise
amiloride	drug	95-103	dofetilide	drug	165-174	advise

DDI-DrugBank.d558.s25	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
macrolide antibiotics	group	36-56	azole antifungal agents	group	59-81	false
macrolide antibiotics	group	36-56	protease inhibitors	group	84-102	false
macrolide antibiotics	group	36-56	serotonin reuptake inhibitors	group	105-133	false
macrolide antibiotics	group	36-56	amiodarone	drug	136-145	false
macrolide antibiotics	group	36-56	cannabinoids	group	148-159	false
macrolide antibiotics	group	36-56	diltiazem	drug	162-170	false
macrolide antibiotics	group	36-56	nefazadone	drug	191-200	false
macrolide antibiotics	group	36-56	norfloxacin	drug	203-213	false
macrolide antibiotics	group	36-56	quinine	drug	216-222	false
macrolide antibiotics	group	36-56	zafirlukast	drug	225-235	false
macrolide antibiotics	group	36-56	TIKOSYN	brand	279-285	advise
macrolide antibiotics	group	36-56	dofetilide	drug	320-329	false
azole antifungal agents	group	59-81	protease inhibitors	group	84-102	false
azole antifungal agents	group	59-81	serotonin reuptake inhibitors	group	105-133	false
azole antifungal agents	group	59-81	amiodarone	drug	136-145	false
azole antifungal agents	group	59-81	cannabinoids	group	148-159	false
azole antifungal agents	group	59-81	diltiazem	drug	162-170	false
azole antifungal agents	group	59-81	nefazadone	drug	191-200	false
azole antifungal agents	group	59-81	norfloxacin	drug	203-213	false
azole antifungal agents	group	59-81	quinine	drug	216-222	false
azole antifungal agents	group	59-81	zafirlukast	drug	225-235	false
azole antifungal agents	group	59-81	TIKOSYN	brand	279-285	advise
azole antifungal agents	group	59-81	dofetilide	drug	320-329	false
protease inhibitors	group	84-102	serotonin reuptake inhibitors	group	105-133	false
protease inhibitors	group	84-102	amiodarone	drug	136-145	false
protease inhibitors	group	84-102	cannabinoids	group	148-159	false
protease inhibitors	group	84-102	diltiazem	drug	162-170	false
protease inhibitors	group	84-102	nefazadone	drug	191-200	false
protease inhibitors	group	84-102	norfloxacin	drug	203-213	false
protease inhibitors	group	84-102	quinine	drug	216-222	false
protease inhibitors	group	84-102	zafirlukast	drug	225-235	false
protease inhibitors	group	84-102	TIKOSYN	brand	279-285	advise
protease inhibitors	group	84-102	dofetilide	drug	320-329	false
serotonin reuptake inhibitors	group	105-133	amiodarone	drug	136-145	false
serotonin reuptake inhibitors	group	105-133	cannabinoids	group	148-159	false
serotonin reuptake inhibitors	group	105-133	diltiazem	drug	162-170	false
serotonin reuptake inhibitors	group	105-133	nefazadone	drug	191-200	false
serotonin reuptake inhibitors	group	105-133	norfloxacin	drug	203-213	false
serotonin reuptake inhibitors	group	105-133	quinine	drug	216-222	false
serotonin reuptake inhibitors	group	105-133	zafirlukast	drug	225-235	false
serotonin reuptake inhibitors	group	105-133	TIKOSYN	brand	279-285	advise
serotonin reuptake inhibitors	group	105-133	dofetilide	drug	320-329	false
amiodarone	drug	136-145	cannabinoids	group	148-159	false
amiodarone	drug	136-145	diltiazem	drug	162-170	false
amiodarone	drug	136-145	nefazadone	drug	191-200	false
amiodarone	drug	136-145	norfloxacin	drug	203-213	false
amiodarone	drug	136-145	quinine	drug	216-222	false
amiodarone	drug	136-145	zafirlukast	drug	225-235	false
amiodarone	drug	136-145	TIKOSYN	brand	279-285	advise
amiodarone	drug	136-145	dofetilide	drug	320-329	false
cannabinoids	group	148-159	diltiazem	drug	162-170	false
cannabinoids	group	148-159	nefazadone	drug	191-200	false
cannabinoids	group	148-159	norfloxacin	drug	203-213	false
cannabinoids	group	148-159	quinine	drug	216-222	false
cannabinoids	group	148-159	zafirlukast	drug	225-235	false
cannabinoids	group	148-159	TIKOSYN	brand	279-285	advise
cannabinoids	group	148-159	dofetilide	drug	320-329	false
diltiazem	drug	162-170	nefazadone	drug	191-200	false
diltiazem	drug	162-170	norfloxacin	drug	203-213	false
diltiazem	drug	162-170	quinine	drug	216-222	false
diltiazem	drug	162-170	zafirlukast	drug	225-235	false
diltiazem	drug	162-170	TIKOSYN	brand	279-285	advise
diltiazem	drug	162-170	dofetilide	drug	320-329	false
nefazadone	drug	191-200	norfloxacin	drug	203-213	false
nefazadone	drug	191-200	quinine	drug	216-222	false
nefazadone	drug	191-200	zafirlukast	drug	225-235	false
nefazadone	drug	191-200	TIKOSYN	brand	279-285	advise
nefazadone	drug	191-200	dofetilide	drug	320-329	false
norfloxacin	drug	203-213	quinine	drug	216-222	false
norfloxacin	drug	203-213	zafirlukast	drug	225-235	false
norfloxacin	drug	203-213	TIKOSYN	brand	279-285	advise
norfloxacin	drug	203-213	dofetilide	drug	320-329	false
quinine	drug	216-222	zafirlukast	drug	225-235	false
quinine	drug	216-222	TIKOSYN	brand	279-285	advise
quinine	drug	216-222	dofetilide	drug	320-329	false
zafirlukast	drug	225-235	TIKOSYN	brand	279-285	advise
zafirlukast	drug	225-235	dofetilide	drug	320-329	false
TIKOSYN	brand	279-285	dofetilide	drug	320-329	false

DDI-DrugBank.d558.s27	Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin.
Digoxin	drug	35-41	TIKOSYN	brand	90-96	false
Digoxin	drug	35-41	digoxin	drug	138-144	false
TIKOSYN	brand	90-96	digoxin	drug	138-144	false

DDI-DrugBank.d558.s28	In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
digoxin	drug	47-53	dofetilide	drug	60-69	effect

DDI-DrugBank.d558.s29	It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin;
TIKOSYN	brand	60-66	digoxin	drug	139-145	false

DDI-DrugBank.d558.s32	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
amlodipine	drug	36-45	phenytoin	drug	48-56	false
amlodipine	drug	36-45	glyburide	drug	59-67	false
amlodipine	drug	36-45	ranitidine	drug	70-79	false
amlodipine	drug	36-45	omeprazole	drug	82-91	false
amlodipine	drug	36-45	estrogens	group	151-159	false
amlodipine	drug	36-45	medroxyprogesterone	drug	165-183	false
amlodipine	drug	36-45	antacid	group	187-193	false
amlodipine	drug	36-45	aluminum hydroxide	drug	196-203;219-227	false
amlodipine	drug	36-45	magnesium hydroxide	drug	209-227	false
amlodipine	drug	36-45	theophylline	drug	235-246	false
amlodipine	drug	36-45	TIKOSYN	brand	287-293	false
phenytoin	drug	48-56	glyburide	drug	59-67	false
phenytoin	drug	48-56	ranitidine	drug	70-79	false
phenytoin	drug	48-56	omeprazole	drug	82-91	false
phenytoin	drug	48-56	estrogens	group	151-159	false
phenytoin	drug	48-56	medroxyprogesterone	drug	165-183	false
phenytoin	drug	48-56	antacid	group	187-193	false
phenytoin	drug	48-56	aluminum hydroxide	drug	196-203;219-227	false
phenytoin	drug	48-56	magnesium hydroxide	drug	209-227	false
phenytoin	drug	48-56	theophylline	drug	235-246	false
phenytoin	drug	48-56	TIKOSYN	brand	287-293	false
glyburide	drug	59-67	ranitidine	drug	70-79	false
glyburide	drug	59-67	omeprazole	drug	82-91	false
glyburide	drug	59-67	estrogens	group	151-159	false
glyburide	drug	59-67	medroxyprogesterone	drug	165-183	false
glyburide	drug	59-67	antacid	group	187-193	false
glyburide	drug	59-67	aluminum hydroxide	drug	196-203;219-227	false
glyburide	drug	59-67	magnesium hydroxide	drug	209-227	false
glyburide	drug	59-67	theophylline	drug	235-246	false
glyburide	drug	59-67	TIKOSYN	brand	287-293	false
ranitidine	drug	70-79	omeprazole	drug	82-91	false
ranitidine	drug	70-79	estrogens	group	151-159	false
ranitidine	drug	70-79	medroxyprogesterone	drug	165-183	false
ranitidine	drug	70-79	antacid	group	187-193	false
ranitidine	drug	70-79	aluminum hydroxide	drug	196-203;219-227	false
ranitidine	drug	70-79	magnesium hydroxide	drug	209-227	false
ranitidine	drug	70-79	theophylline	drug	235-246	false
ranitidine	drug	70-79	TIKOSYN	brand	287-293	false
omeprazole	drug	82-91	estrogens	group	151-159	false
omeprazole	drug	82-91	medroxyprogesterone	drug	165-183	false
omeprazole	drug	82-91	antacid	group	187-193	false
omeprazole	drug	82-91	aluminum hydroxide	drug	196-203;219-227	false
omeprazole	drug	82-91	magnesium hydroxide	drug	209-227	false
omeprazole	drug	82-91	theophylline	drug	235-246	false
omeprazole	drug	82-91	TIKOSYN	brand	287-293	false
estrogens	group	151-159	medroxyprogesterone	drug	165-183	false
estrogens	group	151-159	antacid	group	187-193	false
estrogens	group	151-159	aluminum hydroxide	drug	196-203;219-227	false
estrogens	group	151-159	magnesium hydroxide	drug	209-227	false
estrogens	group	151-159	theophylline	drug	235-246	false
estrogens	group	151-159	TIKOSYN	brand	287-293	false
medroxyprogesterone	drug	165-183	antacid	group	187-193	false
medroxyprogesterone	drug	165-183	aluminum hydroxide	drug	196-203;219-227	false
medroxyprogesterone	drug	165-183	magnesium hydroxide	drug	209-227	false
medroxyprogesterone	drug	165-183	theophylline	drug	235-246	false
medroxyprogesterone	drug	165-183	TIKOSYN	brand	287-293	false
antacid	group	187-193	aluminum hydroxide	drug	196-203;219-227	false
antacid	group	187-193	magnesium hydroxide	drug	209-227	false
antacid	group	187-193	theophylline	drug	235-246	false
antacid	group	187-193	TIKOSYN	brand	287-293	false
aluminum hydroxide	drug	196-203;219-227	magnesium hydroxide	drug	209-227	false
aluminum hydroxide	drug	196-203;219-227	theophylline	drug	235-246	false
aluminum hydroxide	drug	196-203;219-227	TIKOSYN	brand	287-293	false
magnesium hydroxide	drug	209-227	theophylline	drug	235-246	false
magnesium hydroxide	drug	209-227	TIKOSYN	brand	287-293	false
theophylline	drug	235-246	TIKOSYN	brand	287-293	false

DDI-DrugBank.d558.s33	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
TIKOSYN	brand	59-65	warfarin	drug	127-134	false
TIKOSYN	brand	59-65	propranolol	drug	164-174	false
TIKOSYN	brand	59-65	phenytoin	drug	197-205	false
TIKOSYN	brand	59-65	theophylline	drug	208-219	false
TIKOSYN	brand	59-65	contraceptives	group	230-243	false
warfarin	drug	127-134	propranolol	drug	164-174	false
warfarin	drug	127-134	phenytoin	drug	197-205	false
warfarin	drug	127-134	theophylline	drug	208-219	false
warfarin	drug	127-134	contraceptives	group	230-243	false
propranolol	drug	164-174	phenytoin	drug	197-205	false
propranolol	drug	164-174	theophylline	drug	208-219	false
propranolol	drug	164-174	contraceptives	group	230-243	false
phenytoin	drug	197-205	theophylline	drug	208-219	false
phenytoin	drug	197-205	contraceptives	group	230-243	false
theophylline	drug	208-219	contraceptives	group	230-243	false

DDI-DrugBank.d558.s35	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
ACE inhibitors	group	40-53	anticoagulants	group	61-74	false
ACE inhibitors	group	40-53	calcium channel blockers	group	77-100	false
ACE inhibitors	group	40-53	beta blockers	group	103-115	false
ACE inhibitors	group	40-53	cardiac glycosides	group	118-135	false
ACE inhibitors	group	40-53	nitrates	group	240-247	false
ACE inhibitors	group	40-53	sulphonylureas	group	250-263	false
ACE inhibitors	group	40-53	loop diuretics	group	266-279	false
ACE inhibitors	group	40-53	potassium sparing diuretics	group	282-308	false
ACE inhibitors	group	40-53	thiazide diuretics	group	311-328	false
anticoagulants	group	61-74	calcium channel blockers	group	77-100	false
anticoagulants	group	61-74	beta blockers	group	103-115	false
anticoagulants	group	61-74	cardiac glycosides	group	118-135	false
anticoagulants	group	61-74	nitrates	group	240-247	false
anticoagulants	group	61-74	sulphonylureas	group	250-263	false
anticoagulants	group	61-74	loop diuretics	group	266-279	false
anticoagulants	group	61-74	potassium sparing diuretics	group	282-308	false
anticoagulants	group	61-74	thiazide diuretics	group	311-328	false
calcium channel blockers	group	77-100	beta blockers	group	103-115	false
calcium channel blockers	group	77-100	cardiac glycosides	group	118-135	false
calcium channel blockers	group	77-100	nitrates	group	240-247	false
calcium channel blockers	group	77-100	sulphonylureas	group	250-263	false
calcium channel blockers	group	77-100	loop diuretics	group	266-279	false
calcium channel blockers	group	77-100	potassium sparing diuretics	group	282-308	false
calcium channel blockers	group	77-100	thiazide diuretics	group	311-328	false
beta blockers	group	103-115	cardiac glycosides	group	118-135	false
beta blockers	group	103-115	nitrates	group	240-247	false
beta blockers	group	103-115	sulphonylureas	group	250-263	false
beta blockers	group	103-115	loop diuretics	group	266-279	false
beta blockers	group	103-115	potassium sparing diuretics	group	282-308	false
beta blockers	group	103-115	thiazide diuretics	group	311-328	false
cardiac glycosides	group	118-135	nitrates	group	240-247	false
cardiac glycosides	group	118-135	sulphonylureas	group	250-263	false
cardiac glycosides	group	118-135	loop diuretics	group	266-279	false
cardiac glycosides	group	118-135	potassium sparing diuretics	group	282-308	false
cardiac glycosides	group	118-135	thiazide diuretics	group	311-328	false
nitrates	group	240-247	sulphonylureas	group	250-263	false
nitrates	group	240-247	loop diuretics	group	266-279	false
nitrates	group	240-247	potassium sparing diuretics	group	282-308	false
nitrates	group	240-247	thiazide diuretics	group	311-328	false
sulphonylureas	group	250-263	loop diuretics	group	266-279	false
sulphonylureas	group	250-263	potassium sparing diuretics	group	282-308	false
sulphonylureas	group	250-263	thiazide diuretics	group	311-328	false
loop diuretics	group	266-279	potassium sparing diuretics	group	282-308	false
loop diuretics	group	266-279	thiazide diuretics	group	311-328	false
potassium sparing diuretics	group	282-308	thiazide diuretics	group	311-328	false

DDI-DrugBank.d558.s37	The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
dofetilide	drug	23-32	thiazide diuretics	group	72-89	mechanism

DDI-DrugBank.d42.s0	The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.
dolasetron	drug	73-82	hydrodolasetron	drug_n	88-102	false
dolasetron	drug	73-82	hydrodolasetron	drug_n	182-196	false
hydrodolasetron	drug_n	88-102	hydrodolasetron	drug_n	182-196	false

DDI-DrugBank.d42.s1	Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
hydrodolasetron	drug_n	16-30	dolasetron	drug	51-60	false
hydrodolasetron	drug_n	16-30	cimetidine	drug	86-95	false
hydrodolasetron	drug_n	16-30	rifampin	drug	197-204	false
dolasetron	drug	51-60	cimetidine	drug	86-95	mechanism
dolasetron	drug	51-60	rifampin	drug	197-204	mechanism
cimetidine	drug	86-95	rifampin	drug	197-204	false

DDI-DrugBank.d42.s4	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
furosemide	drug	19-28	nifedipine	drug	31-40	false
furosemide	drug	19-28	diltiazem	drug	43-51	false
furosemide	drug	19-28	ACE inhibitors	group	54-67	false
furosemide	drug	19-28	verapamil	drug	70-78	false
furosemide	drug	19-28	glyburide	drug	81-89	false
furosemide	drug	19-28	propranolol	drug	92-102	false
furosemide	drug	19-28	hydrodolasetron	drug_n	178-192	false
nifedipine	drug	31-40	diltiazem	drug	43-51	false
nifedipine	drug	31-40	ACE inhibitors	group	54-67	false
nifedipine	drug	31-40	verapamil	drug	70-78	false
nifedipine	drug	31-40	glyburide	drug	81-89	false
nifedipine	drug	31-40	propranolol	drug	92-102	false
nifedipine	drug	31-40	hydrodolasetron	drug_n	178-192	false
diltiazem	drug	43-51	ACE inhibitors	group	54-67	false
diltiazem	drug	43-51	verapamil	drug	70-78	false
diltiazem	drug	43-51	glyburide	drug	81-89	false
diltiazem	drug	43-51	propranolol	drug	92-102	false
diltiazem	drug	43-51	hydrodolasetron	drug_n	178-192	false
ACE inhibitors	group	54-67	verapamil	drug	70-78	false
ACE inhibitors	group	54-67	glyburide	drug	81-89	false
ACE inhibitors	group	54-67	propranolol	drug	92-102	false
ACE inhibitors	group	54-67	hydrodolasetron	drug_n	178-192	false
verapamil	drug	70-78	glyburide	drug	81-89	false
verapamil	drug	70-78	propranolol	drug	92-102	false
verapamil	drug	70-78	hydrodolasetron	drug_n	178-192	false
glyburide	drug	81-89	propranolol	drug	92-102	false
glyburide	drug	81-89	hydrodolasetron	drug_n	178-192	false
propranolol	drug	92-102	hydrodolasetron	drug_n	178-192	false

DDI-DrugBank.d42.s5	Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
hydrodolasetron	drug_n	13-27	dolasetron mesylate	drug	57-75	false
hydrodolasetron	drug_n	13-27	atenolol	drug	127-134	false
dolasetron mesylate	drug	57-75	atenolol	drug	127-134	mechanism

DDI-DrugBank.d42.s7	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
Dolasetron mesylate	drug	0-18	chemotherapeutic agents	group	67-89	false
Dolasetron mesylate	drug	0-18	cisplatin	drug	92-100	false
Dolasetron mesylate	drug	0-18	5-fluorouracil	drug	103-116	false
Dolasetron mesylate	drug	0-18	doxorubicin	drug	119-129	false
Dolasetron mesylate	drug	0-18	cyclophosphamide	drug	132-147	false
chemotherapeutic agents	group	67-89	cisplatin	drug	92-100	false
chemotherapeutic agents	group	67-89	5-fluorouracil	drug	103-116	false
chemotherapeutic agents	group	67-89	doxorubicin	drug	119-129	false
chemotherapeutic agents	group	67-89	cyclophosphamide	drug	132-147	false
cisplatin	drug	92-100	5-fluorouracil	drug	103-116	false
cisplatin	drug	92-100	doxorubicin	drug	119-129	false
cisplatin	drug	92-100	cyclophosphamide	drug	132-147	false
5-fluorouracil	drug	103-116	doxorubicin	drug	119-129	false
5-fluorouracil	drug	103-116	cyclophosphamide	drug	132-147	false
doxorubicin	drug	119-129	cyclophosphamide	drug	132-147	false

DDI-DrugBank.d325.s0	Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.
dopamine	drug	8-15	dopamine	drug	125-132	false

DDI-DrugBank.d325.s1	Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
MAO inhibitors	group	36-49	dopamine HCl	drug	108-119	advise
MAO inhibitors	group	36-49	dopamine HCl	drug	153-164	false
dopamine HCl	drug	108-119	dopamine HCl	drug	153-164	false

DDI-DrugBank.d325.s2	Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
dopamine HCl	drug	38-49	diuretic agents	group	55-69	effect

DDI-DrugBank.d325.s4	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
dopamine	drug	19-26	beta-adrenergic blocking agents	group	47-77	effect
dopamine	drug	19-26	propranolol	drug	88-98	effect
dopamine	drug	19-26	metoprolol	drug	104-113	effect
beta-adrenergic blocking agents	group	47-77	propranolol	drug	88-98	false
beta-adrenergic blocking agents	group	47-77	metoprolol	drug	104-113	false
propranolol	drug	88-98	metoprolol	drug	104-113	false

DDI-DrugBank.d325.s5	The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
dopamine HCl	drug	56-67	alpha-adrenergic blocking agents	group	87-118	effect

DDI-DrugBank.d325.s6	Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.
Dopamine	drug	0-7	alpha-adrenergic blocking agents	group	80-85;95-120	false
Dopamine	drug	0-7	beta-adrenergic blocking agents	drug	90-120	false
alpha-adrenergic blocking agents	group	80-85;95-120	beta-adrenergic blocking agents	drug	90-120	false

DDI-DrugBank.d325.s7	Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
Butyrophenones	group	0-13	haloperidol	drug	24-34	false
Butyrophenones	group	0-13	phenothiazines	group	41-54	false
Butyrophenones	group	0-13	dopamine	drug	73-80	effect
haloperidol	drug	24-34	phenothiazines	group	41-54	false
haloperidol	drug	24-34	dopamine	drug	73-80	effect
phenothiazines	group	41-54	dopamine	drug	73-80	effect

DDI-DrugBank.d325.s8	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
Cyclopropane	drug	0-11	halogenated hydrocarbon anesthetics	group	16-50	false
Cyclopropane	drug	0-11	catecholamines	group	177-190	effect
Cyclopropane	drug	0-11	dopamine	drug	201-208	effect
halogenated hydrocarbon anesthetics	group	16-50	catecholamines	group	177-190	effect
halogenated hydrocarbon anesthetics	group	16-50	dopamine	drug	201-208	effect
catecholamines	group	177-190	dopamine	drug	201-208	false

DDI-DrugBank.d325.s10	Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
dopamine HCl	drug	66-77	cyclopropane	drug	101-112	advise
dopamine HCl	drug	66-77	halogenated hydrocarbon anesthetics	group	117-151	advise
cyclopropane	drug	101-112	halogenated hydrocarbon anesthetics	group	117-151	false

DDI-DrugBank.d325.s11	It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
dopamine	drug	70-77	propranolol	drug	148-158	effect

DDI-DrugBank.d325.s12	The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
vasopressor	group	23-33	ergonovine	drug	70-79	false
vasopressor	group	23-33	oxytocic drugs	group	91-104	effect
ergonovine	drug	70-79	oxytocic drugs	group	91-104	effect

DDI-DrugBank.d325.s13	Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
phenytoin	drug	18-26	dopamine HCl	drug	50-61	effect

DDI-DrugBank.d325.s14	It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
dopamine HCl	drug	43-54	phenytoin	drug	73-81	advise
dopamine HCl	drug	43-54	anticonvulsant	group	101-114	false
phenytoin	drug	73-81	anticonvulsant	group	101-114	false

DDI-DrugBank.d93.s0	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
Pulmozyme	brand	36-44	antibiotics	group	178-188	false
Pulmozyme	brand	36-44	bronchodilators	group	191-205	false
Pulmozyme	brand	36-44	vitamins	group	228-235	false
Pulmozyme	brand	36-44	corticosteroids	group	254-268	false
Pulmozyme	brand	36-44	analgesics	group	275-284	false
antibiotics	group	178-188	bronchodilators	group	191-205	false
antibiotics	group	178-188	vitamins	group	228-235	false
antibiotics	group	178-188	corticosteroids	group	254-268	false
antibiotics	group	178-188	analgesics	group	275-284	false
bronchodilators	group	191-205	vitamins	group	228-235	false
bronchodilators	group	191-205	corticosteroids	group	254-268	false
bronchodilators	group	191-205	analgesics	group	275-284	false
vitamins	group	228-235	corticosteroids	group	254-268	false
vitamins	group	228-235	analgesics	group	275-284	false
corticosteroids	group	254-268	analgesics	group	275-284	false

DDI-DrugBank.d34.s0	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
dorzolamide	drug	94-104	carbonic anhydrase inhibitors	group	155-183	effect
dorzolamide	drug	94-104	salicylate	group	286-295	false
carbonic anhydrase inhibitors	group	155-183	salicylate	group	286-295	false

DDI-DrugBank.d267.s0	Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.
succinylcholine	drug	24-38	NUROMAX	brand	115-121	false

DDI-DrugBank.d267.s1	The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
NUROMAX	brand	11-17	succinylcholine	drug	26-40	false
NUROMAX	brand	11-17	succinylcholine	drug	83-97	false
succinylcholine	drug	26-40	succinylcholine	drug	83-97	false

DDI-DrugBank.d267.s2	There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.
NUROMAX	brand	49-55	neuromuscular blocking agents	group	83-111	false

DDI-DrugBank.d267.s3	Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
Isoflurane	drug	0-9	enflurane	drug	12-20	false
Isoflurane	drug	0-9	halothane	drug	27-35	false
Isoflurane	drug	0-9	NUROMAX	brand	58-64	mechanism
enflurane	drug	12-20	halothane	drug	27-35	false
enflurane	drug	12-20	NUROMAX	brand	58-64	mechanism
halothane	drug	27-35	NUROMAX	brand	58-64	mechanism

DDI-DrugBank.d267.s5	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
NUROMAX	brand	98-104	antibiotics	group	122-132	effect
NUROMAX	brand	98-104	aminoglycosides	group	142-156	effect
NUROMAX	brand	98-104	tetracyclines	group	159-171	effect
NUROMAX	brand	98-104	bacitracin	group	174-183	effect
NUROMAX	brand	98-104	polymyxins	group	186-195	effect
NUROMAX	brand	98-104	lincomycin	drug	198-207	effect
NUROMAX	brand	98-104	clindamycin	drug	210-220	effect
NUROMAX	brand	98-104	colistin	drug	223-230	effect
NUROMAX	brand	98-104	sodium colistimethate	drug	237-257	effect
NUROMAX	brand	98-104	magnesium	drug	261-269	effect
NUROMAX	brand	98-104	lithium	drug	278-284	effect
NUROMAX	brand	98-104	anesthetics	group	293-303	effect
NUROMAX	brand	98-104	procainamide	drug	306-317	effect
NUROMAX	brand	98-104	quinidine	drug	324-332	effect
antibiotics	group	122-132	aminoglycosides	group	142-156	false
antibiotics	group	122-132	tetracyclines	group	159-171	false
antibiotics	group	122-132	bacitracin	group	174-183	false
antibiotics	group	122-132	polymyxins	group	186-195	false
antibiotics	group	122-132	lincomycin	drug	198-207	false
antibiotics	group	122-132	clindamycin	drug	210-220	false
antibiotics	group	122-132	colistin	drug	223-230	false
antibiotics	group	122-132	sodium colistimethate	drug	237-257	false
antibiotics	group	122-132	magnesium	drug	261-269	false
antibiotics	group	122-132	lithium	drug	278-284	false
antibiotics	group	122-132	anesthetics	group	293-303	false
antibiotics	group	122-132	procainamide	drug	306-317	false
antibiotics	group	122-132	quinidine	drug	324-332	false
aminoglycosides	group	142-156	tetracyclines	group	159-171	false
aminoglycosides	group	142-156	bacitracin	group	174-183	false
aminoglycosides	group	142-156	polymyxins	group	186-195	false
aminoglycosides	group	142-156	lincomycin	drug	198-207	false
aminoglycosides	group	142-156	clindamycin	drug	210-220	false
aminoglycosides	group	142-156	colistin	drug	223-230	false
aminoglycosides	group	142-156	sodium colistimethate	drug	237-257	false
aminoglycosides	group	142-156	magnesium	drug	261-269	false
aminoglycosides	group	142-156	lithium	drug	278-284	false
aminoglycosides	group	142-156	anesthetics	group	293-303	false
aminoglycosides	group	142-156	procainamide	drug	306-317	false
aminoglycosides	group	142-156	quinidine	drug	324-332	false
tetracyclines	group	159-171	bacitracin	group	174-183	false
tetracyclines	group	159-171	polymyxins	group	186-195	false
tetracyclines	group	159-171	lincomycin	drug	198-207	false
tetracyclines	group	159-171	clindamycin	drug	210-220	false
tetracyclines	group	159-171	colistin	drug	223-230	false
tetracyclines	group	159-171	sodium colistimethate	drug	237-257	false
tetracyclines	group	159-171	magnesium	drug	261-269	false
tetracyclines	group	159-171	lithium	drug	278-284	false
tetracyclines	group	159-171	anesthetics	group	293-303	false
tetracyclines	group	159-171	procainamide	drug	306-317	false
tetracyclines	group	159-171	quinidine	drug	324-332	false
bacitracin	group	174-183	polymyxins	group	186-195	false
bacitracin	group	174-183	lincomycin	drug	198-207	false
bacitracin	group	174-183	clindamycin	drug	210-220	false
bacitracin	group	174-183	colistin	drug	223-230	false
bacitracin	group	174-183	sodium colistimethate	drug	237-257	false
bacitracin	group	174-183	magnesium	drug	261-269	false
bacitracin	group	174-183	lithium	drug	278-284	false
bacitracin	group	174-183	anesthetics	group	293-303	false
bacitracin	group	174-183	procainamide	drug	306-317	false
bacitracin	group	174-183	quinidine	drug	324-332	false
polymyxins	group	186-195	lincomycin	drug	198-207	false
polymyxins	group	186-195	clindamycin	drug	210-220	false
polymyxins	group	186-195	colistin	drug	223-230	false
polymyxins	group	186-195	sodium colistimethate	drug	237-257	false
polymyxins	group	186-195	magnesium	drug	261-269	false
polymyxins	group	186-195	lithium	drug	278-284	false
polymyxins	group	186-195	anesthetics	group	293-303	false
polymyxins	group	186-195	procainamide	drug	306-317	false
polymyxins	group	186-195	quinidine	drug	324-332	false
lincomycin	drug	198-207	clindamycin	drug	210-220	false
lincomycin	drug	198-207	colistin	drug	223-230	false
lincomycin	drug	198-207	sodium colistimethate	drug	237-257	false
lincomycin	drug	198-207	magnesium	drug	261-269	false
lincomycin	drug	198-207	lithium	drug	278-284	false
lincomycin	drug	198-207	anesthetics	group	293-303	false
lincomycin	drug	198-207	procainamide	drug	306-317	false
lincomycin	drug	198-207	quinidine	drug	324-332	false
clindamycin	drug	210-220	colistin	drug	223-230	false
clindamycin	drug	210-220	sodium colistimethate	drug	237-257	false
clindamycin	drug	210-220	magnesium	drug	261-269	false
clindamycin	drug	210-220	lithium	drug	278-284	false
clindamycin	drug	210-220	anesthetics	group	293-303	false
clindamycin	drug	210-220	procainamide	drug	306-317	false
clindamycin	drug	210-220	quinidine	drug	324-332	false
colistin	drug	223-230	sodium colistimethate	drug	237-257	false
colistin	drug	223-230	magnesium	drug	261-269	false
colistin	drug	223-230	lithium	drug	278-284	false
colistin	drug	223-230	anesthetics	group	293-303	false
colistin	drug	223-230	procainamide	drug	306-317	false
colistin	drug	223-230	quinidine	drug	324-332	false
sodium colistimethate	drug	237-257	magnesium	drug	261-269	false
sodium colistimethate	drug	237-257	lithium	drug	278-284	false
sodium colistimethate	drug	237-257	anesthetics	group	293-303	false
sodium colistimethate	drug	237-257	procainamide	drug	306-317	false
sodium colistimethate	drug	237-257	quinidine	drug	324-332	false
magnesium	drug	261-269	lithium	drug	278-284	false
magnesium	drug	261-269	anesthetics	group	293-303	false
magnesium	drug	261-269	procainamide	drug	306-317	false
magnesium	drug	261-269	quinidine	drug	324-332	false
lithium	drug	278-284	anesthetics	group	293-303	false
lithium	drug	278-284	procainamide	drug	306-317	false
lithium	drug	278-284	quinidine	drug	324-332	false
anesthetics	group	293-303	procainamide	drug	306-317	false
anesthetics	group	293-303	quinidine	drug	324-332	false
procainamide	drug	306-317	quinidine	drug	324-332	false

DDI-DrugBank.d267.s6	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
nondepolarizing neuromuscular blocking agents	group	19-63	NUROMAX	brand	118-124	false
nondepolarizing neuromuscular blocking agents	group	19-63	phenytoin	drug	201-209	effect
nondepolarizing neuromuscular blocking agents	group	19-63	carbamazepine	drug	214-226	effect
NUROMAX	brand	118-124	phenytoin	drug	201-209	effect
NUROMAX	brand	118-124	carbamazepine	drug	214-226	effect
phenytoin	drug	201-209	carbamazepine	drug	214-226	false

DDI-DrugBank.d332.s0	Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
doxapram	drug	18-25	sympathomimetic	group	57-71	effect
doxapram	drug	18-25	monoamine oxidase inhibiting drugs	group	76-109	effect
sympathomimetic	group	57-71	monoamine oxidase inhibiting drugs	group	76-109	false

DDI-DrugBank.d332.s1	In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
muscle relaxants	group	30-45	doxapram	drug	48-55	false
muscle relaxants	group	30-45	muscle relaxant drugs	group	102-122	false
doxapram	drug	48-55	muscle relaxant drugs	group	102-122	effect

DDI-DrugBank.d367.s1	In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.
doxazosin mesylate	drug	44-61	digoxin	drug	99-105	false
doxazosin mesylate	drug	44-61	warfarin	drug	108-115	false
doxazosin mesylate	drug	44-61	phenytoin	drug	118-126	false
doxazosin mesylate	drug	44-61	indomethacin	drug	131-142	false
digoxin	drug	99-105	warfarin	drug	108-115	false
digoxin	drug	99-105	phenytoin	drug	118-126	false
digoxin	drug	99-105	indomethacin	drug	131-142	false
warfarin	drug	108-115	phenytoin	drug	118-126	false
warfarin	drug	108-115	indomethacin	drug	131-142	false
phenytoin	drug	118-126	indomethacin	drug	131-142	false

DDI-DrugBank.d367.s3	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.
Doxazosin mesylate	drug	0-17	thiazide diuretics	group	115-132	false
Doxazosin mesylate	drug	0-17	beta-blocking agent	group	135-153	false
Doxazosin mesylate	drug	0-17	nonsteroidal anti-inflammatory drugs	group	161-196	false
thiazide diuretics	group	115-132	beta-blocking agent	group	135-153	false
thiazide diuretics	group	115-132	nonsteroidal anti-inflammatory drugs	group	161-196	false
beta-blocking agent	group	135-153	nonsteroidal anti-inflammatory drugs	group	161-196	false

DDI-DrugBank.d367.s4	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
doxazosin	drug	96-104	cimetidine	drug	145-154	mechanism
doxazosin	drug	96-104	doxazosin	drug	219-227	false
doxazosin	drug	96-104	doxazosin	drug	331-339	false
cimetidine	drug	145-154	doxazosin	drug	219-227	false
cimetidine	drug	145-154	doxazosin	drug	331-339	false
doxazosin	drug	219-227	doxazosin	drug	331-339	false

DDI-DrugBank.d367.s9	Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
Analgesic	group	0-8	anti-inflammatory	group	10-26	false
Analgesic	group	0-8	acetaminophen	drug	35-47	false
Analgesic	group	0-8	aspirin	brand	50-56	false
Analgesic	group	0-8	codeine	drug	59-65	false
Analgesic	group	0-8	codeine	drug	71-77	false
Analgesic	group	0-8	ibuprofen	drug	93-101	false
Analgesic	group	0-8	indomethacin	drug	104-115	false
anti-inflammatory	group	10-26	acetaminophen	drug	35-47	false
anti-inflammatory	group	10-26	aspirin	brand	50-56	false
anti-inflammatory	group	10-26	codeine	drug	59-65	false
anti-inflammatory	group	10-26	codeine	drug	71-77	false
anti-inflammatory	group	10-26	ibuprofen	drug	93-101	false
anti-inflammatory	group	10-26	indomethacin	drug	104-115	false
acetaminophen	drug	35-47	aspirin	brand	50-56	false
acetaminophen	drug	35-47	codeine	drug	59-65	false
acetaminophen	drug	35-47	codeine	drug	71-77	false
acetaminophen	drug	35-47	ibuprofen	drug	93-101	false
acetaminophen	drug	35-47	indomethacin	drug	104-115	false
aspirin	brand	50-56	codeine	drug	59-65	false
aspirin	brand	50-56	codeine	drug	71-77	false
aspirin	brand	50-56	ibuprofen	drug	93-101	false
aspirin	brand	50-56	indomethacin	drug	104-115	false
codeine	drug	59-65	codeine	drug	71-77	false
codeine	drug	59-65	ibuprofen	drug	93-101	false
codeine	drug	59-65	indomethacin	drug	104-115	false
codeine	drug	71-77	ibuprofen	drug	93-101	false
codeine	drug	71-77	indomethacin	drug	104-115	false
ibuprofen	drug	93-101	indomethacin	drug	104-115	false

DDI-DrugBank.d367.s11	Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
Antibiotics	group	0-10	erythromycin	drug	19-30	false
Antibiotics	group	0-10	trimethoprim	drug	33-44	false
Antibiotics	group	0-10	sulfamethoxazole	drug	50-65	false
Antibiotics	group	0-10	amoxicillin	drug	68-78	false
erythromycin	drug	19-30	trimethoprim	drug	33-44	false
erythromycin	drug	19-30	sulfamethoxazole	drug	50-65	false
erythromycin	drug	19-30	amoxicillin	drug	68-78	false
trimethoprim	drug	33-44	sulfamethoxazole	drug	50-65	false
trimethoprim	drug	33-44	amoxicillin	drug	68-78	false
sulfamethoxazole	drug	50-65	amoxicillin	drug	68-78	false

DDI-DrugBank.d367.s13	Antihistamines (e.g., chlorpheniramine).
Antihistamines	group	0-13	chlorpheniramine	group	22-37	false

DDI-DrugBank.d367.s15	Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol).
atenolol	drug	29-36	hydrochlorothiazide	drug	39-57	false
atenolol	drug	29-36	propranolol	drug	60-70	false
hydrochlorothiazide	drug	39-57	propranolol	drug	60-70	false

DDI-DrugBank.d367.s23	Sedatives and tranquilizers (e.g., diazepam).
Sedatives	group	0-8	tranquilizers	group	14-26	false
Sedatives	group	0-8	diazepam	drug	35-42	false
tranquilizers	group	14-26	diazepam	drug	35-42	false

DDI-DrugBank.d223.s2	Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	69-93	TCAs	group	96-99	false

DDI-DrugBank.d223.s7	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	Type 1C antiarrhythmics	group	107-129	false
cimetidine	drug	0-9	propafenone	drug	131-141	false
cimetidine	drug	0-9	flecainide	drug	147-156	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	Type 1C antiarrhythmics	group	107-129	false
antidepressants	group	66-80	propafenone	drug	131-141	false
antidepressants	group	66-80	flecainide	drug	147-156	false
phenothiazines	group	83-96	Type 1C antiarrhythmics	group	107-129	false
phenothiazines	group	83-96	propafenone	drug	131-141	false
phenothiazines	group	83-96	flecainide	drug	147-156	false
Type 1C antiarrhythmics	group	107-129	propafenone	drug	131-141	false
Type 1C antiarrhythmics	group	107-129	flecainide	drug	147-156	false
propafenone	drug	131-141	flecainide	drug	147-156	false

DDI-DrugBank.d223.s8	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	citalopram	drug	69-78	false
selective serotonin reuptake inhibitors	group	14-52	escitalopram	drug	81-92	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	95-104	false
selective serotonin reuptake inhibitors	group	14-52	sertraline	drug	107-116	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	123-132	false
SSRIs	group	55-59	citalopram	drug	69-78	false
SSRIs	group	55-59	escitalopram	drug	81-92	false
SSRIs	group	55-59	fluoxetine	drug	95-104	false
SSRIs	group	55-59	sertraline	drug	107-116	false
SSRIs	group	55-59	paroxetine	drug	123-132	false
citalopram	drug	69-78	escitalopram	drug	81-92	false
citalopram	drug	69-78	fluoxetine	drug	95-104	false
citalopram	drug	69-78	sertraline	drug	107-116	false
citalopram	drug	69-78	paroxetine	drug	123-132	false
escitalopram	drug	81-92	fluoxetine	drug	95-104	false
escitalopram	drug	81-92	sertraline	drug	107-116	false
escitalopram	drug	81-92	paroxetine	drug	123-132	false
fluoxetine	drug	95-104	sertraline	drug	107-116	false
fluoxetine	drug	95-104	paroxetine	drug	123-132	false
sertraline	drug	107-116	paroxetine	drug	123-132	false

DDI-DrugBank.d223.s9	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	141-144	false
TCA	group	25-27	SSRI	group	141-144	false

DDI-DrugBank.d223.s10	Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	group	63-66	SSRIs	group	84-88	advise

DDI-DrugBank.d223.s12	Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	156-179	false

DDI-DrugBank.d223.s14	It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	group	27-29	TCA	group	56-58	false

DDI-DrugBank.d223.s16	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
quinidine	drug	42-50	selective serotonin reuptake inhibitors	group	53-91	false
quinidine	drug	42-50	SSRIs	group	94-98	false
quinidine	drug	42-50	doxepin	drug	143-149	mechanism
selective serotonin reuptake inhibitors	group	53-91	SSRIs	group	94-98	false
selective serotonin reuptake inhibitors	group	53-91	doxepin	drug	143-149	mechanism
SSRIs	group	94-98	doxepin	drug	143-149	mechanism

DDI-DrugBank.d223.s19	MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.
MAO Inhibitors	group	0-13	MAO inhibitors	group	123-136	false

DDI-DrugBank.d223.s20	Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
MAO inhibitors	group	11-24	SINEQUAN	brand	117-124	advise

DDI-DrugBank.d223.s22	Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	tricyclic antidepressants	group	136-160	false
Cimetidine	drug	12-21	tricyclic antidepressants	group	136-160	mechanism

DDI-DrugBank.d223.s23	Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
tricyclic antidepressant	group	156-179	cimetidine	drug	186-195	effect

DDI-DrugBank.d223.s24	Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
tricyclic antidepressant	group	35-58	cimetidine	drug	133-142	mechanism

DDI-DrugBank.d223.s25	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
tricyclic antidepressants	group	60-84	cimetidine	drug	107-116	false
tricyclic antidepressants	group	60-84	cimetidine	drug	146-155	false
tricyclic antidepressants	group	60-84	tricyclic antidepressant	group	218-241	false
cimetidine	drug	107-116	cimetidine	drug	146-155	false
cimetidine	drug	107-116	tricyclic antidepressant	group	218-241	false
cimetidine	drug	146-155	tricyclic antidepressant	group	218-241	mechanism

DDI-DrugBank.d223.s26	Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
Alcohol	drug	0-6	alcohol	drug	41-47	false
Alcohol	drug	0-6	SINEQUAN	brand	128-135	false
alcohol	drug	41-47	SINEQUAN	brand	128-135	mechanism

DDI-DrugBank.d223.s28	Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
Tolazamide	drug	0-9	tolazamide	drug	104-113	false
Tolazamide	drug	0-9	doxepin	drug	156-162	false
tolazamide	drug	104-113	doxepin	drug	156-162	effect

DDI-DrugBank.d127.s2	DOXIL  may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.
DOXIL	brand	0-4	doxorubicin HCl	drug	86-100	false

DDI-DrugBank.d500.s0	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	group	8-20	anticoagulant	group	98-110	advise
tetracyclines	group	8-20	anticoagulant	group	161-173	false
anticoagulant	group	98-110	anticoagulant	group	161-173	false

DDI-DrugBank.d500.s1	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
penicillin	drug	73-82	tetracyclines	group	117-129	false
penicillin	drug	73-82	penicillin	group	151-160	false
tetracyclines	group	117-129	penicillin	group	151-160	advise

DDI-DrugBank.d500.s2	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
tetracyclines	group	14-26	antacids	group	43-50	false
tetracyclines	group	14-26	aluminum	drug	63-70	mechanism
tetracyclines	group	14-26	calcium	drug	73-79	mechanism
tetracyclines	group	14-26	magnesium	drug	85-93	mechanism
tetracyclines	group	14-26	iron	drug	100-103	mechanism
antacids	group	43-50	aluminum	drug	63-70	false
antacids	group	43-50	calcium	drug	73-79	false
antacids	group	43-50	magnesium	drug	85-93	false
antacids	group	43-50	iron	drug	100-103	false
aluminum	drug	63-70	calcium	drug	73-79	false
aluminum	drug	63-70	magnesium	drug	85-93	false
aluminum	drug	63-70	iron	drug	100-103	false
calcium	drug	73-79	magnesium	drug	85-93	false
calcium	drug	73-79	iron	drug	100-103	false
magnesium	drug	85-93	iron	drug	100-103	false

DDI-DrugBank.d500.s3	Absorption of tetracycline is impaired by bismuth subsalicylate.
tetracycline	drug	14-25	bismuth subsalicylate	drug	42-62	mechanism

DDI-DrugBank.d500.s4	Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
Barbiturates	group	0-11	carbamazepine	drug	14-26	false
Barbiturates	group	0-11	phenytoin	drug	33-41	false
Barbiturates	group	0-11	doxycycline	drug	69-79	mechanism
carbamazepine	drug	14-26	phenytoin	drug	33-41	false
carbamazepine	drug	14-26	doxycycline	drug	69-79	mechanism
phenytoin	drug	33-41	doxycycline	drug	69-79	mechanism

DDI-DrugBank.d500.s5	The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
tetracycline	drug	22-33	Penthrane	brand	39-47	effect
tetracycline	drug	22-33	methoxyflurane	drug	50-63	effect
Penthrane	brand	39-47	methoxyflurane	drug	50-63	false

DDI-DrugBank.d500.s6	Concurrent use of tetracycline may render oral contraceptives less effective.
tetracycline	drug	18-29	contraceptives	group	47-60	effect

DDI-DrugBank.d387.s0	Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
doxylamine	drug	32-41	doxylamine	drug	74-83	false
doxylamine	drug	32-41	CNS depressant drugs	group	108-127	false
doxylamine	drug	74-83	CNS depressant drugs	group	108-127	effect

DDI-DrugBank.d387.s1	Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
Antihistamines	group	0-13	heparin	drug	71-77	effect
Antihistamines	group	0-13	warfarin	drug	82-89	effect
heparin	drug	71-77	warfarin	drug	82-89	false

DDI-DrugBank.d387.s2	Doxylamine may enhance the effects of epinephrine.
Doxylamine	drug	0-9	epinephrine	drug	38-48	effect

DDI-DrugBank.d129.s2	Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
oxyphenbutazone	drug	29-43	androgens	group	49-57	mechanism
oxyphenbutazone	drug	29-43	oxyphenbutazone	drug	98-112	false
androgens	group	49-57	oxyphenbutazone	drug	98-112	false

DDI-DrugBank.d129.s3	In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
androgens	group	47-55	insulin	drug	99-105	effect

DDI-DrugBank.d254.s0	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
CNS depressant drugs	group	6-25	barbiturates	group	33-44	false
CNS depressant drugs	group	6-25	tranquilizers	group	47-59	false
CNS depressant drugs	group	6-25	opioids	group	62-68	false
CNS depressant drugs	group	6-25	anesthetics	group	82-92	false
CNS depressant drugs	group	6-25	INAPSINE	brand	138-145	effect
barbiturates	group	33-44	tranquilizers	group	47-59	false
barbiturates	group	33-44	opioids	group	62-68	false
barbiturates	group	33-44	anesthetics	group	82-92	false
barbiturates	group	33-44	INAPSINE	brand	138-145	effect
tranquilizers	group	47-59	opioids	group	62-68	false
tranquilizers	group	47-59	anesthetics	group	82-92	false
tranquilizers	group	47-59	INAPSINE	brand	138-145	effect
opioids	group	62-68	anesthetics	group	82-92	false
opioids	group	62-68	INAPSINE	brand	138-145	effect
anesthetics	group	82-92	INAPSINE	brand	138-145	effect

DDI-DrugBank.d254.s2	Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
INAPSINE	brand	32-39	CNS depressant drugs	group	60-79	advise

DDI-DrugBank.d190.s1	However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.
Xigris	brand	59-64	Xigris	brand	99-104	false

DDI-DrugBank.d190.s2	Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.
heparin	drug	93-99	unfractionated heparin	drug	102-123	false
heparin	drug	93-99	low molecular weight heparins	group	174-202	false
unfractionated heparin	drug	102-123	low molecular weight heparins	group	174-202	false

DDI-DrugBank.d190.s3	Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.
heparin	drug	41-47	Xigris	brand	122-127	false

DDI-DrugBank.d190.s4	Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).
Xigris	brand	41-46	Xigris	brand	75-80	false

DDI-DrugBank.d548.s0	Potential for Other Drugs to Affect Duloxetine: Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.
Duloxetine	drug	36-45	duloxetine	drug	91-100	false

DDI-DrugBank.d548.s1	Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
duloxetine	drug	41-50	fluvoxamine	drug	57-67	mechanism
duloxetine	drug	41-50	duloxetine	drug	185-194	false
fluvoxamine	drug	57-67	duloxetine	drug	185-194	false

DDI-DrugBank.d548.s3	Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.
duloxetine	drug	52-61	duloxetine	drug	94-103	false
duloxetine	drug	52-61	duloxetine	drug	177-186	false
duloxetine	drug	94-103	duloxetine	drug	177-186	false

DDI-DrugBank.d548.s4	Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
Paroxetine	drug	0-9	duloxetine	drug	53-62	mechanism
Paroxetine	drug	0-9	paroxetine	drug	157-166	false
duloxetine	drug	53-62	paroxetine	drug	157-166	false

DDI-DrugBank.d548.s5	Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
fluoxetine	drug	77-86	quinidine	drug	89-97	false

DDI-DrugBank.d548.s6	Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.
Duloxetine	drug	14-23	duloxetine	drug	128-137	false

DDI-DrugBank.d548.s8	When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
duloxetine	drug	5-14	desipramine	drug	101-111	mechanism
duloxetine	drug	5-14	desipramine	drug	145-155	false
desipramine	drug	101-111	desipramine	drug	145-155	false

DDI-DrugBank.d548.s9	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
Duloxetine	drug	32-41	antidepressants	group	170-184	advise
Duloxetine	drug	32-41	tricyclic antidepressants	group	187-211	advise
Duloxetine	drug	32-41	TCAs	group	214-217	advise
Duloxetine	drug	32-41	nortriptyline	drug	229-241	advise
Duloxetine	drug	32-41	amitriptyline	drug	244-256	advise
Duloxetine	drug	32-41	imipramine	drug	263-272	advise
Duloxetine	drug	32-41	phenothiazines	group	276-289	advise
Duloxetine	drug	32-41	Type 1C antiarrhythmics	group	295-317	advise
Duloxetine	drug	32-41	propafenone	drug	326-336	advise
Duloxetine	drug	32-41	flecainide	drug	339-348	advise
antidepressants	group	170-184	tricyclic antidepressants	group	187-211	false
antidepressants	group	170-184	TCAs	group	214-217	false
antidepressants	group	170-184	nortriptyline	drug	229-241	false
antidepressants	group	170-184	amitriptyline	drug	244-256	false
antidepressants	group	170-184	imipramine	drug	263-272	false
antidepressants	group	170-184	phenothiazines	group	276-289	false
antidepressants	group	170-184	Type 1C antiarrhythmics	group	295-317	false
antidepressants	group	170-184	propafenone	drug	326-336	false
antidepressants	group	170-184	flecainide	drug	339-348	false
tricyclic antidepressants	group	187-211	TCAs	group	214-217	false
tricyclic antidepressants	group	187-211	nortriptyline	drug	229-241	false
tricyclic antidepressants	group	187-211	amitriptyline	drug	244-256	false
tricyclic antidepressants	group	187-211	imipramine	drug	263-272	false
tricyclic antidepressants	group	187-211	phenothiazines	group	276-289	false
tricyclic antidepressants	group	187-211	Type 1C antiarrhythmics	group	295-317	false
tricyclic antidepressants	group	187-211	propafenone	drug	326-336	false
tricyclic antidepressants	group	187-211	flecainide	drug	339-348	false
TCAs	group	214-217	nortriptyline	drug	229-241	false
TCAs	group	214-217	amitriptyline	drug	244-256	false
TCAs	group	214-217	imipramine	drug	263-272	false
TCAs	group	214-217	phenothiazines	group	276-289	false
TCAs	group	214-217	Type 1C antiarrhythmics	group	295-317	false
TCAs	group	214-217	propafenone	drug	326-336	false
TCAs	group	214-217	flecainide	drug	339-348	false
nortriptyline	drug	229-241	amitriptyline	drug	244-256	false
nortriptyline	drug	229-241	imipramine	drug	263-272	false
nortriptyline	drug	229-241	phenothiazines	group	276-289	false
nortriptyline	drug	229-241	Type 1C antiarrhythmics	group	295-317	false
nortriptyline	drug	229-241	propafenone	drug	326-336	false
nortriptyline	drug	229-241	flecainide	drug	339-348	false
amitriptyline	drug	244-256	imipramine	drug	263-272	false
amitriptyline	drug	244-256	phenothiazines	group	276-289	false
amitriptyline	drug	244-256	Type 1C antiarrhythmics	group	295-317	false
amitriptyline	drug	244-256	propafenone	drug	326-336	false
amitriptyline	drug	244-256	flecainide	drug	339-348	false
imipramine	drug	263-272	phenothiazines	group	276-289	false
imipramine	drug	263-272	Type 1C antiarrhythmics	group	295-317	false
imipramine	drug	263-272	propafenone	drug	326-336	false
imipramine	drug	263-272	flecainide	drug	339-348	false
phenothiazines	group	276-289	Type 1C antiarrhythmics	group	295-317	false
phenothiazines	group	276-289	propafenone	drug	326-336	false
phenothiazines	group	276-289	flecainide	drug	339-348	false
Type 1C antiarrhythmics	group	295-317	propafenone	drug	326-336	false
Type 1C antiarrhythmics	group	295-317	flecainide	drug	339-348	false
propafenone	drug	326-336	flecainide	drug	339-348	false

DDI-DrugBank.d548.s10	Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
TCA	group	7-9	TCA	group	71-73	false
TCA	group	7-9	TCA	group	103-105	false
TCA	group	7-9	Duloxetine	drug	131-140	false
TCA	group	71-73	TCA	group	103-105	false
TCA	group	71-73	Duloxetine	drug	131-140	false
TCA	group	103-105	Duloxetine	drug	131-140	advise

DDI-DrugBank.d548.s11	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
thioridazine	drug	126-137	Duloxetine	drug	140-149	false
thioridazine	drug	126-137	thioridazine	drug	155-166	false
Duloxetine	drug	140-149	thioridazine	drug	155-166	advise

DDI-DrugBank.d548.s13	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
Duloxetine	drug	0-9	Alcohol	drug	87-93	false
Duloxetine	drug	0-9	Duloxetine	drug	101-110	false
Duloxetine	drug	0-9	ethanol	drug	116-122	false
Duloxetine	drug	0-9	Duloxetine	drug	214-223	false
Duloxetine	drug	0-9	alcohol	drug	294-300	false
Alcohol	drug	87-93	Duloxetine	drug	101-110	false
Alcohol	drug	87-93	ethanol	drug	116-122	false
Alcohol	drug	87-93	Duloxetine	drug	214-223	false
Alcohol	drug	87-93	alcohol	drug	294-300	false
Duloxetine	drug	101-110	ethanol	drug	116-122	false
Duloxetine	drug	101-110	Duloxetine	drug	214-223	false
Duloxetine	drug	101-110	alcohol	drug	294-300	false
ethanol	drug	116-122	Duloxetine	drug	214-223	false
ethanol	drug	116-122	alcohol	drug	294-300	false
Duloxetine	drug	214-223	alcohol	drug	294-300	false

DDI-DrugBank.d548.s14	In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.
Duloxetine	drug	7-16	Duloxetine	drug	50-59	false

DDI-DrugBank.d548.s21	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
Duloxetine	drug	30-39	aluminum	drug	46-53	false
Duloxetine	drug	30-39	magnesium	drug	60-68	false
Duloxetine	drug	30-39	antacids	group	81-88	false
Duloxetine	drug	30-39	Duloxetine	drug	102-111	false
Duloxetine	drug	30-39	famotidine	drug	118-127	false
Duloxetine	drug	30-39	duloxetine	drug	181-190	false
aluminum	drug	46-53	magnesium	drug	60-68	false
aluminum	drug	46-53	antacids	group	81-88	false
aluminum	drug	46-53	Duloxetine	drug	102-111	false
aluminum	drug	46-53	famotidine	drug	118-127	false
aluminum	drug	46-53	duloxetine	drug	181-190	false
magnesium	drug	60-68	antacids	group	81-88	false
magnesium	drug	60-68	Duloxetine	drug	102-111	false
magnesium	drug	60-68	famotidine	drug	118-127	false
magnesium	drug	60-68	duloxetine	drug	181-190	false
antacids	group	81-88	Duloxetine	drug	102-111	false
antacids	group	81-88	famotidine	drug	118-127	false
antacids	group	81-88	duloxetine	drug	181-190	false
Duloxetine	drug	102-111	famotidine	drug	118-127	false
Duloxetine	drug	102-111	duloxetine	drug	181-190	false
famotidine	drug	118-127	duloxetine	drug	181-190	false

DDI-DrugBank.d548.s22	It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.
proton pump inhibitors	group	56-77	duloxetine	drug	87-96	false

DDI-DrugBank.d4.s0	Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
xanthine bronchodilators	group	18-41	theophylline	drug	50-61	false
xanthine bronchodilators	group	18-41	ephedrine	drug	65-73	false
xanthine bronchodilators	group	18-41	sympathomimetic bronchodilators	group	86-116	effect
theophylline	drug	50-61	ephedrine	drug	65-73	false
theophylline	drug	50-61	sympathomimetic bronchodilators	group	86-116	effect
ephedrine	drug	65-73	sympathomimetic bronchodilators	group	86-116	effect

DDI-DrugBank.d4.s2	Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
dyphylline	drug	29-38	probenecid	drug	44-53	mechanism
dyphylline	drug	29-38	dyphylline	drug	145-154	false
probenecid	drug	44-53	dyphylline	drug	145-154	false

DDI-DrugBank.d377.s0	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
Phospholine Iodide	drug	0-17	cholinesterase inhibitors	group	37-61	effect
Phospholine Iodide	drug	0-17	succinylcholine	drug	71-85	effect
Phospholine Iodide	drug	0-17	organophosphate insecticide	drug_n	90-104;120-130	effect
Phospholine Iodide	drug	0-17	carbamate insecticide	drug_n	110-130	effect
cholinesterase inhibitors	group	37-61	succinylcholine	drug	71-85	false
cholinesterase inhibitors	group	37-61	organophosphate insecticide	drug_n	90-104;120-130	false
cholinesterase inhibitors	group	37-61	carbamate insecticide	drug_n	110-130	false
succinylcholine	drug	71-85	organophosphate insecticide	drug_n	90-104;120-130	false
succinylcholine	drug	71-85	carbamate insecticide	drug_n	110-130	false
organophosphate insecticide	drug_n	90-104;120-130	carbamate insecticide	drug_n	110-130	false

DDI-DrugBank.d191.s1	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
Steroids	group	0-7	edetate calcium disodium	drug	39-62	effect
Steroids	group	0-7	Edetate calcium disodium	drug	78-101	false
Steroids	group	0-7	zinc insulin	drug	133-144	false
Steroids	group	0-7	zinc	drug	176-179	false
edetate calcium disodium	drug	39-62	Edetate calcium disodium	drug	78-101	false
edetate calcium disodium	drug	39-62	zinc insulin	drug	133-144	false
edetate calcium disodium	drug	39-62	zinc	drug	176-179	false
Edetate calcium disodium	drug	78-101	zinc insulin	drug	133-144	mechanism
Edetate calcium disodium	drug	78-101	zinc	drug	176-179	false
zinc insulin	drug	133-144	zinc	drug	176-179	false

DDI-DrugBank.d44.s1	RAPTIVA should not be used with other immunosuppressive drugs.
RAPTIVA	brand	0-6	immunosuppressive drugs	group	38-60	advise

DDI-DrugBank.d44.s2	Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
Acellular vaccines	group	0-8;36-43	live vaccines	group	11-14;36-43	false
Acellular vaccines	group	0-8;36-43	live-attenuated vaccines	group	20-43	false
Acellular vaccines	group	0-8;36-43	RAPTIVA	brand	79-85	advise
live vaccines	group	11-14;36-43	live-attenuated vaccines	group	20-43	false
live vaccines	group	11-14;36-43	RAPTIVA	brand	79-85	advise
live-attenuated vaccines	group	20-43	RAPTIVA	brand	79-85	advise

DDI-DrugBank.d531.s1	Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).
SUSTIVA	brand	112-118	efavirenz	drug	121-129	false

DDI-DrugBank.d531.s2	In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.
efavirenz	drug	40-48	efavirenz	drug	112-120	false

DDI-DrugBank.d531.s5	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
phenobarbital	drug	40-52	rifampin	drug	55-62	false
phenobarbital	drug	40-52	rifabutin	drug	65-73	false
phenobarbital	drug	40-52	efavirenz	drug	123-131	mechanism
rifampin	drug	55-62	rifabutin	drug	65-73	false
rifampin	drug	55-62	efavirenz	drug	123-131	mechanism
rifabutin	drug	65-73	efavirenz	drug	123-131	mechanism

DDI-DrugBank.d531.s10	Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal
Antihistamines	group	0-13	Benzodiazepines	group	16-30	false
Antihistamines	group	0-13	Anti-Migraine	group	51-63	false
Antihistamines	group	0-13	Antifungal	group	65-74	false
Benzodiazepines	group	16-30	Anti-Migraine	group	51-63	false
Benzodiazepines	group	16-30	Antifungal	group	65-74	false
Anti-Migraine	group	51-63	Antifungal	group	65-74	false

DDI-DrugBank.d531.s11	astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
astemizole	drug	0-9	midazolam	drug	11-19	false
astemizole	drug	0-9	triazolam	drug	22-30	false
astemizole	drug	0-9	cisapride	drug	32-40	false
astemizole	drug	0-9	voriconazole	drug	60-71	false
midazolam	drug	11-19	triazolam	drug	22-30	false
midazolam	drug	11-19	cisapride	drug	32-40	false
midazolam	drug	11-19	voriconazole	drug	60-71	false
triazolam	drug	22-30	cisapride	drug	32-40	false
triazolam	drug	22-30	voriconazole	drug	60-71	false
cisapride	drug	32-40	voriconazole	drug	60-71	false

DDI-DrugBank.d531.s19	When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).
SUSTIVA	brand	25-31	atazanavir	drug	86-95	false
SUSTIVA	brand	25-31	ritonavir	drug	112-120	false
SUSTIVA	brand	25-31	SUSTIVA	brand	133-139	false
atazanavir	drug	86-95	ritonavir	drug	112-120	false
atazanavir	drug	86-95	SUSTIVA	brand	133-139	false
ritonavir	drug	112-120	SUSTIVA	brand	133-139	false

DDI-DrugBank.d531.s20	Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.
SUSTIVA	brand	27-33	atazanavir	drug	39-48	false

DDI-DrugBank.d531.s29	In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
SUSTIVA	brand	61-67	clarithromycin	drug	73-86	effect

DDI-DrugBank.d531.s30	No dose adjustment of SUSTIVA is recommended when given with clarithromycin.
SUSTIVA	brand	22-28	clarithromycin	drug	61-74	false

DDI-DrugBank.d531.s31	Alternatives to clarithromycin, such as azithromycin, should be considered.
clarithromycin	drug	16-29	azithromycin	drug	40-51	false

DDI-DrugBank.d531.s32	Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.
macrolide antibiotics	group	6-26	erythromycin	drug	37-48	false
macrolide antibiotics	group	6-26	SUSTIVA	brand	93-99	false
erythromycin	drug	37-48	SUSTIVA	brand	93-99	false

DDI-DrugBank.d531.s37	The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.
indinavir	drug	20-28	SUSTIVA	brand	62-68	false

DDI-DrugBank.d531.s38	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
indinavir	drug	15-23	indinavir	drug	93-101	false
indinavir	drug	15-23	SUSTIVA	brand	121-127	false
indinavir	drug	93-101	SUSTIVA	brand	121-127	mechanism

DDI-DrugBank.d531.s39	When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
indinavir	drug	5-13	SUSTIVA	brand	75-81	mechanism
indinavir	drug	5-13	indinavir	drug	108-116	false
indinavir	drug	5-13	indinavir	drug	210-218	false
SUSTIVA	brand	75-81	indinavir	drug	108-116	false
SUSTIVA	brand	75-81	indinavir	drug	210-218	false
indinavir	drug	108-116	indinavir	drug	210-218	false

DDI-DrugBank.d531.s40	Lopinavir/ritonavir
Lopinavir	drug	0-8	ritonavir	drug	10-18	false

DDI-DrugBank.d531.s42	A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
lopinavir	drug	19-27	ritonavir	drug	29-37	false
lopinavir	drug	19-27	SUSTIVA	brand	149-155	advise
ritonavir	drug	29-37	SUSTIVA	brand	149-155	advise

DDI-DrugBank.d531.s45	Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
methadone	drug	121-129	opiate	group	144-149	false

DDI-DrugBank.d531.s50	Plasma concentrations increased by SUSTIVA (efavirenz);
SUSTIVA	brand	35-41	efavirenz	drug	44-52	false

DDI-DrugBank.d531.s52	Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
efavirenz	drug	37-45	contraceptives	group	57-70	advise
efavirenz	drug	37-45	contraceptives	group	184-197	false
contraceptives	group	57-70	contraceptives	group	184-197	false

DDI-DrugBank.d531.s56	Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.
rifabutin	drug	22-30	rifabutin	drug	55-63	false

DDI-DrugBank.d531.s63	Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
SUSTIVA	brand	48-54	ritonavir	drug	84-92	advise

DDI-DrugBank.d531.s67	Should not be used as sole protease inhibitor in combination with SUSTIVA.
protease inhibitor	group	27-44	SUSTIVA	brand	66-72	false

DDI-DrugBank.d531.s72	Anticoagulants: Warfarin
Anticoagulants	group	0-13	Warfarin	drug	16-23	false

DDI-DrugBank.d531.s74	Anticonvulsants: Phenytoin Phenobarbital Carbamazepine
Anticonvulsants	group	0-14	Phenytoin	drug	17-25	false
Anticonvulsants	group	0-14	Phenobarbital	drug	27-39	false
Anticonvulsants	group	0-14	Carbamazepine	drug	41-53	false
Phenytoin	drug	17-25	Phenobarbital	drug	27-39	false
Phenytoin	drug	17-25	Carbamazepine	drug	41-53	false
Phenobarbital	drug	27-39	Carbamazepine	drug	41-53	false

DDI-DrugBank.d531.s75	Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
anticonvulsant	group	27-40	efavirenz	drug	49-57	mechanism

DDI-DrugBank.d531.s77	Antifungals: Itraconazole Ketoconazole
Antifungals	group	0-10	Itraconazole	drug	13-24	false
Antifungals	group	0-10	Ketoconazole	drug	26-37	false
Itraconazole	drug	13-24	Ketoconazole	drug	26-37	false

DDI-DrugBank.d531.s78	Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.
SUSTIVA	brand	30-36	imidazole antifungals	group	48-56;71-81	false
SUSTIVA	brand	30-36	triazole antifungals	group	62-81	false
imidazole antifungals	group	48-56;71-81	triazole antifungals	group	62-81	false

DDI-DrugBank.d531.s79	SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
SUSTIVA	brand	0-6	itraconazole	drug	63-74	mechanism
SUSTIVA	brand	0-6	ketoconazole	drug	80-91	mechanism
itraconazole	drug	63-74	ketoconazole	drug	80-91	false

DDI-DrugBank.d531.s80	Anti-HIV protease inhibitors: Saquinavir/ritonavir combination
Anti-HIV protease inhibitors	group	0-27	Saquinavir	drug	30-39	false
Anti-HIV protease inhibitors	group	0-27	ritonavir	drug	41-49	false
Saquinavir	drug	30-39	ritonavir	drug	41-49	false

DDI-DrugBank.d531.s87	Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.
efavirenz	drug	52-60	SUSTIVA	brand	103-109	false

DDI-DrugBank.d531.s90	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
SUSTIVA	brand	104-110	efavirenz	drug	113-121	false
SUSTIVA	brand	104-110	aluminum/magnesium hydroxide antacids	group	153-189	false
SUSTIVA	brand	104-110	azithromycin	drug	192-203	false
SUSTIVA	brand	104-110	cetirizine	drug	206-215	false
SUSTIVA	brand	104-110	famotidine	drug	218-227	false
SUSTIVA	brand	104-110	fluconazole	drug	230-240	false
SUSTIVA	brand	104-110	lamivudine	drug	243-252	false
SUSTIVA	brand	104-110	lorazepam	drug	255-263	false
SUSTIVA	brand	104-110	nelfinavir	drug	266-275	false
SUSTIVA	brand	104-110	paroxetine	drug	278-287	false
SUSTIVA	brand	104-110	zidovudine	drug	294-303	false
efavirenz	drug	113-121	aluminum/magnesium hydroxide antacids	group	153-189	false
efavirenz	drug	113-121	azithromycin	drug	192-203	false
efavirenz	drug	113-121	cetirizine	drug	206-215	false
efavirenz	drug	113-121	famotidine	drug	218-227	false
efavirenz	drug	113-121	fluconazole	drug	230-240	false
efavirenz	drug	113-121	lamivudine	drug	243-252	false
efavirenz	drug	113-121	lorazepam	drug	255-263	false
efavirenz	drug	113-121	nelfinavir	drug	266-275	false
efavirenz	drug	113-121	paroxetine	drug	278-287	false
efavirenz	drug	113-121	zidovudine	drug	294-303	false
aluminum/magnesium hydroxide antacids	group	153-189	azithromycin	drug	192-203	false
aluminum/magnesium hydroxide antacids	group	153-189	cetirizine	drug	206-215	false
aluminum/magnesium hydroxide antacids	group	153-189	famotidine	drug	218-227	false
aluminum/magnesium hydroxide antacids	group	153-189	fluconazole	drug	230-240	false
aluminum/magnesium hydroxide antacids	group	153-189	lamivudine	drug	243-252	false
aluminum/magnesium hydroxide antacids	group	153-189	lorazepam	drug	255-263	false
aluminum/magnesium hydroxide antacids	group	153-189	nelfinavir	drug	266-275	false
aluminum/magnesium hydroxide antacids	group	153-189	paroxetine	drug	278-287	false
aluminum/magnesium hydroxide antacids	group	153-189	zidovudine	drug	294-303	false
azithromycin	drug	192-203	cetirizine	drug	206-215	false
azithromycin	drug	192-203	famotidine	drug	218-227	false
azithromycin	drug	192-203	fluconazole	drug	230-240	false
azithromycin	drug	192-203	lamivudine	drug	243-252	false
azithromycin	drug	192-203	lorazepam	drug	255-263	false
azithromycin	drug	192-203	nelfinavir	drug	266-275	false
azithromycin	drug	192-203	paroxetine	drug	278-287	false
azithromycin	drug	192-203	zidovudine	drug	294-303	false
cetirizine	drug	206-215	famotidine	drug	218-227	false
cetirizine	drug	206-215	fluconazole	drug	230-240	false
cetirizine	drug	206-215	lamivudine	drug	243-252	false
cetirizine	drug	206-215	lorazepam	drug	255-263	false
cetirizine	drug	206-215	nelfinavir	drug	266-275	false
cetirizine	drug	206-215	paroxetine	drug	278-287	false
cetirizine	drug	206-215	zidovudine	drug	294-303	false
famotidine	drug	218-227	fluconazole	drug	230-240	false
famotidine	drug	218-227	lamivudine	drug	243-252	false
famotidine	drug	218-227	lorazepam	drug	255-263	false
famotidine	drug	218-227	nelfinavir	drug	266-275	false
famotidine	drug	218-227	paroxetine	drug	278-287	false
famotidine	drug	218-227	zidovudine	drug	294-303	false
fluconazole	drug	230-240	lamivudine	drug	243-252	false
fluconazole	drug	230-240	lorazepam	drug	255-263	false
fluconazole	drug	230-240	nelfinavir	drug	266-275	false
fluconazole	drug	230-240	paroxetine	drug	278-287	false
fluconazole	drug	230-240	zidovudine	drug	294-303	false
lamivudine	drug	243-252	lorazepam	drug	255-263	false
lamivudine	drug	243-252	nelfinavir	drug	266-275	false
lamivudine	drug	243-252	paroxetine	drug	278-287	false
lamivudine	drug	243-252	zidovudine	drug	294-303	false
lorazepam	drug	255-263	nelfinavir	drug	266-275	false
lorazepam	drug	255-263	paroxetine	drug	278-287	false
lorazepam	drug	255-263	zidovudine	drug	294-303	false
nelfinavir	drug	266-275	paroxetine	drug	278-287	false
nelfinavir	drug	266-275	zidovudine	drug	294-303	false
paroxetine	drug	278-287	zidovudine	drug	294-303	false

DDI-DrugBank.d531.s91	Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.
SUSTIVA	brand	63-69	NRTIs	group	75-79	false
SUSTIVA	brand	63-69	lamivudine	drug	92-101	false
SUSTIVA	brand	63-69	zidovudine	drug	107-116	false
NRTIs	group	75-79	lamivudine	drug	92-101	false
NRTIs	group	75-79	zidovudine	drug	107-116	false
lamivudine	drug	92-101	zidovudine	drug	107-116	false

DDI-DrugBank.d531.s92	Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
NRTIs	group	68-72	efavirenz	drug	117-125	false

DDI-DrugBank.d375.s0	The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
EMTRIVA	brand	41-47	indinavir	drug	86-94	false
EMTRIVA	brand	41-47	stavudine	drug	97-105	false
EMTRIVA	brand	41-47	famciclovir	drug	108-118	false
EMTRIVA	brand	41-47	tenofovir disoproxil fumarate	drug	125-153	false
indinavir	drug	86-94	stavudine	drug	97-105	false
indinavir	drug	86-94	famciclovir	drug	108-118	false
indinavir	drug	86-94	tenofovir disoproxil fumarate	drug	125-153	false
stavudine	drug	97-105	famciclovir	drug	108-118	false
stavudine	drug	97-105	tenofovir disoproxil fumarate	drug	125-153	false
famciclovir	drug	108-118	tenofovir disoproxil fumarate	drug	125-153	false

DDI-DrugBank.d107.s0	Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
diuretics	drug	55-63	enalapril	drug	238-246	effect
diuretics	drug	55-63	enalaprilat	drug	251-261	effect
enalapril	drug	238-246	enalaprilat	drug	251-261	false

DDI-DrugBank.d107.s1	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
enalapril	drug	44-52	enalaprilat	drug	57-67	false
enalapril	drug	44-52	diuretic	drug	114-121	effect
enalapril	drug	44-52	enalapril	drug	191-199	false
enalapril	drug	44-52	enalaprilat	drug	204-214	false
enalaprilat	drug	57-67	diuretic	drug	114-121	effect
enalaprilat	drug	57-67	enalapril	drug	191-199	false
enalaprilat	drug	57-67	enalaprilat	drug	204-214	false
diuretic	drug	114-121	enalapril	drug	191-199	false
diuretic	drug	114-121	enalaprilat	drug	204-214	false
enalapril	drug	191-199	enalaprilat	drug	204-214	false

DDI-DrugBank.d107.s3	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
enalapril	drug	61-69	enalapril	drug	75-83	false
enalapril	drug	61-69	antihypertensive agents	group	104-126	effect
enalapril	drug	61-69	diuretics	group	160-168	effect
enalapril	drug	75-83	antihypertensive agents	group	104-126	effect
enalapril	drug	75-83	diuretics	group	160-168	effect
antihypertensive agents	group	104-126	diuretics	group	160-168	false

DDI-DrugBank.d107.s4	Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
Non-steroidal Anti-inflammatory Agents	group	0-37	nonsteroidal anti-inflammatory drugs	group	116-151	false
Non-steroidal Anti-inflammatory Agents	group	0-37	enalapril	drug	179-187	false
nonsteroidal anti-inflammatory drugs	group	116-151	enalapril	drug	179-187	effect

DDI-DrugBank.d107.s6	In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.
indomethacin	drug	34-45	sulindac	drug	50-57	false
indomethacin	drug	34-45	VASOTEC	brand	111-117	false
sulindac	drug	50-57	VASOTEC	brand	111-117	false

DDI-DrugBank.d107.s8	However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
NSAIDs	group	30-35	ACE inhibitors	group	81-94	effect

DDI-DrugBank.d107.s9	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	group	66-71	ACE inhibitors	group	92-105	advise

DDI-DrugBank.d107.s10	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
Enalapril	drug	29-37	enalapril	drug	43-51	false
Enalapril	drug	29-37	beta adrenergic-blocking agents	group	90-120	false
Enalapril	drug	29-37	methyldopa	drug	123-132	false
Enalapril	drug	29-37	nitrates	group	135-142	false
Enalapril	drug	29-37	calcium-blocking agents	group	145-167	false
Enalapril	drug	29-37	hydralazine	drug	170-180	false
Enalapril	drug	29-37	prazosin	drug	183-190	false
Enalapril	drug	29-37	digoxin	drug	196-202	false
enalapril	drug	43-51	beta adrenergic-blocking agents	group	90-120	false
enalapril	drug	43-51	methyldopa	drug	123-132	false
enalapril	drug	43-51	nitrates	group	135-142	false
enalapril	drug	43-51	calcium-blocking agents	group	145-167	false
enalapril	drug	43-51	hydralazine	drug	170-180	false
enalapril	drug	43-51	prazosin	drug	183-190	false
enalapril	drug	43-51	digoxin	drug	196-202	false
beta adrenergic-blocking agents	group	90-120	methyldopa	drug	123-132	false
beta adrenergic-blocking agents	group	90-120	nitrates	group	135-142	false
beta adrenergic-blocking agents	group	90-120	calcium-blocking agents	group	145-167	false
beta adrenergic-blocking agents	group	90-120	hydralazine	drug	170-180	false
beta adrenergic-blocking agents	group	90-120	prazosin	drug	183-190	false
beta adrenergic-blocking agents	group	90-120	digoxin	drug	196-202	false
methyldopa	drug	123-132	nitrates	group	135-142	false
methyldopa	drug	123-132	calcium-blocking agents	group	145-167	false
methyldopa	drug	123-132	hydralazine	drug	170-180	false
methyldopa	drug	123-132	prazosin	drug	183-190	false
methyldopa	drug	123-132	digoxin	drug	196-202	false
nitrates	group	135-142	calcium-blocking agents	group	145-167	false
nitrates	group	135-142	hydralazine	drug	170-180	false
nitrates	group	135-142	prazosin	drug	183-190	false
nitrates	group	135-142	digoxin	drug	196-202	false
calcium-blocking agents	group	145-167	hydralazine	drug	170-180	false
calcium-blocking agents	group	145-167	prazosin	drug	183-190	false
calcium-blocking agents	group	145-167	digoxin	drug	196-202	false
hydralazine	drug	170-180	prazosin	drug	183-190	false
hydralazine	drug	170-180	digoxin	drug	196-202	false
prazosin	drug	183-190	digoxin	drug	196-202	false

DDI-DrugBank.d107.s11	Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.
Enalapril	drug	0-8	digitalis	group	46-54	false

DDI-DrugBank.d107.s12	Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
Enalapril	drug	35-43	enalapril	drug	49-57	false
Enalapril	drug	35-43	thiazide-type diuretics	group	97-119	effect
enalapril	drug	49-57	thiazide-type diuretics	group	97-119	effect

DDI-DrugBank.d107.s13	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Potassium-sparing diuretics	group	0-26	spironolactone	drug	35-48	false
Potassium-sparing diuretics	group	0-26	triamterene	drug	51-61	false
Potassium-sparing diuretics	group	0-26	amiloride	drug	67-75	false
Potassium-sparing diuretics	group	0-26	potassium	drug	79-87	false
Potassium-sparing diuretics	group	0-26	potassium	drug	105-113	false
spironolactone	drug	35-48	triamterene	drug	51-61	false
spironolactone	drug	35-48	amiloride	drug	67-75	false
spironolactone	drug	35-48	potassium	drug	79-87	false
spironolactone	drug	35-48	potassium	drug	105-113	false
triamterene	drug	51-61	amiloride	drug	67-75	false
triamterene	drug	51-61	potassium	drug	79-87	false
triamterene	drug	51-61	potassium	drug	105-113	false
amiloride	drug	67-75	potassium	drug	79-87	false
amiloride	drug	67-75	potassium	drug	105-113	false
potassium	drug	79-87	potassium	drug	105-113	false

DDI-DrugBank.d107.s16	Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
Lithium	drug	0-6	Lithium	drug	9-15	false
Lithium	drug	0-6	lithium	drug	66-72	false
Lithium	drug	0-6	ACE inhibitors	group	144-157	false
Lithium	drug	9-15	lithium	drug	66-72	false
Lithium	drug	9-15	ACE inhibitors	group	144-157	false
lithium	drug	66-72	ACE inhibitors	group	144-157	effect

DDI-DrugBank.d107.s17	It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
lithium	drug	29-35	enalapril	drug	71-79	false
lithium	drug	29-35	lithium	drug	116-122	false
enalapril	drug	71-79	lithium	drug	116-122	advise

DDI-DrugBank.d6.s2	If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.
Enflurane	drug	145-153	halothane	drug	165-173	false
Enflurane	drug	145-153	nitrous oxide	drug	178-190	false
halothane	drug	165-173	nitrous oxide	drug	178-190	false

DDI-DrugBank.d535.s1	Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.
Antiretroviral Agents	group	0-20	antiretroviral medications	group	55-80	false
Antiretroviral Agents	group	0-20	enfuvirtide	drug	147-157	false
Antiretroviral Agents	group	0-20	antiretroviral medication	group	189-213	false
antiretroviral medications	group	55-80	enfuvirtide	drug	147-157	false
antiretroviral medications	group	55-80	antiretroviral medication	group	189-213	false
enfuvirtide	drug	147-157	antiretroviral medication	group	189-213	false

DDI-DrugBank.d395.s0	Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
Bismuth	drug	0-6	Bismuth subsalicylate	drug	9-29	false
Bismuth	drug	0-6	enoxacin	drug	57-64	false
Bismuth	drug	0-6	enoxacin	drug	90-97	false
Bismuth	drug	0-6	enoxacin	drug	125-132	false
Bismuth subsalicylate	drug	9-29	enoxacin	drug	57-64	mechanism
Bismuth subsalicylate	drug	9-29	enoxacin	drug	90-97	false
Bismuth subsalicylate	drug	9-29	enoxacin	drug	125-132	false
enoxacin	drug	57-64	enoxacin	drug	90-97	false
enoxacin	drug	57-64	enoxacin	drug	125-132	false
enoxacin	drug	90-97	enoxacin	drug	125-132	false

DDI-DrugBank.d395.s1	Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
enoxacin	drug	36-43	bismuth subsalicylate	drug	49-69	advise

DDI-DrugBank.d395.s2	Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
Caffeine	drug	0-7	Enoxacin	drug	10-17	false
Caffeine	drug	0-7	methylxanthines	group	108-122	false
Enoxacin	drug	10-17	methylxanthines	group	108-122	mechanism

DDI-DrugBank.d395.s3	In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
enoxacin	drug	26-33	caffeine	drug	103-110	mechanism
enoxacin	drug	26-33	caffeine	drug	149-156	false
enoxacin	drug	26-33	caffeine	drug	239-246	false
caffeine	drug	103-110	caffeine	drug	149-156	false
caffeine	drug	103-110	caffeine	drug	239-246	false
caffeine	drug	149-156	caffeine	drug	239-246	false

DDI-DrugBank.d395.s4	Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
enoxacin	drug	14-21	caffeine	drug	56-63	false
enoxacin	drug	14-21	enoxacin	drug	69-76	false
caffeine	drug	56-63	enoxacin	drug	69-76	mechanism

DDI-DrugBank.d395.s5	Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
Caffeine	drug	0-7	caffeine	drug	69-76	false
Caffeine	drug	0-7	enoxacin	drug	100-107	false
caffeine	drug	69-76	enoxacin	drug	100-107	effect

DDI-DrugBank.d395.s6	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
Cyclosporine	drug	0-11	cyclosporine	drug	39-50	false
Cyclosporine	drug	0-11	cyclosporine	drug	95-106	false
Cyclosporine	drug	0-11	quinolone class	group	134-148	false
cyclosporine	drug	39-50	cyclosporine	drug	95-106	false
cyclosporine	drug	39-50	quinolone class	group	134-148	false
cyclosporine	drug	95-106	quinolone class	group	134-148	mechanism

DDI-DrugBank.d395.s7	Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
Digoxin	drug	0-6	Enoxacin	drug	9-16	false
Digoxin	drug	0-6	digoxin	drug	34-40	false
Enoxacin	drug	9-16	digoxin	drug	34-40	mechanism

DDI-DrugBank.d395.s8	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
digoxin	drug	36-42	enoxacin	drug	64-71	false
digoxin	drug	36-42	digoxin	drug	77-83	false
digoxin	drug	36-42	digoxin	drug	149-155	false
digoxin	drug	36-42	digoxin	drug	175-181	false
enoxacin	drug	64-71	digoxin	drug	77-83	effect
enoxacin	drug	64-71	digoxin	drug	149-155	false
enoxacin	drug	64-71	digoxin	drug	175-181	false
digoxin	drug	77-83	digoxin	drug	149-155	false
digoxin	drug	77-83	digoxin	drug	175-181	false
digoxin	drug	149-155	digoxin	drug	175-181	false

DDI-DrugBank.d395.s9	Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
Non-steroidal anti-inflammatory agents	group	0-37	enoxacin	drug	87-94	false
Non-steroidal anti-inflammatory agents	group	0-37	nonsteroidal anti-inflammatory drug	group	119-153	false
Non-steroidal anti-inflammatory agents	group	0-37	fenbufen	drug	155-162	false
enoxacin	drug	87-94	nonsteroidal anti-inflammatory drug	group	119-153	false
enoxacin	drug	87-94	fenbufen	drug	155-162	effect
nonsteroidal anti-inflammatory drug	group	119-153	fenbufen	drug	155-162	false

DDI-DrugBank.d395.s12	Sucralfate and antacids: Quinolones form chelates with metal cations.
Sucralfate	drug	0-9	antacids	group	15-22	false
Sucralfate	drug	0-9	Quinolones	group	25-34	false
antacids	group	15-22	Quinolones	group	25-34	false

DDI-DrugBank.d395.s13	Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;
quinolones	group	29-38	antacids	group	45-52	false
quinolones	group	29-38	calcium	drug	65-71	false
quinolones	group	29-38	magnesium	drug	74-82	false
quinolones	group	29-38	aluminum	drug	88-95	false
antacids	group	45-52	calcium	drug	65-71	false
antacids	group	45-52	magnesium	drug	74-82	false
antacids	group	45-52	aluminum	drug	88-95	false
calcium	drug	65-71	magnesium	drug	74-82	false
calcium	drug	65-71	aluminum	drug	88-95	false
magnesium	drug	74-82	aluminum	drug	88-95	false

DDI-DrugBank.d395.s16	or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
multivitamins	group	8-20	zinc	drug	33-36	false
multivitamins	group	8-20	quinolone	group	132-140	false
zinc	drug	33-36	quinolone	group	132-140	mechanism

DDI-DrugBank.d395.s17	Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
Antacids	group	0-7	aluminum hydroxide	drug	20-37	false
Antacids	group	0-7	magnesium hydroxide	drug	43-61	false
Antacids	group	0-7	enoxacin	drug	93-100	false
aluminum hydroxide	drug	20-37	magnesium hydroxide	drug	43-61	false
aluminum hydroxide	drug	20-37	enoxacin	drug	93-100	mechanism
magnesium hydroxide	drug	43-61	enoxacin	drug	93-100	mechanism

DDI-DrugBank.d395.s18	The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
enoxacin	drug	28-35	ranitidine	drug	80-89	mechanism

DDI-DrugBank.d395.s20	Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
Theophylline	drug	0-11	Enoxacin	drug	14-21	false
Theophylline	drug	0-11	methylxanthines	group	112-126	false
Enoxacin	drug	14-21	methylxanthines	group	112-126	mechanism

DDI-DrugBank.d395.s21	Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
Enoxacin	drug	0-7	theophylline	drug	43-54	mechanism
Enoxacin	drug	0-7	theophylline	drug	107-118	false
theophylline	drug	43-54	theophylline	drug	107-118	false

DDI-DrugBank.d395.s22	Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
Theophylline	drug	0-11	theophylline	drug	68-79	false
Theophylline	drug	0-11	enoxacin	drug	85-92	false
theophylline	drug	68-79	enoxacin	drug	85-92	effect

DDI-DrugBank.d395.s23	Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
Warfarin	drug	0-7	Quinolones	group	10-19	false
Warfarin	drug	0-7	enoxacin	drug	32-39	false
Warfarin	drug	0-7	R-warfarin	drug	68-77	false
Warfarin	drug	0-7	warfarin	drug	114-121	false
Quinolones	group	10-19	enoxacin	drug	32-39	false
Quinolones	group	10-19	R-warfarin	drug	68-77	mechanism
Quinolones	group	10-19	warfarin	drug	114-121	false
enoxacin	drug	32-39	R-warfarin	drug	68-77	mechanism
enoxacin	drug	32-39	warfarin	drug	114-121	false
R-warfarin	drug	68-77	warfarin	drug	114-121	false

DDI-DrugBank.d395.s24	Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.
Enoxacin	drug	0-7	enoxacin	drug	120-127	false
Enoxacin	drug	0-7	warfarin	drug	133-140	false
enoxacin	drug	120-127	warfarin	drug	133-140	false

DDI-DrugBank.d395.s25	Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
warfarin	drug	95-102	enoxacin	drug	127-134	advise

DDI-DrugBank.d474.s1	These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
anticoagulants	group	42-55	platelet inhibitors	group	58-76	false
anticoagulants	group	42-55	acetylsalicylic acid	drug	88-107	false
anticoagulants	group	42-55	NSAIDs	group	124-129	false
anticoagulants	group	42-55	ketorolac tromethamine	drug	142-163	false
anticoagulants	group	42-55	dipyridamole	drug	167-178	false
anticoagulants	group	42-55	sulfinpyrazone	drug	184-197	false
platelet inhibitors	group	58-76	acetylsalicylic acid	drug	88-107	false
platelet inhibitors	group	58-76	NSAIDs	group	124-129	false
platelet inhibitors	group	58-76	ketorolac tromethamine	drug	142-163	false
platelet inhibitors	group	58-76	dipyridamole	drug	167-178	false
platelet inhibitors	group	58-76	sulfinpyrazone	drug	184-197	false
acetylsalicylic acid	drug	88-107	NSAIDs	group	124-129	false
acetylsalicylic acid	drug	88-107	ketorolac tromethamine	drug	142-163	false
acetylsalicylic acid	drug	88-107	dipyridamole	drug	167-178	false
acetylsalicylic acid	drug	88-107	sulfinpyrazone	drug	184-197	false
NSAIDs	group	124-129	ketorolac tromethamine	drug	142-163	false
NSAIDs	group	124-129	dipyridamole	drug	167-178	false
NSAIDs	group	124-129	sulfinpyrazone	drug	184-197	false
ketorolac tromethamine	drug	142-163	dipyridamole	drug	167-178	false
ketorolac tromethamine	drug	142-163	sulfinpyrazone	drug	184-197	false
dipyridamole	drug	167-178	sulfinpyrazone	drug	184-197	false

DDI-DrugBank.d455.s4	In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
entacapone	drug	60-69	warfarin	drug	109-116	false
entacapone	drug	60-69	salicylic acid	drug	119-132	false
entacapone	drug	60-69	phenylbutazone	drug	135-148	false
entacapone	drug	60-69	diazepam	drug	155-162	false
warfarin	drug	109-116	salicylic acid	drug	119-132	false
warfarin	drug	109-116	phenylbutazone	drug	135-148	false
warfarin	drug	109-116	diazepam	drug	155-162	false
salicylic acid	drug	119-132	phenylbutazone	drug	135-148	false
salicylic acid	drug	119-132	diazepam	drug	155-162	false
phenylbutazone	drug	135-148	diazepam	drug	155-162	false

DDI-DrugBank.d455.s6	Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.
entacapone	drug	15-24	levodopa	drug	46-53	false
entacapone	drug	15-24	dopa decarboxylase inhibitor	group	55-82	false
levodopa	drug	46-53	dopa decarboxylase inhibitor	group	55-82	false

DDI-DrugBank.d455.s7	No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).
MAO-B inhibitor	group	34-48	selegiline	drug	50-59	false
MAO-B inhibitor	group	34-48	entacapone	drug	107-116	false
MAO-B inhibitor	group	34-48	levodopa	drug	144-151	false
MAO-B inhibitor	group	34-48	dopa decarboxylase inhibitor	group	153-180	false
selegiline	drug	50-59	entacapone	drug	107-116	false
selegiline	drug	50-59	levodopa	drug	144-151	false
selegiline	drug	50-59	dopa decarboxylase inhibitor	group	153-180	false
entacapone	drug	107-116	levodopa	drug	144-151	false
entacapone	drug	107-116	dopa decarboxylase inhibitor	group	153-180	false
levodopa	drug	144-151	dopa decarboxylase inhibitor	group	153-180	false

DDI-DrugBank.d455.s8	More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.
selegiline	drug	71-80	entacapone	drug	102-111	false
selegiline	drug	71-80	levodopa	drug	117-124	false
selegiline	drug	71-80	dopa decarboxylase inhibitor	group	126-153	false
entacapone	drug	102-111	levodopa	drug	117-124	false
entacapone	drug	102-111	dopa decarboxylase inhibitor	group	126-153	false
levodopa	drug	117-124	dopa decarboxylase inhibitor	group	126-153	false

DDI-DrugBank.d455.s9	As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.
entacapone	drug	8-17	entacapone	drug	207-216	false

DDI-DrugBank.d455.s10	These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
probenecid	drug	14-23	cholestyramine	drug	26-39	false
probenecid	drug	14-23	antibiotics	group	51-61	false
probenecid	drug	14-23	erythromycin	drug	69-80	false
probenecid	drug	14-23	ampicillin	drug	96-105	false
probenecid	drug	14-23	chloramphenicol	drug	111-125	false
cholestyramine	drug	26-39	antibiotics	group	51-61	false
cholestyramine	drug	26-39	erythromycin	drug	69-80	false
cholestyramine	drug	26-39	ampicillin	drug	96-105	false
cholestyramine	drug	26-39	chloramphenicol	drug	111-125	false
antibiotics	group	51-61	erythromycin	drug	69-80	false
antibiotics	group	51-61	ampicillin	drug	96-105	false
antibiotics	group	51-61	chloramphenicol	drug	111-125	false
erythromycin	drug	69-80	ampicillin	drug	96-105	false
erythromycin	drug	69-80	chloramphenicol	drug	111-125	false
ampicillin	drug	96-105	chloramphenicol	drug	111-125	false

DDI-DrugBank.d455.s11	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
tricyclic antidepressant	group	24-47	imipramine	drug	49-58	false
tricyclic antidepressant	group	24-47	entacapone	drug	98-107	false
tricyclic antidepressant	group	24-47	levodopa	drug	132-139	false
tricyclic antidepressant	group	24-47	dopa-decarboxylase inhibitor	group	141-168	false
imipramine	drug	49-58	entacapone	drug	98-107	false
imipramine	drug	49-58	levodopa	drug	132-139	false
imipramine	drug	49-58	dopa-decarboxylase inhibitor	group	141-168	false
entacapone	drug	98-107	levodopa	drug	132-139	false
entacapone	drug	98-107	dopa-decarboxylase inhibitor	group	141-168	false
levodopa	drug	132-139	dopa-decarboxylase inhibitor	group	141-168	false

DDI-DrugBank.d295.s0	Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
entecavir	drug	6-14	BARACLUDE	brand	76-84	false
entecavir	drug	6-14	entecavir	drug	208-216	false
BARACLUDE	brand	76-84	entecavir	drug	208-216	false

DDI-DrugBank.d295.s1	Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
entecavir	drug	20-28	lamivudine	drug	35-44	false
entecavir	drug	20-28	adefovir dipivoxil	drug	47-64	false
entecavir	drug	20-28	tenofovir disoproxil fumarate	drug	69-97	false
lamivudine	drug	35-44	adefovir dipivoxil	drug	47-64	false
lamivudine	drug	35-44	tenofovir disoproxil fumarate	drug	69-97	false
adefovir dipivoxil	drug	47-64	tenofovir disoproxil fumarate	drug	69-97	false

DDI-DrugBank.d295.s2	The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.
BARACLUDE	brand	35-43	BARACLUDE	brand	218-226	false

DDI-DrugBank.d247.s1	All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
vasopressors	group	4-15	monoamine oxidase (MAO) inhibitors	group	62-95	advise

DDI-DrugBank.d247.s2	Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
Epinephrine	drug	0-10	sympathomimetic drugs	group	64-84	advise
Epinephrine	drug	0-10	isoproterenol	drug	95-107	advise
sympathomimetic drugs	group	64-84	isoproterenol	drug	95-107	false

DDI-DrugBank.d247.s5	Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
epinephrine	drug	18-28	cyclopropane	drug	52-63	effect
epinephrine	drug	18-28	halogenated hydrocarbon general anesthetics	group	68-110	effect
epinephrine	drug	18-28	halothane	drug	120-128	effect
cyclopropane	drug	52-63	halogenated hydrocarbon general anesthetics	group	68-110	false
cyclopropane	drug	52-63	halothane	drug	120-128	false
halogenated hydrocarbon general anesthetics	group	68-110	halothane	drug	120-128	false

DDI-DrugBank.d247.s7	Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
Epinephrine	drug	0-10	digitalis	group	67-75	advise
Epinephrine	drug	0-10	glycosides	group	78-87	advise
Epinephrine	drug	0-10	sympathomimetic drugs	group	138-158	false
digitalis	group	67-75	glycosides	group	78-87	false
digitalis	group	67-75	sympathomimetic drugs	group	138-158	false
glycosides	group	78-87	sympathomimetic drugs	group	138-158	false

DDI-DrugBank.d247.s8	Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
Diuretic agents	group	0-14	epinephrine	drug	72-82	effect

DDI-DrugBank.d247.s9	Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
Epinephrine	drug	0-10	guanethidine	drug	59-70	effect

DDI-DrugBank.d428.s1	Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
ELLENCE	brand	19-25	calcium channel blockers	group	99-122	advise

DDI-DrugBank.d428.s10	Cimetidine increased the AUC of epirubicin by 50%.
Cimetidine	drug	0-9	epirubicin	drug	32-41	mechanism

DDI-DrugBank.d428.s11	Cimetidine treatment should be stopped during treatment with ELLENCE.
Cimetidine	drug	0-9	ELLENCE	brand	61-67	advise

DDI-DrugBank.d20.s1	A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
INSPRA	brand	74-79	ketoconazole	drug	93-104	mechanism
INSPRA	brand	74-79	eplerenone	drug	198-207	false
INSPRA	brand	74-79	eplerenone	drug	243-252	false
ketoconazole	drug	93-104	eplerenone	drug	198-207	false
ketoconazole	drug	93-104	eplerenone	drug	243-252	false
eplerenone	drug	198-207	eplerenone	drug	243-252	false

DDI-DrugBank.d20.s3	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
eplerenone	drug	18-27	erythromycin	drug	65-76	mechanism
eplerenone	drug	18-27	verapamil	drug	90-98	mechanism
eplerenone	drug	18-27	saquinavir	drug	111-120	mechanism
eplerenone	drug	18-27	fluconazole	drug	135-145	mechanism
eplerenone	drug	18-27	eplerenone	drug	191-200	false
erythromycin	drug	65-76	verapamil	drug	90-98	false
erythromycin	drug	65-76	saquinavir	drug	111-120	false
erythromycin	drug	65-76	fluconazole	drug	135-145	false
erythromycin	drug	65-76	eplerenone	drug	191-200	false
verapamil	drug	90-98	saquinavir	drug	111-120	false
verapamil	drug	90-98	fluconazole	drug	135-145	false
verapamil	drug	90-98	eplerenone	drug	191-200	false
saquinavir	drug	111-120	fluconazole	drug	135-145	false
saquinavir	drug	111-120	eplerenone	drug	191-200	false
fluconazole	drug	135-145	eplerenone	drug	191-200	false

DDI-DrugBank.d20.s4	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
ACE Inhibitors	group	0-13	Angiotensin II Receptor Antagonists	group	19-53	false
ACE Inhibitors	group	0-13	INSPRA	brand	152-157	false
ACE Inhibitors	group	0-13	ACE inhibitors	group	185-198	false
ACE Inhibitors	group	0-13	angiotensin II receptor antagonists	group	203-237	false
ACE Inhibitors	group	0-13	ACEI	group	240-243	false
ACE Inhibitors	group	0-13	ARB	group	245-247	false
Angiotensin II Receptor Antagonists	group	19-53	INSPRA	brand	152-157	false
Angiotensin II Receptor Antagonists	group	19-53	ACE inhibitors	group	185-198	false
Angiotensin II Receptor Antagonists	group	19-53	angiotensin II receptor antagonists	group	203-237	false
Angiotensin II Receptor Antagonists	group	19-53	ACEI	group	240-243	false
Angiotensin II Receptor Antagonists	group	19-53	ARB	group	245-247	false
INSPRA	brand	152-157	ACE inhibitors	group	185-198	false
INSPRA	brand	152-157	angiotensin II receptor antagonists	group	203-237	false
INSPRA	brand	152-157	ACEI	group	240-243	false
INSPRA	brand	152-157	ARB	group	245-247	false
ACE inhibitors	group	185-198	angiotensin II receptor antagonists	group	203-237	false
ACE inhibitors	group	185-198	ACEI	group	240-243	false
ACE inhibitors	group	185-198	ARB	group	245-247	false
angiotensin II receptor antagonists	group	203-237	ACEI	group	240-243	false
angiotensin II receptor antagonists	group	203-237	ARB	group	245-247	false
ACEI	group	240-243	ARB	group	245-247	false

DDI-DrugBank.d20.s5	Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.
ACEI	group	97-100	ARB	group	102-104	false

DDI-DrugBank.d20.s6	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
ACE Inhibitors	group	0-13	Angiotensin II Receptor Antagonists	group	19-53	false
ACE Inhibitors	group	0-13	INSPRA	brand	138-143	false
ACE Inhibitors	group	0-13	ACE inhibitors	group	161-174	false
ACE Inhibitors	group	0-13	angiotensin II receptor antagonists	group	180-214	false
Angiotensin II Receptor Antagonists	group	19-53	INSPRA	brand	138-143	false
Angiotensin II Receptor Antagonists	group	19-53	ACE inhibitors	group	161-174	false
Angiotensin II Receptor Antagonists	group	19-53	angiotensin II receptor antagonists	group	180-214	false
INSPRA	brand	138-143	ACE inhibitors	group	161-174	effect
INSPRA	brand	138-143	angiotensin II receptor antagonists	group	180-214	effect
ACE inhibitors	group	161-174	angiotensin II receptor antagonists	group	180-214	false

DDI-DrugBank.d20.s7	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
INSPRA	brand	46-51	ACE inhibitor	group	78-90	false
INSPRA	brand	46-51	enalapril	drug	92-100	effect
INSPRA	brand	46-51	enalapril	drug	189-197	false
ACE inhibitor	group	78-90	enalapril	drug	92-100	false
ACE inhibitor	group	78-90	enalapril	drug	189-197	false
enalapril	drug	92-100	enalapril	drug	189-197	false

DDI-DrugBank.d20.s8	Lithium-A drug interaction study of eplerenone with lithium has not been conducted.
Lithium	drug	0-6	eplerenone	drug	36-45	false
Lithium	drug	0-6	lithium	drug	52-58	false
eplerenone	drug	36-45	lithium	drug	52-58	false

DDI-DrugBank.d20.s9	Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
lithium	drug	6-12	INSPRA	brand	55-60	false
lithium	drug	6-12	lithium	drug	97-103	false
INSPRA	brand	55-60	lithium	drug	97-103	advise

DDI-DrugBank.d20.s10	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	NSAIDs	group	38-43	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	eplerenone	drug	74-83	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	NSAID	group	93-97	false
NSAIDs	group	38-43	eplerenone	drug	74-83	false
NSAIDs	group	38-43	NSAID	group	93-97	false
eplerenone	drug	74-83	NSAID	group	93-97	false

DDI-DrugBank.d20.s11	The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
potassium-sparing antihypertensives	group	28-62	NSAIDs	group	69-74	effect

DDI-DrugBank.d20.s12	Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
INSPRA	brand	16-21	NSAIDs	group	27-32	advise

DDI-DrugBank.d241.s0	Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
FLOLAN	brand	55-60	diuretics	group	83-91	effect
FLOLAN	brand	55-60	antihypertensive agents	group	94-116	effect
FLOLAN	brand	55-60	vasodilators	group	128-139	effect
diuretics	group	83-91	antihypertensive agents	group	94-116	false
diuretics	group	83-91	vasodilators	group	128-139	false
antihypertensive agents	group	94-116	vasodilators	group	128-139	false

DDI-DrugBank.d241.s1	When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
antiplatelet agents	group	11-29	anticoagulants	group	34-47	false
antiplatelet agents	group	11-29	FLOLAN	brand	100-105	effect
anticoagulants	group	34-47	FLOLAN	brand	100-105	effect

DDI-DrugBank.d241.s2	However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.
FLOLAN	brand	41-46	anticoagulants	group	86-99	false

DDI-DrugBank.d241.s3	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
FLOLAN	brand	20-25	digoxin	drug	41-47	false
FLOLAN	brand	20-25	diuretics	group	50-58	false
FLOLAN	brand	20-25	anticoagulants	group	61-74	false
FLOLAN	brand	20-25	vasodilators	group	82-93	false
FLOLAN	brand	20-25	oxygen	drug	113-118	false
FLOLAN	brand	20-25	furosemide	drug	202-211	false
FLOLAN	brand	20-25	digoxin	drug	216-222	false
FLOLAN	brand	20-25	FLOLAN	brand	245-250	false
FLOLAN	brand	20-25	furosemide	drug	302-311	false
FLOLAN	brand	20-25	digoxin	drug	326-332	false
digoxin	drug	41-47	diuretics	group	50-58	false
digoxin	drug	41-47	anticoagulants	group	61-74	false
digoxin	drug	41-47	vasodilators	group	82-93	false
digoxin	drug	41-47	oxygen	drug	113-118	false
digoxin	drug	41-47	furosemide	drug	202-211	false
digoxin	drug	41-47	digoxin	drug	216-222	false
digoxin	drug	41-47	FLOLAN	brand	245-250	false
digoxin	drug	41-47	furosemide	drug	302-311	false
digoxin	drug	41-47	digoxin	drug	326-332	false
diuretics	group	50-58	anticoagulants	group	61-74	false
diuretics	group	50-58	vasodilators	group	82-93	false
diuretics	group	50-58	oxygen	drug	113-118	false
diuretics	group	50-58	furosemide	drug	202-211	false
diuretics	group	50-58	digoxin	drug	216-222	false
diuretics	group	50-58	FLOLAN	brand	245-250	false
diuretics	group	50-58	furosemide	drug	302-311	false
diuretics	group	50-58	digoxin	drug	326-332	false
anticoagulants	group	61-74	vasodilators	group	82-93	false
anticoagulants	group	61-74	oxygen	drug	113-118	false
anticoagulants	group	61-74	furosemide	drug	202-211	false
anticoagulants	group	61-74	digoxin	drug	216-222	false
anticoagulants	group	61-74	FLOLAN	brand	245-250	false
anticoagulants	group	61-74	furosemide	drug	302-311	false
anticoagulants	group	61-74	digoxin	drug	326-332	false
vasodilators	group	82-93	oxygen	drug	113-118	false
vasodilators	group	82-93	furosemide	drug	202-211	false
vasodilators	group	82-93	digoxin	drug	216-222	false
vasodilators	group	82-93	FLOLAN	brand	245-250	false
vasodilators	group	82-93	furosemide	drug	302-311	false
vasodilators	group	82-93	digoxin	drug	326-332	false
oxygen	drug	113-118	furosemide	drug	202-211	false
oxygen	drug	113-118	digoxin	drug	216-222	false
oxygen	drug	113-118	FLOLAN	brand	245-250	false
oxygen	drug	113-118	furosemide	drug	302-311	false
oxygen	drug	113-118	digoxin	drug	326-332	false
furosemide	drug	202-211	digoxin	drug	216-222	false
furosemide	drug	202-211	FLOLAN	brand	245-250	mechanism
furosemide	drug	202-211	furosemide	drug	302-311	false
furosemide	drug	202-211	digoxin	drug	326-332	false
digoxin	drug	216-222	FLOLAN	brand	245-250	mechanism
digoxin	drug	216-222	furosemide	drug	302-311	false
digoxin	drug	216-222	digoxin	drug	326-332	false
FLOLAN	brand	245-250	furosemide	drug	302-311	false
FLOLAN	brand	245-250	digoxin	drug	326-332	false
furosemide	drug	302-311	digoxin	drug	326-332	false

DDI-DrugBank.d241.s5	However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
digoxin	drug	21-27	digoxin	drug	52-58	false
digoxin	drug	21-27	FLOLAN	brand	108-113	mechanism
digoxin	drug	21-27	digoxin	drug	173-179	false
digoxin	drug	52-58	FLOLAN	brand	108-113	false
digoxin	drug	52-58	digoxin	drug	173-179	false
FLOLAN	brand	108-113	digoxin	drug	173-179	false

DDI-DrugBank.d525.s0	Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.
Eprosartan	drug	0-9	digoxin	drug	71-77	false
Eprosartan	drug	0-9	warfarin	drug	107-114	false
Eprosartan	drug	0-9	glyburide	drug	120-128	false
digoxin	drug	71-77	warfarin	drug	107-114	false
digoxin	drug	71-77	glyburide	drug	120-128	false
warfarin	drug	107-114	glyburide	drug	120-128	false

DDI-DrugBank.d525.s2	Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
eprosartan	drug	8-17	ketoconazole	drug	149-160	false
eprosartan	drug	8-17	fluconazole	drug	166-176	false
eprosartan	drug	8-17	eprosartan	drug	266-275	false
ketoconazole	drug	149-160	fluconazole	drug	166-176	false
ketoconazole	drug	149-160	eprosartan	drug	266-275	false
fluconazole	drug	166-176	eprosartan	drug	266-275	false

DDI-DrugBank.d525.s3	Ranitidine also has no effect on eprosartan pharmacokinetics.
Ranitidine	drug	0-9	eprosartan	drug	33-42	false

DDI-DrugBank.d525.s4	Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).
Eprosartan	drug	0-9	thiazide diuretic	group	97-113	false
Eprosartan	drug	0-9	hydrochlorothiazide	drug	116-134	false
thiazide diuretic	group	97-113	hydrochlorothiazide	drug	116-134	false

DDI-DrugBank.d525.s5	Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
Eprosartan	drug	0-9	calcium channel blockers	group	99-122	false
Eprosartan	drug	0-9	nifedipine	drug	143-152	false
calcium channel blockers	group	99-122	nifedipine	drug	143-152	false

DDI-DrugBank.d278.s0	Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.
Enoxaparin	drug	0-9	eptifibatide	drug	113-124	false

DDI-DrugBank.d471.s0	Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
Mineral oil	drug	0-10	fat-soluble vitamins	group	46-65	mechanism
Mineral oil	drug	0-10	vitamin D preparations	group	78-99	mechanism
fat-soluble vitamins	group	46-65	vitamin D preparations	group	78-99	false

DDI-DrugBank.d471.s1	Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
thiazide diuretics	group	18-35	ergocalciferol	drug	105-118	effect

DDI-DrugBank.d59.s0	The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
ERGOMAR	brand	15-21	triacetyloleandomycin	drug	45-65	mechanism
ERGOMAR	brand	15-21	ergotamine	drug	100-109	false
triacetyloleandomycin	drug	45-65	ergotamine	drug	100-109	mechanism

DDI-DrugBank.d59.s1	The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
ERGOMAR	brand	23-29	vasoconstrictor drugs	group	41-61	effect

DDI-DrugBank.d456.s0	Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
ketoconazole	drug	46-57	erlotinib	drug	69-77	mechanism

DDI-DrugBank.d456.s1	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
TARCEVA	brand	52-58	ketoconazole	drug	65-76	advise
TARCEVA	brand	52-58	atazanavir	drug	142-151	advise
TARCEVA	brand	52-58	clarithromycin	drug	154-167	advise
TARCEVA	brand	52-58	indinavir	drug	170-178	advise
TARCEVA	brand	52-58	itraconazole	drug	181-192	advise
TARCEVA	brand	52-58	nefazodone	drug	195-204	advise
TARCEVA	brand	52-58	nelfinavir	drug	207-216	advise
TARCEVA	brand	52-58	ritonavir	drug	219-227	advise
TARCEVA	brand	52-58	saquinavir	drug	230-239	advise
TARCEVA	brand	52-58	telithromycin	drug	242-254	advise
TARCEVA	brand	52-58	troleandomycin	drug	257-270	advise
TARCEVA	brand	52-58	TAO	drug	273-275	advise
TARCEVA	brand	52-58	voriconazole	drug	283-294	advise
ketoconazole	drug	65-76	atazanavir	drug	142-151	false
ketoconazole	drug	65-76	clarithromycin	drug	154-167	false
ketoconazole	drug	65-76	indinavir	drug	170-178	false
ketoconazole	drug	65-76	itraconazole	drug	181-192	false
ketoconazole	drug	65-76	nefazodone	drug	195-204	false
ketoconazole	drug	65-76	nelfinavir	drug	207-216	false
ketoconazole	drug	65-76	ritonavir	drug	219-227	false
ketoconazole	drug	65-76	saquinavir	drug	230-239	false
ketoconazole	drug	65-76	telithromycin	drug	242-254	false
ketoconazole	drug	65-76	troleandomycin	drug	257-270	false
ketoconazole	drug	65-76	TAO	drug	273-275	false
ketoconazole	drug	65-76	voriconazole	drug	283-294	false
atazanavir	drug	142-151	clarithromycin	drug	154-167	false
atazanavir	drug	142-151	indinavir	drug	170-178	false
atazanavir	drug	142-151	itraconazole	drug	181-192	false
atazanavir	drug	142-151	nefazodone	drug	195-204	false
atazanavir	drug	142-151	nelfinavir	drug	207-216	false
atazanavir	drug	142-151	ritonavir	drug	219-227	false
atazanavir	drug	142-151	saquinavir	drug	230-239	false
atazanavir	drug	142-151	telithromycin	drug	242-254	false
atazanavir	drug	142-151	troleandomycin	drug	257-270	false
atazanavir	drug	142-151	TAO	drug	273-275	false
atazanavir	drug	142-151	voriconazole	drug	283-294	false
clarithromycin	drug	154-167	indinavir	drug	170-178	false
clarithromycin	drug	154-167	itraconazole	drug	181-192	false
clarithromycin	drug	154-167	nefazodone	drug	195-204	false
clarithromycin	drug	154-167	nelfinavir	drug	207-216	false
clarithromycin	drug	154-167	ritonavir	drug	219-227	false
clarithromycin	drug	154-167	saquinavir	drug	230-239	false
clarithromycin	drug	154-167	telithromycin	drug	242-254	false
clarithromycin	drug	154-167	troleandomycin	drug	257-270	false
clarithromycin	drug	154-167	TAO	drug	273-275	false
clarithromycin	drug	154-167	voriconazole	drug	283-294	false
indinavir	drug	170-178	itraconazole	drug	181-192	false
indinavir	drug	170-178	nefazodone	drug	195-204	false
indinavir	drug	170-178	nelfinavir	drug	207-216	false
indinavir	drug	170-178	ritonavir	drug	219-227	false
indinavir	drug	170-178	saquinavir	drug	230-239	false
indinavir	drug	170-178	telithromycin	drug	242-254	false
indinavir	drug	170-178	troleandomycin	drug	257-270	false
indinavir	drug	170-178	TAO	drug	273-275	false
indinavir	drug	170-178	voriconazole	drug	283-294	false
itraconazole	drug	181-192	nefazodone	drug	195-204	false
itraconazole	drug	181-192	nelfinavir	drug	207-216	false
itraconazole	drug	181-192	ritonavir	drug	219-227	false
itraconazole	drug	181-192	saquinavir	drug	230-239	false
itraconazole	drug	181-192	telithromycin	drug	242-254	false
itraconazole	drug	181-192	troleandomycin	drug	257-270	false
itraconazole	drug	181-192	TAO	drug	273-275	false
itraconazole	drug	181-192	voriconazole	drug	283-294	false
nefazodone	drug	195-204	nelfinavir	drug	207-216	false
nefazodone	drug	195-204	ritonavir	drug	219-227	false
nefazodone	drug	195-204	saquinavir	drug	230-239	false
nefazodone	drug	195-204	telithromycin	drug	242-254	false
nefazodone	drug	195-204	troleandomycin	drug	257-270	false
nefazodone	drug	195-204	TAO	drug	273-275	false
nefazodone	drug	195-204	voriconazole	drug	283-294	false
nelfinavir	drug	207-216	ritonavir	drug	219-227	false
nelfinavir	drug	207-216	saquinavir	drug	230-239	false
nelfinavir	drug	207-216	telithromycin	drug	242-254	false
nelfinavir	drug	207-216	troleandomycin	drug	257-270	false
nelfinavir	drug	207-216	TAO	drug	273-275	false
nelfinavir	drug	207-216	voriconazole	drug	283-294	false
ritonavir	drug	219-227	saquinavir	drug	230-239	false
ritonavir	drug	219-227	telithromycin	drug	242-254	false
ritonavir	drug	219-227	troleandomycin	drug	257-270	false
ritonavir	drug	219-227	TAO	drug	273-275	false
ritonavir	drug	219-227	voriconazole	drug	283-294	false
saquinavir	drug	230-239	telithromycin	drug	242-254	false
saquinavir	drug	230-239	troleandomycin	drug	257-270	false
saquinavir	drug	230-239	TAO	drug	273-275	false
saquinavir	drug	230-239	voriconazole	drug	283-294	false
telithromycin	drug	242-254	troleandomycin	drug	257-270	false
telithromycin	drug	242-254	TAO	drug	273-275	false
telithromycin	drug	242-254	voriconazole	drug	283-294	false
troleandomycin	drug	257-270	TAO	drug	273-275	false
troleandomycin	drug	257-270	voriconazole	drug	283-294	false
TAO	drug	273-275	voriconazole	drug	283-294	false

DDI-DrugBank.d456.s2	Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
rifampicin	drug	38-47	erlotinib	drug	59-67	mechanism

DDI-DrugBank.d456.s5	If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
TARCEVA	brand	7-13	rifampicin	drug	97-106	advise

DDI-DrugBank.d456.s6	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.
rifabutin	drug	55-63	rifapentine	drug	66-76	false
rifabutin	drug	55-63	phenytoin	drug	79-87	false
rifabutin	drug	55-63	carbamazepine	drug	90-102	false
rifabutin	drug	55-63	phenobarbital	drug	105-117	false
rifapentine	drug	66-76	phenytoin	drug	79-87	false
rifapentine	drug	66-76	carbamazepine	drug	90-102	false
rifapentine	drug	66-76	phenobarbital	drug	105-117	false
phenytoin	drug	79-87	carbamazepine	drug	90-102	false
phenytoin	drug	79-87	phenobarbital	drug	105-117	false
carbamazepine	drug	90-102	phenobarbital	drug	105-117	false

DDI-DrugBank.d456.s13	Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR
warfarin	drug	16-23	coumarin-derivative anticoagulants	group	34-67	false

DDI-DrugBank.d329.s0	When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
ertapenem	drug	5-13	probenecid	drug	39-48	false
ertapenem	drug	5-13	probenecid	drug	79-88	false
ertapenem	drug	5-13	ertapenem	drug	163-171	false
probenecid	drug	39-48	probenecid	drug	79-88	false
probenecid	drug	39-48	ertapenem	drug	163-171	false
probenecid	drug	79-88	ertapenem	drug	163-171	mechanism

DDI-DrugBank.d329.s1	Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
ertapenem	drug	15-23	probenecid	drug	41-50	mechanism

DDI-DrugBank.d329.s3	Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
probenecid	drug	68-77	ertapenem	drug	106-114	advise

DDI-DrugBank.d329.s4	In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
ertapenem	drug	31-39	digoxin	drug	95-101	false
ertapenem	drug	31-39	vinblastine	drug	106-116	false
ertapenem	drug	31-39	ertapenem	drug	127-135	false
digoxin	drug	95-101	vinblastine	drug	106-116	false
digoxin	drug	95-101	ertapenem	drug	127-135	false
vinblastine	drug	106-116	ertapenem	drug	127-135	false

DDI-DrugBank.d397.s0	Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
Erythromycin	drug	0-11	theophylline	drug	61-72	effect
Erythromycin	drug	0-11	theophylline	drug	118-129	false
Erythromycin	drug	0-11	theophylline	drug	152-163	false
theophylline	drug	61-72	theophylline	drug	118-129	false
theophylline	drug	61-72	theophylline	drug	152-163	false
theophylline	drug	118-129	theophylline	drug	152-163	false

DDI-DrugBank.d397.s1	In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
theophylline	drug	11-22	theophylline	drug	55-66	false
theophylline	drug	11-22	theophylline	drug	88-99	false
theophylline	drug	11-22	erythromycin	drug	162-173	false
theophylline	drug	55-66	theophylline	drug	88-99	false
theophylline	drug	55-66	erythromycin	drug	162-173	false
theophylline	drug	88-99	erythromycin	drug	162-173	advise

DDI-DrugBank.d397.s2	Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
erythromycin	drug	30-41	digoxin	drug	47-53	mechanism
erythromycin	drug	30-41	digoxin	drug	95-101	false
digoxin	drug	47-53	digoxin	drug	95-101	false

DDI-DrugBank.d397.s3	There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
erythromycin	drug	64-75	anticoagulants	group	86-99	effect

DDI-DrugBank.d397.s5	Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
erythromycin	drug	18-29	ergotamine	drug	35-44	effect
erythromycin	drug	18-29	dihydroergotamine	drug	49-65	effect
ergotamine	drug	35-44	dihydroergotamine	drug	49-65	false

DDI-DrugBank.d397.s6	Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
Erythromycin	drug	0-11	triazolam	drug	60-68	mechanism
Erythromycin	drug	0-11	midazolam	drug	74-82	mechanism
Erythromycin	drug	0-11	benzodiazepines	group	140-154	effect
triazolam	drug	60-68	midazolam	drug	74-82	false
triazolam	drug	60-68	benzodiazepines	group	140-154	false
midazolam	drug	74-82	benzodiazepines	group	140-154	false

DDI-DrugBank.d397.s8	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
erythromycin	drug	43-54	carbamazepine	drug	61-73	int
erythromycin	drug	43-54	cyclosporine	drug	76-87	int
erythromycin	drug	43-54	tacrolimus	drug	90-99	int
erythromycin	drug	43-54	hexobarbital	drug	102-113	int
erythromycin	drug	43-54	phenytoin	drug	116-124	int
erythromycin	drug	43-54	alfentanil	drug	127-136	int
erythromycin	drug	43-54	cisapride	drug	139-147	int
erythromycin	drug	43-54	disopyramide	drug	150-161	int
erythromycin	drug	43-54	lovastatin	drug	164-173	int
erythromycin	drug	43-54	bromocriptine	drug	176-188	int
erythromycin	drug	43-54	valproate	drug	191-199	int
erythromycin	drug	43-54	terfenadine	drug	202-212	int
erythromycin	drug	43-54	astemizole	drug	219-228	int
carbamazepine	drug	61-73	cyclosporine	drug	76-87	false
carbamazepine	drug	61-73	tacrolimus	drug	90-99	false
carbamazepine	drug	61-73	hexobarbital	drug	102-113	false
carbamazepine	drug	61-73	phenytoin	drug	116-124	false
carbamazepine	drug	61-73	alfentanil	drug	127-136	false
carbamazepine	drug	61-73	cisapride	drug	139-147	false
carbamazepine	drug	61-73	disopyramide	drug	150-161	false
carbamazepine	drug	61-73	lovastatin	drug	164-173	false
carbamazepine	drug	61-73	bromocriptine	drug	176-188	false
carbamazepine	drug	61-73	valproate	drug	191-199	false
carbamazepine	drug	61-73	terfenadine	drug	202-212	false
carbamazepine	drug	61-73	astemizole	drug	219-228	false
cyclosporine	drug	76-87	tacrolimus	drug	90-99	false
cyclosporine	drug	76-87	hexobarbital	drug	102-113	false
cyclosporine	drug	76-87	phenytoin	drug	116-124	false
cyclosporine	drug	76-87	alfentanil	drug	127-136	false
cyclosporine	drug	76-87	cisapride	drug	139-147	false
cyclosporine	drug	76-87	disopyramide	drug	150-161	false
cyclosporine	drug	76-87	lovastatin	drug	164-173	false
cyclosporine	drug	76-87	bromocriptine	drug	176-188	false
cyclosporine	drug	76-87	valproate	drug	191-199	false
cyclosporine	drug	76-87	terfenadine	drug	202-212	false
cyclosporine	drug	76-87	astemizole	drug	219-228	false
tacrolimus	drug	90-99	hexobarbital	drug	102-113	false
tacrolimus	drug	90-99	phenytoin	drug	116-124	false
tacrolimus	drug	90-99	alfentanil	drug	127-136	false
tacrolimus	drug	90-99	cisapride	drug	139-147	false
tacrolimus	drug	90-99	disopyramide	drug	150-161	false
tacrolimus	drug	90-99	lovastatin	drug	164-173	false
tacrolimus	drug	90-99	bromocriptine	drug	176-188	false
tacrolimus	drug	90-99	valproate	drug	191-199	false
tacrolimus	drug	90-99	terfenadine	drug	202-212	false
tacrolimus	drug	90-99	astemizole	drug	219-228	false
hexobarbital	drug	102-113	phenytoin	drug	116-124	false
hexobarbital	drug	102-113	alfentanil	drug	127-136	false
hexobarbital	drug	102-113	cisapride	drug	139-147	false
hexobarbital	drug	102-113	disopyramide	drug	150-161	false
hexobarbital	drug	102-113	lovastatin	drug	164-173	false
hexobarbital	drug	102-113	bromocriptine	drug	176-188	false
hexobarbital	drug	102-113	valproate	drug	191-199	false
hexobarbital	drug	102-113	terfenadine	drug	202-212	false
hexobarbital	drug	102-113	astemizole	drug	219-228	false
phenytoin	drug	116-124	alfentanil	drug	127-136	false
phenytoin	drug	116-124	cisapride	drug	139-147	false
phenytoin	drug	116-124	disopyramide	drug	150-161	false
phenytoin	drug	116-124	lovastatin	drug	164-173	false
phenytoin	drug	116-124	bromocriptine	drug	176-188	false
phenytoin	drug	116-124	valproate	drug	191-199	false
phenytoin	drug	116-124	terfenadine	drug	202-212	false
phenytoin	drug	116-124	astemizole	drug	219-228	false
alfentanil	drug	127-136	cisapride	drug	139-147	false
alfentanil	drug	127-136	disopyramide	drug	150-161	false
alfentanil	drug	127-136	lovastatin	drug	164-173	false
alfentanil	drug	127-136	bromocriptine	drug	176-188	false
alfentanil	drug	127-136	valproate	drug	191-199	false
alfentanil	drug	127-136	terfenadine	drug	202-212	false
alfentanil	drug	127-136	astemizole	drug	219-228	false
cisapride	drug	139-147	disopyramide	drug	150-161	false
cisapride	drug	139-147	lovastatin	drug	164-173	false
cisapride	drug	139-147	bromocriptine	drug	176-188	false
cisapride	drug	139-147	valproate	drug	191-199	false
cisapride	drug	139-147	terfenadine	drug	202-212	false
cisapride	drug	139-147	astemizole	drug	219-228	false
disopyramide	drug	150-161	lovastatin	drug	164-173	false
disopyramide	drug	150-161	bromocriptine	drug	176-188	false
disopyramide	drug	150-161	valproate	drug	191-199	false
disopyramide	drug	150-161	terfenadine	drug	202-212	false
disopyramide	drug	150-161	astemizole	drug	219-228	false
lovastatin	drug	164-173	bromocriptine	drug	176-188	false
lovastatin	drug	164-173	valproate	drug	191-199	false
lovastatin	drug	164-173	terfenadine	drug	202-212	false
lovastatin	drug	164-173	astemizole	drug	219-228	false
bromocriptine	drug	176-188	valproate	drug	191-199	false
bromocriptine	drug	176-188	terfenadine	drug	202-212	false
bromocriptine	drug	176-188	astemizole	drug	219-228	false
valproate	drug	191-199	terfenadine	drug	202-212	false
valproate	drug	191-199	astemizole	drug	219-228	false
terfenadine	drug	202-212	astemizole	drug	219-228	false

DDI-DrugBank.d397.s10	Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
Erythromycin	drug	0-11	antihistamines	group	84-97	false
Erythromycin	drug	0-11	terfenadine	drug	99-109	mechanism
Erythromycin	drug	0-11	astemizole	drug	115-124	mechanism
antihistamines	group	84-97	terfenadine	drug	99-109	false
antihistamines	group	84-97	astemizole	drug	115-124	false
terfenadine	drug	99-109	astemizole	drug	115-124	false

DDI-DrugBank.d397.s12	In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
terfenadine	drug	81-91	erythromycin	drug	97-108	effect

DDI-DrugBank.d397.s13	There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
erythromycin	drug	64-75	cisapride	drug	100-108	effect
erythromycin	drug	64-75	cisapride	drug	289-297	false
erythromycin	drug	64-75	erythromycin	drug	302-313	false
cisapride	drug	100-108	cisapride	drug	289-297	false
cisapride	drug	100-108	erythromycin	drug	302-313	false
cisapride	drug	289-297	erythromycin	drug	302-313	mechanism

DDI-DrugBank.d397.s15	Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
lovastatin	drug	31-40	erythromycin	drug	46-57	advise

DDI-DrugBank.d568.s1	Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
Alcohol	drug	0-6	LEXAPRO	brand	19-25	false
Alcohol	drug	0-6	alcohol	drug	81-87	false
Alcohol	drug	0-6	psychotropic medications	group	124-147	false
Alcohol	drug	0-6	alcohol	drug	161-167	false
Alcohol	drug	0-6	LEXAPRO	brand	188-194	false
LEXAPRO	brand	19-25	alcohol	drug	81-87	false
LEXAPRO	brand	19-25	psychotropic medications	group	124-147	false
LEXAPRO	brand	19-25	alcohol	drug	161-167	false
LEXAPRO	brand	19-25	LEXAPRO	brand	188-194	false
alcohol	drug	81-87	psychotropic medications	group	124-147	false
alcohol	drug	81-87	alcohol	drug	161-167	false
alcohol	drug	81-87	LEXAPRO	brand	188-194	false
psychotropic medications	group	124-147	alcohol	drug	161-167	false
psychotropic medications	group	124-147	LEXAPRO	brand	188-194	advise
alcohol	drug	161-167	LEXAPRO	brand	188-194	advise

DDI-DrugBank.d568.s2	Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors	group	0-27	MAOIs	group	30-34	false

DDI-DrugBank.d568.s3	Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
NSAIDs	group	38-43	Aspirin	brand	46-52	false
NSAIDs	group	38-43	Warfarin	drug	55-62	false
Aspirin	brand	46-52	Warfarin	drug	55-62	false

DDI-DrugBank.d568.s5	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
psychotropic drugs	group	115-132	NSAID	group	269-273	effect
psychotropic drugs	group	115-132	aspirin	brand	278-284	effect
NSAID	group	269-273	aspirin	brand	278-284	false

DDI-DrugBank.d568.s7	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
Cimetidine	drug	0-9	citalopram	drug	71-80	false
Cimetidine	drug	0-9	cimetidine	drug	121-130	false
Cimetidine	drug	0-9	citalopram	drug	170-179	false
citalopram	drug	71-80	cimetidine	drug	121-130	mechanism
citalopram	drug	71-80	citalopram	drug	170-179	false
cimetidine	drug	121-130	citalopram	drug	170-179	false

DDI-DrugBank.d568.s9	Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
Digoxin	drug	0-6	citalopram	drug	68-77	false
Digoxin	drug	0-6	citalopram	drug	107-116	false
Digoxin	drug	0-6	digoxin	drug	122-128	false
Digoxin	drug	0-6	citalopram	drug	212-221	false
Digoxin	drug	0-6	digoxin	drug	226-232	false
citalopram	drug	68-77	citalopram	drug	107-116	false
citalopram	drug	68-77	digoxin	drug	122-128	false
citalopram	drug	68-77	citalopram	drug	212-221	false
citalopram	drug	68-77	digoxin	drug	226-232	false
citalopram	drug	107-116	digoxin	drug	122-128	false
citalopram	drug	107-116	citalopram	drug	212-221	false
citalopram	drug	107-116	digoxin	drug	226-232	false
digoxin	drug	122-128	citalopram	drug	212-221	false
digoxin	drug	122-128	digoxin	drug	226-232	false
citalopram	drug	212-221	digoxin	drug	226-232	false

DDI-DrugBank.d568.s10	Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
Lithium	drug	0-6	citalopram	drug	38-47	false
Lithium	drug	0-6	lithium	drug	77-83	false
Lithium	drug	0-6	citalopram	drug	163-172	false
Lithium	drug	0-6	lithium	drug	177-183	false
citalopram	drug	38-47	lithium	drug	77-83	false
citalopram	drug	38-47	citalopram	drug	163-172	false
citalopram	drug	38-47	lithium	drug	177-183	false
lithium	drug	77-83	citalopram	drug	163-172	false
lithium	drug	77-83	lithium	drug	177-183	false
citalopram	drug	163-172	lithium	drug	177-183	false

DDI-DrugBank.d568.s11	Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.
lithium	drug	21-27	lithium	drug	91-97	false

DDI-DrugBank.d568.s12	Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
lithium	drug	8-14	escitalopram	drug	56-67	effect
lithium	drug	8-14	LEXAPRO	brand	103-109	false
lithium	drug	8-14	lithium	drug	115-121	false
escitalopram	drug	56-67	LEXAPRO	brand	103-109	false
escitalopram	drug	56-67	lithium	drug	115-121	false
LEXAPRO	brand	103-109	lithium	drug	115-121	advise

DDI-DrugBank.d568.s13	Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
Pimozide	drug	0-7	Celexa	brand	13-18	false
Pimozide	drug	0-7	pimozide	drug	62-69	false
Pimozide	drug	0-7	citalopram	drug	105-114	false
Pimozide	drug	0-7	pimozide	drug	238-245	false
Celexa	brand	13-18	pimozide	drug	62-69	false
Celexa	brand	13-18	citalopram	drug	105-114	false
Celexa	brand	13-18	pimozide	drug	238-245	false
pimozide	drug	62-69	citalopram	drug	105-114	effect
pimozide	drug	62-69	pimozide	drug	238-245	false
citalopram	drug	105-114	pimozide	drug	238-245	false

DDI-DrugBank.d568.s14	Racemic citalopram did not alter the mean AUC or Cmax of pimozide.
citalopram	drug	8-17	pimozide	drug	57-64	false

DDI-DrugBank.d568.s16	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
Sumatriptan	drug	0-10	selective serotonin reuptake inhibitor	group	149-186	false
Sumatriptan	drug	0-10	SSRI	group	189-192	false
Sumatriptan	drug	0-10	sumatriptan	drug	199-209	false
selective serotonin reuptake inhibitor	group	149-186	SSRI	group	189-192	false
selective serotonin reuptake inhibitor	group	149-186	sumatriptan	drug	199-209	effect
SSRI	group	189-192	sumatriptan	drug	199-209	effect

DDI-DrugBank.d568.s17	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
sumatriptan	drug	30-40	SSRI	group	49-52	advise
sumatriptan	drug	30-40	fluoxetine	drug	61-70	advise
sumatriptan	drug	30-40	fluvoxamine	drug	73-83	advise
sumatriptan	drug	30-40	paroxetine	drug	86-95	advise
sumatriptan	drug	30-40	sertraline	drug	98-107	advise
sumatriptan	drug	30-40	citalopram	drug	110-119	advise
sumatriptan	drug	30-40	escitalopram	drug	122-133	advise
SSRI	group	49-52	fluoxetine	drug	61-70	false
SSRI	group	49-52	fluvoxamine	drug	73-83	false
SSRI	group	49-52	paroxetine	drug	86-95	false
SSRI	group	49-52	sertraline	drug	98-107	false
SSRI	group	49-52	citalopram	drug	110-119	false
SSRI	group	49-52	escitalopram	drug	122-133	false
fluoxetine	drug	61-70	fluvoxamine	drug	73-83	false
fluoxetine	drug	61-70	paroxetine	drug	86-95	false
fluoxetine	drug	61-70	sertraline	drug	98-107	false
fluoxetine	drug	61-70	citalopram	drug	110-119	false
fluoxetine	drug	61-70	escitalopram	drug	122-133	false
fluvoxamine	drug	73-83	paroxetine	drug	86-95	false
fluvoxamine	drug	73-83	sertraline	drug	98-107	false
fluvoxamine	drug	73-83	citalopram	drug	110-119	false
fluvoxamine	drug	73-83	escitalopram	drug	122-133	false
paroxetine	drug	86-95	sertraline	drug	98-107	false
paroxetine	drug	86-95	citalopram	drug	110-119	false
paroxetine	drug	86-95	escitalopram	drug	122-133	false
sertraline	drug	98-107	citalopram	drug	110-119	false
sertraline	drug	98-107	escitalopram	drug	122-133	false
citalopram	drug	110-119	escitalopram	drug	122-133	false

DDI-DrugBank.d568.s18	Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
Theophylline	drug	0-11	citalopram	drug	50-59	false
Theophylline	drug	0-11	theophylline	drug	110-121	false
Theophylline	drug	0-11	theophylline	drug	186-197	false
citalopram	drug	50-59	theophylline	drug	110-121	false
citalopram	drug	50-59	theophylline	drug	186-197	false
theophylline	drug	110-121	theophylline	drug	186-197	false

DDI-DrugBank.d568.s19	The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.
theophylline	drug	14-25	citalopram	drug	54-63	false

DDI-DrugBank.d568.s20	Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
Warfarin	drug	0-7	citalopram	drug	47-56	false
Warfarin	drug	0-7	warfarin	drug	109-116	false
citalopram	drug	47-56	warfarin	drug	109-116	false

DDI-DrugBank.d568.s22	Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
Carbamazepine	drug	0-12	citalopram	drug	51-60	false
Carbamazepine	drug	0-12	carbamazepine	drug	90-102	false
Carbamazepine	drug	0-12	carbamazepine	drug	194-206	false
citalopram	drug	51-60	carbamazepine	drug	90-102	false
citalopram	drug	51-60	carbamazepine	drug	194-206	false
carbamazepine	drug	90-102	carbamazepine	drug	194-206	false

DDI-DrugBank.d568.s23	Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
citalopram	drug	16-25	carbamazepine	drug	98-110	false
citalopram	drug	16-25	carbamazepine	drug	134-146	false
citalopram	drug	16-25	escitalopram	drug	180-191	false
carbamazepine	drug	98-110	carbamazepine	drug	134-146	false
carbamazepine	drug	98-110	escitalopram	drug	180-191	false
carbamazepine	drug	134-146	escitalopram	drug	180-191	mechanism

DDI-DrugBank.d568.s24	Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
Triazolam	drug	0-8	citalopram	drug	47-56	false
Triazolam	drug	0-8	triazolam	drug	119-127	false
Triazolam	drug	0-8	citalopram	drug	214-223	false
Triazolam	drug	0-8	triazolam	drug	228-236	false
citalopram	drug	47-56	triazolam	drug	119-127	false
citalopram	drug	47-56	citalopram	drug	214-223	false
citalopram	drug	47-56	triazolam	drug	228-236	false
triazolam	drug	119-127	citalopram	drug	214-223	false
triazolam	drug	119-127	triazolam	drug	228-236	false
citalopram	drug	214-223	triazolam	drug	228-236	false

DDI-DrugBank.d568.s25	Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
Ketoconazole	drug	0-11	citalopram	drug	50-59	false
Ketoconazole	drug	0-11	ketoconazole	drug	73-84	false
Ketoconazole	drug	0-11	ketoconazole	drug	125-136	false
Ketoconazole	drug	0-11	citalopram	drug	225-234	false
citalopram	drug	50-59	ketoconazole	drug	73-84	mechanism
citalopram	drug	50-59	ketoconazole	drug	125-136	false
citalopram	drug	50-59	citalopram	drug	225-234	false
ketoconazole	drug	73-84	ketoconazole	drug	125-136	false
ketoconazole	drug	73-84	citalopram	drug	225-234	false
ketoconazole	drug	125-136	citalopram	drug	225-234	false

DDI-DrugBank.d568.s26	Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
Ritonavir	drug	0-8	ritonavir	drug	56-64	false
Ritonavir	drug	0-8	escitalopram	drug	138-149	false
Ritonavir	drug	0-8	ritonavir	drug	205-213	false
Ritonavir	drug	0-8	escitalopram	drug	218-229	false
ritonavir	drug	56-64	escitalopram	drug	138-149	false
ritonavir	drug	56-64	ritonavir	drug	205-213	false
ritonavir	drug	56-64	escitalopram	drug	218-229	false
escitalopram	drug	138-149	ritonavir	drug	205-213	false
escitalopram	drug	138-149	escitalopram	drug	218-229	false
ritonavir	drug	205-213	escitalopram	drug	218-229	false

DDI-DrugBank.d568.s28	However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.
escitalopram	drug	29-40	ritonavir	drug	54-62	false
escitalopram	drug	29-40	escitalopram	drug	157-168	false
ritonavir	drug	54-62	escitalopram	drug	157-168	false

DDI-DrugBank.d568.s29	Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.
escitalopram	drug	8-19	escitalopram	drug	123-134	false

DDI-DrugBank.d568.s31	In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
citalopram	drug	44-53	citalopram	drug	181-190	false
citalopram	drug	44-53	escitalopram	drug	232-243	false
citalopram	drug	44-53	escitalopram	drug	332-343	false
citalopram	drug	181-190	escitalopram	drug	232-243	false
citalopram	drug	181-190	escitalopram	drug	332-343	false
escitalopram	drug	232-243	escitalopram	drug	332-343	false

DDI-DrugBank.d568.s32	However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
escitalopram	drug	89-100	escitalopram	drug	129-140	false
escitalopram	drug	89-100	tricyclic antidepressant	group	175-198	false
escitalopram	drug	89-100	desipramine	drug	200-210	false
escitalopram	drug	89-100	desipramine	drug	325-335	false
escitalopram	drug	129-140	tricyclic antidepressant	group	175-198	false
escitalopram	drug	129-140	desipramine	drug	200-210	mechanism
escitalopram	drug	129-140	desipramine	drug	325-335	false
tricyclic antidepressant	group	175-198	desipramine	drug	200-210	false
tricyclic antidepressant	group	175-198	desipramine	drug	325-335	false
desipramine	drug	200-210	desipramine	drug	325-335	false

DDI-DrugBank.d568.s35	Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
Metoprolol	drug	0-9	LEXAPRO	brand	41-47	false
Metoprolol	drug	0-9	beta-adrenergic blocker	group	149-171	false
Metoprolol	drug	0-9	metoprolol	drug	173-182	false
LEXAPRO	brand	41-47	beta-adrenergic blocker	group	149-171	false
LEXAPRO	brand	41-47	metoprolol	drug	173-182	mechanism
beta-adrenergic blocker	group	149-171	metoprolol	drug	173-182	false

DDI-DrugBank.d568.s37	Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.
LEXAPRO	brand	20-26	metoprolol	drug	32-41	false

DDI-DrugBank.d568.s39	Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
Citalopram	drug	40-49	Citalopram	drug	51-60	false
Citalopram	drug	40-49	escitalopram	drug	70-81	false
Citalopram	drug	40-49	citalopram	drug	115-124	false
Citalopram	drug	40-49	Celexa	brand	127-132	false
Citalopram	drug	51-60	escitalopram	drug	70-81	false
Citalopram	drug	51-60	citalopram	drug	115-124	false
Citalopram	drug	51-60	Celexa	brand	127-132	false
escitalopram	drug	70-81	citalopram	drug	115-124	advise
escitalopram	drug	70-81	Celexa	brand	127-132	advise
citalopram	drug	115-124	Celexa	brand	127-132	false

DDI-DrugBank.d422.s0	Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
reserpine	drug	37-45	beta blocking agents	group	92-111	effect

DDI-DrugBank.d422.s1	Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
BREVIBLOC	brand	35-43	esmolol HCl	drug	46-56	false

DDI-DrugBank.d422.s2	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
BREVIBLOC	brand	31-39	warfarin	drug	45-52	false
BREVIBLOC	brand	31-39	BREVIBLOC	brand	96-104	false
BREVIBLOC	brand	31-39	warfarin	drug	110-117	false
BREVIBLOC	brand	31-39	warfarin	drug	134-141	false
warfarin	drug	45-52	BREVIBLOC	brand	96-104	false
warfarin	drug	45-52	warfarin	drug	110-117	false
warfarin	drug	45-52	warfarin	drug	134-141	false
BREVIBLOC	brand	96-104	warfarin	drug	110-117	false
BREVIBLOC	brand	96-104	warfarin	drug	134-141	false
warfarin	drug	110-117	warfarin	drug	134-141	false

DDI-DrugBank.d422.s3	BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
BREVIBLOC	brand	0-8	warfarin	drug	65-72	mechanism

DDI-DrugBank.d422.s4	When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
digoxin	drug	5-11	BREVIBLOC	brand	17-25	mechanism
digoxin	drug	5-11	digoxin	drug	126-132	false
BREVIBLOC	brand	17-25	digoxin	drug	126-132	false

DDI-DrugBank.d422.s5	Digoxin did not affect BREVIBLOC pharmacokinetics.
Digoxin	drug	0-6	BREVIBLOC	brand	23-31	false

DDI-DrugBank.d422.s6	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
morphine	drug	17-24	BREVIBLOC	brand	30-38	false
morphine	drug	17-24	morphine	drug	105-112	false
morphine	drug	17-24	BREVIBLOC	brand	141-149	false
morphine	drug	17-24	morphine	drug	218-225	false
BREVIBLOC	brand	30-38	morphine	drug	105-112	false
BREVIBLOC	brand	30-38	BREVIBLOC	brand	141-149	false
BREVIBLOC	brand	30-38	morphine	drug	218-225	false
morphine	drug	105-112	BREVIBLOC	brand	141-149	false
morphine	drug	105-112	morphine	drug	218-225	false
BREVIBLOC	brand	141-149	morphine	drug	218-225	mechanism

DDI-DrugBank.d422.s8	The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.
BREVIBLOC	drug	14-22	succinylcholine	drug	43-57	false

DDI-DrugBank.d422.s9	The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
succinylcholine	drug	39-53	BREVIBLOC	brand	73-81	effect

DDI-DrugBank.d422.s10	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
BREVIBLOC	brand	102-110	digoxin	drug	188-194	advise
BREVIBLOC	brand	102-110	morphine	drug	197-204	advise
BREVIBLOC	brand	102-110	succinylcholine	drug	207-221	advise
BREVIBLOC	brand	102-110	warfarin	drug	226-233	advise
digoxin	drug	188-194	morphine	drug	197-204	false
digoxin	drug	188-194	succinylcholine	drug	207-221	false
digoxin	drug	188-194	warfarin	drug	226-233	false
morphine	drug	197-204	succinylcholine	drug	207-221	false
morphine	drug	197-204	warfarin	drug	226-233	false
succinylcholine	drug	207-221	warfarin	drug	226-233	false

DDI-DrugBank.d422.s13	Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
BREVIBLOC	brand	56-64	verapamil	drug	70-78	advise

DDI-DrugBank.d422.s15	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
BREVIBLOC	brand	14-22	dopamine	drug	158-165	advise
BREVIBLOC	brand	14-22	epinephrine	drug	168-178	advise
BREVIBLOC	brand	14-22	norepinephrine	drug	185-198	advise
dopamine	drug	158-165	epinephrine	drug	168-178	false
dopamine	drug	158-165	norepinephrine	drug	185-198	false
epinephrine	drug	168-178	norepinephrine	drug	185-198	false

DDI-DrugBank.d29.s3	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
esomeprazole	drug	41-52	phenytoin	drug	113-121	false
esomeprazole	drug	41-52	warfarin	drug	124-131	false
esomeprazole	drug	41-52	quinidine	drug	134-142	false
esomeprazole	drug	41-52	clarithromycin	drug	145-158	false
esomeprazole	drug	41-52	amoxicillin	drug	163-173	false
phenytoin	drug	113-121	warfarin	drug	124-131	false
phenytoin	drug	113-121	quinidine	drug	134-142	false
phenytoin	drug	113-121	clarithromycin	drug	145-158	false
phenytoin	drug	113-121	amoxicillin	drug	163-173	false
warfarin	drug	124-131	quinidine	drug	134-142	false
warfarin	drug	124-131	clarithromycin	drug	145-158	false
warfarin	drug	124-131	amoxicillin	drug	163-173	false
quinidine	drug	134-142	clarithromycin	drug	145-158	false
quinidine	drug	134-142	amoxicillin	drug	163-173	false
clarithromycin	drug	145-158	amoxicillin	drug	163-173	false

DDI-DrugBank.d29.s4	Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.
warfarin	drug	107-114	esomeprazole	drug	120-131	false

DDI-DrugBank.d29.s6	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
proton pump inhibitors	group	22-43	warfarin	drug	49-56	effect

DDI-DrugBank.d29.s7	Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.
Esomeprazole	drug	0-11	esomeprazole	drug	63-74	false

DDI-DrugBank.d29.s8	Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
esomeprazole	drug	20-31	diazepam	drug	43-50	mechanism
esomeprazole	drug	20-31	diazepam	drug	117-124	false
diazepam	drug	43-50	diazepam	drug	117-124	false

DDI-DrugBank.d29.s12	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
esomeprazole	drug	11-22	ketoconazole	drug	136-147	mechanism
esomeprazole	drug	11-22	iron	drug	150-153	mechanism
esomeprazole	drug	11-22	digoxin	drug	165-171	mechanism
ketoconazole	drug	136-147	iron	drug	150-153	false
ketoconazole	drug	136-147	digoxin	drug	165-171	false
iron	drug	150-153	digoxin	drug	165-171	false

DDI-DrugBank.d29.s13	Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
contraceptives	group	25-38	diazepam	drug	41-48	false
contraceptives	group	25-38	phenytoin	drug	51-59	false
contraceptives	group	25-38	quinidine	drug	65-73	false
contraceptives	group	25-38	esomeprazole	drug	129-140	false
diazepam	drug	41-48	phenytoin	drug	51-59	false
diazepam	drug	41-48	quinidine	drug	65-73	false
diazepam	drug	41-48	esomeprazole	drug	129-140	false
phenytoin	drug	51-59	quinidine	drug	65-73	false
phenytoin	drug	51-59	esomeprazole	drug	129-140	false
quinidine	drug	65-73	esomeprazole	drug	129-140	false

DDI-DrugBank.d29.s14	Concomitant administration of clarithromycin with pimozide is contraindicated.
clarithromycin	drug	30-43	pimozide	drug	50-57	advise

DDI-DrugBank.d338.s1	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
benzodiazepines	group	18-32	anticonvulsants	group	56-70	effect
benzodiazepines	group	18-32	antihistamines	group	73-86	effect
benzodiazepines	group	18-32	alcohol	drug	89-95	effect
benzodiazepines	group	18-32	barbiturates	group	98-109	effect
benzodiazepines	group	18-32	monoamine oxidase inhibitors	group	112-139	effect
benzodiazepines	group	18-32	narcotics	group	142-150	effect
benzodiazepines	group	18-32	phenothiazines	group	153-166	effect
benzodiazepines	group	18-32	psychotropic medications	group	169-192	effect
anticonvulsants	group	56-70	antihistamines	group	73-86	false
anticonvulsants	group	56-70	alcohol	drug	89-95	false
anticonvulsants	group	56-70	barbiturates	group	98-109	false
anticonvulsants	group	56-70	monoamine oxidase inhibitors	group	112-139	false
anticonvulsants	group	56-70	narcotics	group	142-150	false
anticonvulsants	group	56-70	phenothiazines	group	153-166	false
anticonvulsants	group	56-70	psychotropic medications	group	169-192	false
antihistamines	group	73-86	alcohol	drug	89-95	false
antihistamines	group	73-86	barbiturates	group	98-109	false
antihistamines	group	73-86	monoamine oxidase inhibitors	group	112-139	false
antihistamines	group	73-86	narcotics	group	142-150	false
antihistamines	group	73-86	phenothiazines	group	153-166	false
antihistamines	group	73-86	psychotropic medications	group	169-192	false
alcohol	drug	89-95	barbiturates	group	98-109	false
alcohol	drug	89-95	monoamine oxidase inhibitors	group	112-139	false
alcohol	drug	89-95	narcotics	group	142-150	false
alcohol	drug	89-95	phenothiazines	group	153-166	false
alcohol	drug	89-95	psychotropic medications	group	169-192	false
barbiturates	group	98-109	monoamine oxidase inhibitors	group	112-139	false
barbiturates	group	98-109	narcotics	group	142-150	false
barbiturates	group	98-109	phenothiazines	group	153-166	false
barbiturates	group	98-109	psychotropic medications	group	169-192	false
monoamine oxidase inhibitors	group	112-139	narcotics	group	142-150	false
monoamine oxidase inhibitors	group	112-139	phenothiazines	group	153-166	false
monoamine oxidase inhibitors	group	112-139	psychotropic medications	group	169-192	false
narcotics	group	142-150	phenothiazines	group	153-166	false
narcotics	group	142-150	psychotropic medications	group	169-192	false
phenothiazines	group	153-166	psychotropic medications	group	169-192	false

DDI-DrugBank.d338.s4	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
estazolam	drug	70-78	carbamazepine	drug	153-165	mechanism
estazolam	drug	70-78	phenytoin	drug	168-176	mechanism
estazolam	drug	70-78	rifampin	drug	179-186	mechanism
estazolam	drug	70-78	barbiturates	group	193-204	mechanism
estazolam	drug	70-78	estazolam	drug	237-245	mechanism
carbamazepine	drug	153-165	phenytoin	drug	168-176	false
carbamazepine	drug	153-165	rifampin	drug	179-186	false
carbamazepine	drug	153-165	barbiturates	group	193-204	false
carbamazepine	drug	153-165	estazolam	drug	237-245	false
phenytoin	drug	168-176	rifampin	drug	179-186	false
phenytoin	drug	168-176	barbiturates	group	193-204	false
phenytoin	drug	168-176	estazolam	drug	237-245	false
rifampin	drug	179-186	barbiturates	group	193-204	false
rifampin	drug	179-186	estazolam	drug	237-245	false
barbiturates	group	193-204	estazolam	drug	237-245	false

DDI-DrugBank.d338.s5	Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
Estazolam	drug	0-8	estazolam	drug	108-116	false
Estazolam	drug	0-8	4-hydroxy-estazolam	drug_n	154-172	false
Estazolam	drug	0-8	triazolobenzodiazepines	group	202-224	false
estazolam	drug	108-116	4-hydroxy-estazolam	drug_n	154-172	false
estazolam	drug	108-116	triazolobenzodiazepines	group	202-224	false
4-hydroxy-estazolam	drug_n	154-172	triazolobenzodiazepines	group	202-224	false

DDI-DrugBank.d338.s6	Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
estazolam	drug	14-22	ketoconazole	drug	64-75	advise
estazolam	drug	14-22	itraconazole	drug	81-92	advise
ketoconazole	drug	64-75	itraconazole	drug	81-92	false

DDI-DrugBank.d338.s8	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
benzodiazepines	group	85-99	nefazodone	drug	142-151	mechanism
benzodiazepines	group	85-99	fluvoxamine	drug	154-164	mechanism
benzodiazepines	group	85-99	cimetidine	drug	167-176	mechanism
benzodiazepines	group	85-99	diltiazem	drug	179-187	mechanism
benzodiazepines	group	85-99	isoniazide	drug	190-199	mechanism
benzodiazepines	group	85-99	macrolide antibiotics	group	211-231	mechanism
nefazodone	drug	142-151	fluvoxamine	drug	154-164	false
nefazodone	drug	142-151	cimetidine	drug	167-176	false
nefazodone	drug	142-151	diltiazem	drug	179-187	false
nefazodone	drug	142-151	isoniazide	drug	190-199	false
nefazodone	drug	142-151	macrolide antibiotics	group	211-231	false
fluvoxamine	drug	154-164	cimetidine	drug	167-176	false
fluvoxamine	drug	154-164	diltiazem	drug	179-187	false
fluvoxamine	drug	154-164	isoniazide	drug	190-199	false
fluvoxamine	drug	154-164	macrolide antibiotics	group	211-231	false
cimetidine	drug	167-176	diltiazem	drug	179-187	false
cimetidine	drug	167-176	isoniazide	drug	190-199	false
cimetidine	drug	167-176	macrolide antibiotics	group	211-231	false
diltiazem	drug	179-187	isoniazide	drug	190-199	false
diltiazem	drug	179-187	macrolide antibiotics	group	211-231	false
isoniazide	drug	190-199	macrolide antibiotics	group	211-231	false

DDI-DrugBank.d338.s9	Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.
Fluoxetine	drug	22-31	fluoxetine	drug	94-103	false
Fluoxetine	drug	22-31	estazolam	drug	142-150	false
fluoxetine	drug	94-103	estazolam	drug	142-150	false

DDI-DrugBank.d338.s10	The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.
estazolam	drug	24-32	fluoxetine	drug	88-97	false

DDI-DrugBank.d338.s11	Estazolam: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
Estazolam	drug	0-8	estazolam	drug	157-165	false

DDI-DrugBank.d301.s14	Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
corticosteroids	group	170-184	sex steroids	group	190-201	false

DDI-DrugBank.d481.s0	Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
calcium	drug	25-31	EMCYT	brand	82-86	mechanism

DDI-DrugBank.d216.s0	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
Ethanol	drug	17-23	eszopiclone	drug	105-115	false
Ethanol	drug	17-23	ethanol	drug	121-127	false
Ethanol	drug	17-23	ethanol	drug	163-169	false
eszopiclone	drug	105-115	ethanol	drug	121-127	effect
eszopiclone	drug	105-115	ethanol	drug	163-169	false
ethanol	drug	121-127	ethanol	drug	163-169	false

DDI-DrugBank.d216.s1	Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
Paroxetine	drug	0-9	eszopiclone	drug	48-58	false
Paroxetine	drug	0-9	paroxetine	drug	69-78	false
eszopiclone	drug	48-58	paroxetine	drug	69-78	false

DDI-DrugBank.d216.s2	Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.
Lorazepam	drug	0-8	eszopiclone	drug	47-57	false
Lorazepam	drug	0-8	lorazepam	drug	68-76	false
eszopiclone	drug	47-57	lorazepam	drug	68-76	false

DDI-DrugBank.d216.s3	Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
Olanzapine	drug	0-9	eszopiclone	drug	32-42	false
Olanzapine	drug	0-9	olanzapine	drug	53-62	false
eszopiclone	drug	32-42	olanzapine	drug	53-62	effect

DDI-DrugBank.d216.s6	Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.
Ketoconazole	drug	27-38	eszopiclone	drug	96-106	false

DDI-DrugBank.d216.s7	The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
eszopiclone	drug	11-21	ketoconazole	drug	69-80	mechanism

DDI-DrugBank.d216.s9	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
itraconazole	drug	41-52	clarithromycin	drug	55-68	false
itraconazole	drug	41-52	nefazodone	drug	71-80	false
itraconazole	drug	41-52	troleandomycin	drug	83-96	false
itraconazole	drug	41-52	ritonavir	drug	99-107	false
itraconazole	drug	41-52	nelfinavir	drug	110-119	false
clarithromycin	drug	55-68	nefazodone	drug	71-80	false
clarithromycin	drug	55-68	troleandomycin	drug	83-96	false
clarithromycin	drug	55-68	ritonavir	drug	99-107	false
clarithromycin	drug	55-68	nelfinavir	drug	110-119	false
nefazodone	drug	71-80	troleandomycin	drug	83-96	false
nefazodone	drug	71-80	ritonavir	drug	99-107	false
nefazodone	drug	71-80	nelfinavir	drug	110-119	false
troleandomycin	drug	83-96	ritonavir	drug	99-107	false
troleandomycin	drug	83-96	nelfinavir	drug	110-119	false
ritonavir	drug	99-107	nelfinavir	drug	110-119	false

DDI-DrugBank.d216.s10	Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
Rifampicin	drug	26-35	zopiclone	drug	46-54	false
Rifampicin	drug	26-35	rifampicin	drug	104-113	false
zopiclone	drug	46-54	rifampicin	drug	104-113	mechanism

DDI-DrugBank.d216.s15	Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
Digoxin	drug	38-44	eszopiclone	drug	63-73	false
Digoxin	drug	38-44	digoxin	drug	119-125	false
eszopiclone	drug	63-73	digoxin	drug	119-125	false

DDI-DrugBank.d216.s16	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
Warfarin	drug	0-7	Eszopiclone	drug	10-20	false
Warfarin	drug	0-7	(R)-warfarin	drug	95-98;107-114	false
Warfarin	drug	0-7	(S)-warfarin	drug	104-115	false
Warfarin	drug	0-7	warfarin	drug	233-240	false
Eszopiclone	drug	10-20	(R)-warfarin	drug	95-98;107-114	false
Eszopiclone	drug	10-20	(S)-warfarin	drug	104-115	false
Eszopiclone	drug	10-20	warfarin	drug	233-240	false
(R)-warfarin	drug	95-98;107-114	(S)-warfarin	drug	104-115	false
(R)-warfarin	drug	95-98;107-114	warfarin	drug	233-240	false
(S)-warfarin	drug	104-115	warfarin	drug	233-240	false

DDI-DrugBank.d341.s1	However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.
ENBREL	brand	54-59	methotrexate	drug	91-102	false

DDI-DrugBank.d341.s2	In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
ENBREL	brand	92-97	anakinra	drug	104-111	effect
ENBREL	brand	92-97	ENBREL	brand	209-214	false
anakinra	drug	104-111	ENBREL	brand	209-214	false

DDI-DrugBank.d341.s3	Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
ENBREL	brand	50-55	anakinra	drug	62-69	effect

DDI-DrugBank.d341.s4	Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
sulfasalazine	drug	66-78	ENBREL	brand	90-95	effect
sulfasalazine	drug	66-78	ENBREL	brand	216-221	false
sulfasalazine	drug	66-78	sulfasalazine	drug	229-241	false
ENBREL	brand	90-95	ENBREL	brand	216-221	false
ENBREL	brand	90-95	sulfasalazine	drug	229-241	false
ENBREL	brand	216-221	sulfasalazine	drug	229-241	false

DDI-DrugBank.d414.s0	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	drug	0-6	diuretics	group	43-51	mechanism
Lithium	drug	0-6	lithium	drug	116-122	false
diuretics	group	43-51	lithium	drug	116-122	false

DDI-DrugBank.d414.s2	EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
EDECRIN	brand	0-6	aminoglycoside	group	67-80	effect
EDECRIN	brand	0-6	cephalosporin antibiotics	group	91-115	effect
aminoglycoside	group	67-80	cephalosporin antibiotics	group	91-115	false

DDI-DrugBank.d414.s4	A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
ethacrynic acid	drug	29-43	warfarin	drug	74-81	mechanism

DDI-DrugBank.d414.s6	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
non- steroidal antiinflammatory agent	group	42-78	loop diuretics	group	150-153;188-196	effect
non- steroidal antiinflammatory agent	group	42-78	potassium- sparing diuretics	group	156-173;188-196	effect
non- steroidal antiinflammatory agent	group	42-78	thiazide diuretics	group	179-196	effect
loop diuretics	group	150-153;188-196	potassium- sparing diuretics	group	156-173;188-196	false
loop diuretics	group	150-153;188-196	thiazide diuretics	group	179-196	false
potassium- sparing diuretics	group	156-173;188-196	thiazide diuretics	group	179-196	false

DDI-DrugBank.d414.s7	Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
EDECRIN	brand	16-22	non- steroidal anti- inflammatory agents	group	28-67	effect
EDECRIN	brand	16-22	diuretic	group	174-181	false
non- steroidal anti- inflammatory agents	group	28-67	diuretic	group	174-181	false

DDI-DrugBank.d160.s0	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
ethambutol	drug	46-55	aluminum hydroxide	drug	76-93	mechanism
ethambutol	drug	46-55	antacid	group	106-112	false
ethambutol	drug	46-55	ethambutol	drug	220-229	false
ethambutol	drug	46-55	ethambutol	drug	314-323	false
ethambutol	drug	46-55	antacid products	group	349-364	false
aluminum hydroxide	drug	76-93	antacid	group	106-112	false
aluminum hydroxide	drug	76-93	ethambutol	drug	220-229	false
aluminum hydroxide	drug	76-93	ethambutol	drug	314-323	false
aluminum hydroxide	drug	76-93	antacid products	group	349-364	false
antacid	group	106-112	ethambutol	drug	220-229	false
antacid	group	106-112	ethambutol	drug	314-323	false
antacid	group	106-112	antacid products	group	349-364	false
ethambutol	drug	220-229	ethambutol	drug	314-323	false
ethambutol	drug	220-229	antacid products	group	349-364	false
ethambutol	drug	314-323	antacid products	group	349-364	false

DDI-DrugBank.d160.s1	It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
ethambutol	drug	56-65	aluminum hydroxide	drug	72-89	advise
ethambutol	drug	56-65	antacids	group	102-109	false
ethambutol	drug	56-65	ethambutol	drug	142-151	false
aluminum hydroxide	drug	72-89	antacids	group	102-109	false
aluminum hydroxide	drug	72-89	ethambutol	drug	142-151	false
antacids	group	102-109	ethambutol	drug	142-151	false

DDI-DrugBank.d405.s0	Dicumarol and warfarin may decrease hypoprothrombinemic effect.
Dicumarol	drug	0-8	warfarin	drug	14-21	false

DDI-DrugBank.d405.s1	Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
alcohol	drug	27-33	barbiturates	group	36-47	false
alcohol	drug	27-33	MAOIs	group	54-58	false
alcohol	drug	27-33	ethchlorvynol	drug	110-122	effect
barbiturates	group	36-47	MAOIs	group	54-58	false
barbiturates	group	36-47	ethchlorvynol	drug	110-122	effect
MAOIs	group	54-58	ethchlorvynol	drug	110-122	effect

DDI-DrugBank.d376.s0	May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).
central nervous system (CNS) depressants	group	52-91	alcohol	drug	185-191	false
central nervous system (CNS) depressants	group	52-91	ethinamate	drug	320-329	false
alcohol	drug	185-191	ethinamate	drug	320-329	false

DDI-DrugBank.d152.s0	Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
estrogen	group	62-69	contraceptives	group	87-100	false

DDI-DrugBank.d166.s0	Trecator has been found to temporarily raise serum concentrations of isoniazid.
Trecator	brand	0-7	isoniazid	drug	69-77	mechanism

DDI-DrugBank.d166.s1	Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
Trecator	brand	0-7	antituberculous drugs	group	53-73	effect

DDI-DrugBank.d166.s2	In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
ethionamide	drug	51-61	cycloserine	drug	84-94	effect

DDI-DrugBank.d240.s0	Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
Ethopropazine	drug	0-12	alcohol	drug	32-38	effect
Ethopropazine	drug	0-12	CNS depressants	group	49-63	effect
alcohol	drug	32-38	CNS depressants	group	49-63	false

DDI-DrugBank.d240.s1	It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.
amantadine	drug	26-35	anticholinergic drugs	group	46-66	false
amantadine	drug	26-35	MAOIs	group	71-75	false
anticholinergic drugs	group	46-66	MAOIs	group	71-75	false

DDI-DrugBank.d240.s2	Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
Ethopropazine	drug	0-12	chlorpromazine	drug	32-45	mechanism
Ethopropazine	drug	0-12	chlorpromazine	drug	77-90	false
chlorpromazine	drug	32-45	chlorpromazine	drug	77-90	false

DDI-DrugBank.d205.s0	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
Zarontin	brand	6-13	ethosuximide	drug	16-27	false
Zarontin	brand	6-13	antiepileptic drugs	group	74-92	int
Zarontin	brand	6-13	ethosuximide	drug	168-179	false
Zarontin	brand	6-13	phenytoin	drug	193-201	false
Zarontin	brand	6-13	valproic acid	drug	220-232	false
Zarontin	brand	6-13	ethosuximide	drug	282-293	false
ethosuximide	drug	16-27	antiepileptic drugs	group	74-92	int
ethosuximide	drug	16-27	ethosuximide	drug	168-179	false
ethosuximide	drug	16-27	phenytoin	drug	193-201	false
ethosuximide	drug	16-27	valproic acid	drug	220-232	false
ethosuximide	drug	16-27	ethosuximide	drug	282-293	false
antiepileptic drugs	group	74-92	ethosuximide	drug	168-179	false
antiepileptic drugs	group	74-92	phenytoin	drug	193-201	false
antiepileptic drugs	group	74-92	valproic acid	drug	220-232	false
antiepileptic drugs	group	74-92	ethosuximide	drug	282-293	false
ethosuximide	drug	168-179	phenytoin	drug	193-201	mechanism
ethosuximide	drug	168-179	valproic acid	drug	220-232	false
ethosuximide	drug	168-179	ethosuximide	drug	282-293	false
phenytoin	drug	193-201	valproic acid	drug	220-232	false
phenytoin	drug	193-201	ethosuximide	drug	282-293	false
valproic acid	drug	220-232	ethosuximide	drug	282-293	mechanism

DDI-DrugBank.d359.s1	Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
PEGANONE	brand	44-51	Phenurone	brand	87-95	advise
PEGANONE	brand	44-51	phenacemide	drug	98-108	advise
Phenurone	brand	87-95	phenacemide	drug	98-108	false

DDI-DrugBank.d359.s2	A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
hydantoin antiepileptic	group	34-56	phenytoin	drug	59-67	int
hydantoin antiepileptic	group	34-56	coumarin anticoagulant	group	78-99	int
phenytoin	drug	59-67	coumarin anticoagulant	group	78-99	false

DDI-DrugBank.d359.s3	Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
phenytoin	drug	12-20	coumarin	group	46-53	mechanism
phenytoin	drug	12-20	coumarin anticoagulants	group	127-149	mechanism
coumarin	group	46-53	coumarin anticoagulants	group	127-149	false

DDI-DrugBank.d359.s4	Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
coumarin anticoagulants	group	16-38	phenytoin	drug	123-131	mechanism

DDI-DrugBank.d359.s5	Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.
ethotoin	drug	74-81	coumarin anticoagulants	group	91-113	false

DDI-DrugBank.d359.s6	Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
PEGANONE	brand	48-55	coumarin anticoagulants	group	79-101	advise

